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Abstract
RNA viruses are a major cause of disease that in the last fifteen years 
counted for frequent outbreaks, infecting both humans and animals. 
Examples of emerging or ri-emerging viral pathogens are the Foot-and-
Mouth disease virus (FMDV) for animals, Chikungunya virus (CHIKV), 
Coxsackie virus B3 (CVB3) and Respiratory Syncytial virus (RSV) for 
humans, all responsible for infections associated with mild to severe 
complications. Although both vaccines and small-molecule compounds are 
at different stages of development, no selective antiviral drugs have been 
approved so far, therefore for all four these viruses improved treatment 
strategies are required. Promising targets  are the viral non-structural 
proteins, which are commonly evaluated for the identification of new 
antivirals. Starting from the study of different viral proteins, several 
computer-aided techniques were applied, aiming to identify hit molecules 
first, and secondly to synthesise new series of potential antiviral 
compounds. The available crystal structures of some of the proteins  that 
play a role in viral replication were used for structure- and ligand-based 
virtual screenings of commercially available compounds against CVB3, 
FMDV and RSV. New families  of potential anti-CHIKV compounds were 
rationally designed and synthesized, in order to establish a structure-
activity relationship study on a lead structure previously found in our 
group. Finally, a de-novo drug design approach was performed to find a 
suitable scaffold for the synthesis of a series  of zinc-ejecting compounds 
against RSV. Inhibition of virus replication was evaluated for all the new 
compounds, of which different showed antiviral potential.
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Abbreviations and Acronyms
3D        Three-dimensional
3Dpol       3D polymerase
Å          Angstrom
ALRI        Acute lower respiratory infection
Anhyd.       Anhydrous
Arg        Arginine
Asn        Asparagine
Asp        Aspartic acid
CADD       Computer-aided drug design
CC50        Cytotoxic concentration to observe 50% adverse effect 
CPE        Cytopathic effect
CNS        Central nervous system
CP         Capsid protein
Cys        Cysteine
DCM        Dichloromethane
DIPEA       N,N-Diisopropylethylamine
DMF        Dimethylformamide
DMSO        Dimethylsulfoxide
EC50        Effective concentration to observe 50% activity
EC90        Effective concentration to observe 90% activity
ER        Endoplasmic reticulum
FDA        Food and Drug Administration
F         Fusion
GE        Gene end
Glu        Glutamic acid
Gly        Glycine
GS         Gene start
h         Hour
His        Histidine
HTS        High-throughput screening
HTVS        High-throughput virtual screening
Hz        Hertz
kb        Kilobases
Ile         Isoleucine
IC50        Inhibitory concentration to observe 50% effect
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Le         Leader
LogP        Partition coefficient
Lys        Lysine
Leu        Leucine
LBDD       Ligand-based drug design
MOE        Molecular operating environment
MS        Mass Spectroscopy
mRNA       Messenger ribonucleic acid
NMR        Nuclear magnetic resonance
NS        Non-structural
NTP        Nucleoside triphosphate
NS        Non-structural protein
ORF        Open reading frame
O.n.        Over night
PDB        Protein Data Bank
PV        Poliovirus
Phe        Phenylalanine
RdRp       RNA-dependent RNA polymerase
r.t.        Room temperature
Rf         Retention factor
RMSD       Root-mean-square deviation
RNA        Ribonucleic acid
ROCS       Rapid Overlay of Chemical Structures
SAR        Structure-activity relationship
SBVS        Structure-Based Virtual Screening
Ser        Serine
Ss         Single-stranded
TBTU        O-(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
         tetrafluoroborate 
THF        Tetrahydrofuran
Thr        Threonine
TLC        Thin layer chromatography 
Tr         Trailer
Trp        Tryptophan
UTR        Untranslated region
Val        Valine
VP         Viral protein
VPg        Viral Protein genome-linked
ZBD        Zinc binding domain
 Molecular modelling in 
drug discovery
Chapter I
1.1 The drug discovery ‘game’
Drug discovery is  a long and complex process through which novel drugs 
are identified. Figure 1.1 shows  the typical workflow of drug discovery and 
development over the time. The process is not so  linear as  represented: 
most of the time, it is a random sequence of events, driven by uncertainty 
and highly-dependent on knowledge about human biological systems 
which are still not completely known.1,2 ,3 
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Figure 1.1: States of the drug discovery process
There is no formula that can be applied to define if a molecule will be a 
drug candidate. It is more an ‘exercise’ of trial-and-error that takes between 
10 and 15 years  for a potential new drug to move from the early drug 
discovery to the market. According to a recent article published in Forbes 
in 2013, 95% of experimental medicines  fail. Moreover, the price for 
developing a new drug has increased to $5b, which includes the cost to 
bring a drug from discovery to clinical trials (around $800 thousand per 
drug) and the loss of money for those drugs  that fail during the overall 
process.4,5 
The early discovery research is one of the most consuming phases in terms 
of time and cost, along with preclinical and clinical development.6 Different 
strategies can be applied for lead identification: first of all, high-
throughput screenings (HTS) of synthetic chemical libraries or natural 
products  are commonly used to find a hit molecule; secondly, working with 
compounds that already have some desired properties. Another 
methodology that has  played an important role since its beginnings in the 
1970s is  the use of computational approaches. Computer-aided drug 
design (CADD) has been demonstrated to  be successful in the discovery of 
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several drugs when the 3D crystal structure of a target protein is  available. 
The first drug on the market that was discovered through a structure-
based drug design approach was the carbonic anhydrase inhibitor 
dorzolamide.7 Another example of drug developed by rational drug design 
is imatinib, a tyrosine kinase inhibitor, marketed by Novartis as Glivec®. 
This anticancer drug was designed to target the bcr-abl fusion protein by 
chemical modification of a starting lead compound found through a virtual 
screening.8 Among antiviral compounds, there are few examples that can 
be cited: saquinavir (Invirase®), a HIV protease inhibitor, designed on the 
basis  of a crystal structure between the protein and a peptidic inhibitor,9 
and zanamivir, marketed as Relenza®, which is  the first neuraminidase 
inhibitor for the treatment of influenza. This drug was  discovered through 
studies conducted on the binding site of the target 3D structure that led to 
modifications aiming to improve the binding mode of a first inhibitor in 
the active site.10  All these examples  are a proof that computer-aided 
techniques have contributed in the recent years for the discovery of several 
compounds that are on the market and represent an important tool for the 
development of new target-based drugs.
1.2 Introduction to Molecular Modelling
Molecular modelling is  regarded as a set of computational techniques 
based on theoretical methods and experimental data that can be used to 
understand molecules and molecular systems or to  predict molecular, 
chemical and biochemical properties.11 Programs or algorithms are used to 
calculate the energetic  aspects  of a molecular system. There are two main 
approaches to  compute the energy: quantum mechanics and molecular 
mechanics.
1.2.1 Quantum mechanics 
Quantum mechanics methods allow to calculate the electronic properties 
by considering the interactions  between electrons  and nuclei of the 
molecule. Electrons are explicitly considered to be moving around a fixed 
nucleus, therefore it is  possible to  consider properties that depend on the 
electrostatic  distribution. Quantum mechanics can be divided into ab initio 
and semi-empirical methods. The first one is able to reproduce 
experimental data but does not employ stored empirical parameters; it is 
rigorous and restricted to small molecules. Semi-empirical methods are 
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quicker and less accurate than the previous ones  and can be used for larger 
molecules. They differ from ab initio methods for the use of empirical 
parameters in order to  reduce the high costs of computer time necessary.11 
The core of quantum mechanics is the Schroëdinger equation, which is  a 
wave function that can be exactly solved for the hydrogen atom. For atoms 
with more than one electron, simplifications of this equation need to be 
applied, like the Born-Oppenheimer approximation. Since the nuclei are 
much heavier than the electrons, this  approximation considers the nuclear 
and electronic  motions separately, therefore the system total energy is 
considered as composed by the nuclear energy and the electronic  energy, 
which is calculated by solving the Schroëdinger equation:12
Etot = Eelectrons + Enuclei
Quantum mechanics is suitable for calculating a vast range of properties, 
such as the molecular orbital energies and coefficients, heat of formation 
for specific conformations, partial atomic  charges, electrostatic potentials, 
bond dissociation energies, transition state geometries and energies13. 
1.2.2 Molecular mechanics 
For large biomolecules, quantum mechanics cannot be applied; in these 
cases, molecular mechanics can be used to  study their structures and 
behaviors. This method is fast and less time consuming than quantum 
mechanics because it does not consider the electronic motions. Nuclei and 
electrons are treated as a unit, with no  distinction. Therefore, the major 
limit is the impossibility of calculating properties  that depends on the 
electronic  distribution.14 The energy of the molecule is  represented by the 
equation:
Etot = Ebend + Estr + Etors + Evdw + Eelec + ...
The total energy of a molecule has to be seen in terms  of deviations from 
reference “unstrained” bond lengths, angles, torsions and non-bonded 
interactions. To these elements, additional components can be added in 
more complex calculations. The force field is a collection of these values. 
The energies  obtained by such calculations have no physical meaning if 
considered by themselves. They can be considered as deviations  from the 
standard values defined in the force field (denoted as force field 
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parameters). Each deviation will result in an increase of the total energy of 
the molecule, therefore the total energy derives  from a comparison 
between the intramolecular strain of the molecule and a hypothetical 
molecule with an ideal geometry.28 AMBER, MMFF and OPLS force fields  are 
examples  of common force fields used for drug design applications. The 
first one is primarily used for molecular dynamics of macromolecules but 
it is also applied for energy minimization. MMFF force field may be 
considered the most widely used, as it has  been integrated into a number 
of different software packages (e.g. MOE), and gives reasonable  results in a 
wide range of chemical systems.15 The concept of atom type is one of the 
basis  of molecular mechanics. The atom type describes a particular 
chemical situation of each atom. Behind the concept of atom type is the 
idea that an atom, within a molecule, does not have the same behavior. In 
fact, an atom is  described by hybridization, formal charge and it also 
depends on the bonded atoms. Thus, molecular mechanics considers 
interactions between atom types and not elements, and the number of 
atom-types respects the number of possible chemical situations in which 
an atom can be found in building different molecular structures. A brief 
example of atom types for AMBER force field is reported below. 
                                    H amide or imino hydrogen
                                    HC explicit hydrogen attached to carbon
                                    HO hydrogen or hydroxyl oxygen
hydrogen types HS hydrogen attached to sulfur
           HW hydrogen water
   H2 amido hydrogen in NH2
   H3 hydrogen of lysine or arginine (positively 
    charged)
1.2.3 Energy minimisation
Energy minimization is a method that allows  finding the (global) minimum 
energy conformation of a molecule by locating all the local minima of the 
function describing the potential energy surface. Energy minimization is 
useful for bringing a molecule to, or close to, its equilibrium conformation. 
The process consists of calculating the energy of a starting molecule, then 
variating the bond lengths, bond angles, and torsion angles  to create a new 
configuration. The energy associated is  measured to see whether the 
generated configuration is  more stable or not in terms of energy. The 
program carries out more changes and is  able to recognize these 
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conformations which lead to stabilisation and those which do not.30 This 
analysis is  commonly performed in molecular modelling, as  well as  related 
procedures  like conformational analysis, with the aim of avoiding any 
unfavorable interaction in the system. 
Figure 1.2: Energy minimization graph
1.2.4 Conformational analysis
The energy minimization is able to  produce a stable conformation for a 3D 
structure. However, the product obtained could not be the most stable 
conformation. In fact, the energy minimisation stops as soon as  it reaches 
the first stable conformation it finds, closest in structure to the starting 
one. This may represent a local energy minimum, far away from the most 
stable conformation. Even if the bioactive conformation of a drug molecule 
is not necessarily identical to the lowest-energy conformation, it cannot be 
high in energy. Thus, the identification of low-energy conformations is an 
important task to understand the relationship between the structure and 
the biological activity of a molecule.16 Conformational analysis  is able to 
identify the preferred conformations of a molecule and evaluate their 
influence on its properties. 
Energy'
Varia+on'
ΔE'
Energe+cally'unstable'structure'
Energy'minimun'
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1.3 Computational approaches in drug discovery
Computer-aided techniques are useful tools for new hit identification, as 
already described. In this  section, the techniques that were applied in the 
project will be discussed. Computer-aided methods can be classified in two 
main categories: structure-based drug design (SBDD) and ligand-based drug 
design (LBDD). Structure-based approaches  depend on the availability of 
information on the target protein, and are used to predict interaction 
energies of screened compounds with the given binding pocket. Ligand-
based methods  focus instead on the chemical structure of known active 
molecules  through chemical or shape similarity searches, or quantitative 
structure-activity relationship (QSAR) analyses. Depending on the 
information available on the specific drug targets or known active 
compounds, the most suitable computational method can be applied. 
1.3.1 Homology Modelling
In a drug design project, the best ideal condition is to  have X-ray 
crystallographic data of the protein structure to study. In this case, a 
structure-based drug design approach (SBDD) can be applied.17 Additional 
information about the conformational changes  of the protein can be 
derived if structures of the protein with and without a ligand are available. 
Unfortunately, proteins  are known to be difficult to crystallize. In addition 
to this, crystal structures, in some cases, might not be entirely exact. When 
3D structures or 2D NMR models are not available, homology modelling is 
the best way of predicting the actual three-dimensional structure of a 
protein. This tool is  used to build this  putative structure for an unknown 
protein using its amino acid sequence and a comparative three-dimensional 
crystal structure.18 An alignment is required between the two amino acid 
sequences of the target protein and the template (carrying the 3D 
information). This  strategy is based on the assumption that in two 
homologous proteins  the most relevant structural and functional sites tend 
to remain conserved and that the tertiary structure of a protein is more 
conserved than the amino acid sequence.19,20  Therefore, two proteins  that 
diverge from the primary sequence can have some similarity in terms  of 
structural properties, such as the overall fold.
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1.3.2 Ligand-based drug design
When the protein target is  unknown, designing an innovative compound 
can become a difficult task. In this case, the approach to  use is called 
ligand-based drug design (LBDD): it enables to study a collection of active 
compounds, in order to understand their structural and physico-chemical 
properties that are in correlation with their pharmacological activity. 
Several studies have shown that the molecular shape is  an important 
indicator for protein-ligand recognition.21  The majority of docking 
programs generates a number of poses for a ligand within the active site 
and gives a score to the docked conformation according to its  binding 
energy with the target. On the other hand, shape comparison, for which 
more accurate results  have been demonstrated rather than docking 
algorithms, focuses on the occupational volume associated with each 
molecule.22  In ligand docking, the binding site area is the centre of 
attention, while shape-based similarity methods  dismiss the protein and 
focus only on the conformation of the ligand.
1.3.3 Pharmacophore models
The basic idea of pharmacophore models is to identify the common 
structural features  that are necessary for binding a certain target or are 
essential for biological activity (e.g. disposition of hydrogen bond acceptors 
or donors, hydrophobic and ionic  groups). A pharmacophore is  a 
representation of points in 3D space surrounded by a spherical region: a 
molecule must place these relevant features within restricted spatial 
portions. One of the advantages of building a pharmacophore is  that it can 
be generated also  when no  information about the binding site is available. 
A better result would be obtained if the active conformation of the ligand 
is known and a good combination of pharmacophoric  groups is  found.  If 
the pharmacophore is generated starting from the geometry of the binding 
site, it is important that it contains features able to  mimic the presence of 
the receptor: these are represented by exclusion volumes that indicate 
those regions within the pharmacophore where the ligand should not place 
any of its parts (fig.13).32
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Figure1.3: Example of pharmacophore model. Coloured spheres are the 
pharmacophoric features. Grey spheres represent the exclusion volumes
1.3.4 Structure-based drug design
Structure-based drug design is  the preferred method in a the drug design 
process because it can give a prediction of how a drug works, thus allowing 
to improve activity, pharmacokinetics  and other properties concerning the 
molecule. In silico virtual screening using docking techniques enables to 
screen electronic libraries  of known chemical structures to find those that 
might fit the active site. A pharmacophore search, at this step, may be 
useful because it has  the advantage of not requiring a particular backbone. 
It only needs molecule annotations  related to ligand-receptor binding, like 
H-bond donor, H-bond acceptor, etc. A second strategy that can be carried 
out is to  design new structures rather than screen libraries. This approach 
is named de novo drug design and it also depends on the available 
information of the targeted protein binding site.
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1.3.5 Docking and Scoring
Docking techniques are commonly used in hit identification and lead 
optimisation with the scope to  predict the potential binding mode of a 
ligand in the target site of a protein as well as estimate the strength of the 
interactions between the ligand and the protein. Thanks to  the increasing 
improvements in techniques  for structure determination, the number of 3D 
structures  is  increasing over the years and, as a consequence, structure-
based approach in drug design has become very common.23 Two steps are 
typically involved in all docking programs, the first of which is  the 
generation of many ligand conformations in the active site and the second 
one is the evaluation of the protein-ligand affinity, a process  known as 
scoring.24 It is very challenging to satisfy all these tasks: in fact, even the 
simplest organic molecules  can have many conformational degrees of 
freedom originating from the presence of rotatable bonds, flexibility of 
ring structures in the ligand molecule, as well as  the flexibility of the 
protein structure.25  There are several algorithms that can be used to 
generate ligand conformations, while the receptor is assumed to be rigid. 
In order to consider also the receptor conformational space, the most 
common analysis is  to perform a molecular dynamics simulation of the 
ligand-receptor complex. However, these calculations are computer 
demanding and can be useful only to refine structures produced by 
docking methods  as they are not able to explore all the possible binding 
modes, except for small flexible ligands. Docking algorithms predict 
several poses for a ligand within the binding site, but it is  crucial to 
evaluate and rank the results in order to identify the most interesting ones. 
Scoring functions  are mathematical methods used to find the docked 
orientation that represents  the most probable structure. Many scoring 
functions evaluate the binding free energy between a protein and a ligand 
by considering various elements:
ΔGbind= ΔGsolvent +ΔGconf +ΔGint + ΔGmotion
ΔGsolvent is the contribution due to solvent effects, ΔGconf takes  into  account 
the conformational changes in the ligand and the receptor, ΔGint is  the free 
energy variation related to specific protein-ligand interactions and, finally, 
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ΔGrot takes into account the motions (rotational, translational and 
vibrational) during the formation of the ligand-receptor complex. One limit 
of scoring functions is that they result from ligands  that are bound very 
tightly to their receptors, while docking usually identifies  ligands of a 
moderate potency. For this  reason, it is  more appropriate to  combine the 
results of different scoring functions such that a molecule is scored by 
different scoring functions rather than use only a single one. This 
procedure is called Consensus Scoring (CS) and compensates the possible 
errors or lacks of each scoring function.26,27
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1.4 Aims of the study
In the 21st century, there are still viruses that have a dramatic socio-
economical impact worldwide and for which no efficient antiviral therapy 
has been approved so far. This project aims to apply different molecular 
modelling techniques to design and synthesise small molecules  against 
four RNA viruses. In particular, some of the non-structural proteins 
required for viral replication of Coxsackie virus B3, Foot-and-Mouth 
Disease and Chikungunya viruses, all positive-strand RNA viruses will be 
targeted by structure-based or ligand-based virtual screenings  for the 
identification and synthesis  of potential inhibitors of viral replication. 
Molecular modelling studies, such as de novo drug design, will be 
performed  for the synthesis of small-molecule compounds  against 
Respiratory Syncytial Virus, a negative-strand RNA virus. All of the 
molecules  synthesized will be evaluated for their antiviral activity and 
cytotoxicity in cell-based assays  and the biological results will be used to 
direct further investigations.
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Coxsackie Virus B3
Chapter 2
Introduction to the virus
2.1 Coxsackie Virus B3
Coxsackie Virus B3 (CVB3) is  a subgroup of the Coxsackievirus, a member 
of the Enterovirus genus, of the family Picornaviridae, which is  responsible 
for viral myocarditis that mostly affects  children.1  Although most of the 
time infections caused by this virus are characterized by mild symptoms, 
e.g. gastrointestinal distress, fever, headache, sore throat, CVB3 is  also 
associated to pancreatitis, meningitis  and encephalitis.2 The greatest risk is 
in the case of congenital infection,3 when the illness develops in the first 
days of life and is often associated with high mortality due to the 
involvement of several organs (liver, heart, brain and lungs). In some cases, 
the myocardial inflammation may persist producing a chronic state that 
can progress to dilated cardiomyopathy (DCM), which involves the 
enlargement of the heart muscle. The incidence of infections, which is 
seasonal between June and October, is  more frequent in males than 
females. Epidemiological studies of the Centers for Disease Control and 
Prevention accounted for approximately 5.9 % of neonatal enterovirus 
infections related to CVB3 from 1983 to 2003 in USA only. Outbreaks  of 
aseptic meningitis caused by CVB3 have also  been reported between 2001 
and 2008 in Taiwan,4 Argentine,5 Korea,6 France7 and in a region of China.8 
CVB3 can be transmitted by four modes: fecal-oral, vertical (maternal-fetal) 
respiratory and inoculation; the first one is, by far, the major mode of 
transmission. The lack of adequate hygienic condition in developing 
countries contribute to this mode of transmission. After the virus  entries 
via oral cavity and/or respiratory tract, it invades and replicates in pharynx 
and in the lower gastrointestinal tract, especially in the lymphoid tissue 
(e.g. tonsils). Then, it enters the bloodstream, resulting in a ‘minor 
viraemia’ and spreads to a vast number of target organs, like heart, liver, 
pancreas, skin, leading to the typical signs and symptoms.9  A ‘major 
viraemia’ occurs during this infection, involving the central nervous system 
(CNS).
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2.1.1 Virion Structure
The crystal structure of CVB3 virion has been resolved at 3.5 Å 
resolution.10  Figure 2.1 shows a general model of virion structure for 
Picornaviruses. The virion particles  are spherical, with a diameter of 30 nm 
and do not have a lipid envelope. They are surrounded by a shell called 
capsid formed by four structural proteins, VP1, VP2, VP3 and VP4. VP4 is  in 
the inner surface and anchors the capsid to the RNA genome, while VP1, 
VP2 and VP3 are on the outer surface where there is a deep depression, 
called canyon, which corresponds to the receptor-binding site.
Figure 2.1: Picornavirus virion structure
2.1.2 Genome organization
Virion particles contain a single, positive strand RNA from 7 to 8.5 kb in 
length, with similar organization across  the Picornavirus family (Figure 
2.2). 
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Capsid Non-structural proteins
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Figure 2.2: Picornavirus genome organization
The genome is divided in three regions: a 5’-untranslated region (5’-UTR), a 
central open reading frame (ORF) encoding a single  large polyprotein and a 
3’-untranslated region (3’-UTR) which contains  a poly-adenine tail. 5’-UTR 
contains the internal ribosome entry sites (IRES), an element responsible 
for the translation of the mRNA. A small protein called VPg (Virion Protein 
genome linked) is covalently attached at the 5’ end and takes part in the 
VP2 
VP3 
VP4 
VP1 
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RNA initiation replication. The coding region of the viral genome contains 
the precursors of structural and non-structural proteins (P1, P2, P3). The P1 
portion comprises the structural proteins of the capsid (VP1-VP4), while P2 
and P3 regions encode non-structural proteins.
2.1.3 Viral proteins 
Viral particles are classified as structural and non structural proteins, the 
former being part of the viral particle, while  the second ones do not form 
the virion structure but take part in several processes  of viral replication. 
Non-structural proteins are are produced by the translation of a single 
open reading frame (ORF) that is followed by cleavage of the polyprotein 
through proteinases encoded in the viral genome. Most of the members of 
Picornavirus family encode for 2A and 3C proteinases. The 2A protease has 
been associated with multiple roles. First of all, its  proteolytic  function at 
the junction between the P1 and P2 domains. Secondly, it cleaves  the 
eukaryotic initiation factor polypeptide eIF4F which is required for the 
attachment of mRNAs to the ribosome.11 Cleavage of this factor impairs 
this process, leading to the so-called ‘host cells shut off’ which means that 
the synthesis of host cell proteins  is blocked. Finally, 2A may directly be 
involved in the pathogenesis of viral-induced dilated cardiomyopathy in 
coxsackievirus B3 through its  ability to  cleave dystrophin and 
glycoproteins associated to this protein.12  2B protein is  a small, 
hydrophobic  membrane-associated protein that is  localized at endoplasmic 
reticulum (ER) and Golgi membranes. The precise role  is yet poorly 
understood, but several studies  have demonstrated that it is responsible 
for disassembly of Golgi complex, causing the release of virus from 
cells.13,14  2C protein is one of the most conserved proteins in the 
Picornaviridae family with multiple roles  in viral replication.15  It has a 
nucleoside triphosphatase (NTPase) activity, it is  also involved in the 
formation of membrane vesicles and it may direct the formation of the 
replication complex.12 P3 region encodes for 3A, 3B (also  called VPg), 3C 
protease and 3D polymerase. The 3A is a small protein that forms 
homodimers. It has  an hydrophobic region that is  important for its binding 
to membranes. This protein is  able  to  alter the structures of host-cell 
membranes16 and to  inhibit the protein transport from the endoplasmic 
reticulum to the Golgi complex, a phenomenon that is thought to have a 
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link with the suppression of the immune response.17  3C is a 
chemotrypsine-like serine protease that cleaves between 2C and 3A 
proteins and also the P1 and P2 precursors.12 The non-structural protein 
3D is  a viral RNA-dependent RNA polymerase (RdRP) that catalyses both 
negative and positive-strand RNA synthesis. It takes part also in the VPg 
uridylylation, which is the first step in the RNA replication.18
2.1.4 Viral life cycle
The replication of picornaviruses  consists  of several steps that entirely 
takes place in the cell cytoplasm (Figure 2.3).
Figure 2.3: Picornavirus life cycle
The first step in the infection of target cells is the attachment to  the host 
cell membrane through host receptors.12 CVB3 viruses attach the cells 
through binding to  the canyon.10 Once the virus particle has  attached to its 
cellular receptor, the viral RNA is  released into the cytoplasm, which is the 
site of the genome replication. Since the RNA is positive sense it can be 
used as mRNA and can be translated into a single polyprotein, which is 
subsequently cleaved to produce viral proteins by encoded proteases 2A 
and 3C. Negative strand RNA is synthesized using the parental positive-
strand RNA as a template. The resulting minus  RNA is  subsequently used 
in order to  produce new  positive-strand RNAs via multi-stranded 
replicative intermediate structures. When sufficient genome is made, virion 
assembly occurs: a single molecule of new  viral RNA is  inserted in the so-
called procapsid, which is  a preformed, empty capsid. The new virus 
particle can finally be released through cell lysis.12
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2.1.5 Current treatment
There is no approved antiviral therapy for the treatment of CVB3 
infections, nor an efficient vaccine is at hand. Only supportive treatment is 
used. Patients with dilated cardiomyopathy are treated with agents 
commonly used for heart failure as  their symptoms are similar.19  In the 
case of viral meningitis, patients  recover in the majority of cases  within 7 
to 10 days. Sometimes, a hospital stay could be necessary, especially for 
people with a weak immune system.
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2.2 3A protein and 3D polymerase as antiviral targets
In this project, two proteins were taken into account for computer-aided 
studies. The first one is the 3A protein that has been explored to a less 
extent as antiviral target. The second one is the 3D polymerase, which is 
typically considered as a good target for the identification of potential 
antivirals, as demonstrated by several examples among viral RdRPs.
2.2.1 3A protein
3A protein is a homodimer involved in the formation of the replication 
complex on the surface of membranous vesicles in infected cells, along 
with other non-structural proteins. So far, the 3A protein has not been 
taken into account as  a target for drug design. There is no  crystal structure 
available for CVB3 3A protein, only a soluble N domain (1-59 aa) of the 
protein has been determined by NMR spectroscopy for Poliovirus  (PV), 
member of the Enterovirus genus ( figure 2.4).20 
Figure 2.4: NMR solution structure of PV 3A protein
3A protein, as formerly said, is  responsible for the inhibition of protein 
transport from the ER to  the Golgi complex, a process that might have 
some relevance in viral evasion from the host immune response. 
Mutational studies in the 3A region of the 3AB precursor have indicated a 
loss of virus  replication and resistance to  enviroxime, a known inhibitor of 
viral replication. This  information supported the idea that 3A has  a role in 
the replication complex that is still not completely understood.25 Based on 
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these information, CVB3 3A protein was chosen as a target for the 
identification of potential antivirals. An homology model of this protein for 
CVB3 3A was built in 2006,21  using as a template the NMR resolution 
structure of PV 3A. With a similar sequence identity to PV 3A, the model 
has 60 aa and is membrane-associated via the C-terminal hydrophobic 
domain. In addition, CVB3 3A protein was predicted to form a homodimer, 
with the two helical monomers  connected each other via a hydrophobic 
interface. In vitro mutational analysis showed the ability of the protein to 
dimerize and, like PV 3A, the dimerization of the 3A protein was 
demonstrated to  be important for protein function. In the same study,21 
the amino acids involved in the dimerization process  were determined: 
when mutating the amino acids that were predicted to  form the 
hydrophobic  interactions between the two monomers, dimerization was 
lost and the replication process was reduced. Two main regions seem to  be 
essential for the homodimerization: the hydrophobic interface between the 
helical regions of the two monomers, formed by residues Ile22, Leu25, 
Leu26, Val29 and Val34 and an intermolecular salt bridge between Asp24 
of one monomer and Lys41 of the other one.26
2.2.2 RNA-dependent RNA Polymerase
The RNA-dependent RNA polymerase (RdRP), also named 3Dpol, is a multi-
functional protein, responsible for chain elongation during the RNA 
synthesis, RNA binding and nucleotidyl transfer. In addition, it participates 
in the uridylylation process of VPg, which is  the first step in the genome 
replication. The PV 3Dpol was  the first complete crystal structure 
determined and has a similar structure observed in other nucleic acid 
polymerases. To date, several crystal structures of RdRPs from the 
Picornavirus family are available. Despite the little sequence identity 
shared, they adopt a similar fold that resembles  a cupped right hand with 
‘fingers’, ‘palm’ and ‘thumb’ domains (figure 2.5). The ‘palm’ domain is 
composed of 5 sub-domains (A-E), four of which (A-D) are highly conserved 
among polymerases and fold into a structure that generates the core of 
this domain. This core is  composed of two α-helices that pack under a 
four-stranded antiparallel β-sheet. Motif C  of ‘palm’ domain has a relevant 
importance: it contains the ‘GDD’ motif active site (Gly-Asp-Asp) found in 
all RdRPs. The ‘thumb’ domain is the most different feature among the 
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RdRPs and is mainly composed of C-terminal amino acid residues. The 
‘fingers’ domain is  composed of four separate sub-domains, ‘index’, 
‘middle’, ‘ring’ and ‘pinky’ fingers. ‘Fingers’ and ‘thumb’ domains, 
interconnecting each other, generate the so-called ‘closed-hand 
conformation’ of the protein and completely encircle the active site of the 
enzyme.22 
INDEX PINKY A D E THUMB
1 69 96 150 180 191 269 286
B
G
D
D
381 461 aa
palm domain
RING
MIDDLE
C
Figure 2.5: Top view of the 3D structure of Picornavirus polymerase and 3Dpol 
sequence differently colored according to the structural elements. Ribbon of the 
RNA is represented in green
These interactions also create a small tunnel, positively charged, where the 
template-primer RNA binds.23 The crystal structure of the FMDV 3Dpol in 
complex with the template-primer RNA has confirmed the function of this 
channel which is also used by a new incoming nucleotide; for this  reason, it 
is also called NTP entry tunnel.24 It is believed that all the five motifs  of 
‘palm’ domain are involved in several steps of the replication process: for 
example, motifs  A and B participate in the nucleotide recognition and 
binding, motifs A and C in the phosphoryl transfer, motif D in structural 
integrity of the ‘palm’ domain and finally motif E in priming nucleotide 
binding.23
Chapter 2 - Coxsackie Virus B3
24
A new binding site into the polymerase 
A small molecule that inhibits RNA replication by targeting the 3D 
polymerase in a region near the active binding site was recently discovered 
(unpublished data kindly received from our collaborator at Utrecht 
University, Dr. Frank van Kuppeveld). This compound, named GPC-N114, 
has been found active against a broad spectrum of Enteroviruses and 
Encephalomyocarditis virus (EMCV), a member of Cardiovirus genus, of the 
family Picornaviridae. The activity of the compound extends from 0.1µM to 
1.7µM. No inhibitory effect was detected, by contrast, against two 
Aphthoviruses, FMDV and equine rhinitis A virus (ERAV), also  belonging to 
the Picornavirus family. According to biochemical studies, the elongation 
activity was inhibited by this compound, which was crysallized with the 
CVB3 3Dpol (figure 2.6).
O
Cl
NO2
NC
O
NO2
CN
Figure 2.6: Chemical structure of GPC-N114 and crystal structure of CVB3 3Dpol-
GPC-N114 complex
The binding region is located at the bottom of the RNA template site, 
according to the X-ray crystallographic analysis, where the compound 
seems to mimic the position of the template acceptor nucleotide. In the 
crystal structure, the inhibitor makes  contacts, mainly, with three different 
regions of the polymerase: the template entry channel, regarding residues 
Leu110, Thr114 and Lys127, an hydrophobic area where this molecule 
strongly interacts with His199 and makes stacking interactions between its 
central ring and Tyr195. Additional interactions with residues Gly290, 
Cys291, Ser292, Gly293, Thr294, Ile296 have also been individuated. The 
resolved crystal structure of the FMDV 3Dpol with GPC-N114 (figure 2.7) 
has also  explained why the virus in not sensitive to  the inhibitor. Despite 
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the fact that GPC-N114 binds FMDV 3Dpol in a relatively similar pocket 
found for CVB3, the conformation assumed and the binding mode are 
completely different. It is, therefore, likely that the very few  contacts of 
GPC-N114 with the polymerase have an influence on the polymerase 
activity. 
Figure 2.7: Crystal structure of FMDV-GPC-N114 complex
A close up of the two different conformations of GPC-N114 found in the 
resolved crystal structures of CVB3 and FMDV polymerases is represented 
in figure 2.8.
Figure 2.8: Representation of GPC-N114 in two conformations. The jellow one is the 
ligand conformation in the CVB3 3Dpol, the orange one is the one observed in the 
FMDV 3Dpol. The predicted position of the RNA template was determined using the 
FMDV 3Dpol-RNA complex (PDB ID: 1WNE) as a guide
Chapter 2 - Coxsackie Virus B3
26
Results and discussion
2.3 Structure based Virtual Screening on 3A protein
The non-structural protein 3A of CVB3 was investigated and a structure-
based virtual screening approach (SBVS) was applied. So  far, no antiviral 
compound is  known to prevent protein dimerization.25 Having information 
on the essential residues that are responsible  for the 3A protein function, 
the scope of this study was to identify molecules that could bind on the 
interface of the protein, thus competing with the protein-protein 
interaction.
2.3.1 Homology model
Since no crystal structure of the CVB3 3A protein is available, an homology 
model was constructed using the solution structure of PV 3A protein 
soluble domain (PDB ID: 1NG7).26 Figure 2.9 shows the sequence alignment 
between the model generated and PV 3A protein used as a template: the 
structures  share 47%  sequence identity and a common fold, with an RMSD 
value of 1.822 Å observed when they were superposed. Moreover, the 
RMSD value at the level of the dimeric  interface is  significantly lower (0.56 
Å), confirming the accuracy of the model.
Figure 2.9: Sequence alignment of PV 3A protein (PDB ID: 1NG7) and the model 
generated. Identity between amino acid sequences are shown with an asterisks. 
Conservative substitutions are represented by a colon and semiconservative 
substitutions are indicated by a period
2.3.2 Pharmacophore models
The model generated, like the template, has two monomers; each one 
consists  of two α-helices (amino acids 20-27 and 31-42) connected by a 
loop. The two helical hairpins  have a hydrophobic  interface with residues 
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Ile22, Leu25, Leu26, Val29, Val34 which are fundamental for the 
intermolecular interactions responsible for the homodimerization. Similarly 
to the PV 3A protein,26 four amino acids  are in the right position to 
contribute to the dimerization: Asp24 and Lys41 are supposed to form an 
intermolecular salt bridge, together with Ser28 and Tyr37, which could 
interact by an intermolecular hydrogen bond. Since these residues are 
essential for the dimerization process, they were taken into  account for the 
generation of two pharmacophoric models. In figure 2.10, an alignment of 
the 3A structures  of PV and CVB3 is  reported, with a close up of the dimer 
interface.
Figure 2.10: PV 3A structure aligned (purple and blue ribbon) with the model 
created (green and orange ribbon). A close up of the dimer interface is represented 
below
The Specs database27 is  a public library of around 450,000 commercially 
available compounds that was used in this search. These structures were 
downloaded and analysed with MOE 2010.10 conformational search tool, 
setting 500 low-energy conformations to be for each input molecule.28 For 
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each chain, a pharmacophore model was  built, with all the necessary 
features  in correspondence to the key residues important for the 
dimerisation. For chain 1, an anionic group (F1:Ani), adjacent to Lys41 was 
kept as  essential for the pharmacophoric search; a donor group (F2:Don) 
was added to interact with Glu40, along with three hydrophobic features 
(F3:Hyd, F4:HydA and F5:Hyd) in close proximity to the aromatic rings of 
Tyr37 and Trp42, but also in correspondence to Leu25 of chain 2, which is 
known to take part in the hydrophobic packing essential for the 
homodimerization. An additional hydrophobic interaction (F5:Hyd) was 
added and set as  essential since it is in a cleft where ligands could be 
anchored. Finally, a donor group (F6: Don) was introduced to  create a 
possible repulsive interaction with the carbonyl group of Leu25, in the 
opposite monomer (figure 2.11). Exclusion volumes corresponding to the 
protein surface were added to the pharmacophoric model, with the scope 
to prevent that any compound could fit to this region of exclusion. The 
pharmacophoric search, which is able to pre-filter a large molecular 
database, was run requiring a partial match of at least 2 features. 6760 
molecules  were found to respond to the chosen criteria and were used for 
the following docking step.
Figure 2.11: Pharmacophoric model of chain 1. Backbone of chain 2 is represented 
as blue ribbon
In a similar way, a second pharmacophore was created using the chain 2 of 
the dimeric protein. The target site is  represented by several residues: 
Asp24, a key residue for the formation of a salt bridge essential for protein 
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dimerization, Ile22, Leu25 and 26, Val29 and Val34 predicted to be part of 
the hydrophobic packing. Finally, Ser28 which forms an intermolecular 
hydrogen bond with Tyr37 of chain 2 in the PV 3A structure. The 
pharmacophore model was  made by four features: a donor group (F1:Don), 
in correspondence to the carbonyl group of Val34, a cationic group 
(F2:Cat), which is one of the essential features set in proximity of Asp24, 
and, finally, two hydrophobic features (F3:Hyd and F4:Hyd) to  interact with 
amino acids Ile22, Leu25, Leu26, Val29 and Val34 (figure 2.12). At least two 
partial matches  were enabled in the pharmacophoric search panel, with 
two features (F2 and F4) kept as essential. 4157 entries  were found and 
used for docking calculations.
Figure 2.12: Pharmacophoric model of chain 2. Backbone of chain 1 is represented 
as purple ribbon
2.3.3 Molecular docking and consensus scoring
Those molecules matching the search criteria in both pharmacophores 
were analysed within the putative binding site of the homologous model 
with Glide docking under the Standard Precision (SP) screening mode.29 
This  docking program generates a series of docked poses, which 
correspond to the minimum energy conformations, and calculates for them 
the predicted binding free energies. The conformational database produced 
by docking was successively evaluated with the scoring functions 
implemented in two programs: Plants30 and FlexX.31 Using only one scoring 
function is not recommended, since every scoring function gives different 
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relevance to diverse aspects that may be irrelevant to evaluate the binding 
potential of a compound.32,33  A good strategy is to use multiple  scoring 
functions and to combine all the results  obtained through a consensus 
scoring, aiming to give the same relevance to the three scoring algorithms 
(section 1.3.5). Those structures belonging to  the best 25 % according to all 
the functions applied to elaborate the consensus scoring were subjected to 
a more precise docking analysis using Glide under an Extra Precision (XP) 
screening mode. All the poses  identified were subsequently minimized in 
order to avoid potential steric clashes within the protein. To  make a 
selection of the best molecules  coming from the extra precision docking, 
cluster of different groups were defined according to the diversity of their 
chemical structure. For each cluster, only the conformation with the 
highest score was retained. A visual inspection of the best poses  allowed to 
select 20 compounds  (see Appendix I) that were purchased and tested in in 
vitro assays. One compound (1, figure 2.13) was found to inhibit RNA 
replication of CVB3 in Vero cells (subtype A) with EC50 value of 129 µM. 
From a molecular modelling point of view, this  relatively high value can be 
still taken into account, therefore it represented a starting point for a 
structure-activity relationship (SAR) evaluation.
2.4 Design and synthesis of tetrazole derivatives
2.4.1 (Benzylthio)-1-aryl 1H-tetrazoles (1, 21-23, 25-31)
A small series of tetrazole derivatives was  prepared in order to confirm 
and improve the activity of the hit compound. The structure of the hit 
compound 1 is characterized by a central tetrazole moiety that is linked to 
a benzylthio ring in position 5 and has  a benzoic acid in position 1 of the 
tetrazole (figure 2.13). Different aromatic substitutions were introduced to 
explore their effect on the activity of the molecule. In addition, the original 
compound was prepared in order to confirm the first activity results.
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Figure 2.13: Chemical structure of compound 1 and its predicted binding mode
Scheme 2.1 shows the synthetic pathway used to prepare analogues 20-25, 
while in scheme 2.2 is reported the procedure followed for the synthesis of 
the original hit compound 1, its ester derivative 30 and the synthesis of 
compounds 29, 31. 
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O
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RNH2
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N
HS
R
N
N
N
N
S
R'
, EtOAc, over 30', 0oC R
N
C
S
EtOAc, 12h, r.t.
NaN3
H2O, 100 oC, 16h
, K2CO3 DMF, 80 oC
    4.5 h
20-25
R1
Br
Cl
S
Cl
2-6 7-11
12-16
17-19
2,7,12: R= COOEt
3,8,14: R= NO2
4,9,14: R= Me
5,10,15: R= OMe
6,11,16: R= OH
17: R1= H
18: R1= Me
19: R1= Cl
Intermediates
Products
20: R= COOEt, R1= H
21: R= NO2, R1= H
22: R= Me, R1= H
23: R= OMe, R1= H
24: R= COOEt, R1= Me
25: R= COOEt, R1= Cl
Scheme 2.1: Synthetic pathway for compounds 20-25
Isothiocyanate intermediates 7-11 (Scheme 2.3) were synthesized through 
the reaction between a primary aromatic amine and thiophosgene. By 
treating them with a solution of sodium azide in water, tetrazole-5-thiones 
12-16 (Scheme 2.5) were obtained. Compounds 20-25 (Scheme 2.5) were 
prepared through a nucleophilic  substitution by the thiol group on the aryl 
bromide leaving group. Ethyl 4-(5-(benzylthio)4,5-dihydro-1H-tetrazol-1-
yl)benzoate 20 was used for the synthesis of hit compound 1 through 
hydrolysis of the ester moiety with a solution of lithium hydroxide 
monohydrate. The same reaction was applied for the synthesis  of acid 
derivatives 28, 29 (Scheme 2.9) by conversion of, respectively, 
intermediates 24, 25.
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Since it was not possible to obtain the pure ester compounds 24, 25, they 
were re-synthesised by a Fisher esterification of the correspondent acids 1, 
28 (scheme 2.2). 
LiOH, H2O
THF, 24h, r.t.
EtOOC
N
N
N
N
S
R
20, 24, 25
HOOC
N
N
N
N
S
R
1, 28, 29
EtOOC
N
N
N
N
S
R
30, 31
EtOH, H2SO4
reflux, o.n.
20, 1: R= H
24, 28, 30: R= Me
25, 29, 31: R= Cl
Scheme 2.2: Synthetic pathway for compounds 1, 29, 30, 31
Synthesis of aryl isothiocyanates (7-11)
Aryl isothiocyanates were prepared by acylation of amines with 
thiophosgene in the presence of a base, according to  the reported 
procedure.34 
Aryl amine R Product Yield %
2 COOEt 7 99
3 NO2 8 90
4 Me 9 91
5 OMe 10 98
Scheme 2.3: Synthesis of compounds 7-10
A different strategy was applied for the synthesis of the intermediate 11, 4-
hydroxyl isothiocyanate, because the product was obtained in low yield 
using the reaction conditions above described. According to a different 
reported procedure,35 p-aminophenol 6 was  treated with thiophosgene and 
1M HCl solution, the latter one being responsible for the protonation of the 
R
NH2
, EtOAc, over 30', 0oC R
N
C
S
EtOAc, 12h, r.t.
Cl
S
Cl
2-5 7-10
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hydroxyl group, thus preventing any undesired reaction with thiophosgene. 
The modified conditions were helpful for the acylation of the amine group 
only  the yield of the reaction (scheme 2.4). 
Scheme 2.4: Synthesis of compound 11
Synthesis of 1-aryl-1H-tetrazole-5(4H)-thiones (12-16)
1-Aryl-1H-tetrazole-5(4H)-thiones 12-16 were obtained by treating the 
isothiocyanate intermediates 7-11 with sodium azide in water at 100 oC. 
The reaction was  quenched with 1M HCl solution to  obtain tetrazole 
derivatives 12-16 (scheme 2.5).36
Aryl isothiocyanate R Product Yield %
7 COOEt 12 40
8 NO2 13 38
9 Me 14 58
10 OMe 15 70
11 OH 16 78
    Scheme 2.5: Synthesis of compounds 12-16
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The postulated mechanism for the formation of the tetrazole ring can be 
described as  a nucleophilic attack of the azide ion on the carbon atom of 
the isothiocyano group, followed by electrocyclization. 
R
N C S R
N N
N
N
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N
N
N
N
R
S
N
N
N
N
R
S
H Cl
N
N
NH
N
R
S
Na N3
N
N
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N
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Scheme 2.6: Postulated mechanism for the tetrazole formation
Synthesis of 5-(benzylthio)-1-aryl-1H-tetrazoles (21-23, 25)
Final products 21-23 and 25 were obtained through a nucleophilic 
substitution between the aryl mercapto tetrazole intermediate and aryl 
bromides under basic reaction conditions (scheme 2.7).37  Ethyl 4-(5-((4-
methylbenzyl)thio)-1H-tetrazol-1-yl)benzoate 24 was  not obtained as pure 
product after standard purification techniques, therefore was first 
converted to the acid derivative 28.  By Fisher esterification, compound 28 
was converted to the final ester product 31. 
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N
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R1
20-25
R
N
NH
N
N
S
12-15
DMF, K2CO3
80 oC, 4.5h
R1
Br+
17-19
Aryl mercapto tetrazole 
intermediates
R
Aryl 
bromide
R1 Product Yield %
12 COOEt 17 H 20 83
13 NO2 17 H 21 39
14 Me 17 H 22 57
15 OMe 17 H 23 60
12 COOEt 18 Me 24 48
12 COOEt 19 Cl 25 15
Scheme 2.7: Synthesis of compounds 20-25
The reaction between benzyl bromide and 1-(4-hydroxyphenyl)-1H-
tetrazole-5(4H)-thione 16 gave two products in one-step synthesis, the 
desired compound 26 and the disubstituted derivative 27, as  a product of 
bis nucleophilic substitution on two  positions, the hydroxyl group and the 
thione group. Compounds 26 and 27 were successfully isolated by flash 
column chromatography (scheme 2.8).
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Aryl mercapto tetrazole Product Yield %
16 26 21.5
16 27 28.5
Scheme 2.8: Synthesis of compounds 26, 27
Synthesis of 4-(5-(Arylthio)-1H-tetrazol-1-yl)benzoic acids (1, 28-29)
Hit compound 1 and final products 28,  29 were synthesised by a base-
catalysed hydrolysis reaction of intermediates 20, 24 and 25 (scheme 2.9). 
Ethyl ester groups were hydrolyzed into the free carboxylic acids with 
lithium hydroxide, stirring the reaction mixture at r.t. over night. Final 
products  1,  28,  29 were precipitated after removal of the organic  solvent 
and subsequent acidification of the water residue to pH 5.38
5-(Benzylthio)-1-aryl-1H-tetrazoles R Product Yield %
20 H 1 32
24 Me 28 34
25 Cl 29 33
Scheme 2.9: Synthesis of compounds 1, 28, 29
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Synthesis of ethyl 4-(5-(benzylthio)-1H-tetrazol-1-yl)benzoates (30, 31)
Compounds 30, 31 were synthesised following a Fisher esterification by 
refluxing over night compounds 1, 28 with ethanol and sulfuric  acid. Upon 
reaction completion, NaHCO3 was added to  neutralize the excess of acid 
used (scheme 2.10).39 
Ethyl 4-(5-(benzylthio)-1H-tetrazol-1-
yl)benzoate
R Product Yield %
1 H 30 88
28 Me 31 26
Scheme 2.10: Synthesis of compounds 30, 31
HOOC
N
N
N
N
S
R
1, 28
EtOOC
N
N
N
N
S
R
30, 31
EtOH, H2SO4
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2.4.2 Biological evaluation
All compounds prepared were tested in a cell-based assay at Rega Institute 
for Medical Research in Leuven, under the supervision of Dr. Johan Neyts.
Activity is expressed for each compound in terms of EC50, that is  the 
effective concentration (µM) of compound required to reduce viral 
replication by 50%, and EC90, that is the effective concentration (µM) of 
compound required to reduce CVB3 replication by 90%. Cytotoxicity is 
evaluated in terms of CC50, that is the cytostatic/cytotoxic concentration 
(µM) required to observe 50% of adverse effect on the host cell. The 
selectivity index, SI, is evaluated by calculating the ratio CC50/EC50.
Compound R1 R EC50 (µM) EC90 (µM) CC50 (µM)
1 COOH H 130 130 -
21 NO2 H >239 >239 -
22 Me H >266 >266 -
23 OMe H >251.6 >251.6 -
25 COOEt Cl >33.4 >33.4 -
26 OH H >264 >264 -
27 OCH2Ph H >66.8 >66.8 -
28 COOH Me >306 >306 -
29 COOH Cl >216 >216 -
30 COOEt H >220 >220 -
31 COOEt Me >211 >211 -
Table 2.1: Activity and cytotoxicity data for compounds 1, 21-23, 25-31
The biological evaluation shows  that the activity of the re-synthesised hit 
compound 1 is confirmed. However, the data for new derivatives show a 
loss of antiviral activity associated to the modifications applied.
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R
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2.5 Computer-aided approaches on the 3D polymerase
One of the most common targets for the identification of novel antivirals is 
the RNA-dependent RNA polymerase. Using the available crystal structure 
of the CVB3 polymerase, different computer-aided approaches were 
applied.
2.5.1 Structure-based Virtual Screening 
As already mentioned in section 2.2.2, a small molecule, GPC-N114, was 
recently identified as  a new non-nucleoside inhibitor with a broad 
spectrum of activity against several members  of the Picornavirus family. 
Although the activity data were very promising, this compound 
encountered poor bioavailability issues when tested in animals, therefore 
the aim of this study was  to identify new scaffolds with an improved 
solubility and a similar or better biological activity. The structure of GPC-
N114 was not accessible for our project at the beginning, therefore, using 
the available information on the binding region of GPC-N114, a structure 
based virtual screening was performed. The area within the polymerase is  a 
tight pocket, near the nucleotide entry tunnel. GPC-N114 was found to 
make contacts with Leu110, Thr114 and Lys127. It strongly interacts with 
Arg188, His199 and Tyr195 and it is  close to residues Gly290, Cys291, 
Gly293 and Ile296. 
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Figure 2.14: Crystal structure of the CVB3 3D polymerase and close-up of the 
binding site of GPC-N114
Using the available crystal structure of CVB3 RNA-dependent RNA 
polymerase in complex with a pyrophosphate (PDB ID: 3CDU),40  a 
pharmacophore model of six features was built: a hydrogen bond acceptor, 
(F1:Acc), near Ser115, two hydrogen bond donors, (F2/F3:Don) to interact, 
respectively, with Thr114 and Gly290, a hydrogen bond acceptor (F4:Acc) 
in close vicinity to  Arg188, a hydrophobic  feature to interact with Tyr195 
(F5:Hyd) and finally an additional hydrogen bond acceptor (F6:Acc), near 
Gly293. F5 was kept as essential due to the essential stacking interactions 
for the ligand binding with the aromatic ring of Tyr195 (figure 2.15). 
Exclusion volumes  corresponding to the protein occupational space were 
added before the first pre-filtration of the conformational database of the 
SPECS compounds. Around 3000 molecules matched these criteria.
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Figure 2.15: Pharmacophoric model built on 3CDU
These molecules  were evaluated by a docking procedure using Glide SP 
mode which produced a conformational database of docked poses for each 
molecule. A re-scoring process  was finally performed for all the 
conformations obtained, using FlexX and Plants. By a consensus scoring 
method, described in section 1.3.5, the best 25% results  were selected, 
reducing the number of the molecules to 410. These compounds 
underwent to an extra precision docking (XP) mode. A final visual 
inspection allowed to select 18 compounds that were purchased for 
biological testing (Appendix I). Unfortunately, none of these compounds 
showed antiviral activity on a cell-based assay.
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2.5.2 Model of the GPC-N114 bound to the polymerase
A second approach was carried out when the chemical structure of the 
ligand GPC-N114 was revealed (figure 216).
 Figure 2.16: Chemical structure of GPC-N114
The 3D structure of the co-crystallized ligand in the polymerase was not 
accessible yet, therefore a model of the complex between the polymerase 
and the inhibitor was generated, using the information on the ligand 
interactions that were obtained. The compound is bound in a cavity of the 
polymerase located at the bottom of the template channel, mimicking the 
template acceptor nucleotide. Both hydrophobic and polar interactions are 
responsible for the inhibitor binding. One of the 2-cyano-4-nitrophenyl 
rings  is  involved in van der Waals contacts with side chains of residues 
Leu110 and Asp111; it also  interacts with Arg188 and makes contacts  with 
Gly290, Cys291 and Gly292. One nitro group is hydrogen-bonded to the 
amide group of Asp111 and Thr114, while the central chlorophenyl ring 
makes van der Waals contacts with Leu107, Tyr195, Cys293 and Ile296. 
Furthermore, the chloride atom is  hydrogen-bonded to the side chain of 
His199. The second 2-cyano-4-nitrophenyl ring seems to  occupy the 
position expected for the template acceptor base, with the nitro  group 
hydrogen bonded with Ser295 and Tyr327. This moiety also interacts with 
residues from Gly293 to  Ile296. Finally, the oxygen atom linkers are 
involved in contacts with amino acids  Ser292 and Gly293. The model 
created contains  a RNA chain, the coordinates of which were taken from 
the crystal structure of the FMDV 3Dpol-RNA complex (PDB ID: 1WNE).41 
The scope of this  model is to reproduce the active conformation of the 
inhibitor GPC-N114. After energy minimization of the complex created, in 
silico approaches were applied (figure 2.17).
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Figure 2.17: Model of GPC-N114 in its binding site. The predicted position of the 
RNA template was determined using the FMDV 3Dpol -RNA complex (PDB ID: 
1WNE) as a guide
2.5.3 Design of new GPC-N114 analogues
Aiming to identify new scaffolds active against CVB3 replication, the GPC-
N114 structure was taken into  account for structural modifications  that 
allowed the design and synthesis of six new scaffolds. Figure 2.18 shows 
the positions modified for the preparation of the new derivatives that were 
all analysed with the flexible alignment technique, available in MOE 
2010.10, to compare them with the known inhibitor.42
Figure 2.18: Chemical structure of GPC-N114. 
The applied modifications were also represented: cyano groups were removed, the 
oxygen linker was replaced with a C or a N and the central ring was substituted 
with several new groups
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This application is  able to align two molecules  by maximising steric and 
feature overlap and minimising the internal ligand strain. A score is 
produced for each alignment which is an evaluation of how good the 
alignment is. Different parameters, in particular, can be generated: the 
average internal strain energy, U, the total mutual similarity score, F which, 
for a good alignment, should be a low value and the function S, which 
corresponds to the sum of U and F values. Two molecules are well aligned 
when the S value is low, together with the dU that, ideally, should be lower 
than 1 kcal/mol. Four new  scaffolds were designed with the aim to  explore 
a different central ring and a diverse atom linker between the two aromatic 
moieties. All the structures designed had good scoring when aligned to the 
modelled conformation of the GPC-N114. Figures 2.19 shows the chemical 
structure and alignment of the derivative bearing nitro groups like the 
reference molecule. 
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Figure 2.19: Structure and alignment results of designed compounds 32-35
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The new derivatives  present a good overlapping to the known inhibitor, 
with the central ring and the two nitro  groups  well aligned to  the GPC-N114 
ligand. The good superimposition was also confirmed by energy strain 
values  that were all lower than 1 kcal/mol. Apart from compound 35, for 
which a border line LogP (partition coefficient) value was predicted (5.16), 
all the other compounds showed an acceptable LogP value. A better 
calculated value was reported for compound 34, compared to GPC-N114. 
For each scaffold, two derivatives, the unsubstituted and the one bearing 
two nitro groups, were synthesised. Cyano groups were not kept in the new 
structures, as  they were not related to GPC-N114 activity (data not shown, 
personal communication with Dr. Gherard Purstinger). The reason behind 
the synthesis of the unsubstituted compound was to  confirm the relevance 
of the nitro groups, as already observed being essential features of the 
reference inhibitor.
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2.6 Synthesis of GPC-N114 analogues
2.6.1 2,5-bis-Aryl-1,3,4-oxadiazoles (32, 40)
The first designed chemical scaffold is  characterized by a central 
oxadiazole ring and a carbon linker between the two lateral benzene 
moieties and the central part. 
Figure 2.20: Chemical features of the oxadiazole scaffold
The followed chemical pathway is a condensation between aryl 
acetohydrazides  and aryl acetic acids in the presence of phosphorus 
oxychloride (POCl3). 
Scheme 2.11: Synthetic pathway for compounds 32, 40
R
N N
O
R
C linker
oxadiazole ring
OH
O
R
H
N
O
R
36, 37
+
NH2
R
N N
O
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32, 40
38, 39
POCl3
reflux, o.n.
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Synthesis of 4-(nitrophenyl)acetohydrazide (36)                                    
Starting materials were not commercially available and were, therefore, 
prepared. For the synthesis  of final product bis-(4-nitrophenyl)-1,3,4-
oxadiazole 32, the available 4-nitro  phenyl acetic acid 38 was first 
converted to the correspondent ethyl ester by a Fisher esterification using 
EtOH and sulfuric  acid. The ester derivative 41 was  then converted to 4- 
(nitrophenyl)acetohydrazide intermediate 36 by nucleophilic addition of 
hydrazine monohydrate (scheme 2.12). 
Scheme 2.12: Synthetic pathway for the synthesis of intermediate 36
Synthesis of 2-phenylacetohydrazide (37) and 2-phenyl acetic acid (39)
In order to  obtain the unsubstituted derivative 40, starting material 2-
phenylacetohydrazide 37 was synthesized by reaction of the commercially 
available ethyl phenyl acetate 42 with hydrazine monohydrate, following 
reported procedure.43  Ethyl phenyl acetate was also used to  prepare 2-
phenyl acetic acid 39 by a base-catalyzed hydrolysis in the presence of 
lithium hydroxide monohydrate (scheme 2.13).
O
O
O
O2N
O2N
H
N
NH2
NH2NH2 . H2O
EtOH, reflux, 24h
H2SO4
EtOH, reflux, o.n.
OH
O
O2N 41, 51.4%
36, 62%
38
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Scheme 2.13: Synthetic pathway for the synthesis of intermediates 37, 39
Synthesis of ethyl 2,5-bis-aryl-1,3,4-oxadiazoles (32, 40)
Following a reported procedure, the desired products were synthesized by 
cyclodehyrogenation of aryl acetohydrazide and aryl acetic acid using 
phosphorus oxychloride (POCl3).44
H
N
O
NH2
R
 reflux, o.n.
R
N N
O
R
OH
O
R
+
POCl3
36, 37 38, 39 32, 40
Aryl acetohydrazide Aryl acetic acid R Product Yield %
36 38 NO2 32 53
37 39 H 40 54
Scheme 2.24: Synthesis of compounds 32, 40
2.6.2 1,3-bis-Aryl-1H-benzo[d]imidazol-2(3H)-ones (33, 46)
A second selected scaffold, according to the flexible alignment analysis, 
was used for the synthesis of two new analogues of the GPC-N114. In this 
case, the central 4-chlorobenzene was replaced with a benzoimidazol-2-one 
and a C-linker was  inserted in place of the original O atom, as already seen 
in the previous family of compounds (figure 2.21). Also in this  case, two 
derivatives were prepared, the unsubstituted and the nitro ones.
H
N
O
O
O
NH2
O
OH
LiOH
THF, r.t., 24h
NH2NH2 . H2O
EtOH, reflux, 24h
39, 88%
37, 62%42
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Fig. 2.21: Structure and features of benzoimidazol-2-one scaffold
The synthetic  strategy applied is  a two-step synthesis  that starts with the 
formation of the central ring, by treating o-phenylendiamine with the 
carbonylating agent carbonyl diimidazole. Final products were obtained 
through nucleophilic displacement of bromide leaving group by the 1H-
benzo[d]imidazol-2(3H)-one intermediate.
Scheme 2.15: Synthetic pathway for the synthesis of compounds 33, 46
Synthesis of 1H-benzo[d]imidazol-2-(3H)-one (43)
In a first attempt to prepare intermediate 43, o-phenylendiamine was 
dissolved in THF and then carbonyl diimidazole was  added to the reaction 
mixture, according to a reported procedure (scheme 2.16).45 After stirring 
at room temperature for 22 h, the reaction mixture was heated at 50oC for 
additional 6 h, due to  the presence of unreacted starting material. From the 
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reaction, a mixture of products  was formed, from which the desired 
product 43 could not be isolated by standard purification techniques.
Scheme2.16: First attempt for the synthesis of compound 43
A second attempt was  made using a different procedure that allowed to 
obtain the desired intermediate (scheme 2.17).46 The title  compound was 
obtained by carrying out the reaction in dimethyl formamide and stirring 
at room temperature for 2 hours. The title  compound was  obtained 
without purification in 50 % yield.
Scheme 2.17: Second attempt for the synthesis of compound 43
Synthesis of 1,3-bis-aryl-1H-benzo[d]imidazol-2(3H)-ones (33, 46)
Final products  33, 46 were obtained with a one-step synthesis  through 
nucleophilic substitution between intermediate benzoimidazol-2-one 43 
and aryl bromides.
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N
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N
O
R
R
43 33, 46
44, 45
Aryl bromide R Product Yield %
44 NO2 33 16
45 H 46 11
Scheme 2.18: Synthesis of final products 33, 46
2.6.3 1-Methyl-3,4-bis-(phenylamino)-1H-pyrrole-2,5-dione (47)
A third modification made on the query molecule, GPC-N114, was  the 
introduction of a maleimide ring. From docking studies, this ring is 
predicted to establish similar interactions observed for the reference 
molecule and an additional hydrogen bond between one carbonyl group 
and Arg 188 (figure 2.22). The oxygen linker was replaced by a nitrogen 
atom. Two derivatives  were planned for the synthesis, as previously seen 
for the other two families of compounds. 
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Figure 2.22: Chemical scaffold of compound 47 and its predicted binding mode
According to the literature, the synthetic pathway consists of a 3-step 
reaction, with the synthesis of the central maleimide ring intermediate that 
reacts by two conjugate addition/elimination reactions  with the aryl aniline 
(scheme 2.19).
N
O
O
N
H
HN
N-methyl maleimide ring
N linker
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Scheme 2.19: Synthetic pathway for compound 47
Synthesis of N-methyl-3,4-dibromomaleimide (49)
The initial method adopted to synthesise maleimide 49 was  to obtain N-
substituted 2,5-dibromopyrrole by a reaction between N-methyl pyrrole 
and two equivalents of N-dibromosuccinimide. The following oxidation of 
the intermediate allowed to obtain the desired product, according to a 
reported procedure (scheme 2.20).47 
N
O
O
Br
Br
N
N
O
O
N
H
Br
N
O
O
N
H
HN
+
NH2
NH2
NH
O
O
Br
Br
THF, r.t., 16 h
HNO3, 0 oC, 10'
(CH3O)2SO2
K2CO3, acetone, 56 oC, 2h
Na2CO3
THF, r.t., 2h; 40 oC, 2h
NBS
Et3N
DMF, r.t., 72h;
100 oC, 24h
48 49
50
47
Chapter 2 - Coxsackie Virus B3
56
Scheme 2.20: Synthesis of intermediate 49
Scheme 2.21 shows the suggested mechanism. According to the literature, 
this reaction is  described as a transposition of both bromides  to the 3,4-
positions, followed by the oxidation with nitric acid at 0 oC.
Scheme 2.21: Mechanism of N-methyl maleimide formation
Due to the low yield of the reaction linked to the difficulty of obtaining the 
only dibrominated product, it was decided to start from the 3,4-
dibromomaleimide 48 to synthesize N-methyl-3,4-dibromomaleimide 49 by 
N-alkylation with dimethyl sulfate (scheme 2.22).48 The reaction went to 
completion after 2 h and the product was obtained without purification 
and with a increased yield (54.4%).
Scheme 2.22: Second procedure for the synthesis of intermediate 49
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2.6.4 1-Methyl-3,4-bis-(4-nitrophenylamino)-1H-pyrrole-2,5-dione (34)
The designed compound 34, bis-(4-nitrophenylamino)-maleimide, was not 
obtained after trying several reaction conditions (scheme 2.23). In a first 
attempt, a solution of N-methyl-3,4-dibromomaleimide 49 in 
dimethylformamide was treated with an excess of 4-nitroaniline, under 
basic  condition with Et3N for 24 h.49 After that time, the starting material 
was still present, therefore the reaction mixture was heated at 90oC for 24 
h. Flash column chromatography was performed to  separate a mixture of 
new species formed, but it was not possible to isolate the desired 
intermediate. A second attempt was made prolonging the reaction time to 
7 total days, stirring the mixture at room temperature and then heating it 
at 80oC for 6 days. The reaction was constantly monitored by TLC. Starting 
materials were still present, together with a mixture of new species. Also  in 
this case, purification by flash column chromatography did not allow to 
isolate the desired product. 
N
O
O
N
H
HN
Et3N, DMF, r.t., 24h; 90 oC, 24h
N
O
O
Br
Br
O2N
NO2
+
NH2
O2N
Et3N, DMF
X
X
49 34
r.t., 7 days; reflux, 6 days
Scheme 2.23: Attempts for the synthesis of bis-(4-nitrophenylamino)-maleimide 34
A probable explanation is the poor reactivity of 4-nitroaniline: the electron 
withdrawing and inductive effects of the nitro  group deactivate the 
aromatic  ring, rendering the amine a poor nucleophile and thus explaining 
the failure of the coupling reaction. However, it was possible to obtain the 
unsubstituted product, 1-methyl-3,4-bis-(4-nitrophenyl)amino)-1H-
pyrrole-2,5-dione 47.
Synthesis of 1-methyl-3,4-bis-(phenylamino)-1H-pyrrole-2,5-dione (47)
The unsubstituted derivative  47 was obtained by two coupling reactions 
with aniline. While milder conditions were followed for the first step of the 
synthesis, the second conjugation reaction required a longer reaction time 
and heating to boost the formation of the designed product.
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Scheme 2.24: Synthetic pathway for the synthesis of compound 47
Synthesis of 3-bromo-1-methyl-4-(phenylamino)-1H-pyrrole-2,5-dione (50)
According to a reported procedure, N-methylmaleimide 49 was  treated 
with an excess of sodium carbonate and aniline (scheme 2.25).9 The 
reaction was stirred for 2 hours at r.t. in THF and heated at 40oC  for 2 h in 
order to  enhance the formation of the probable product. The crude mixture 
was purified by chromatography and the monosubstituted intermediate 50 
was obtained with 53 % yield. 
Scheme 2.25: Synthesis of intermediate 50
Synthesis of 1-methyl-3,4-bis(phenylamino)-1H-pyrrole-2,5-dione (47)
Following a reported procedure, the symmetrical unsubstituted maleimide 
was finally obtained despite the discouraging discussion presented in the 
referred paper.50 It is  suggested, in fact, that the coupling of the second 
amine could be achieved only forcing the reaction conditions and using an 
amine with a more nucleophilic profile. In the monoaminated intermediate, 
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the carbon bearing the Br group has  a reduced electrophilicity, thus 
preventing the addition of a second aniline molecule. Final product 47 was 
obtained using 3 equivalents of both, the aniline and triethylamine (scheme 
2.26). The reaction was stirred at r.t. for 3 days in dimethyl formamide. To 
enhance the formation of the product, the reaction was heated to 100oC for 
additional 24h. The title compound was finally isolated as a pure product 
in low yield (6 %) by flash column chromatography and recrystallization 
purification. 
Scheme 2.26: Synthesis of compound 47
2.6.5 N1-Phenylbenzene-1,2-diamine (52)
Bearing a nitrogen atom in place of the oxygen linker, a series of two 
compounds was designed.
Figure 2.23: Chemical scaffold for compound 52
As in the reference molecule, the central phenyl ring was kept, while the 
cyano groups were not conserved on the new  derivatives. The synthetic 
pathway planned was a variation of Ullmann reaction between aryl 1,2-
diamine and iodobenzene, according to  a reported procedure.51  A first 
attempt was made starting from o-phenylenediamine and iodobenzene to 
get the formation of the unsubstituted derivative 51 (scheme 2.27). 
Formation of the desired disubstituted product was confirmed by NMR 
experiment, but it was not possible to purify it, due to the simultaneous 
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formation of a mixture of products. However, from chromatographic 
purification, the mono substituted compound, N1-phenylbenzene-1,2-
diamine 52, was  obtained as pure product and evaluated for its antiviral 
activity.
NH2
NH2
I
+
K2CO3, CuI, L-Proline
DMSO, 80 oC, 18h
NH
N
H
H
N
NH2
52, 18%
X
51
Scheme 2.27: First attempt for the synthesis of compound 51
2.6.6 N1,N2-Diphenylbenzene-1,2-diamine (51)
Another attempt to obtain the disubstituted derivative was carried out with 
a second procedure, where o-phenylenediamine and iodobenzene were 
stirred in DMF with copper as a catalyst, CuI, Pyr and Et3N (scheme 2.28). 
Only unreacted starting materials were recovered, therefore it was  decided 
not to make further effort to get the desired products, as  it would have 
been even more difficult to obtained the planned nitroderivative 35.
NH2
NH2
I
+
Cu, CuI, Pyr, Et3N
DMF, r.t., o.n.
NH
N
H
X
51
Scheme 2.28: Second attempt for the synthesis of compound 51
Chapter 2 - Coxsackie Virus B3
61
2.6.7 Biological evaluation
Compounds 32-33,  40,  46-47 and 52 were evaluated for their antiviral 
activity and cytotoxicity in a virus-cell-based assay (tables 2.2, 2.3).
Compound X R R1 EC50 (µM) EC90 (µM) CC50 (µM)
32 a CH2 NO2 >300 >300 -
40 a CH2 H >294 >294 -
33 b CH2 NO2 >238 >238 -
46 b CH2 H >30.9 >30.9 -
47 c N H >300 >300 -
Table 2.2: Activity and cytotoxicity data for compounds 32-33, 40, 46-47
The biological evaluation for the new derivatives suggests that there is no 
correlation between the modifications applied and the antiviral activity. It 
is not possible to speculate if the absence of the activity for compounds 
32, 40, bearing a central oxadiazole ring, is  linked to the presence of a 
smaller central moiety. A second series of compounds was  designed by 
introducing a benzoimidazol-2one ring and maintaining the C atom as 
linker between the central and the two lateral aromatic moieties. Also in 
this case, the biological results highlight the absence of antiviral effect 
against CVB3 replication for compounds 33,  46. A third planned scaffold 
was based on the replacement of the oxygen atom with a nitrogen linker 
and on a new  central ring that, according to  the putative docking mode, 
seems to maintain the essential interaction with residues of the binding 
site. Unfortunately, no antiviral activity was observed for the new 
R1
R
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R
R1
N N
O
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;
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b
H
NO
O
c
;
Chapter 2 - Coxsackie Virus B3
62
derivative 47, leading to the conclusion that the modifications applied were 
not successful. Due to the impossibility to understand the relation between 
the loss of activity and the new chemical structures, a final scaffold was 
designed with the scope to  maintain the overall structure of the reference 
inhibitor GPC-N114 and to change only the oxygen atom linker with a 
nitrogen. In a first attempt to synthesise the unsubstituted derivative 51, it 
was not possible to obtain the desired compound. However, a side product, 
the mono-substituted derivative 52 was isolated and tested in in vitro 
assays.
Compound EC50 (µM) EC90 (µM) CC50 (µM) SI
52 42.5 55.4 170 4
Table 2.3: Activity and cytotoxicity data for compound 52
Compound 52 is associated with a certain activity in terms of EC50, but the 
antiviral effect is reduced if compared to  the the original GPC-N114. The 
low selectivity index also  emphasizes poor antiviral properties  for this 
compound, of which the chemical scaffold was not taken in consideration 
for further studies.
H
N
NH2
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2.7 Design and docking validation of new GPC-N114 analogues
In an attempt to find a new chemical structure with a similar or better 
antiviral activity of the reference GPC-N114, a further modification was 
made. The collected data from the four new families of compounds 
analysed so far suggest that the replacement of either the central ring or 
the atom linker was not associated to  any activity improvement. It was 
decided, therefore, to change only one position (the atom linker), 
maintaining the overall structure close to the reference molecule. The 
oxygen linker was substituted with two functional groups that were never 
explored before, a sulphonamido and an amido moieties (figure 2.24). 
Figure 2.24: Chemical structure of GPC-N114 (above) and scaffolds of the new 
derivatives (below)
For each family of the new compounds, two sub-structures were 
considered, a symmetrical one, having a central benzene ring, and a non 
symmetrical scaffold, bearing a chlorine atom on the central moiety, like 
the reference GPC-N114 compound. In addition, different chemical groups 
were explored in para position of the two lateral moieties, based on a 
previous SAR study on a series of GPC-N114 analogues made elsewhere 
(unpublished data kindly received by Dr. Gherard Purstinger, from 
Innsbruck University). In particular, only those substituents  that showed 
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antiviral activity were introduced on the new  chemical scaffolds. Docking 
studies were performed on the new compounds using the Glide Docking 
standard precision SP mode. Figure 2.25 shows an example of the 
predicted binding mode of the sulphonamido structures: compound 63 
nicely fits the binding pocket of the CVB3 polymerase, maintaining the 
essential interactions observed for GPC-N114. Although the sulphonamido 
linker contains two atoms in comparison with the oxygen in the reference 
molecule, additional interactions were observed between the oxygen atoms 
of the new linker and the hydroxyl group of Tyr195.
Figure 2.25: Predicted binding pose of compound 58
An analogous situation was found for the amido derivatives, where docking 
studies gave a valid predicted binding mode, similar to  the one described 
above. 
2.7.1 bis-Aryl sulfonamides (61-72)
Two families of arylsulfonamido derivatives were designed and 
synthesized through a nucleophilic displacement by the amine groups of o-
phenylenediamine 53 or 4-chloro-o-phenylenediamine 54 (Scheme 2.29) on 
the electrophilic site of the sulfonyl chloride.52  The reaction conditions 
allowed a bis nucleophilic  substitution in a one step synthesis that was 
monitored by TLC. The new derivatives were obtained as pure product by 
recrystallization, with reasonable yields that are reported in scheme 2.29.
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53, 54 55-60 61-72
Aryl 1,2-diamine R Aryl sulfonylchloride R1 Product Yield %
53 H 55 H 61 67.5
53 H 56 Cl 62 45
53 H 57 NO2 63 51
53 H 58 CN 64 30
53 H 59 OMe 65 73
53 H 60 CF3 66 21
54 Cl 55 H 67 21
54 Cl 56 Cl 68 29
54 Cl 57 NO2 69 46
54 Cl 58 CN 70 24
54 Cl 59 OMe 71 39
54 Cl 60 CF3 72 28
Scheme 2.29: Synthesis of compounds 61-72
2.7.2 bis-Aryl amides (79-90)
A further modification applied on the level of the oxygen linker was the 
introduction of an amido group. Twelve new derivatives were prepared, 
according to a reported procedure.53  The chemical pathway chosen 
consists  in a one-step reaction that was  carried out with a bis nucleophilic 
displacement of the chloride leaving group by the amine groups of o-
phenylenediamine 53 or 4-chloro-o-phenylenediamine 54 (scheme 2.30).
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Aryl 1,2-diamine R Aryl chloride R1 Product Yield %
53 H 73 H 79 59
53 H 74 Cl 80 41
53 H 75 NO2 81 84
53 H 76 CN 82 65
53 H 77 OMe 83 53
53 H 78 CF3 84 33
54 Cl 73 H 85 27
54 Cl 74 Cl 86 80
54 Cl 75 NO2 87 71
54 Cl 76 CN 88 48
54 Cl 77 OMe 89 70
54 Cl 78 CF3 90 30
Scheme 2.30: Synthesis of compounds 79-90
2.7.3 Biological evaluation
Bis arylsulfonamides 61-72 and bis  aryl amides 79-90 were evaluated for 
their antiviral activity and cytotoxicity in a virus-cell-based assay (table 
2.4).
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Chapter 2 - Coxsackie Virus B3
67
Compound R R1 X EC50 (µM) CC50 (µM) SI
61 H H NHSO2 >100 >100 -
62 H Cl NHSO2 >100 >100 -
63 H NO2 NHSO2 >100 >100 -
64 H CN NHSO2 >100 >100 -
65 H OMe NHSO2 >100 >100 -
66 H CF3 NHSO2 >100 >100 -
67 Cl H NHSO2 >100 >100 -
68 Cl Cl NHSO2 >100 >100 -
69 Cl NO2 NHSO2 >100 >100 -
70 Cl CN NHSO2 >100 >100 -
71 Cl OMe NHSO2 >100 >100 -
72 Cl CF3 NHSO2 >100 >100 -
79 H H NHCO >100 >100 -
80 H Cl NHCO >100 >100 -
81 H NO2 NHCO >100 >100 -
82 H CN NHCO >100 >100 -
83 H OMe NHCO >100 >100 -
84 H CF3 NHCO >100 >100 -
85 Cl H NHCO >100 >100 -
86 Cl Cl NHCO >100 >100 -
87 Cl NO2 NHCO >100 >100 -
88 Cl CN NHCO >100 >100 -
89 Cl OMe NHCO >100 >100 -
90 Cl CF3 NHCO >100 >100 -
Table 2.4: Activity and cytotoxicity data for compounds 61-72 and 79-90
R
X
X
R1
R1
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A clear outcome can be drawn: the modifications applied were not 
tolerated, there was no observed antiviral activity, therefore these scaffolds 
were not object of further studies. At this  stage of the study, the crystal 
structure of CVB3 polymerase with the ligand GPC-N114 co-crystallized 
was accessible and was used as  a target for a ligand-based virtual screening 
approach.
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2.8 Ligand-Based Virtual Screening
A final attempt for the identification of new, potential hit compounds was 
applied when the crystal structure of CVB3 3Dpol in complex with the non-
nucleoside inhibitor GPC-N114. With the accessible crystal structure, a 
shape comparison was performed using the active conformation of the 
molecule.
2.8.1 Shape complementarity search with ROCS
ROCS (Rapid Overlay of Chemical Structures) is an efficient software that 
was used for a ligand-based virtual screening approach. The principle 
behind ROCS is to find those molecules that have a well volume 
overlapping with the query target in its  active conformation.54  This 
program has also the advantage to integrate the information about the 
bioactive conformation with the chemical features that are essential for 
ligand-receptor recognition. The volume of screened compounds is 
superimposed to the target query and each shape density overlapping is 
quantified on the basis of a shape Tanimoto  value which would be equal to 
1 if two shapes are identical, and 0 if they are different. It is therefore 
evident that the conformation of the query molecule has a primary role for 
the screening. The fact that only shape complementarity is  considered, 
could be of advantage in finding new, different chemical scaffolds that 
have a similar shape to the query. However, it was found that the results 
obtained from a virtual screening can be more accurate if the overlapping 
of groups with a certain chemical relevance is also considered.55  The 
evaluation of the alignment of groups having binding properties  (for 
example, donor, acceptor, hydrophobic features) is made by the so-called 
Combo score. Ranking molecules  considering the sum of the shape-
Tanimoto and Combo score considerably improve the reliability of the 
screening performed. In this  study, the conformation of GPC-N114 was 
used as the query target and the conformational database of Specs 
compounds was analysed with vROCS 3.1.2 version. Both shape and 
electrostatics properties were used for the evaluation and all 
conformations found (max limit of 20000) were ranked according to their 
value of similarity using Combo-shape and Tanimoto score. Four features 
were considered essential: the three aromatic rings as hydrophobic  groups 
and one of the nitro  group as  acceptor group. In this manner, those 
conformations with the highest values of shape similarity and those that 
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have the major number of different conformation overlapping the query 
molecule were taken into account. 
Figure 2.26: Shape and selected electrostatic features for GPC-N114
Around 6000 molecules were found to match the set parameters; all the 
ligands were preprocessed using LigPrep (Maestro, package version 2.3, 
Schrödinger, LLC, New York, NY, 2009),56  which enables to  make 
corrections  to the structures, optimise or eliminate unwanted structures. 
The general iter described for docking procedures  (see section 1.3.5) was 
applied also in this case: Glide standard precision (SP) docking mode was 
performed and the output database was re-scored with three scoring 
functions (Glide XP, Plants and FlexX). After a visual inspection of the best 
25% from docking results, 10 compounds were selected and purchased 
from the Specs company to be tested (Appendix I). Unfortunately, none of 
the selected molecules showed an interesting antiviral profile.
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Conclusions
In this  study, different computer-based methods were used for the 
identification of potential inhibitors against CVB3 replication.
A structure-based virtual screening performed on the homodimer 3A 
protein guided the identification of a hit structure active against viral 
replication at 129 µM. Its  chemical scaffold was taken for the design and 
synthesis  of 11 tetrazole-based analogues that explored several aromatic 
substitutions.
Biological data revealed no antiviral effect of the new derivatives. The 
preliminary data obtained for the hit compound, however, were confirmed. 
Targeting the surface of a protein, which is  water exposed, could represent 
an issue to  design inhibitors of protein-protein interactions, such as in the 
case of the 3A protein of CVB3. The lack of information on this target and 
the difficulties  that should be faced led to  the conclusion that this protein 
is not feasible enough from a computer-aided approach, therefore a 
different target was chosen for the identification of potential antivirals.
Starting from the available information on a novel inhibitor, GPC-N114, 
targeting the polymerase of CVB3, a series  of molecular modelling 
techniques were applied.
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Ligand-based optimisation using flexible alignment method led to the 
design of new chemical structures. Data obtained so far suggest the 
essential role of the oxygen linker which is associated to a loss of antiviral 
activity when replaced. A first series of compounds was designed in order 
to explore the oxygen atom and the central moiety. On the level of the 
linker, a C or N atoms were introduced, while the central moiety was 
modified by inserting a maleimido, a benzoimidazol-2-one and an 
oxadiazole groups. 
For the first two families  having the oxadiazole and the benzoimidazol-2-
one rings  in the centre, the derivative bearing nitro groups on the two 
lateral benzene ring was prepared, as the activity of GPC-N114 was linked 
to the presence of these functional groups. As  a useful comparison, the 
unsubstituted molecule  was also prepared. All the modifications were not 
associated to antiviral activity and it is not possible to understand from 
these data wether one or both modifications  were not tolerated. A third 
scaffold with a central maleimide ring was  also validated with docking 
techniques and used for the synthesis of the unsubstituted product, for 
which no antiviral activity was observed.The only derivative that was 
obtained in an attempt to synthesize the N1, N2-disubstituted compound 
51 was N1-phenylbenzene-1,2-diamine 52, that showed a EC50 of 40 µM but 
also cytotoxic effects on the cells.
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Compound 52
Based on the first series of results, a second family of compounds  was 
planned by changing the atom linker only: a sulfonamido and an amido 
groups were introduced in this position, while maintaining those aromatic 
substituents that were linked to biological activity on the reference 
compound. A total of 24 compounds were synthesised and tested against 
viral replication. Unfortunately, no antiviral activity was  observed for the 
new derivatives. A possible explanation could be the conformation of the 
reference molecule on the crystal structure, which is highly strained and 
impossible to reproduce with docking studies. As a consequence of that, 
using a model which is not completely reliable increases the probabilities 
to fail in identifying new active compounds. Nevertheless, no interesting 
outcomes were achieved when a ligand-based virtual screening was 
performed, using the crystal structure of GPC-N114 within the CVB3 
polymerase that was finally accessible. In conclusion, no interesting 
scaffold was found using computer-aided techniques. Further studies  are 
required in order to establish clear structure-activity relationships of the 
reference molecule that could be used as a starting point for lead 
optimisation.
H
N
NH2
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Foot-and-Mouth-Disease 
Virus
Chapter 3
Introduction to the virus
3.1 Foot-and-mouth disease virus
Foot-and-mouth disease virus (FMDV) has  been considered one of the most 
economically devastating animal diseases mainly affecting cattle, pigs, 
sheep, goats and occurring throughout the world.1,2  The disease causes 
high fever, blisters inside the mouth and on the feet that can lead to 
lameness. Animals could loose weight and milk production may decline. 
FMDV is highly contagious and is transmitted animal-to-animal by close 
contact. For this reason, a way to eradicate the virus and control epidemics 
is to kill infected animals and those that have been in contact with them. 
Several outbreaks have been reported during the last decade in many 
countries in East Asia and in South Africa. In 2001, the virus expanded also 
in Europe, in particular Britain was affected by a serious outbreak: over 10 
million sheep and cattle were killed to stop the virus spreading, with an 
estimated cost of £8billion ($16bn).3  Other cases of FMDV were also 
reported in Ireland, France and The Netherlands during the same period4 
and, more recently, in 2010, in Japan.5
3.1.1 Diversity and similarity to other Picornaviruses
FMDV is the prototype of the Aphthovirus genus that belongs  to the 
Picornaviridae family.6 It is  a positive, single-strand RNA virus, for which 
seven different serotypes have been identified, named O, A, C, SAT1, SAT2, 
SAT3 and Asia-1, according to the place where they were discovered. Many 
sub-types are also present that can be different from other strains of the 
same serotype. FMDV shares common functional and structural analogies 
with other Picornaviruses, e.g. CVB3. For this reason, the virion structure, 
genome organization and life cycle will not described in this  section, but 
can be referred to the previous sections 2.1.1-2.2.4. However, some 
differences that distinguish the virus are reported here:
1) while Enteroviruses, Cardioviruses, Hepatoviruses  and Parechoviruses 
are acid stable and are infectious  at pH of 3 and lower, Aphthoviruses 
are less resistant to pH values less  than 6.0. This  is due to the 
different sites of virus replication: the former ones replicate in the 
intestine, therefore they have to  pass  through the stomach and must 
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be acid stable. Aphthoviruses, on the other hand, replicate in the 
respiratory tract, therefore they don’t need to be acid-resistant.7 
2) FMDV is the only Picornavirus  member to  encode in the genome three 
VPg genes required for replication in cell culture8 and for infectivity 
and pathogenicity in host cells.9  It has also a proteinase, named L 
protein, at the 5’-end of the genome that is responsible for protein 
cleavage.
3) There is  no canyon on the surface of the viral particle for FMDV. It is 
believed that the attach to cell receptors is through surface loops.7
4) FMDV has been shown to have resistance to the Golgi disruption by 
brefeldin A, an inhibitor of viral replication in some Picornaviruses, 
and to induce a different membrane reorganization in infected cells.10
5) FMDV is the only one to  evade the innate and acquired immune 
responses through 2B and 2BC, instead of 3A protein, as already seen 
for CVB3 (section 2.2.1).11
3.1.2 Current treatment
Currently, no antiviral therapy is  available for the treatment of FMDV. 
Although the frequency of outbreaks have been reduced in the past by the 
use of a vaccine,12,13  there are some issues to overcome, like the high 
variability of FMDV serotypes and subtypes that make it difficult the 
animal immunization. In addition, it seems that some FMDV episodes have 
derived from a vaccine due to incomplete inactivation of the live virus.14 A 
valid alternative to the vaccine is the use of drugs against FMDV replication 
which are not present at the moment on the market.
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Results and discussion
3.2 Structure-Based Virtual Screening of the FMDV polymerase
As already mentioned in section 2.2.2, GPC-N114 showed a broad spectrum 
of activity against several members of the genus Enterovirus and EMCV. On 
the contrary, this compound did not prove any activity against FMDV. A 
possible explanation for that derived from the observation made on the 
crystal structure of FMDV 3Dpol with the co-crystallized ligand. 
Interestingly, the binding area of the ligand in FMDV 3Dpol is 
approximately the same individuated for the polymerase of CVB3, but the 
ligand assumed different conformations in the two complexes.
Figure 3.1: Binding site of GPC-N114 in CVB3 3Dpol (blue ribbon) and FMDV 3Dpol 
(orange ribbon)
In FMDV, the central ring pointed towards the template entry channel, 
while one of the 2-cyano-4-nitrophenyl groups  is  exposed to  the solvent 
(Fig. 3.2). It is  likely that the lack of activity is  due to the different fit of the 
molecule, if compared with the binding mode in the CVB3 3Dpol.
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Figure 3.2: Close up of GPC-N114 binding pose in FMDV 3Dpol
Few residues differ from FMDV and CVB3 polymerases; one of these 
residues is  supposed to  be relevant for ligand binding in CVB3, hence, for 
the activity of the compound. As  already mentioned, it is  believed that 
stacking interactions between Tyr195 and the central chlorophenyl ring of 
the inhibitor play an essential role in the GPC-N114 binding. The presence 
of a cysteine in the FMDV 3Dpol and, therefore, the absence of the bulky 
aromatic  ring of the tyrosine residue, alters the modality of the ligand 
binding. As a result, there is  a reduction of contacts between the ligand 
and the binding site of the protein.
Figure 3.3: Ribbon representation of the superposed structures of CVB3 3Dpol 
(orange) and FMDV 3Dpol (blu)
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The available crystal structure of the complex between GPC-N114 and 
FMDV 3Dpol was taken as a starting point for a structure-based virtual 
screening that was performed with the aim to find molecules that could 
better fit the binding pocket, making more interactions with the amino 
acids present in this  area. FMDV RNA-dependent RNA polymerase crystal 
structure in complex with a template-primer RNA (PDB ID: 1WNE)15  was 
used for the virtual screening. Due to the high level of the program, Glide 
was used with the scope to  search for favorable interactions between the 
receptor and the ligand molecules in the database. The strategy planned in 
this case was to perform a docking-based virtual screening using the high-
throughput virtual screening (HTVS) mode that is  able to roughly screen a 
very large number of molecules without using a pharmacophore. The initial 
filtration was  performed by using a grid in the area of the binding site, 
where three amino acids (Arg188, Cys200, Ser301) were selected to 
delimitate the site. The Specs database was used after pre-processing all 
the molecules with the LigPrep step.24 Conformations with a positive value 
of docking score (which indicates a bad docking pose) were discarded. 
Around 117,000 conformations were obtained, of which the best 10% were 
taken for the standard precision Glide docking (SP) mode. The output 
database was  used for re-scoring the results using Glide Extra Precision 
(XP) mode, Plants and FlexX scoring functions. The predicted poses  were 
evaluated using the already described consensus scoring process  (see 
section 1.3.5). A final visual inspection allowed us  to select 17 compounds 
that were purchased and were evaluated in in vitro tests (Appendix I). From 
the biological results, however, no  interesting results came out, therefore a 
different approach was tried.
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3.3 De novo drug design approach
A second study performed for the identification of selective inhibitors of 
FMDV 3D polymerase was a de novo drug design approach, which involves 
the design of novel structures based on the geometry of the binding site. In 
this study, a multi-fragment search using a list of ligands  available from 
MOE 2010.10 and a in-house selection of small fragments was carried out 
within the binding site in order to target Cys200. Among all, the coumarin 
ring represented an interesting fragment to use for the design of new 
compounds: it acts by irreversible binding to the cysteine residue through 
Michael addition reaction. In order to  fit the pocket, 2-benzimidazole and 
4,5-diphenyl-1H-imidazole were found to be suitable groups. To link these 
chemical entities  with the coumarin ring, five linkers  were used according 
to chemical feasibility. 
Figure 3.4: General chemical scaffold for compounds 91, 94, 99-100, 105-108
O OX
R
R =
N
H
N
N
H
N;
a
b
X = CH2O, NHCO, CH2S, CH2S=O, CH2SO2
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3.4 Synthesis of coumarin-based structures 
3.4.1 7-((1H-Benzo[d]imidazol-2-yl)methoxy)-2H-chromen-2-one (91)
The first scaffold prepared was a 2-benzimidazole group linked to the 
coumarin ring by a methoxy function. The predicted binding mode, shown 
in figure 3.5, highlights three hydrogen bonds, the first one between 
Cys200 and the carbonyl group of the coumarin moiety and two others 
between the nitrogen atom of benzimidazole and residues Met111 and 
Glu112.
Figure 3.5: Chemical structure of compound 91 and its predicted binding mode
A first attempt was made by mixing 7-hydroxyl coumarin 92 and 2-
chloromethyl benzimidazole 93 in the presence of potassium carbonate 
(Scheme 3.1). The designed product was  not obtained and it could be 
speculated that the base reacted with 2-chloromethyl benzimidazole by 
deprotonating the nitrogen, instead of acting on the hydroxyl group of the 
coumarin moiety.
N
H
N O
O
O
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OHO O
N
H
N O
O
O
N
H
N Cl
KI, DMF, K2CO3 110 oC, o.n.
X
9192
93
Scheme 3.1: First attempt for the synthesis of compound 91, 94, 99
A different procedure was, therefore, applied (scheme 3.2): the proton of 
the 7-hydroxyl coumarin was first removed by treating it with 1 equivalent 
of NaH in anhydrous DMF, followed by the addition of 2-chloromethyl 
benzimidazole to the reaction mixture in order to obtain the displacement 
of the chloride by the oxygen lone pair.16 The compound was obtained as 
pure product after chromatographic purification with a 10 % of yield.
N
H
N
Cl
OHO O
1. NaH, DMF, 0 oC; rt, 1h
2. , over 10'; r.t., o.n.
N
H
N O
O
O
9192
93
Scheme 3.2: Synthetic pathway for compound 91
3.4.2 N-(2-Oxo-2H-chromen-7-yl)-1H-Benzo[d]imidazole-2-carboxamide 
(94)
A second linker introduced between the coumarin ring and the 
benzimidazole function was  the amido group (e.g., compound 94, Figure 
3.6). 
Figure 3.6: Chemical structure of compound 94
Several attempts were made before finding the right conditions  to obtain 
the desired product (scheme 3.3). At first, DMAP and Et3N were added to a 
solution of DCM and 6-aminocoumarin 96 (previously obtained by reducing 
6-nitrocoumarin 95 with hydrogen and palladium on carbon as catalyst).17 
1H-Benzo[d]imidazole-2-carbonyl chloride 98, synthesised from the 
N
H
N O
NH O O
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correspondent acid 97, was added and the mixture was stirred at 0 oC for 
2h. Unreacted starting acid was the major component of the reaction 
mixture, therefore the reaction conditions were adjusted by using toluene 
as solvent and stirring the reaction for 48 h (scheme 3.3). Desired product 
94 was not the main species  formed, starting material was still present, 
therefore this procedure was discarded due to the very low yield obtained. 
A third attempt was tried following reported procedure.18  1H-
Benzimidazole-2-carboxylic acid 97 was refluxed with carbonyldiimidazole 
for 30’. After cooling down to r.t., 6-aminocoumarin was added to the 
reaction mixture that was  stirred for 16 h at reflux. Unfortunately, in this 
case, the formation of the desired product was not observed, only starting 
materials were isolated.
 
N
H
N O
OH
Cl
O
O
Cl
cat. DMF, DCM
N
H
N O
Cl
N
H
N O
NH O O
O O
H2N
DMAP, Et3N, DCM
         0oC, 2h
DMAP, Et3N, toluene
            r.t., 48h
O O
H2N
CDI, DMF, 30', reflux;
16h, reflux
96, 92%
H2, Pd/C
EtOH
O O
O2N
X X
X
94
+
N
H
N O
OH
97 98
95
97
96
Scheme 3.3: First three attempts for the synthesis of compound 94
A fourth attempt, finally, led to the synthesis  of the desired product 
(scheme 3.4). According to  a reported procedure,19  the amido derivative 
was obtained with a 18%  of yield by a coupling reaction between 6-
aminocoumarin 96 and 1H-benzimidazole-2-carboxylic acid 97, using TBTU 
as a coupling reagent.
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Scheme 3.4: Synthetic pathway for compound 92
3.4.3 7-Aryl thio methyl-2H-chromen-2-ones (99, 100)
Another series  of compounds, aiming to bind the pocket of the FMDV 
polymerase, was characterised by a thiol moiety that links together the 
coumarin ring and two types  of aryl substituents, a 2-benzimidazole and 
4,5-diphenyl-1H-imidazole (e.g., compounds 99 and 100, Scheme 3.7).
Figure 3.7: Chemical scaffold of compounds 99, 100
The synthetic pathway followed is a one step synthesis that started from 
the preparation of intermediate 7-bromomethyl coumarin 102 (Scheme 
3.5). According to  a reported procedure,20  the designed molecules were 
obtained by nucleophilic displacement of the bromide leaving group.
N
H
N O
NH O O
TBTU, DIPEA
THF, r.t., 4hN
H
N O
OH
O O
H2N
O O
O2N H2, Pd/C
EtOH
94, 18%
96, 92%95
97
O O
S
R
R =
N
H
N
N
H
N;
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Scheme3.5: Synthetic pathway for the synthesis of compounds 99, 100
Synthesis of 7-bromomethyl coumarin (102)
Intermediate 7-bromomethyl coumarin was obtained by bromination of 7-
methylcoumarin 101 with N-bromosuccinimide in presence of a catalytic 
amount of benzoyl peroxide (Scheme 3.5).21 The product was obtained with 
66% yield.
Synthesis of aryl thio methyl-2H-chromen-2-ones (99, 100)
Aryl thiol derivatives 99, 100 (Scheme 3.6) were obtained through a 
nucleophilic substitution by the thiol group on the methyl bromide portion 
of 7-methyl bromocoumarin in basic conditions. The reaction was carried 
out at r.t. for 48 h. From the reaction mixture, the product was isolated 
from unreacted starting material through flash column chromatography.
OH3C O O O
Br
NBS, (PhCO2)2
CH3CN, 3h, reflux; o.n., r.t
H
S
R     Cs2CO3DMF, r.t., 48 h
O O
S
R
 102, 66%
99, 100
103, 104R =
N
H
N
N
H
N
103
104
;
101
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Starting aryl thiol compounds R Product Yield %
103 a 99 42
104 b 100 8.5
Scheme 3.6: Synthesis of compounds 99, 100
3.4.4 7-Aryl sulfinyl methyl-2H-chromen-2-ones (105, 106)
Another small series of sulfinyl compounds was prepared in order to be 
tested against FMDV replication (e.g. compounds 105 and 106, Scheme 
3.8).
Figure 3.8: Chemical scaffold of compounds 105, 106
Following a reported procedure,22 aryl thio methyl-2H-chromen-2-ones 99, 
100, previously synthesised, were converted to the sulfoxide derivatives 
105,  106 by oxidation through m-CPBA at -20 oC, that was  neutralised with 
NaHCO3 (Scheme 3.7).
H
S
R
O O
S
RCs2CO3, DMF, r.t., 48 h
Br O O
R =
N
H
N
N
H
N;
a
b
103, 104 99, 100
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O O
S
R
R =
N
H
N
N
H
N;
O
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O O
S
R
mCPBA
DCM, -20 oC, 5-10'
O O
S
R
O
R =
N
H
N
N
H
N;
99, 100 105, 106
a
b
Starting aryl thio methyl-2H-
chromen-2-ones
R Product Yield %
99 a 105 59
100 b 106 20
Scheme 3.7: Synthesis of compounds 105, 106
3.4.5 7-Aryl sulfonyl methyl-2H-chromen-2-ones (107, 108)
The last family of derivatives designed as potential inhibitors of FMDV 
polymerase was made by sulfonyl compounds obtained by oxidation of the 
previously described thiol derivatives 99,  100 (Scheme 3.6). Docking 
studies were performed to  validate this scaffold, for which two derivatives 
were prepared, the one bearing a 2-benzimidazole and the other one with a 
4,5-diphenyl-1H-imidazole group. For the 2-benzimidazole derivative, two 
main interactions  were predicted: one hydrogen bond between Cys200 and 
the coumarin ring and another one between Glu112 and an oxygen of the 
sulfonyl group. The second derivative, not only contains the same 
interactions, but has an additional hydrogen bond with Arg189 and better 
fills the occupational space thanks to the two benzene substituents.
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Figure 3.9: Chemical scaffold of compounds 107, 108 (above). Predicted binding 
mode for compound 108 (below)
The synthetic  pathway applied is  the one previously described for the 
synthesis  of sulfinyl derivatives, consisting in an oxidation reaction 
through m-CPBA (Scheme 3.8). The conditions were adjusted by stirring the 
mixture at r.t. and keeping the reaction longer (o.n.). 
O O
S
R
R =
N
H
N
N
H
N;
O
O
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Starting aryl thio methyl-2H-
chromen-2-ones
R Product Yield %
99 a 107 13
100 b 108 39
Scheme 3.8: Synthetic pathway for the synthesis of compounds 107, 108
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3.4.6 Biological evaluation
Eight new coumarin-based structures were tested for their antiviral activity 
and cytotoxicity in a MTT cell viability assay against three strains of FMDV 
(FMDV 01 Manisa, FMDV A22 Iraq, FMDV A96 Iran) and ERAV, Equine 
rhinitis A virus, a serotype of Aphthovirus, which is very similar to FMDV 
genome (table 3.1). Biological tests were carried out at Aratana 
Therapeutics in Leuven, Belgium under the supervision of Dr. Nesya Goris.
Compound R X
EC50 (µM)
(FMDV)
EC50 (µM)
(ERAV)
CC50 (µM) SI
91 a O >50 >50 >250 -
94 a NC=O >50 >50 >250 -
99 a CH2S >50 >50 >250 -
100 b CH2S >50 >50 111 -
105 a CH2S=O >50 >50 170 -
106 b CH2S=O >50 >50 81 -
107 a CH2SO2 >50 >50 >250 -
108 b CH2SO2 >50 >50 >250 -
Table 3.1: Activity and cytotoxicity data of compounds 91, 94, 99-100, 105-108
All the new  compounds were tested with the highest concentration of 50 
µM and were found inactive against FMDV and ERAV replication. However, 
from the CC50 values, it could be speculated a possible Michael adduct 
formation, known to be a mechanism of toxicity. In conclusion, the 
modifications applied were not successful for the identification of a new 
FMDV inhibitors and further studies are required.
O OX
R
R =
N
H
N
N
H
N;
a
b
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Conclusions 
In an attempt to identify a new scaffold with a selective activity against 
FMDV replication, molecular modelling techniques were applied. A 
structure-based virtual screening was carried out on the region where GPC-
N114 binds  the polymerase of FMDV without inhibiting the viral 
replication. Selected molecules  were evaluated for their activity, but no 
interesting antiviral profile emerged from that batch of molecules. A de 
novo drug design approach was  then applied. Taking into  account the 
geometry of the binding site and the available information on the ligand 
binding within the polymerase, a multi-fragment search was performed in 
order to find which molecules could fit the target where Cys200 is located. 
O O
X
R
X = CH2O, NC=O
O OX
N
N
H
X =  CH2O, NHCO, CH2S, CH2S=O, CH2SO2
N
H
N
N
H
N
;
The coumarin ring was chosen as the best one to  interact with this key 
residue. Two functional groups were chosen to  be linked to  this moiety in 
order to fill the empty space of the active site and improve the binding. 
Five linkers were also  analysed to connect the two main portions of the 
molecule. According to the biological results obtained, this  scaffold is not 
associated to  antiviral activity. The lack of activity may be due to the fact 
that these compounds, like GPC-N114, bind but do not inhibit the 
enzymatic activity. One other possibility of course is that these tested 
compounds are inactive because they do not bind to the enzyme. Not 
knowing whether the test compounds bind as intended or not, it is not 
possible to learn much.
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Chikungunya Virus
Chapter 4
Introduction to the virus
4.1 Chikungunya virus
Chikungunya is a re-emerging viral disease that is  transmitted to humans 
by infected mosquitoes. This viral pathogen causes a serious socio-
economical impact, being responsible for an acute febrile illness 
characterized by joint pain and rush.1,2  Febrile symptoms usually last 3-4 
days, but arthralgia may persist for months, involving knees, elbows, 
ankles. Cases  of eye, neurologic  and heart complications have been also 
reported to happen occasionally, as well as  other non-specific symptoms, 
like headache and gastrointestinal upset.3 Chikungunya has been reported 
in many countries  of Asia4  and Africa.5  From 2001 and 2007, major 
outbreaks  occurred in the Mauritius, Mayotte, Madagascar; in the Reunion 
Island, one third of the population was infected and 235 cases of death 
were registered.6 In 2007, CHIKV virus spread also in Europe for the first 
time, in Italy.7 Cases of viral infections have been reported in the Americas8 
and, more recently, in Venenzuela.9  Two ways  of transmission are 
described for CHIKV: the sylvatic cycle, limited within Africa, where forest-
dwelling mosquitoes are the principal vectors that transmit the virus to 
primates6 and the human-mosquito-human urban cycle, common in Asia, 
where Aedes Aegypti and, more recently, Aedes Albopictus, are the main 
responsible for virus spreading.10  The transmission is mediated by the 
salivary glands of the mosquito. The virus directly enters the bloodstream 
of humans through mosquito bites  and combines with the cells of the nose, 
throat and mouth.
4.1.1 Virion structure
The Chikungunya viral particle is  spherical, icosahedral, of about 70-100 
nm in diameters. It has a lipid bilayer that is formed by 80 flower-like 
structures  made of three subunits. These heterodimers are formed by 
glycoproteins E1 and E2. The envelope represents the outer surface that 
surrounds the nucleocapsid, which is  made of 240 copies of capsid 
proteins and contains one molecule of RNA.
 Chapter 4 - Chikungunya Virus
103
Figure 4.1: Structure of the Chikungunya virion particle
4.1.2 Genome organization
Chikungunya is an Arbovirus that belongs to the Alphavirus genus, of the 
family Togaviridae.11 Viruses of the Alphavirus genus are divided in two 
main groups: the Old and the New World viruses. The genus is composed 
of three subgroups, the Semliki Forest virus (SFV), the Eastern Equine 
Encephalitis  virus (EEEV) and the Sinbis  virus. Taxonomically, CHIKV is part 
of the first complex, SFV.12 CHIKV is an enveloped, single  strand RNA virus. 
The genome, 11.8 kb in length, is formed by a 5’ cap-untranslated region 
(UTR), non-structural proteins (nsP1-4), structural proteins  (C-E3-E2-6K-E1) 
and a 3’ terminal poly-A tail.13 
nsP1 nsP2 nsP3 nsP4 CP PE2 6K E1
Non structural proteins Structural proteins
5’ Cap An  3’
Figure 4.2: Chikungunya genome organization
4.1.3 Viral proteins
The role of the non-structural proteins, nsP1, nsP2, nsP3 and nsP4 is to 
carry out the synthesis of viral RNAs. nsP1 participates in the anchorage of 
replicase complex on the plasma membrane and has a methyltransferase 
activity.14,15  nsP2 is  a multifunctional enzyme: while the N-terminal part 
has NTPase, RNA triphosphatase and helicase properties, the C-terminal 
section has  protease activity.16,17,18  A more detail description is given 
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below. The function of nsP3 is  not well known, but it is  thought to be a 
phosphoprotein responsible for recruiting several cellular proteins  to the 
replicase complex.19  Finally, nsP4 has RNA-dependent RNA polymerase 
activity and replicates genomic  and antigenomic RNA through specific 
signals.20  Among the structural proteins, capsid protein (CP) forms the 
nucleocapsid and has a protease activity that makes an autocatalytic 
cleavage of itself from the polyprotein.21  Capsid protein is also able to 
associate with ribosomes and to bind the genome RNA, thus forming viral 
particles.22 E3 protein is  the amino-terminal part of the E2 precursor (PE2) 
and is  able to  provide the signal sequence for the translocation of PE2 into 
the ER.23  E2 protein is involved in viral attachment to target host cells,24 
while 6K is responsible for virus assembly and budding of viral proteins.25 
Finally, E1 protein, a type I transmembrane glycoprotein, takes part in the 
viral nucleocapsid release in cytoplasm after endosome and viral 
membrane fusion.26 
4.1.4 Viral life cycle
Virus uptake, for CHIKV, is a receptor-mediated endocytosis process. The 
attachment is mediated by E2 protein that binds  cellular receptors of 
different type. Once in the endosomal vesicles, the genomic RNA is 
released into the cytoplasm by fusion to  the endosomal membranes and 
the replication process  can start.27,28 The first step, after releasing the RNA 
from the nucleocapsid, is the translation of the genome by cellular 
ribosomes. From this process, the P1234 polyprotein is initially cleaved in a 
P123 complex and nsP4, then a second complex made by nsP1, nsP23 and 
nsP4 is formed (Figure 4.3).29 
Figure 4.3: Translation of the genome
Non-structural proteins
stop 
codon
Structural proteins
3’
P123
early
P123 RdRP nsP4
late
nsP1 nsP2 nsP3 RdRP nsP4
late
CP E3 E2 6k E1
Subgenomic RNA
3’
C5’
C5’
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In the early phase of infection, full-length negative strand antigenome RNA 
is synthesized by the complex formed between P123 and nsP4. The 
antigenome is the template for the synthesis  of full-length RNA and also 
subgenomic mRNAs. After final cleavage to nsP1, nsP2, nsP3 and nsP4 the 
switch from synthesis of negative to positive strands occurs. The 
replication process starts, along with the translation of proteins  that 
eventually encapsidate nascent genome RNA before viral release by 
budding through the cell membrane (figure 4.4).30
Figure 4.4: Chikungunya life cycle
4.1.5 Current treatment
At the moment, there is no antiviral therapy nor a vaccine available. 
Treatment of chikungunya disease is only symptomatic, by using non-
steroidal anti-inflammatory analgesics and fluids. Corticosteroids  are used 
to decrease the inflammation.31  The antimalarial drug chloroquine and 
other examples of compounds, like ammonium chloride, amantadine and 
methylamine have been used against Alphaviruses, but only for their anti-
inflammatory properties.31 Chloroquine entered phase 3 clinical trials in 
France in 2006, but was  stopped in 2007 because of no antiviral results.32 
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In the literature, several examples of active compounds  against viral 
replication have been described. They all range from well-known antivirals, 
like ribavirin33  and arbidol,34  to  natural sources, like prostatin, 12-O-
tetradecanoyl- phorbol 13-acetate 35  and the antitumor compound 
harringtonine.36  Bassetto et al. identified for the first time through a in 
silico approach one hit compound active at low micromolar range (EC50 of 5 
µM) that was the starting point of further optimization studies which will 
described in section 4.3.37 Many efforts  have been done in the past 30 years 
to develop a vaccine against CHIKV. Potential candidates were obtained 
using live inactivated or attenuated strains, but they were stopped due to 
lack of funding or no commercial potential.38 Some of them are still under 
evaluation.39  Recently, a very promising vaccine candidate that uses  a 
virus-like particle is in the early stages of preclinical development.40
4.2 nsP2 protease
4.2.1 Structure
The nsP2 protease has an essential function in the viral replication and 
propagation. Its  crystal structure has been solved in 2011 with a 2.40 Å 
resolution (PDB ID: 3TRK).41 Two main domains characterise nsP2 protease: 
the N-terminal domain (aa 1-470) has NTPase42,43  and RNA triphosphatase 
activities, involved in viral RNA capping. It has also an important RNA 
helicase activity.44  The C-terminal domain (aa 471-798) exhibits  protease 
activity, with the presence of the catalytic dyad cystein and histidine 
residues.45,46  The active site is  at the interface between the two main 
domains that are involved in substrate recognition. Among Alphavirus 
nsP2 protease, there is little sequence similarity, but the catalytic residues 
are conserved. In addition, the three residues that follow each catalytic 
residue do not vary and one of them, Trp has been shown to  be important 
for proteolytic activity. The proteolytic processing happens at three 
different cleavage sites, nsP1-2, nsP2-3 and nsP3-4, with a preference for 
nsP3-4> nsP1-2>> nsP2-3. Studies on the Venezuelan Equine Encephalitis 
Virus (VEEV) revealed the essential residues  for cleavage site  recognition. 
Homology modelling studies carried out for different members of the 
Aphavirus genus demonstrated common characteristics  that may be 
present also in the case of CHIKV.47
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Figure 4.4: Ribbon representation of Chikungunya nsP2 protease. Close up of the 
nsP2 protease binding site in presence of a model of nsP3-4 junction peptide
4.2.2 Mechanism of action
The catalytic  mechanism of nsP2 proteases is similar to the one proposed 
for papain-like proteases.48,49  The protease cleft can accommodate a 
substrate of five residues, defined P1’-P1-P2-P3-P4. To each residue 
corresponds a protein subsite. They are termed S1’, S1, S2, S3 and S4. The 
cleavage occurs between P1’ and P1 and the mechanism consists in the 
formation of a thiolate-imidazolium ion pair of the catalytic dyad. The 
substrate is  ready to  bind the active site: the P1 carbonyl can be attacked 
by the deprotonated thiol and the reaction can proceed.47 
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Results and discussion
4.3 nsP2 Protease as a target for the identification of new 
antivirals
The nsP2 protease is  one of the most promising targets  since it is 
responsible for the formation of the four mature nsPs that are  required for 
virus replication. Potential inhibitors can be identified by targeting the 
critical residues for the proteolytic cleavage.
4.3.1 Project background
Previous work done in our lab explored the nsP2 protease as a target for 
the development of selective inhibitors  of CHIKV replication. A structure-
based virtual screening on the active site of a homology model of the nsP2 
protein was performed using a library of ~5 million compounds. The 
original database was pre-filtered using a pharmacophore model set on the 
nsP2 binding site. Nine compounds were purchased and their antiviral 
activity was assessed in a cell-based assay. Compound 109 (Figure 4.5) 
selectively inhibited CHIKV-induced cell death at low µM concentration, 
with an EC50 value of 5.0 µM in the cytophatic effect (CPE) reduction assay. 
This molecule was chosen as a starting point for the development of novel 
potential nsP2 protease inhibitors.37
Figure 4.5: Chemical structure of hit compound 109
The predicted binding mode is shown in figure 4.6. This compound nicely 
fits in the central portion of the nsP2 protease active site, with the 
hydrazone group placed near the catalytic dyad, Cys579 and His649, and in 
close proximity to Trp650. Several interactions have been identified by 
docking studies as  essential: a hydrophobic bond between the t-butylic 
group of 109 and His649, two hydrogen-bonds  between the hydrazide 
function and the backbone amido groups of Tyr645 and Asn648, and 
H
N
O
N
O
O
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another hydrophobic contact between the 3,4-diethoxyphenyl ring and the 
lateral chain of Trp650.
Figure 4.6: Predicted binding mode of compound 109 in the nsP2 binding site
The chemical scaffold of compound 109 was  explored to investigate its 
potential for the design of new anti-CHIKV compounds. First of all, 23 
analogues  were directly purchased from the SPECS library and tested for 
their antiviral activity. From the biological data, two structural elements 
seemed essential for antiviral activity: the cyclopropylic ring and the 
presence of an aliphatic group in para position of the benzylidene portion. 
The data obtained guided the design and synthesis of a first series of 
compounds aimed to optimise the identified hit structure. The main 
modification regarded the cyclopropylic moiety, that was replaced by a 
trans-ethenylic group, as the presence of two  chiral centers on this  ring 
represented an issue for the preparation and purification of new 
analogues. The double bond in its trans configuration had the advantage of 
avoiding the presence of chiral centers while maintaining the length and 
geometry of the original cyclopropylic ring. Compound 110 (Figure 4.7) 
was prepared and tested in in vitro assays. Interestingly, the biological 
evaluation showed retained antiviral activity, which proofed that the 
replacement of the cyclopropylic ring with a trans-ethenylic bond was 
acceptable. The new derivative showed a EC50 value of 3.2 µM and was 
taken as a starting point for SAR studies.35 
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Figure 4.7: Chemical structure of compound 110
Docking analysis  of compound 110 in the nsP2 binding site (Figure 4.8) 
showed great similarities  with the hit structure 109: the t-butyl group has 
maintained its  position and makes hydrophobic interaction with His649; 
the hydrogen-bonds between the hydrazone group and residues Tyr613 
and Asn648 are also present, along with hydrophobic contacts between the 
second aromatic ring and Trp650.
Figure 4.8: Predicted binding pose of compound 110 in the nsP2 binding site
110
N
H
O
N
O
O
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4.3.2 Design and synthesis of novel derivatives
The chemical structure of compound 110 was taken as a lead compound 
for this study, with the aim to improve the activity of the original molecule 
and better understand its structure-activity relationships. Four families of 
compounds were designed, validated with docking techniques and finally 
prepared in order to be tested.
1) A first series of compounds was  synthesized in order to explore 
different substituents in place of the t-butyl group;
2) Another series of compounds was designed with the aim to protect the 
overall molecule from chemical instability, by introducing a 
benzimidazole ring on the level of the hydrazone group. Furthermore, a 
new scaffold bearing a triazole ring was designed in place of the 
hydrazide group;
3) An additional modification was  the introduction of a urea and, 
successively, a thiourea group in place of the hydrazide moiety, in order 
to increase the hydrophilicity of the molecule.
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4.4 Synthesis of (2E)-N’-benzylidene aryl acrylohydrazides
With the purpose to  better understand the importance of the t-butylic 
moiety, four different functional groups were introduced in place of it.
Phenyl and isopropyl groups were chosen to explore the effect of similar or 
bulkier substituents and analyse activity related to  their steric  effect. To 
evaluate the influence of electronic contributions on the original molecule, 
a methoxy and a trifluoromethyl groups were also  introduced, while on 
positions R3 and R4 the most active groups (m,p-diethoxy, p-methyl, p-
hydroxyl and p-cyclohexyl groups) were maintained, based on previous SAR 
studies. Figure 4.9 shows the predicted binding mode of compound 137 as 
a representative example, which is  consistent with the one previously 
described for the lead compound, showing an hydrogen bond between the 
carbonyl group and the indole of Trp650.
Figure 4.9: Chemical structure and predicted binding mode of compound 137 as a 
representative example
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4.4.1 (2E)-N’-Benzylidene aryl acrylohydrazides
The planned strategy for the synthesis  of the new derivatives was a three 
step synthetic pathway, that begins with the formation of substituted 
acrylic  acids, successively converted to their correspondent chloride forms. 
Final compounds were obtained by a condensation reaction between the 
acryloyl chloride intermediates and aryl hydrazones previously 
synthesized.
O
R1
111: i-Pr
112: CF3
113: OMe
114: C6H5
+ HOOC COOH
pyr, reflux, 2h
R1
OH
O
115-118
Cl
Cl
O
O
DCM, r.t., 5h
R1
Cl
O
119-122
R2
O
R4
R3
NH2NH2 . H2O
EtOH, reflux, 3h
N
R4
R3
NH2
123: R2, R3 = H; R4 = Me
124: R2 = H; R3, R4 = OEt
125: R2, R3 = H; R4 = C6H11
126-128
R2
R1
N
H
O
N
R2
R3
R4
129-140
THF, Et3N
r.t., o.n.
cat. piperidine
Scheme 4.1: Common synthetic strategy applied for compounds 129-140
Synthesis of aryl acrylic acids (115-118)
The first step is a Knoevenagel condensation between malonic  acid and the 
appropriate aldehyde to  give aryl acrylic  acid derivatives 115-118 (Scheme 
4.2).50 All the four intermediates  were obtained as  pure products  by flash 
chromatographic purification with high yields.
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OR1
+ HOOC COOH
Pyr, reflux, 2h
R1
OH
O
107-110
cat. piperidine
103-106
Starting aldehyde R1 Product Yield %
111 i-Pr 115 91
112 CF3 116 91
113 OMe 117 80
114 C6H5 118 92
Scheme 4.2: First step synthesis for compounds 115-118
Synthesis of acryloyl chlorides (119-122)
The correspondent aryl acrylic acids 115-118 (Scheme 4.3) were 
chlorinated, according to reported procedures, with oxalyl chloride to 
prepare acryloyl chloride intermediates 119-122.51
R1
OH
O
115-118
DCM, r.t., 5h
Cl
Cl
O
O
+
R1
Cl
O
119-122
Acryloyl acid 
intermediate
R1 Product Yield %
115 i-Pr 119 100
116 CF3 120 91
117 OMe 121 94
118 C6H5 122 98
Scheme 4.3: Second step synthesis for compounds 119-122
Synthesis of aryl hydrazones (126-128)
Aryl hydrazone intermediates 126-128 (Scheme 4.4) were synthesized 
through the formation of a Schiff base between the aldehydes 123-125 
with hydrazine monohydrate.52  All products were obtained with good 
yields and used for the following step without further purification.  
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Starting 
aldehyde
R2 R3 R4 Product Yield %
123 H H Me 126 76
124 H OEt OEt 127 91
125 Me H C6H11 128 94
Scheme 4.4: Third step synthesis for compounds 126-128
Synthesis of (2E)-N’-benzylidene aryl acrylohydrazides (129-140)
Final compounds 129-140 (Scheme 4.5) were prepared by adding the 
hydrazone intermediates 126-128 to  a solution of acryloyl chlorides 
119-122 in anhydrous THF and triethylamine, which was  used to neutralize 
the hydrochloric acid formed.53
R4
O
R2
R3
NH2NH2 . H2O
EtOH, reflux, 3h
R4
N
R3
R2
NH2
123-125 126-128
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R1
Cl
O
119-122
Et3N, THF, r.t., o.n.
R4
N
R2
NH2
126-128
R3
R1
N
H
O
N
R2
R3
R4
129-140
Acryloyl 
chloride
R1
Aryl 
hydrazones
R2 R3 R4 Product Yield %
119 i-Pr 126 H H Me 129 58
119 i-Pr 127 H OEt OEt 130 13
119 i-Pr 128 Me H C6H11 131 18
120 CF3 126 H H Me 132 6
120 CF3 127 H OEt OEt 133 5
120 CF3 128 Me H C6H11 134 12
121 OMe 126 H H Me 135 55
121 OMe 127 H OEt OEt 136 35
121 OMe 128 Me H C6H11 137 9
122 C6H5 126 H H Me 138 10
122 C6H5 127 H OEt OEt 139 6
122 C6H5 128 Me H C6H11 140 5
Scheme 4.5: Synthesis of compounds 129-140
4.4.2 (2E)-N'-(4-Hydroxybenzylidene)-3-(4-
isopropylphenyl)acrylohydrazide (143)                 
The described procedure for the synthesis of (2E)-N’-benzylidene aryl 
acrylohydrazides was also  applied for the preparation of derivatives 
bearing a hydroxyl group on the aryl hydrazone moiety. In these 
conditions, a complex mixture of multiple  products was  obtained and it 
was not possible to purify the designed compounds by chromatographic or 
recrystallisation techniques. This might be due to the presence of the 
triethylamine base in the reaction mixture, that might deprotonate the 
hydroxyl group causing the formation of a nucleophile center able to  react 
with the acryloyl chloride, thus preventing the condensation with the 
hydrazones. A different synthetic  pathway was attempted. By a one-pot 
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reaction, acryloyl acid derivatives were converted to the correspondent 
acrylohydrazides without isolating the intermediate acryloyl chlorides.54 
Unfortunately, the only acrylohydrazide obtained from this reaction was 
the one bearing the i-Pr group, 141, which was finally used to obtain the 
Schiff base with 4-hydroxyaldehyde 142, following a modified procedure.55 
The desired compound 143 was purified by recrystallization from EtOH 
and obtained with a 7% of yield. 
Scheme 4.6: Synthetic pathway applied for compound 143
Synthesis of (E)-3-(4-isopropylphenyl)acryloyl chloride (119)
Intermediate 119 (Scheme 4.6) was obtained through chlorination of acrylic 
acid 115 by oxalyl chloride, in DCM, at r.t., for 5 h, according to  the same 
procedure previously described.3 The product was  not isolated and directly 
used for the following step.
OH
O
115, 91%
Cl
O
Cl
O
DCM, r.t., 5h
Cl
O
119
NH2NH2.H2O
.
Et2O, r.t., 2h, under N2
N
H
O
NH2
141, 15%
HO
O
EtOH, r.t., 72h
N
H
O
N
OH
143, 7%
142
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Synthesis of (E)-3-(4-isopropylphenyl)acrylohydrazide (143)
Nucleophilic displacement of the chloride leaving group with aqueous 
hydrazine was carried out to obtain the correspondent acrylohydrazide 
141.  The intermediate was used for the final step as crude product, as it 
was not possible to purify it from a mixture of impurities that could not be 
identified by column chromatography or recrystallization.
Synthesis of (2E)-N'-(4-hydroxybenzylidene)-3-(4-
isopropylphenyl)acrylohydrazide (143)
The desired product bearing a hydroxyl group at the level of the hydrazone 
moiety was obtained through the formation of a Schiff base between 
acrylohydrazide 141 and 4-hydroxylaldehyde 142. Although from the 
crude mixture multiple products were observed by T.L.C., final compound 
142 was  isolated through flash column chromatography and further 
purified by recrystallization from ethanol with a 7% of yield.
4.4.3 Biological evaluation
Thirteen new derivatives  were evaluated for their antiviral activity and 
cytotoxicity in a virus-cell-based assay (table 4.1).
The evaluation was  performed at the Rega Institute for Medical Research in 
Leuven, Belgium, under the supervision of Professor Johan Neyts. Activity 
is espressed as EC50 and EC90 and cytotoxicity as CC50, as already described 
in section 2.4.2
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Compound R1 R2 R3 R4 EC50 (µM) EC90 (µM) CC50 (µM) SI
110 (lead 
compound)
t-But H OEt OEt 3.2 11 101 32
129 i-Pr H H Me 25.9 - 25 0
130 i-Pr H OEt OEt >29.2 >29.2 - -
131 i-Pr Me H C6H11 >193 >193 - -
132 CF3 H H Me 96.3 >150 203 2
133 CF3 H OEt OEt 48.9 84.2 84.1 2
134 CF3 Me H C6H11 >241 >241 - -
135 OMe H H Me >112 >112 - -
136 OMe H OEt OEt >271 >271 - -
137 OMe Me H C6H11 >87.7 >87.7 - -
138 C6H5 H H Me 230 >294 >294 -
139 C6H5 H OEt OEt >80.2 >80.2 - -
140 C6H5 Me H C6H11 >29.6 >29.6 - -
143 i-Pr H H OH >324 >324 - -
Table 4.1: activity and cytotoxicity data for compounds 129-140, 143
As can be deduced from the biological data shown above, the new 
derivatives bearing four different functional groups in place of the t-butylic 
group are associated to  loss of antiviral activity. Compound 129, with an 
isopropyl group in para position of the acrylic moiety, is the only one that 
shows a certain activity at higher concentration than the original 
compound, but it is also associated to an increased toxicity against the cell.
These data, therefore, confirmed previous indications  of the essential role 
occupied by the t-butyl group.
R1
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4.5 Synthesis of N-(1H-benzo[d]imidazol-2-yl)aryl amides	

A first attempt to replace the hydrazone linker, known to be poorly stable 
in aqueous systems, was the introduction of a benzimidazole ring. 
Figure 4.10: Chemical scaffold of N-(1H-benzo[d]imidazol-2-yl)aryl amides. The 
predicted binding pose of compound 144 is a representative example
For this  series of compounds, a total of four derivatives  were designed and 
synthesised. As previously said, the general approach in this drug 
optimisation study is  to prepare new derivatives  while maintaining the 
aromatic  substituents  that were associated to antiviral activity on the hit 
structure. In this  case, the t-butyl group on the aromatic acryloyl moiety 
was kept, but it was not possible  to purchase or prepare the benzimidazole 
moiety with 3,4-diethoxy, p-hydroxyl and p-cyclohexyl functional groups. 
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Following reported procedures and according to the starting materials 
commercially available, the unsubstituted and para methyl derivatives 
were prepared. The introduction of the benzimidazole ring increases the 
rigidity of the overall structure, therefore the double bond at the level of 
the acryloyl moiety was  reduced in two of the four derivatives, in order to 
understand the effect of this modification on the activity of the new 
compounds. Figure 4.10 shows the predicted binding mode for compound 
144 as  a representative example. Docking studies  for the two  scaffolds 
exhibit a similar occupational space comparable to lead structure 110, with 
all the key interactions maintained. 
4.5.1 N-(1H-Benzo[d]imidazol-2-yl)-3-(4-tert-butylphenyl)acrylamides 
(144, 145)
The synthetic pathway toward the synthesis of 144 and 145 (Scheme 4.7) 
consists  in a coupling reaction between (E)-3-(4-tert-butylphenyl)acrylic acid 
153 and substituted 2-aminobenzimidazoles 150, 151 using TBTU as 
coupling agent.56 (E)-3-(4-tert-butylphenyl)acrylic acid 153 was synthesized 
from 4-tert-butylbenzaldehyde 152, following the procedure described 
above for compounds 119-122, while substituted 2-aminobenzimidazoles 
150,  151 were obtained by cyclization of aryl 1,2-diamines 148,  149 using 
cyanogen bromide.
TBTU, DIPEA
THF, r.t., 4h
N
H
O
N
H
N
R
O
OH
O
HOOC COOH+
pyr, reflux, 2h
cat. piperidine
144: R = H
145: R = Me
BrCN
N
H
N
NH2
R
+
R NH2
NH2
H2O/MeOH (1:1) 
     50 oC, 1h
148: R = H
149: R = Me
150: R = H
151: R = Me
153, 84%152
Scheme 4.7: Synthetic pathway for compounds 144, 145
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Synthesis of substituted 2-aminobenzimidazoles (150, 151)
Following reported procedures, compounds 150,  151 (Scheme 4.8) were 
obtained by addition of cyanogen bromide to a 1:1 solution of MeOH and 
water where the aryl 1,2-diamine was previously dissolved.57  The 
mechanism of this reaction is  a nucleophilic addition between one amino 
group of the aryl 1,2-diamine and the electrophilic carbon of the cyanogen 
bromide. Final substituted 2-aminobenzimidazoles  150,  151 were obtained 
by ring closure of the N-(2-aminoaryl)cyanamide intermediate formed.58
Aryl 1,2-diamine R Product Yield %
148 H 150 87
149 Me 151 87
Scheme 4.8: First step synthesis for compounds 150, 151
(E)-3-(4-tert-butylphenyl)acrylic acid (153)    
                                                                                       
Intermediate 153 (Scheme 4.9) was synthesised according to a Knoevenagel 
reaction, previously described for compounds 119-122, starting from 4-
tert-butyl benzaldehyde 152. The crude product was purified through flash 
column chromatography to obtain the pure product with a 84 % of yield.
S y n t h e s i s o f ( E ) - N - ( 1 H - b e n z o [ d ] i m i d a z o l - 2 - y l ) - 3 - ( 4 - t e r t -
butylphenyl)acrylamides (144, 145)
Final amide derivatives were prepared by a coupling reaction between 
substituted 2-aminobenzimidazoles 150,  151 and (E)-3-(4-tert-
butylphenyl)acrylic acid 153 using TBTU as a coupling reagent (Scheme 
4.9). O-(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate 
is a member of the uronium-type reagents  used for efficient amide bond 
formation under mild reaction conditions. Like most coupling agents, 
uronium reagents  are able to enhance the electrophilic characteristic of the 
H2O/MeOH (1:1) 
     50 oC, 1h
R NH2
NH2 N
H
N
NH2
R
BrCN
148, 149 150, 151
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carbonyl carbon towards nucleophilic substitution by the formation of a 
highly reactive intermediate ester. 59
OH
O
153
TBTU, DIPEA
THF, r.t., 4h
N
H
O
N
H
N
R
144, 145150, 151
N
H
NR
NH2
Aryl 1,2-diamine intermediate R Product Yield %
150 H 144 12
151 Me 145 10
Scheme 4.9: Final step synthesis for compounds 144, 145
4.5.2 (N)-)1H-Benzo[d]imidazol-2-yl)-3-(4-tert-butylphenyl)propanamides 
(146, 147)
A second series of derivatives bearing the benzimidazole ring at the level 
of the hydrazone group was  designed with an additional modification: the 
C-C double bond was reduced in order to decrease the rigidity of the 
molecule, that was intensified by the introduction of the ring. For the 
preparation of compounds  146,  147 a different synthetic pathway was 
followed (Scheme 4.10). (E)-3-(4-tert-Butylphenyl)acrylic acid 153 was first 
reduced to  3-(4-tert-butylphenyl)propanoic acid 154 that was successively 
converted to the correspondent aryl propanoyl chloride 155. Final 
compounds 146, 147 were obtained by a nucleophlic  substitution between 
2-aminobenzimidazoles 150, 151 and 3-(4-tert-butylphenyl)propanoyl 
chloride 155.
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Scheme 4.10: Synthetic pathway for compounds 146, 147
Synthesis of 3-(4-tert-butylphenyl)propanoic acid (154)
Following reported procedures, the C-C double bound in (E)-3-(4-tert-
butylphenyl)acrylic acid 153 (Scheme 4.10) was reduced by a Pd/C-
catalyzed hydrogenation in THF. The desired product was obtained without 
further purification with a 99 % of yield.60
Synthesis of 3-(4-tert-butylphenyl)propanoyl chloride (155)
3-(4-tert-Butylphenyl)propanoyl chloride 155 (Scheme 4.10) was 
synthesized by a chlorination reaction with oxalyl chloride in DCM, 
following reported procedures.61 Final compound 155 was obtained with 
83% of yield and was used for the following step without further 
purification.
OH
O
OH
O
H2, Pd/C
THF, r.t., 4h
154, 99%
Cl
O
155, 83%
Cl
Cl
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DCM, r.t., 5h
N
N
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NH2
R
      DIPEA
THF, reflux, 2h
N
H
O
N
HN
R
146, 147
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150, 151
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Synthesis of benzoimidazol-3-(4-tert-butylphenyl)propanamides (146, 
147)
Final amide derivatives  146,  147 were prepared by nucleophilic 
displacement of the chloride leaving group by primary amino function of 
substituted 2-aminobenzimidazoles 150,  151 in anhydrous conditions, 
using DIPEA to neutralize the hydrochloric acid formed.62
Cl
O
N
N
H
NH2
DIPEA, THF, reflux, 2h NH
O
N
HN
R
R 155
150, 151 146, 147
Aryl 1,2-diamine intermediate R Product Yield %
150 H 146 5
151 Me 147 5
Scheme 4.11: Final step synthesis for compounds 146, 147
4.5.3 Biological evaluation
New derivatives  144-147 were evaluated for their antiviral activity and 
cytotoxicity in a virus-cell-based assay (table 4.2).
Compound X R EC50 (µM) EC90 (µM) CC50 (µM) SI
110 (lead compound) 3.2 11 101 32
144 CH=CH H >157 >157 - -
145 CH=CH Me >300 >300 - -
146 CH2CH2 H >311 >311 - -
146 CH2CH2 Me >298 >298 - -
Table 4.2: activity and cytotoxicity data for compounds 144, 145
X
H
N
O N
H
N
R
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None of the new four derivatives was  related to  activity improvement. It 
could be speculated that the increased rigidity of the overall molecule by 
the introduction of a benzimidazole ring has affected the activity of the 
molecules. For the derivatives  bearing the reduced C-C  bond, it is not 
possible to hypothesize if one or both modifications affected the activity of 
the molecule. Different new modifications were planned aiming to  improve 
the stability of the overall structure.
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4.6 Synthesis of 1-phenethyl-4-phenyl-1H-1,2,3-triazole (157)
A second attempt to reduce the instability of the molecule due to the 
presence of the hydrazone group was the introduction of a triazole ring. 
The design of this compound was also  supported by the biological data on 
derivative 156 (Scheme 4.11), that was  previously synthesized in our lab. 
The rational behind the design of this compound was to  replace the 
hydrazide group with an oxadiazole ring. Derivative 156 was found to have 
a retained antiviral activity. Based on these results, compound 157 
designed and prepared in order to see the effect of a different 5-
heterocyclic ring on the biological activity.
Figure 4.11: Chemical scaffold of triazole-based structures and predicted binding 
mode of compound 157. Key interactions with the residues of the binding site were 
maintained
A three-step synthetic pathway was planned for the preparation of 
compound 157 (Scheme 4.12), starting with the synthesis  of 2-
(azidoethyl)benzene 159 that was used for a regiospecific copper(I)-
N
NN
O
N N
EC50 = 17 µM
EC90 = 21 µM
156
157
 Chapter 4 - Chikungunya Virus
128
catalyzed reaction with the formation of the only 1,4-disubstituted 1,2,3-
triazole 159.63
Scheme 4.12: Synthetic pathway applied for the synthesis of compound 157
Synthesis of 2-(Azidoethyl)benzene (159)  
                                                  
Intermediate 159 was prepared by a nucleophilic displacement of the 
bromide leaving group by sodium azide.64  The desired product was 
obtained with a 73 %  yield and was used for the following step without 
further purification.
Synthesis of 1-phenethyl-4-p-tolyl-1H-1,2,3-triazole (157)     
                                                                                                                       
Final compound 157 was prepared by a variant of the Huisgen 1,3-dipolar 
cycloaddition, which enables the formation of 1,4-disubstituted 1,2,3-
triazole in a regiospecific manner by a copper(I)-catalyzed reaction between 
a terminal acetylene and an azide. The reaction was performed according 
to a referred procedure, preparing the catalyst in situ by reduction of CuII 
salts.65 CuSO4 . 5 H2O was used as  a source of CuII and sodium ascorbate as 
the reducing agent. The reaction can be carried out at r.t. and in different 
solvents with no base or co-solvent needed. The mechanism of reaction 
was postulated by Vsevolod et al. and it is shown in scheme 4.13. It is 
believed that the stepwise catalytic process starts with the formation of a 
NaN3
DMF, 80 oC, 24h
Na ascorbate
 CuSO4
H2O, DCM, r.t., 
 24h
Br N3
+
N
NN
158 159, 73%
160
157, 25%
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Cu (I) acetylide intermediate and successively with the formation of a six-
membered copper-containing intermediate. Protonation then takes place 
followed by dissociation of the product and regeneration of the catalyst-
ligand complex.66  Final product 157 was  obtained pure after 
recrystallization, in acceptable yield (25 %).
N
N
N
LnCu
R'
R
N
N
N
R'
R
+H+
[LnCu]+
R'R'
- H+
N
N
LnCu
NR
R'
N
N
LnCu
R
N
R'
direct
NR N N
LnCu
I
II
III
IV
Scheme 4.13: Proposed mechanism of triazole formation
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4.6.1 Biological evaluation
1-Phenethyl-4-p-tolyl-1H-1,2,3-triazole was evaluated for its antiviral 
activity and cytotoxicity in a virus-cell-based assay (table 4.4).
Compound EC50 (µM) EC90 (µM) CC50 (µM) SI
110 (lead compound) 3.2 11 101 32
157 122 189 200 1.6
Table 4.3: activity and cytotoxicity data for compound 157
The biological result revealed a loss of antiviral activity for compound 157 
compared to the lead compound 110. It is not possible to infer if the loss 
of activity is  related to the ring introduced or to  the absence of the t-butyl 
group. Based on these preliminary data, no additional modifications were 
planned on this  scaffold. Further improvement studies led to the design 
and preparation of new classes of compounds that will be described below.
N
NN
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4.7 Synthesis of N-((E)-(4-tert-butyl)styryl)-2-
(benzylidene)hydrazinecarboxamides 
Based on previous results obtained from a series of semicarbazone-based 
compound (e.g. compound 161, Figure 4.12), the aim of this series of 
compounds was to introduce this group on the structure of the lead 
compound 110. The rational behind the preparation of compound 161 was 
to replace the hydrazide group of the lead compound 110 with a new 
moiety that could decrease the liposolubility (LogP 110= 5.94; LogP 161= 
4.18). The new  derivatives 162-165 would benefit from the presence of the 
semicarbazone moiety, since it is  a more chemically stable functional 
group. The essential functional groups on the two aromatic moieties, which 
are the t-butyl group on one benzene ring and four groups (3,4-OEt, 4-OH, 
4-Me, 4-C6H11) on the level of the benzene ring, were kept as  already known 
to be the most relevant for the antiviral activity. 
Figure 4.12: Chemical scaffold of semicarbazone derivatives and predicted binding 
mode for compound 163 as a representative example
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4.7.1 N-((E)-(4-tert-Butyl)styryl)-2-(benzylidene)hydrazinecarboxamides 
The synthetic  pathway followed (Scheme 4.14) consists of three steps, 
starting from the preparation of (E)-3-(4-tert-butylphenyl)acrylic  acid 153, 
according to  described procedures,67 that was used for the synthesis of the 
correspondent azide 166. Through Curtis rearrangement, intermediate 166 
was converted to  (E)-1-(tert-butyl)-4-(2-isocyanatovinyl)benzene 167, that 
was not isolated and used for the condensation with aryl hydrazones 
126-128 and 168 to finally obtain the designed compounds 162-165.
N3
O
N
C
O
H
N
H
N
O
N
R3
R2
N NH2
R3
R2
R1
Toluene
120 oC, 4h
OH
O
I. Et3N, ClCOOEt, 0 oC, 1h
II. NaN3, H2O, 0 oC, 7h
r.t., o.n.
R1
166, 63%153
167
126-128, 168
162-165
Scheme 4.14: Synthetic pathway applied for the synthesis of compounds 162-165
S y n t h e s i s o f ( E ) - 3 - ( 4 - t e r t - b u t y l p h e n y l ) a c r y l o y l a z i d e 
(166)
The synthesis of the azide intermediate 166 (Scheme 4.14) was carried out 
following a reported procedure.68 (E)-3-(4-tert-Butylphenyl)acrylic acid 153, 
synthesized by Knoevenagel reaction, was converted to the corresponding 
anhydride (which was  not isolated) by reaction with ethyl chloroformate in 
the presence of a base (triethylamine).69 The azide ion was then attached to 
the most electrophilic  carbonyl which gave the desired product in a 63 % 
yield.
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Synthesis of 4-(hydrazonomethyl)phenol (168)
Intermediate 168 (Scheme 4.15) was synthesized through the formation of 
a Schiff base between 4-hydroxybenzaldehyde 169 and hydrazine 
monohydrate.70 
Scheme 4.15: Synthesis of compound 168
Synthesis of N-((E)-(4-tert-butyl)styryl)-2-
(benzylidene)hydrazinecarboxamides (162-165)
Final compounds 162-165 (Scheme 4.16) were prepared by reaction 
between the isocyanate derivative 167, formed by the azide intermediate 
166, and aryl hydrazones. The isocyanate derivative 167 was prepared by a 
Curtius rearrangement that was not isolated. Curtius rearrangement is a 
concerted two-step reaction. Nitrogen gas  is  lost with heating, forming an 
acyl nitrene derivative which is  unstable. The second step is  a thermal 
decomposition of acyl nitrene to form the desired isocyanate. Aryl 
hydrazones  126-128 and 168, previously prepared by reported procedures, 
were added to  the reaction mixtures to react with the electrophilic carbon 
of the isocyanate group to give the final products. 
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162-165
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167
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R3
N
R1
NH2
126-128, 168
R2
Aryl hydrazones R1 R2 R3 Product Yield %
126 H H Me 162 43
127 H OEt OEt 163 11
128 Me H C6H11 164 29
168 H H OH 165 40
Scheme 4.16: Final step synthesis for compounds 162-165
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4.7.2 Biological evaluation
Newly synthesized derivatives  were evaluated for their antiviral activity 
and cytotoxicity in a virus-cell-based assay (table 4.4).
Compound R1 R2 R3 EC50 (µM) EC90 (µM) CC50 (µM) SI
110 (lead compound) 3.2 11 101 32
162 H H Me 246 >298 192 0.8
163 H OEt OEt >100 >100 - -
164 Me H C6H11 42.3 78.7 123 2.9
165 H H OH 5.63 7.48 10.4 1.8
Table 4.4: Biological data for compounds 162-165
From the biological data, it can be inferred that this modification has not 
improved the activity of the original compound 110.  From a EC50 point of 
view, 165 has a retained activity but this  compound is  mainly associated 
with an adverse effect against cells (low CC50). Compound 164 is  linked to 
a certain activity but at higher concentrations than the lead compound, 
while the other two derivatives were associated to loss of antiviral activity.
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4.8 Synthesis of 2-(benzylidene)-N-aryl hydrazinecarbothiamides
Similarly to the semicarbazone derivatives, a second attempt to increase 
the solubility of the original hit structure was  the introduction of a 
thiosemicarbazone (LogP 170= 8.41; LogP 172= 6.21). This  modification 
was also supported by biological results  of a previous compound, 170 
(data not shown, Scheme 4.13), bearing the thiourea linker that showed 
antiviral activity at low micromolar concentration, even if it was associated 
also to cytotoxicity effect (unpublished data).
Figure 4.13: Chemical scaffold of the thiosemicarbazone derivatives and predicted 
binding mode of compound 172 as a representative example. Key interactions are 
maintained
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4.8.1 2-(Benzylidene)-N-aryl hydrazinecarbothiamides
The chemical pathway followed (Scheme 4.17) consists  of a two step 
synthesis  starting from the formation of (2-isothiocyanatoethyl)benzene, 
that gives  final compounds 171-174 by condensation reaction with aryl 
hydrazones, previously synthesized according to reported procedures.71
Scheme 4.17: Synthetic pathway applied for the synthesis of compounds 171-174
Synthesis of (2-isothiocyanatoethyl)benzene (176)   
                                            
The synthesis  of (2-isothiocyanatoethyl)benzene 176 (Scheme 4.17) was 
realized by nucleophilic attack of 2-phenylethanamine 175 and 
thiophosgene in THF, in the presence of triethylamine that neutralizes the 
hydrochloric  acid formed.72 The product was obtained with 100 %  yield and 
was used for the following step without further purification.
2-(Benzylidene)-N-aryl hydrazinecarbothiamides (171-174)
Final derivatives  171-174 (Scheme 4.18) were obtained by a condensation 
reaction between (2-isothiocyanatoethyl)benzene 175 and the substituted 
hydrazones  118-120 and 168, using toluene as solvent and stirring the 
reaction at r.t., o.n.
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Aryl hydrazone 
intermediates
R1 R2 R3 Product Yield %
118 H H Me 171 15
119 H OEt OEt 172 10.5
120 Me H C6H11 173 10
168 H H OH 174 16
Scheme 4.18: Final step synthesis for compounds 171-174
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4.8.2 Biological evaluation
Four derivatives were prepared and evaluated for their antiviral activity 
and cytotoxicity in a virus-cell-based assay (table 4.6).
Compound R1 R2 R3 EC50 (µM) EC90 (µM) CC50 (µM) SI
110 (lead 
compound)
3.2 11 101 32
171 H H Me >336 >336 - -
172 H OEt OEt 5.91 9.82 109 18
173 Me H C6H11 4.32 5.95 52.9 12.2
174 H H OH 48.3 51.8 87.8 1.8
Table 4.5: Antiviral activity and cytotoxicity of compounds 171-174
Among the new scaffolds, compounds  172 and 173 were associated with a 
positive antiviral effect against CHIKV replication, with an EC50 value that 
indicated activity retention compared to  lead compound 110.  Considering 
the biological data, it is  possible to assume that the antiviral activity is 
correlated with the presence of a bulky group in para position of the aryl 
hydrazone, as it was already seen for the reference compound 102. While 
compound 171 shows to a loss of antiviral activity, compound 174 is 
associated mainly to a cytotoxic effect.
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Conclusions
A structure-activity relationship approach was applied in this study, where 
several modifications were made on the lead structure 110,  previously 
identified in our lab. 26 compounds were synthesized and evaluated for 
their antiviral activity against CHIKV replication.
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From the biological results, it can be inferred that the removal of t-butyl 
group is detrimental for antiviral activity, since its  replacement with 
bulkier and smaller groups is associated to loss of activity. Many attempts 
were made to replace the poorly water stable hydrazide group. From the 
data obtained so  far, the introduction of a group that increases  the rigidity 
of the molecule, such as benzimidazole, is linked to loss of activity, while 
an increased cytotoxic effect was observed for the semicarbazone 
derivatives that were synthesized not only to contribute to the stability of 
the structure, but also to increase the solubility in water of the new 
derivatives. 
Two new scaffolds were explored, based on previous compounds showing 
antiviral activity. While for the triazole derivative 157 no  interesting 
activity profile was observed, two compounds bearing a thiosemicarbazone 
linker, derivatives 172,  173 were associated to a retained biological 
activity. This scaffold could be subject of further development to confirm 
these preliminary data.
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Respiratory Syncytial 
Virus
Chapter 5
Introduction
5.1 Respiratory Syncytial virus
Respiratory syncytial virus  (RSV) is considered as the major cause of lower 
respiratory tract infections  in infants and young children.1 Worldwide, RSV 
is responsible for nearly 34 million episodes of acute lower respiratory 
tract infections yearly and 3.4 million episodes that required 
hospitalization.2  The risk of death is not even rare: about 66,000 to 
199,000 deaths  per year of children younger than 5 years old were 
estimated to be caused by RSV infection.1,3  RSV is  highly contagious  and 
can infect people multiple times. RSV is  transmitted in humans via the 
nasopharynx and the eyes; it spreads through contact with infected 
individuals  or through coughing and sneezing. Period of incubation is 
around 3-5 days. RSV can cause a variety of symptoms: mild upper tract 
illness, like rhinitis, cough, ear infection that can progress to acute otitis, 
apnoea, but also  more severe diseases, like pneumonia and bronchiolitis, 
that are indication of the virus spreading into the lower respiratory tract. 
Older adults and children with pathologies like congenital heart disease, 
lung malformations and neuromuscular disease are at risk for severe 
infections.4 The virus replicates  in the superficial layer of the respiratory 
epithelial cells and is shed from the apical surface to  get into the lumen of 
the respiratory tract.5
5.1.1 Virion structure
The RSV virus particle has a diameter ranging from 150 to 350 nm that is 
surrounded by a lipid bilayer envelope. Two proteins are inserted into the 
envelope, forming spikes  on it: the glycoprotein (G), responsible for 
binding of the virus to receptors  on the host cell surface and the fusion (F) 
glycoprotein that participates in the fusion event between the viral particle 
and the host cell membrane.6,7  An additional small hydrophobic (SH) 
glycoprotein is also made by the virus, for which the function is unknown.
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Figure 5.1: Schematic representation of RSV virion structure
5.1.2 Genome organization
RSV is  a enveloped, negative, single strand RNA virus that belongs to the 
Paramyoxiviridae family (Pneumovirinae subfamily of the Mononegavirales 
order).8 It is  divided in two groups: 10 genotypes are in the subgroup A, 
while 13 have been designated in group B.9  Its genome is 5.2 kb and 
encodes 10 genes that are transcribed into ten separate mRNAs.10  Two 
extragenic sites are present at both extremities  of the genome: at the 3’-
end, a leader region (Le) contains promoter sequences  essential for 
transcription of subgenomic mRNAs and RNA replication of a full-length 
antigenome intermediate;11 at the 5’-end, a trailer (Tr) region that contains 
the promoter that signals the synthesis of genome RNA in the antigenome 
intermediate.12 
NS1 NS2 N P M SH G F M2
L
3’
le tr
5’
1 2
End Intergenic Start
Figure 5.2: Representation of the eleven viral genes, including one example of 
intergenic sequence, with end (GE) and start (SG) genes
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Downstream of the Le region are NS1-NS2-N-P-M-SH-F-G-M2-L genes. 
Between two sequential genes, there is an intergenic sequence composed of 
a gene start (GS) and a gene end (GE) sequences that regulates  transcription 
termination, polyadenylation and reinitiation.13
5.1.3 Viral proteins
RSV is one of the most complex virus  of the Paramyxoviridae family with 
its ten proteins that can be divided into two groups. The first group is 
made by structural proteins, which are the polymerase L, the nucleoprotein 
N, the phosphoprotein P, the matrix, the transmembrane proteins G, the F, 
SH and M2-1 proteins. The second group is characterized by NS1, NS2 
which are defined as non-structural proteins, while M2-2 is  a regulatory 
factor. As in most of the RNA viruses, the L polymerase has a crucial role. 
It takes part in the synthesis  of complementary, positive-sense RNA that 
must occur before the translation of the RNA genome, once the virus has 
entered into the cell. This event distinguishes the RNA process between 
positive and negative RNA viruses. Positive RNA genome is  infectious itself 
when introduced to host cells and does not package an RNA polymerase. It 
can be directly translated into several proteins, including the RNA 
polymerase that will replicate the viral genome and synthesize mRNAs. 
Negative RNA viruses  are not infectious  themselves, they need to be 
transcribed into  positive-sense mRNAs and, for this reason, they require 
the polymerase which is packaged in the virion. Once it enters the host cell 
with the genome RNA, it uses cellular ribonucleoside triphosphates for the 
mRNA synthesis. L polymerase is also responsible for capping, methylation 
at the 5’-end and polyadenylation at the 3’-end.14  The nucleoprotein N, 
encoded in the N gene, is a protein bound to the genome responsible for 
the formation of the helical nucleocapsid and it is relevant for genome 
replication and transcription.15,16 ,17 ,18  The phosphoprotein P coordinates 
binding between L and N proteins19 and affects the functionality of M2-1 
protein by interacting with it.20 Furthermore, it participates in the assembly 
of the N protein on RNA chains  for the formation of nucleocapsid.21 While 
M2-1 protein is an antitermination trasnscription factor,22  for which a 
detailed description will be provided, M2-2 protein is responsible for 
switching the RNA transcription step to the RNA replication.23  Three 
glycoproteins form the envelope of the virion: protein G, a type II 
transmembrane glycoprotein, responsible for the virus attachment, the 
fusion F protein, which mediates the viral entry by a mechanism of fusion 
between the virion and the host cell membrane and, finally, the small SH 
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glycoprotein that increases the function of G and F proteins.24,25 ,26  G, F and 
SH proteins, all together, form the typical spikes  of RSV virions. Finally, the 
matrix M protein, which is on the inner surface of the viral envelope, seems 
responsible for virus assembly and budding,27 but also inhibits the host-
cell transcription.28  Non-structural proteins NS1 and NS2 are 
multifunctional accessory proteins. It has been suggested that they could 
have a role in the RNA synthesis, but they also seem to interfere with the 
induction of interferon (IFN) transcription.29,30
5.1.4 Viral life cycle
The life cycle of RSV starts, as in most of the cases, with the recognition of 
cellular receptors that allows the attachment of the viral particle. Upon 
binding to the receptor mediated by the G protein, F protein is  activated 
and the fusion process between the envelope and the host cell membrane 
occurs. The viral nucleocapsid then enters the cell and transcription is 
activated. This event, that leads  to the synthesis  of 10 subgenomic mRNAs, 
occurs by a sequential mechanism named ‘stop and re-start process’: when 
RdRP locates a gene start (GS), it starts synthesizing mRNA; when it comes 
across to a gene end (GE), it polyadenylates and releases the new 
mRNA.31,3233  The transcription is then (re)initiated when RdRP scans the 
template and finds a new GS signal. On the contrary, when the polymerase 
replicates the full genome, GS and GE are ignored and a full length positive 
sense, the antigenome, is produced.34  Eventually, newly nucleocapsids 
migrate from the cytoplasm to the plasma membrane and will interact with 
the M protein. Viral particles are then assembled and released from the 
infected cells by budding from the plasma membrane.35
Figure 5.3: RSV life cycle
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5.1.5 Current treatment
There is  no specific  cure for treating viral RSV infection at the moment, 
although RSV is  considered one of the most common pathogens among 
children worldwide.36  Current treatment is mainly supportive and is 
focused on curing symptoms and avoiding complications.37,38  The major 
actions  consist in providing adequate oxygenation, hydration and 
ventilation, mechanical and through the use of broncodilators. 
Corticosteroids, nebulized agents, like albuterol and epinephrine are 
commonly used.39  Prevention is limited to  a humanized monoclonal 
antibody, Palizumab (Synagis®) that is used only in pediatric patients with 
risk for developing acute lower respiratory infection (ALRI) due to the high 
cost of the product.40,41  The only available drug approved in 1986 from 
FDA for the treatment of RSV is  ribavirin (Virazole®) that can be used 
intravenously, orally and as  aerosol.42 However, for safety and economical 
reasons, its clinical use is limited to people at high risk for developing 
complication.43 
5.1.6 New treatments under development
At the moment, there are several compounds  in clinical trials  for the 
treatment of RSV infection. Two drugs targeting the nucleocapsid N protein 
are currently in Phase II clinical trials: ALN-RSV01,44  a siRNA that could 
represent a new class of agents  to treat human disease and the small 
molecule RSV-604 (Figure 5.4).45  Many efforts have been spent on the 
development of molecules targeting F protein. No clinical studies  have been 
reported for BMS433771, a promising molecule discovered by Bristol-Meyer 
Squibb.46 In other cases, the clinical development has been stopped, as was 
for BTA9881 produced by Biota Holdings Ltd. Only two molecules under 
clinical development are reported: MDT-637, developed by MicroDose 
Therapeutic, is  currently in phase I47  and GS-5806 in Phase 2.48 Among 
entry inhibitors, MBX-300, a sulphated sialyl lipid, has been developed as 
an attachment inhibitor active against G protein. This agent has been 
evaluated in preclinical studies, but no further studies have been recently 
announced. Finally, nucleoside analogues were developed by Chimerix and 
are currently under preclinical studies.
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Therapeutic description Company/Istitution
Development 
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Figure 5.4: Overview of the RSV therapeutic agents currently in clinical evaluation 
and chemical structures of RSV-604, MDT-637 and GS-5806
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5.1.7 Vaccines under development
Despite the socio-economical impact of RSV infections, no vaccine is 
available so far. Several strategies have been made in the past and are 
currently under studies.49 Figure 5.5 shows an overview of vaccines that 
are now in clinical evaluation.
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Figure 5.5: Overview of vaccines currently under clinical evaluation50 
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5.2 M2-1 Protein
The HRSV M2-1 protein is  an essential transcription antitermination 
cofactor of the viral RNA-dependent RNA polymerase (RdRP) complex that 
increases the polymerase function. It is important for the synthesis of full-
length mRNAs but also enhances  the synthesis  of polycistronic 
mRNAs.51,52 ,53  More specifically, the functional activity of this  protein is  to 
prevent the termination of the transcription event, which has been already 
described. Furthermore, M2-1 protein is important for HRSV replication, 
but the role is still unknown. All these important functions makes the M2-1 
protein a good target for the design of antiviral compounds.54
5.2.1 Structure 
The crystal structure of the M2-1 protein has  been recently released (PDB 
ID: 4C3B).54 M2-1 has  been classified as  a RNA binding protein that is 
associated to the viral genome, together with three other proteins (the 
nucleoprotein N, the phosphoprotein P and the polymerase subunit L). 
These four proteins form the holonucleocapsid.55 M2-1 protein is formed 
by 194 amino acid and it assumes a tetrameric structure in solution (figure 
5.6).56 
Figure 5.6: Ribbon model of HRSV M2-1 tetramer. Each monomer has a different 
color
Previous studies have predicted four functionally important domains of the 
M2-1 protein: an N-terminal zinc-binding domain (ZBD, residues 7-25), with 
a Cys3-His1 motif that is  thought to be involved in RNA binding; an 
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oligomerization domain (residues 33-45); a central part, or core domain 
(residues 53-177), that is related to RNA and phosphoprotein P binding 
and, finally, a C-terminal tail which is less structured.57,58 ,59 The only stable 
form of this protein is the tetramer: each monomer has extensive contact 
regions with other protomers. The structure of the core domain reveals a 4-
helix bundle at its  center (α1, α2, α5, α6) and an hairpin (α3-α4).54 Extensive 
interactions have been identified between the ZBD and the N-terminal face 
of the core of the neighboring monomer, which confirms the importance of 
the zinc motif for the tetramer integrity. In addition, it is  possible that ZBD 
is involved in RNA binding due to  its  close proximity to the RNA binding 
surface.
Figure 5.7: Cartoon representation of the α helical core domain of M2-1 protein
RNA binding site
A vast positively charged surface is  present in the M2-1 protein that would 
facilitate electrostatic interactions with the negatively charged RNA and P 
protein. Several studies54,57 led to the identification of the M2-1 residues 
involved in RNA binding: Ser58 and 61, Lys92 and 150, Arg151 and Lys159, 
which are within the core, but also  Arg3 and 4 that are on the N-terminal 
region. Ser58 and 61 are critical for the protein activity: they are 
phosphorylated during infection, which reflects a reduced RNA binding 
ability, thus affecting the antitermination function of the protein. 
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Moreover, those residues  outside and within the core are believed to be 
essential for RNA binding and, as a consequence, for protein function.
P binding site
A second surface of the M2-1 protein critical for its  function is  the binding 
site of the phosphoprotein P. It is  suggested that this  protein binds to 
residues of the helices α4, α5, α6. The P region is proximal and partially 
overlaps with the RNA binding site. By mutagenesis  studies, the residues 
involved in P binding were also confirmed: mutants  of Arg126, Thr130, 
Lys148, Thr160 and Asn163 did not bind P in vitro and were related to  an 
M2-1 transcription impairment. A final conclusion can be arisen: binding of 
both RNA and P is essential for M2-1 transcription antitermination. 
Figure 5.8: Surface representation formed by 8 residues and colored according to 
the region of the M2-1 they belong: red for the RNA binding and blu for P binding 
5.2.2 Mechanism of action
The mechanism of action of M2-1 is  still not completely clear, but different 
hypotheses were postulated. A first scenario could be an increased affinity 
of the polymerase for the genomic RNA template, while a second 
hypothesis suggests that the M2-1 protein binds  the nascent mRNA 
transcript and enables  the transcription elongation by preventing the 
mRNA to form certain secondary structures that could make the 
transcription complex less stable.7
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5.3 Fusion protein
The process of RSV infection consists  in the attachment and fusion of the 
viral particle to the target cell membrane through envelope glycoproteins. 
The G protein, in particular, is  responsible for the binding to receptors 
present on the surface of the host cells, while the fusion protein enables 
the viral genome to enter into the cell through fusion of the viral 
membrane with the target cell membrane.60,61 ,62 Due to  its essential role for 
viral entry, the F protein is an attractive target for drug and vaccine 
development. 
5.3.1 Structure 
The fusion protein is a type I transmembrane surface protein63  and it is 
synthesised as  an inactive precursor, F0,64 that is activated by proteolytic 
cleavage to yield two subunits linked by a disulfide bridge: F1 and F2.65,33 
The fusion peptide region, located at the N terminus of the F1 subunit, 
inserts into the target cellular membrane during the fusion process.66  The 
transmembrane region is  close to the C terminus  of the F1 subunit. 
Between these two segments, there are two regions  containing heptad 
repeats  (HR1 and HR2).67  A dramatic  conformational change in the 
structure of the F protein occurs when the fusion process  is triggered. A 
pre-hairpin intermediate is formed, in which the fusion peptide region is 
inserted in the target cell membrane. This intermediate, then, undergoes to 
a refolding that leads  to a highly stable post-fusion structure characterized 
by a six-helix bundle (6HB) containing heptad repeats HR1 and HR2.68 The 
fusion pore finally opens and leads the viral genome to  enter the target cell 
(figure 5.9). 
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Figure 5.9: Mechanism of viral and cell membrane fusion mediated by F protein
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5.3.2 RSV entry inhibitors targeting F protein
The literature describes several small molecules that inhibit the RSV entry 
by targeting the F protein. To our knowledge, there are currently only two 
drugs in clinical trials: MDT-637 in Phase I69  and GS-5806 in Phase 2.49 
Several of these inhibitors (BMS-433771, RFI-641, VP-14637, and BTA-9881) 
have been stopped at preclinical or Phase 1-2 studies, because of their lack 
of appropriate pharmaceutical properties. For most of them, the region 
targeted was a hydrophobic pocket formed by the trimeric coiled-coil. JNJ 
identified one compound, JNJ-2408068, with an extremely potent anti-RSV 
activity (EC50 = 0.16 nM).70 Further optimization studies, aiming to improve 
the low  elimination in tissue observed for JNJ-2408068, led to  the 
identification of a very promising drug candidate, TMC-353121 (Figure 
5.10), that is under preclinical studies for further development.71 
Figure 5.10: Chemical structure of TMC-353121
This compound has been found to  bind to  the 6-HB and to interact with 
both the HR1 and HR2 domains.72  In 2010, the crystal structure of 
TMC-353121 with a 6HB construct was resolved (PDB ID: 3KPE) in order to 
understand the binding mode of the compound. It was  suggested that the 
binding of the ligand induces the formation of a distorted 6HB, with the 
most conformational change involving a partial unwinding of the α-helical 
backbone of HR2. The rotameric state of three residues (Asp486, Asp200 
and Glu487), in particular, was  altered by this conformational change in 
order to have better interactions with the ligand. The crystal structure 
shows a network of hydrophobic and electrostatic interactions. The 
molecule nicely anchors the protein through the hydroxypyridine group 
that is  involved in several interactions with HR1, like a hydrogen bond with 
the carboxylate group of Asp200 and stacking interactions with Tyr198. 
The ligand interacts also  with residues of HR2, e.g. a hydrogen bond with 
Asp486 and the amino substituent group of the benzimidazole. Additional 
hydrogen bonds mediated by a molecule of water are established between 
N
HO
N
N
NH
N O
N
H
OH
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Glu487, the hydroxyl group in the hydroxypropyl chain and the 
hydroxypyridine. A mechanism of action has been hypothesized from the 
ligand binding mode. Although the compound bound to the protein 
disrupts the essential interactions between the two heptad-repeats, 
TMC-353121 increases the stability of the 6HB. However, it could prevent 
the formation of the appropriate protein conformation for the fusion step.
 
Figure 5.11: Binding mode and close-up interactions of TMC-353121
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Results and discussion
5.4 M2-1 protein as a target for drug design of new antivirals
The current research to combat RSV infection is  mainly concentrated to 
develop a safe vaccine for infants, but identifying antiviral compounds that 
would target specific viral functions, such as the RdRP complex, may 
represent a promising approach. M2-1 protein is an interesting target for 
the design of small molecules.4 In this study, two areas  were studied: the 
zinc binding domain that was evaluated to design and synthesise potential 
zinc-ejecting compounds, and the surfaces  where RNA and P bind, which 
are critical for the M2-1 function.
5.4.1 Zinc-binding domain of M2-1 protein as a target for de novo design
As already described, the zinc binding domain (ZBD) is one of the essential 
regions of the M2-1 protein. The zinc finger motif is specifically in the N-
terminus of the protein and interacts  with a proximal protomer, thus 
increasing the stability of the tetramer. There are evidences that the 
integrity of this motif represents a key element for maintaining the 
functionality of M2-1 protein.60 The sequence of the zinc finger motif (C-X7-
C-X5-C-X3-H), which has the Zn2+ ion coordinated by three cysteine residues 
and one histidine, is  slightly different if compared to other ZBDs, but 
resembles the one revealed for the human transcription factor Nup475. 
Figure 5.12: Close up of zinc binding domain. Cys3-His1 coordinated zinc atoms are 
shown in green with the N-terminal face of the core of an adjacent monomer 
represented in blue (PDB ID: 43CB).
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Based on a study that described the ability of 2,2’-dithiodipyridine 
(aldrithiol, AT-2),73 a known zinc  finger reactive compound, to inhibit RSV 
infectivity due to  modifications of the ZBD of M2-1 protein, the aim of this 
study was to design potential inhibitors  of RSV infection that, like AT-2, 
would act by modifying the zinc finger motif.
Zinc-ejecting compounds
Zinc ejection has been already described in the literature as a method of 
enzyme inhibition.74  A successful example of metal chelation by zinc-
ejecting compounds is represented by the effect of azodicarbonamides on 
the HIV nucleocapsid (NCp7) that selectively eject zinc  ions.75,76,77,78,79 One 
of these NCp7 zinc-ejecting compounds  is currently in phase I/II clinical 
trials against advanced acquired immunodeficiency disease syndrome 
(AIDS).80 On the basis of these promising results, the aim of this study was 
to design new scaffolds containing zinc-chelating moieties to interact with 
the zinc ion on the M2-1, thus affecting the functionality of the protein. 
5.4.2 De novo drug design
A computer-aided approach guided the design of a series of zinc-reactive 
compounds. The ZBD of M2-1 protein is a very tight binding pocket, 
defined by three cysteine residues and a histidine that have a simple 
geometry and form a planar ring that surrounds the Zn ion. Due to the 
delimited region, our approach was to use a library of small fragments that 
could guide the design of molecules  containing a zinc-ejecting group. To 
do so, a library of 1,611,889 ‘clean’ fragments from the commercially 
available ZINC database compounds was downloaded.81 ‘Clean’ fragments 
defines a subset of small ligands  for which filtering rules were applied, e.g. 
aldehyes and thiols are removed, logP is less  or equal to 3.5, molecular 
weight less than 250 and rotatable bonds equal or less than 5. The input 
database was further filtered by molecular weight in order to have a 
feasible number of small molecules to analyze: only those fragments with a 
molecular weight less  than 150 were taken into account for docking 
studies. A total of 12,420 ligands  was then docked to  the binding site, 
defined by the zinc  ion that is encircled by Cys7, Phe9, Glu10, Cys15, 
Asn17, Cys21, Phe23 and His25 residues. Since the purpose of this analysis 
is to explore the chemical space and evaluate which fragments could be 
able to interact with the residues selected, it was not necessary to use 
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accurate scoring functions, therefore the docking study was  performed 
with MOE. Three sites were specifically targeted: the one in close proximity 
to Cys3-His1 motif and two areas that surrounds the zinc finger. 
Figure 5.13: Representation of several fragments docked in the zinc binding site. 
Fragments are differently colored according to the targeted area
According to  docking results  and the availability of accessible reagents, 7 
fragments  were selected for the design and synthesis of a new  series of 
compounds. 
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5.5. Synthesis of aryl dithiocarbamates
Figure 4.14 shows the chemical scaffold of the new derivatives bearing a 
dithiocarbamate moiety, which is known to have metal ejecting 
properties.82
Figure 5.14: chemical scaffolds of designed compounds
According to the results  obtained from docking studies, a family of aryl-
dithiocarbamates was synthesised by reaction of an heterocyclic  amine 
with aryl chloride or bromide, as shown in sheme 5.1, where the common 
synthetic pathway applied is reported. Piperazine, N-methyl piperazine, 
benzyl piperazine, morpholine and piperidine were selected among the 
secondary amines validated in silico, while a set of aryl substituents was 
selected in order to  occupy the space in the pocket and increase the ligand 
binding.
Me Y2.
1. CS2, anhyd. NaOMe, DMF, 0 oC; r.t, 30'NH
X
N
X
S
S
Ar
(Cl, Br)
182-190,
194-197, 206-223
177-181
X = CH2, O, NCH3, NH, C6H5CH2CH
Scheme 5.1: Common synthetic pathway for the synthesis of aryl dithiocarbamates 
182-190, 194-197, 206-223
5.5.1 2-Chloromethyl benzimidazole carbodithioates (182-186)
In this first series  of compounds, a benzimidazole moiety was selected in 
order to  synthesise final dithiocarbamates  182-186 (Scheme 5.2), according 
to a reported procedure.83 
SN
S
X R
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177: X = CH2
178: X = O
179: X = -NCH3
180: X= -NH
181: X= C6H5CH2CH
2.
1. CS2, anhyd. NaOMe, DMF, 0 oC; r.t, 30'NH
X
N
X
S
S
N
H
N
N
H
N Cl
182-186
93
Scheme 5.2: Synthesis of compounds 182-186
Synthesis of benzyl piperazine (181)
Intermediate 181 (Scheme 5.3) was obtained by adding benzyl bromide to 
an excess of piperazine 180, according to  a referred procedure,84 in order 
to achieve a single nucleophilic displacement on the chloride leaving group. 
The desired compound was obtained in high yield (89%) and was used for 
the next step without further purification.
Scheme 5.3: Synthesis of compound 181
Synthesis of 2-chloromethyl benzimidazole carbodithioates (182-186)
Final compounds  182-186 were prepared in a one-pot reaction according to 
a general procedure for which an equimolar ratio of the appropriate 
alicyclic  secondary amine (177-181) and carbon disulfide were stirred at 
0 oC for 30’, in the presence of sodium methoxide, in order to get the 
formation of the dithiocarbamate salt. 2-Chloromethyl benzimidazole 93 
was successively added in order to get final compounds 182-186  (TLC 
analysis) through displacement of the chloride leaving group by the 
dithiocarbamate salt (scheme 5.4). The reaction conditions were adjusted 
for the synthesis of the derivative bearing a piperazine group: 0.5 
equivalents of carbon disulfide was added to piperazine 180 in order to 
prevent a double nucleophilic attachment on the two free amino groups. 
HN
NH
HN
NDCM, 0 oC, 1h
181, 89%180
Br
45
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2.
1. CS2, anhyd. NaOMe, DMF, 0 oC; r.t, 30'NH
X
N
X
S
S
N
H
N
N
H
N Cl
182-186177-181
93
Y Y
Starting alicyclic 
secondary amine 
X Y Product Yield %
177 CH2 - 182 12.3
178 O - 183 10.2
179 NCH3 - 184 11
180 NH - 185 10.3
181 CH C6H5CH2 186 17
Scheme 5.4: Pathway for the synthesis of compounds 182-186
5.5.2 2-Chloromethyl benzoxazole carbodithioates (187-190)
A second series of dithiocarbamates, 187-190, was synthesised following 
the general procedure described above and using this time 2-bromomethyl 
benzoxazole 193 (Scheme 5.5).
2.
1. CS2, anhyd. NaOMe, DMF, 0 oC; r.t, 30'NH
X
N
X
S
S
N
O
N
O Br
193
187-190177: X = CH2
178: X = O
179: X = -NCH3
181: X= C6H5CH2CH
Scheme 5.5: Pathway for the synthesis of compounds 187-190
Synthesis of 2-bromomethyl benzoxazole (193)
Intermediate 193 was  prepared according to a referred procedure (Scheme 
5.6) by a condensation reaction between 2-aminophenol 191 and 
bromoacetic acid 192, in the presence of an excess of polyphosphoric  acid 
(PPA).85 The reaction gives  the formation of the intermediate 2-bromo-N-(2-
hydroxyphenyl)acetamide, then the energy given by heating leads to ring 
closure with the synthesis of intermediate 193. The desired compound was 
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isolated from the unreacted intermediate through purification by flash 
column chromatography. 
NH2
OH
N
O Br
OH
O
Br+
polyphosphoric acid
130 oC, 48 h
193, 43%191 192
Scheme 5.6: Synthesis of intermediate 193
Synthesis of chloromethyl benzoxazole carbodithioates (187-190)
Final benzoxazole derivatives 187-190 were obtained following the 
common synthetic strategy described above.
2.
1. CS2, anhyd. NaOMe, DMF, 0 oC; r.t, 30'NH
X
N
X
S
S
N
O
N
O Br
193
187-190177-179, 181
Y Y
Starting alicyclic 
secondary amine 
X Y Product Yield %
177 CH2 - 187 94
178 O - 188 14
179 NCH3 - 189 19.5
181 CH C6H5CH2 190 29
Scheme 5.7: Synthesis of compounds 187-190
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5.5.3 2-Chloromethyl benzothiazole carbodithioates (194-197)       
                                 
A final series of heterocyclic aromatic compounds, 194-197 (Scheme 5.8), 
was obtained by reaction of secondary alicyclic amines with 2-chloromethyl 
benzothiazole.
2.
1. CS2, anhyd. NaOMe, DMF, 0 oC; r.t, 30'NH
X
N
X
S
S
N
S
N
S Cl
200 194-197
177: X = CH2
178: X = O
179: X = -NCH3
181: X= C6H5CH2CH
Scheme 5.8: Pathway for the synthesis of compounds 194-197
Synthesis of 2-chloromethyl benzothiazole (200)
Intermediate 200 was synthesized by condensation reaction between 2-
aminothiophenol 198 and chloroacetic  acid 199 (Scheme 5.9). The desired 
compound was  obtained with a 50% yield after purification by flash column 
chromatography.
Scheme 5.9 Synthetic pathway for intermediate 200
SH
NH2
r.t., o.n. N
S Cl
Toluene
HO
O
Cl+
200, 50%198 199
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Synthesis of 2-chloromethyl benzothiazole carbodithioates (194-197)
Final compounds 194-197 were obtained by the already described pathway, 
through nucleophilic attack on the chloromethyl benzimidazole by the 
dithiocarbamate ion (Scheme 5.9).
2.
1. CS2, anhyd. NaOMe, DMF, 0 oC; r.t, 30'NH
X
N
X
S
S
N
S
N
S Cl
200 194-197177-179, 181
Y Y
Starting alicyclic 
secondary amine 
X Y Product Yield %
177 CH2 - 194 66
178 O - 195 75
179 NMe - 196 27
181 CH C6H5CH2 197 42
Scheme 5.9: Synthesis of compounds 194-197
5.5.4 Aryl dithioates (196-220)
The same strategy applied for the previous compounds was  carried out 
used for the synthesis of another family of aryl dithioates, 206-220 
(Scheme 5.10). Different substituents in the meta and/or para positions  of 
the aryl bromide were explored, as they were predicted to give interactions 
with the residues of the ZBD, while on the other side of the molecule the 
alicyclic amines used before were maintained. 
 CS2, anhyd. NaOMeNH
X
N
X
S
S
Br
R
177-181 203-205 206-220
DMF, 0 oC; r.t, 30'
+
177: X = CH2
178: X = O
179: X = -NCH3
181: X= C6H5CH2CH
203: R = H, R1 = CF3
204: R = NO2, R1 = H
205: R = NO2, R1 = COOMe
R1
R
R1
Scheme 5.10: Synthetic pathway for compounds 196-220
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Synthesis of methyl 4-(bromomethyl)-3-nitrobenzoate (202)
The intermediate methyl 4-(bromomethyl)-3-nitrobenzoate 202 was 
synthesised by reaction of the correspondent carboxylic acid 201 in MeOH 
(Scheme 5.11). 
Scheme 5.11: General procedure for the synthesis of intermediate 202
Synthesis of aryl dithioates (196-220)
According to the described procedure,14 fifteen new derivatives were 
prepared (Scheme 5.12).
NO2
HO
O
Br
NO2
O
O
Br
SOCl2, MeOH
reflux, o.n.
202, 82%201
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 CS2, anhyd. NaOMeNH
X
N
X
S
S
Br
R
177-181 203-205 206-220
DMF, 0 oC; r.t, 30'
+
R1
R
R1
Y Y
 
Alicyclic 
secondar
y amine
X Y
Aryl 
bromid
e
R R1 Product
Yield 
%
177 CH2 - 203 CF3 H 206 88.5
178 O - 203 CF3 H 207 18.5
179 NMe - 203 CF3 H 208 11.5
180 NH - 203 CF3 H 209 32
181 CH C6H5CH2 203 CF3 H 210 16.5
177 CH2 - 204 H NO2 211 20
178 O - 204 H NO2 212 29
179 NCH3 - 204 H NO2 213 14
180 NH - 204 H NO2 214 16
181 CH C6H5CH2 204 H NO2 215 16
177 CH2 - 205 CO2Me NO2 216 83
178 O - 205 CO2Me NO2 217 26
179 NCH3 - 205 CO2Me NO2 218 33
180 NH - 205 CO2Me NO2 219 75.5
181 CH C6H5CH2 205 CO2Me NO2 220 82.7
Scheme 5.12: Synthetic pathway for final compounds 206-220
5.5.5 Dithiocarbamate methyl aryl acids (221-224)
Methyl ester derivatives  216-218 and 220 were used for the synthesis  of 
their related acids 221-224 by a base-catalysed hydrolysis with lithium 
hydroxide, as shown in Scheme 5.13.86
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XN S
S NO2
O
O
X
N S
S NO2
OH
O
LiOH, H2O
THF, 24h, r.t.
216-218, 220 221-224
Y
Ester 
derivative
X Y Product Yield %
216 CH2 - 221 94
217 O - 222 14
218 NCH3 - 223 19.5
220 CH C6H5CH2 224 10
Scheme 5.13: Synthetic pathway for final compounds 221-224
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5.5.6 Biological evaluation
All designed compounds were kindly tested in cell-based assay by Dr. Ivy 
Widjaja, under the supervision of Professor Xander den Haan at Utrech 
University. Activity is  expressed for each compound in terms of IC50, that is 
the inhibitory concentration (µM) of compound required to  inhibit RSV 
replication by 50%. Cytotoxicity is evaluated in terms of CC50, that is the 
cytostatic/cytotoxic concentration (µM) required to observe 50% of adverse 
effect on the host cell. The selectivity index, SI, is evaluated by calculating 
the ratio CC50/IC50 (table 5.1, 5.2).
Compound X Z Y IC50 (µM) CC50 (µM) SI
182 CH2 - N 20 130 6.5
183 O - N 47 NA -
184 NMe - N 56 NA -
185 NH - N NI NA -
186 CH C6H5CH2 N 18 29 1.6
187 CH2 - O 39 NA -
188 O - O NI NA -
189 NMe - O NI NA -
190 CH C6H5CH2 O 36 123 3.4
194 CH2 - S NI NA -
195 O - S NI NA -
196 NMe - S NI 102 -
197 CH C6H5CH2 S 6 NA -
Table 5.2: Antiviral activity and cytotoxicity of compounds 182-197; NI= no 
concentration-dependent inhibition, NA= not affected
X
N S
S
N
Y
Z
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Compound X Y R R1
IC50 
(µM)
CC50 
(µM)
SI
206 CH2 - CF3 H 25 95 3.8
207 O - CF3 H 43 133 3
208 NCH3 - CF3 H 19 78 4.1
209 NH - CF3 H NI NA -
210 CH C6H5CH2 CF3 H 30 NA -
211 CH2 - H NO2 43 130 3
212 O - H NO2 20 27 1
213 NCH3 - H NO2 27 36 1.3
214 NH - H NO2 NI NA -
215 CH C6H5CH2 H NO2 26 160 6.1
216 CH2 - CO2Me NO2 155 NA -
217 O - CO2Me NO2 42 NA -
218 NCH3 - CO2Me NO2 90 NA -
219 NH - CO2Me NO2 49 44 0.8
220 CH C6H5CH2 CO2Me NO2 27 NA -
221 CH2 - CO2H NO2 36 NA -
222 O - CO2H NO2 NI NA -
223 NCH3 - CO2H NO2 NI NA -
224 CH C6H5CH2 NO2 99 NA -
Table 5.2: Antiviral activity and cytotoxicity of compounds 206-220; NI= no 
concentration-dependent inhibition, NA= not affected
In general, all the analogues having a piperazine moiety are not associated 
to antiviral effect, as well the aryl acid derivatives, 221-224, for which no 
concentration-dependent inhibition was observed. The most active 
compound is the benzothiazole carbodithioate derivative 197, showing a 
IC50 value of 6 µM and no cytotoxic effect on the cells. An antiviral effect 
X
N S
S R1
RY
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was also  observed for two  analogues, 215,  220, sharing the common 
benzyl piperazine moiety with the derivative 197. 
Figure 5.15: Chemical structure and predicted binding mode of compound 197
Figure 5.15 shows the putative binding mode for compound 197 that 
occupies the region, lying on the surface of the binding pocket and 
interacting with Cys15 through a H-bond.
On the other hand, all the other derivatives  bearing the 4-
benzylpiperazine-1-carbodithioate group, were associated with cytotoxic 
effect, as in the case of compound 186, or with an higher IC50, as for 
compounds 190, 210. Three more derivatives, 182,  206 and 208 showed a 
range of activity of 20-25 µM, sharing between each other some common 
features. Both compounds 182 and 206 contain the piperidine ring, while 
the derivative 208, which has a N-methyl piperazine on the level of the 
alicyclic  amine, shares the 4-trifluoromethyl benzyl moiety with the 
analogue 206.
N
N S
S
N
S
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5.6 Structure-based virtual screening on the M2-1 protein
A structure-based virtual screening was performed on the M2-1 protein. 
The target site selected was  the dual P/RNA binding site. Although both, P- 
and RNA-binding sites, are on the surface of the protein, hence solvent 
exposed, the first one has a cleft that may accommodate a ligand. Due to 
the essential role demonstrated for Arg126, Thr130, Lys148, Lys150, 
Arg151, Thr160, and Asn163, the aim was to  identify compounds that 
would be able to bind the region delimited by these residues. A recently 
published crystal structure of M2-1 protein (PDB ID: 4C3B), with high 
resolution (2.95 Å), was  used for a structure-based virtual screening. The 
region selected for this computational study is delimited by the already 
cited residues, of which Thr160 represent a key amino acid, since it buries 
into the protein domain and can represent a good anchoring point for the 
molecules. 
5.6.1 Pharmacophoric filter and docking methods
A pharmacophore was designed and used to pre-screen the Specs library. 
As had been previously done for the other studies, a conformational search 
with MOE2010.10 was performed for the creation of a conformational 
database of the compounds to be screened.87 The target residues of the P/
RNA binding site were considered in order to build the pharmacophoric 
query, made by seven features: two acceptor and metal ligator groups to 
interact, respectively with Arg126 (F1:Acc&ML) and Arg151 (F2:Acc&ML), 
the latter one being a key amino acid that is  on the interface between the 
RNA and phosphoprotein P binding sites; a donor group to interact with 
Thr160 (F3:Don) and a hydrophobic atom group to interact with side 
chains of Asp163 and Thr130 (F4:HydA); a donor & metal ligator group in 
correspondence to  Asn163 (F5: Don&ML) and, finally, two  hydrophobic  and 
linker groups to interact with Tyr134 side chain (F6:Hyd&Link) and with 
Leu148 (F6:Hyd&Link). Excluded volumes were added after selecting the 
features, of which four were kept as  essential and a partial match of 5 was 
required.
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Figure 5.15: Pharmacophoric model based on the 4C3B crystal structure
A pharmacophoric  search was run on the conformational database of the 
Specs compounds and a total of 5636 hit molecules was found and kept 
for the docking phase. Ligand preparation (LigPrep) was  then performed on 
the output conformational database and two low energy conformations per 
ligand were produced. As already described in section 2.3.3, the usual 
docking procedure was followed, running Glide docking standard precision 
(SP) mode and re-scoring the output database with Plants 88 and FlexX 89  
scoring functions, which were combined in a final consensus scoring 
analysis (section 1.3.5). The 25% best performing structures (1416) were 
selected and visually inspected to  identify which ones  could best interact 
with the selected residues. Fourteen molecules were selected and 
purchased for biological evaluation (Appendix I). The biological results 
were performed by Dr. Ivy Widjaja, under the supervision of Professor 
Xander den Haan at Utrecht University. Some of the selected compounds 
showed antiviral effect as well as cytotoxicity in cell-based assay. 
Compound 225 was found to have a good activity profile: the IC50 value for 
RSV replication was 16 µM, with a CC50 of 76 µM. Its structure and 
predicted binding mode are shown in figure 5.16.
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Figure 5.16: Chemical structure of compound 225 and its predicted binding mode
Compound 225 is predicted to be located on the lower part of the binding 
site, making hydrogen bonds with Lys159 and Thr160, while showing 
hydrophobic  interactions with the side chain of Thr130. Further biological 
data are required to confirm the preliminary data and to  assess  the activity 
of the compound on the M2-1 protein. 
N
N
OH
O
IC50 = 16 µM; 
CC50 = 76 µM;
SI = 4.75
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5.7 Ligand-based Virtual Screening on the F protein
A ligand-based virtual screening was performed on the crystallized ligand, 
TMC-353121, with the aim to find new scaffolds that would interact with 
the binding site of the F protein, by sharing the active conformation of the 
reference compound. The iter followed for this study is  the one previously 
described in section 2.9.1. The conformational database of the SPECS 
compounds was  analysed against the selected conformation of 
TMC-353121 with the vROCS 3.1.2 software,90 considering both shape and 
electrostatics  complementarity with the target query for the evaluation of 
screened structures. In figure 5.17, the queries chosen as  essential 
parameters for the screening are highlighted. They were selected on the 
base of previous studies that revealed the importance of those functional 
groups for the activity of the molecule.42
Figure 5.17: Chemical structure of TMC0353121 and its electrostatic features set 
for the screening.
All screened conformations  that answered to the required parameters were 
analyzed by docking and rescoring procedures. Around 600 molecules 
were selected from the consensus  scoring and were visually inspected in 
order to reduce the final selection to 7 molecules, purchased and tested in 
cell-based assays  (Appendix I). Among them, two  molecules showed 
antiviral effect at concentration values to be considered for a structure-
activity evaluation. However, these compounds  were also associated to 
cytotoxic effect on cell viability assay, thus  excluding their chemical 
structure for further optimization studies.
N
HO
N
N
NH
N O
N
H
OH
Donor 
Ring 
Acceptor/donor 
Acceptor 
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Compound Chemical structure IC50 (µM) CC50 (µM) SI
226
N
N
N
HN
HN
S
O
15 36 2.4
227 N N O
CF3
24 48 2
Table 5.3: Antiviral activity and cytotoxicity of compounds 226-227
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Conclusions
Computer-aided approaches were performed, aiming to identify potential 
RSV inhibitors. Starting from the active conformation of a known inhibitor 
of the fusion protein, a ligand-based virtual screening led to the selection 
of seven compounds, of which two were found active with a IC50 of 20 µM, 
but also having cytotoxic  effect. In parallel, a structure-based drug design 
virtual screening was  performed on the recently released crystal structure 
of M2-1 protein. The targeted binding area corresponds to the RNA and P 
binding sites. Among the 14 chosen compounds, several were associated to 
antiviral activity but were toxic for the cells. Compound 225 showed a 
good activity profile, with a IC50 of 16 µM, and will represent a valuable 
starting point for drug optimisation.
An additional study was  performed on the zinc-binding domain of the 
same protein, M2-1, where a de novo design approach was applied. Using a 
library of small fragments that was docked within the active site, a series 
of 32 compounds, all having a common zinc-ejecting moiety, was designed 
and synthesized. Preliminary biological data reveal a good activity profile 
for compound 197, sharing a common chemical group with derivatives 215 
and 220 that were also associated to antiviral effect against RSV.
N
N
HO
225
O
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From these evaluation, it can be inferred that the length of the molecule is 
important for activity, with longer structures associated with a better 
antiviral profile and no cytotoxic effect on the cell viability assay, while for 
a second set of shorter compounds, 182,  206 and 208,  the CC50 values, 
even if still acceptable, were lower than the previous  ones, thus reducing 
their selectivity index.
N
N S
S
R
 R =
       197
IC50 = 6 µM
CC50 = NA
N
S
         215
IC50 = 26 µM
CC50 = 160 µM
NO2
MeOOC
        220
IC50 = 27 µM
CC50 = NA
O2N
; ;
                  182 
IC50 = 20 µM; CC50 = 130 µM
                     206
IC50 = 25 µM; CC50 = 95 µM
N S
S
R
;
N
N S
S
CF3
                   208
IC50 = 19 µM; CC50 = 78 µM
N
H
N F3C
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Conclusions
Conclusions
The main scope of this  project was  to use in silico approaches for the 
identification of potential antivirals. During the course of this study, 
different structural proteins of four RNA viruses were investigated. For 
CVB3, in particular, the homodimer 3A protein was evaluated for a 
structure-based virtual screening on the two chains of the dimer after 
building an homology model of the protein. One compound was selected 
from the in vitro assays  with a certain antiviral activity, which was taken as 
a starting point for the design and synthesis of a small series of 10 
analogues.
1
The biological evaluation of the new compounds did not reveal an activity 
improvement. Due to  the lack of information on the protein and on the 
existence of inhibitors of the 3A protein, a second non-structural protein 
was targeted for drug design. The 3D polymerase was  the objective of a 
second study based on the available information on a novel non-nucleoside 
inhibitor, GPC-N114 that inhibits the viral replication by competing with an 
incoming nucleotide. Several computer-aided approaches were used: at 
first, a structure-based virtual screening on the putative active site; 
secondly, flexible alignment of six new scaffolds that were designed with 
the aim to change the central chlorobenzene ring and the two oxygen 
linker of the GPC-N114 structure.
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A total of 32 new derivatives were synthesized, of which only compound 
52 was  associated to antiviral activity, higher than the GPC-N114 
compound. 
52
Due to the poor antiviral properties, its  chemical scaffold was not further 
investigated. A final attempt was made to use the active conformation of 
the GPC-N114 compound for a ligand-based virtual screening, from which 
no new interesting scaffolds were selected. The investigation around GPC-
N114 implied also a study on a new virus, FMDV, which belongs  to  the 
Picornavirus family, like CVB3. This inhibitor, however, is not active against 
FMDV but was found to bind the same pocket individuated for CVB3 3D. A 
structure-based drug design was first attempted in order to find small 
molecules  that could have a better interaction with the residues  of the 
binding site. From the biological results  of the selected molecules, no 
potential inhibitors were identified. A second de novo approach was then 
attempted which led to the selection of a common scaffold bearing a 
coumarin ring. A small series  of 8 compounds was synthesized and tested 
against FMDV, but no antiviral activity was observed. 
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A more classic medicinal chemistry approach was  used in the case of 
Chikungunya virus, for which a novel inhibitor has been previously 
identified with a structure-based virtual screening on the nsP2 protease. 
Based on its  chemical structure and on the biological results obtained for 
the novel analogues that followed the discovery of the new inhibitor, four 
new families of compounds were designed, validated with docking 
techniques and synthesised in order to establish a SAR study. Of these, the 
chemical scaffold bearing a thiourea linker seems to  be associated to  a 
retained antiviral activity. Additional studies, however, are required to 
evaluate the activity of these compounds on the target nsP2 protease that 
was evaluated for in silico studies.
Some interesting results were also  obtained on a series  of studies  drove on 
the M2-1 protein of RSV. From a structure-based virtual screening 
performed on the surface of the protein where RNA and the 
phosphoprotein P binds, compound 225 inhibits viral replication. 
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On the same crystal structure of M2-1 protein, but targeting the zinc 
binding domain, a de novo drug design guided the selection of a common 
scaffold bearing a zinc-ejecting moiety that was  specifically chosen in 
order to design and prepare 32 zinc-reactive molecules. Of these, six 
compounds inhibited RSV replication at low micromolar concentration 
without substantial effect on cell viability.
This scaffold represents  a promising starting point for future structural 
modifications. However, additional biological tests have already planned to 
investigate their mechanism of action of these compounds  and see whether 
the entry or the viral replication is affected. In conclusion, this project 
confirms the relevance of molecular modelling techniques in drug design: 
their advantages and the usefulness  for the identification of novel, 
potential active compounds.
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Experimental part
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Chapter 6
6.1 General information
All chemicals, reagents and solvents were purchased from Aldrich or 
purified by standard techniques.
Thin Layer Chromatography
Silica gel plates (Merck Kieselgel 60F254) were used and were developed by 
the ascending method. After solvent evaporation, compounds were 
visualised by irradiation with UV light at 254 nm and 366 nm.
Column Chromatography
Glass columns were dry packed in the appropriate eluent under gravity, 
with Woelm silica (32-63 µm). Samples  were applied as  a concentrated 
solution in the same eluent. Fractions containing the product were 
identified by TLC, combined and the solvent removed under pressure.
NMR Spectroscopy
1H, 13C, NMR spectra were recorded on a Bruker AVANCE 500 spectrometer 
(500 MHz and 75 MHz respectively) and auto  calibrated to the deuterated 
solvent reference peak. Chemical shifts are given in δ relative to 
tetramethylsilane (TMS); the coupling constants (J) are given in Hertz. TMS 
was used as an internal standard (δ = 0 ppm) for 1H NMR and CDCl3 served 
as an internal standard (δ = 77.0 ppm) for 13C NMR.
Melting Point
Melting points  were determined on an electrothermal instrument, Griffin 
apparatus and are uncorrected.
Mass Spectroscopy
Low resolution mass spectra ES (Electrospray) were recorded on a Micro 
TOF LC Bruker Daltonic instrument, operating in a positive ion mode.
Microanalysis
Microanalysis data were performed by Medac Ltd., Brunel Centre, Surrey. 
6.1.1 Molecular Modelling
Molecular Operating Environment (MOE) 2010.10 and the Maestro platform 
(Schrodinger version 9.0) were used as molecular modelling softwares.
All minimisations were performed with MOE until RMSD gradient of 0.001 
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Kcal mol-1 Å-1 with the AMBER99 force field and the partial charges were 
automatically calculated.
Pharmacophoric filters were created within MOE 2010.10 choosing the PCH 
(polar-charged-hydrophobic) scheme.
Docking experiments were carried out with Glide SP mode in Maestro. All 
molecule databases  used for virtual screening were processed with the 
LigPreP tool in Maestro which enables to make corrections, optimise or 
eliminate structures. Outputs generated were refined with Glide SP, ‘refine-
do not score’ tool. All refined docking results were re-scored using Plants, 
FlexX and Glide XP scoring functions. Molecules were selected by a 
consensus scoring function which combines  information from every 
docking analysis in order to balance errors in single scores. Three 
functions were searched for every set of docking score. The first quartile 
value which splits  the lowest 25 %  of data (negative energy values) 
representing the best values  of the scoring results. The mathematical 
function sign was  calculated in order to  define whether a docked pose 
belongs  to  the best 25% for every scoring function. A value of ‘+1’ was 
assigned if that docked pose is  among the best 25%  solutions and a value 
of ‘-1’ if not. Finally, the three sign values, each one for every scoring 
function, was calculated in order to take into account only the ones with a 
sign sum equal to +3. 
The shape-comparison screening was performed with vROCS version 3.1.2. 
Both shape and colour screen criteria were applied to the query. Output 
conformations were ranked by the Tanimoto  Combo score and the Shape 
Tanimoto score.
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6.2 Synthesis of tetrazole derivatives
6.2.1 General procedures 1-5
General procedure 1: synthesis of aryl isothiocyanates
A solution of aryl aniline (1 eq.) and triethylamine (2.2 eq.) in ethyl acetate 
(5.9 mL/mmol eq.) was  treated with thiophosgene (1.09 eq.) in ethyl acetate 
(4.4 mL/mmol eq.), dropwise over 30 min at 0oC. After the addition, the 
cooling bath was removed and the reaction mixture was allowed to 
gradually warm up to  room temperature over 12 h. The reaction mixture 
was diluted with ethyl acetate, then washed with water (2 x 6.6 mL/mmol 
eq.) and brine (2 x 6.6 mL/mmol eq.). The organic layer was evaporated at 
reduced pressure after drying over MgSO4 and the product was  purified by 
flash column chromatography or obtained as pure aryl isothiocyanate.
General procedure 2: synthesis of aryl mercaptotetrazoles
To a sodium azide (3 eq.) solution in water (2 mL/mmol eq.), was added the 
aryl isothiocyanate (1 eq.). The reaction mixture was  heated at 100 oC  for 
16 h. The reaction was  quenched in an ice-bath with 0.1 M HCl to pH 1 and 
then extracted with EtOAc (2 x 3.3 mL/mmol eq.). The organic  layer was 
evaporated at reduced pressure after drying over MgSO4 and the product 
was purified by flash column chromatography or recrystallisation to  afford 
pure 1-aryl mercaptotetrazoles.
R
NH2
, EtOAc, 30', 0 oC
EtOAc, 12h, r.t.
Cl Cl
S
R
N
C
S
R
N
C
S
R
N
NH
N
N
S
NaN3
H2O, 100 oC, 16h
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General procedure 3: synthesis of (benzylthio)-1-aryl-1H-tetrazoles
To a mixture of 1-aryl mercaptotetrazole (1 eq.) and K2CO3 (1.5 eq.) in dry 
DMF (3.66 mL/mmol eq.) was  added the benzyl bromide (1 eq.) and the 
reaction was stirred under N2 at 80oC for 4.5 h. Upon completion, the 
reaction was suspended in H20 (2x 10.5 mL/mmol eq.), brine (2x 10.5 mL/
mmol eq.) and dried over MgSO4. The organic layer was removed at 
reduced pressure and then purified by flash column chromatography or 
recrystallization to afford the pure 5-(benzylthio)-1-aryl-1H-tetrazole.
General procedure  4: synthesis of (5-(benzylthio)-1H-tetrazol-1-
yl)benzoic acids
5-(Benzylthio)-1-aryl-1H-tetrazole (1 eq.) in THF (36.4 mL/mmol eq.) was 
treated with LiOH monohydrate (7.26 eq., 0.3 g in 17 mL of water). The 
mixture was stirred at room temperature for 24 h. Upon completion, the 
organic solvent was removed at reduced pressure and the residue was 
washed with EtOAc (2 x 33 mL/mmol eq.). The aqueous layer, cooled in an 
ice bath, was acidified with 3M HCl to pH 1-2 and stirred until the 
formation of a white precipitate. The precipitate was filtrated and dried to 
afford the pure product.
R
N
NH
N
N
S
R1
Br
K2CO3, DMF, 80 oC, 4.5h
R
N
N
N
N
S
R1
N
N N
NS
N
N N
NS
R
O OHO O
THF, r.t., 24h
R
LiOH.H2O
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General procedure  5:  synthesis of ethyl 4-(5-(benzylthio)-1H-tetrazol-1-
yl)benzoates
A solution of 4-(5-benzylthio)-1H-tetrazol-1-yl)benzoic  acid (1eq.) in EtOH 
(15.4 mL/mmol eq) was treated with sulphuric acid (1.15 mL/mmol eq.) at 
reflux, overnight. Upon completion, the solvent was  removed at reduced 
pressure and the residue was dissolved in ethyl acetate and saturated 
aqueous  NaHCO3 solution. The combined organic  layers were washed with 
NaHCO3 sat. (2 x 40 mL/mmol eq.) and water (2 x 40 mL/mmol eq.), dried 
over MgSO4 and concentrated at reduced pressure to afford the pure 
products.
N
N N
NS
N
N N
NS
R
O OO OH
R
EtOH
H2SO4, reflux, o.n.
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6.2.2 Aryl isothiocyanates (7-11)
Ethyl-4-isothiocyanatobenzoate (7)1 
(C10H9NO2S; M.W.= 207.25)
  2     7
General procedure: 1;
Reagent: Ethyl 4-aminobenzoate 2 (1 g, 6 mmol);
T.L.C. System: n-hexane -EtOAc 9:1 v/v, Rf: 0.43;
Yellow crystals;
Yield: 1.24 g, 99%
1H-NMR (CDCl3), δ: 1.42 (t, J= 7.1 Hz, 3H, H-3’), 4.40 (q, J= 7.1 Hz, 2H, H-2’), 
7.29 (d, J= 8.7 Hz, 2H, H-aromatic), 8.06 (d, J= 8.7 Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  14.29 (CH3, C-3’), 61.32 (CH2, C-2’), 125.60 (CH, C-
aromatic), 129.10 (C, C-aromatic), 131.01 (CH, C-aromatic), 136.9 (C, C-
aromatic), 146.9 (C, C-4’), 165.9 (C, C-1’).
1-Isothiocyanato-4-nitrobenzene (8)2 
(C7H4N2O2S; M.W.= 180.18)
           3            8
General procedure 1;
Reagent: 4-nitroaniline 3 (1 g, 7.24 mmol)
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.83;
Yellow solid;
Purification by flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 96:4 v/v);
NH2 N
C
S
O O
O O
1
2
2
3
4
4'
1'
2' 3
3'
NH2 N
C
S
1
2
2
3
4
1'
3O2N O2N
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Yield: 1.17 g, 90 %
1H-NMR (CDCl3),  δ:  7.37 (d, J= 2.1 Hz, 2H, H-aromatic), 8.27 (d, J= 2.1 Hz, 
2H, H-aromatic).
13C-NMR (CDCl3), δ:  125.27, 126.35 (CH, C-aromatic), 129.10 (C, C1), 136.9 
(C, C-aromatic), 146.9 (C, C-aromatic).
1-Isothiocyanato-4-methylbenzene (9)3 
(C8H7NS; M.W.= 149.21)
      4              9
General procedure 1;
Reagent: toluidine 4 (1 g, 9.33 mmol);
T.L.C. System: n-hexane -EtOAc 95:5 v/v, Rf: 0.9;
Brown oleum;
Yield: 1.26 g, 90.6 %
1H-NMR (CDCl3),  δ:  2.37 (s, 3H, H-aliphatic), 7.15 (d, J= 8.4 Hz, 2H, H-
aromatic), 7.17 (d, J= 8.4 Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  21.41 (CH3, C-2’), 125.86 (CH, C-aromatic), 129.90 (C, 
C-4), 137.53 (C, C-1), 146.9 (C, C-1’).
NH2 N
C
S
1
2
2
3
4
1'
32'
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1-Isothiocyanato-4-methoxybenzene (10)4 
(C8H7NOS; M.W.= 165.21)
         5             10
General procedure 1;
Reagent: 4-methoxyaniline 5 (1 g, 8.12 mmol);
T.L.C. System: n-hexane -EtOAc 9:1 v/v, Rf: 0.3;
Brown oleum;
Yield: 1.32 g, 98.5 %
1H-NMR (CDCl3),  δ: 3.82 (s, 3H, H-1’), 6.86 (d, J= 9.0 Hz, 2H, H-aromatic), 
7.18 (d, J= 9.0 Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  55.51 (CH3, C-1’), 114.23 (CH, C-aromatic), 123.53 (C, C-
aromatic), 125.06, 126.48 (CH, C-aromatic), 133.77 (C, C-aromatic), 158.58 
(C, C-2’).
4-Isothiocyanatophenol (11)5 
(C7H5NOS; M.W.= 151.19)
           6           11
p-Aminophenol 6 (1 g, 9.16 mmol) was  stirred with 1M HCl (11 mL) and 
thiophosgene (0.7 mL, 9.16 mmol) was added dropwise. The mixture was 
stirred at r.t. for 7 h. The oily product was extracted with diethyl ether (2 x 
15 mL) and dichloromethane (2 x 15 mL). The organic  layer was dried 
under MgSO4 to afford the pure product 4-isothiocyanatophenol as brown 
oleum.
T.L.C. System: EtOAc-MeOH 8:2 v/v, Rf: 0.45;
NH2 N
C
S
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2
2
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4
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3O O1'
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Yield: 1.37 g, 99 %
1H-NMR (CDCl3),  δ:  6.65 (bs, OH), 6.82 (d, J= 8.9 Hz, 2H, H-aromatic), 7.10 
(d, J= 8.9 Hz, 4H, H-aromatic).
13C-NMR (CDCl3),  δ:  116.40 (CH, C-aromatic), 123.34 (C, C-aromatic), 126.49 
(CH, C-aromatic), 133.77, 152.29 (C, C-1’).
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6.2.3 Aryl mercaptotetrazoles (12-16)
Ethyl 4-(5-thioxo-4,5-dihydro-1H-tetrazol-1-yl)benzoate (12)
(C10H10N4O2S; M.W.= 250.28)
  7     12
General procedure 2;
Reagent: ethyl 4-isothiocyanatobenzoate 7 (1.24 g, 5.98 mmol);
T.L.C. System: EtOAc-MeOH 9:1 v/v, Rf: 0.4;
Yellow solid;
Purification: flash column chromatography (n-n-hexane:EtOAc 100:0 v/v 
increasing to 50:50 v/v);
Yield: 0.6 g, 40%
1H-NMR (CDCl3),  δ:  1.45 (t, J= 7.2 Hz, 3H, H-3’), 4.46 (q, J= 7.2 Hz, 2H, H-2’), 
8.20 (d, J= 8.7 Hz, 2H, H-aromatic), 8.27 (d, J= 8.7 Hz, 2H, H-aromatic),  13.2 
(bs, H, NH).
13C-NMR (CDCl3),  δ:  14.48 (CH3, C-3’), 61.51 (CH2, C-2’), 125.76 (C, C-
aromatic), 125.79 (CH, C-aromatic), 129.27 (C, C-aromatic), 131.13, (CH, C-
aromatic), 166.0, 174.50 (C, C-1’, C-4’). 
1-(4-Nitrophenyl)-1H-tetrazole-5(4H)-thione (13)6
(C7H5N5O2S; M.W.= 223.21)
        8     13
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General procedure 2;
Reagent: 1-isothiocyanato-4-nitrobenzene 8 (1.17 g, 6.5 mmol);
T.L.C. System: EtOAc-MeOH 9:1 v/v, Rf: 0.46;
Orange solid;
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v 
increasing to 50:50 v/v);
Yield: 0.55 g, 38%
1H-NMR (DMSO-d6), δ:  8.35 (d, J= 9.1 Hz, 2H, H-aromatic), 8.45 (d, J= 9.1 
Hz, 2H, H-aromatic).
13C-NMR (DMSO-d6),  δ:  125.10, 125.17 (CH, C-aromatic), 138.98 (C, C-
aromatic), 146.98 (C, C-aromatic), 164.12 (C, C-1’).
1-(p-tolyl)-1H-tetrazole-5(4H)-thione (14)7 
(C8H8N4S; M.W.= 192.24)
         9           14
General procedure 2;
Reagent: 1-isothiocyanato-4-methylbenzene 9 (1.26 g, 8.44 mmol);
T.L.C. System: EtOAc-MeOH 9:1 v/v, Rf: 0.54;
White solid;
Purification: recrystallization from MeOH;
Yield: 0.94 g, 58%
1H-NMR (CDCl3),  δ:  2.48 (s, 3H, H-1’), 7.40 (d, J= 8.4 Hz, 2H, H-aromatic), 
7.81 (d, J= 8.4 Hz, 2H, H-aromatic), 13.98 (bs, NH).
13C-NMR (CDCl3),  δ:  21.32 (CH3, C-1’), 123.77 (CH, C-aromatic), 129.96 (CH, 
C-aromatic), 131.42 (C, C-aromatic), 140.32 (C, C-aromatic), 174.12 (C, C-1’).
N
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S
N
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N
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1-(4-Methoxyphenyl)-1H-tetrazole-5(4H)-thione (15)8
(C8H8N4OS; M.W.= 208.24)
        10     15
General procedure 2;
Reagent: 1-isothiocyanato-4-methoxybenzene 10 (1.32 g, 7.98 mmol);
T.L.C. System: EtOAc-MeOH 9:1 v/v, Rf: 0.59;
Brown oleum;
Yield: 1.16 g, 70 %
1H-NMR (CDCl3),  δ:  3.91 (s, 3H, H-1’), 7.08 (d, J= 9.0 Hz, 2H, H-aromatic), 
7.81 (d, J= 9.0 Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  55.68 (CH3, C-1’), 114.53, 125.65 (CH, C-aromatic), 
126.64 (C, C-aromatic), 160.52 (C, C-aromatic), 174.12 (C, C-2’).
1-(4-Hydroxyphenyl)-1H-tetrazole-5(4H)-thione (16)                 
(C7H6N4OS; M.W.= 194.21)
        11     16
General procedure 2;
Reagent: 4-isothiocyanatophenol 11 (1.37 g, 9.06 mmol);
T.L.C. System: EtOAc-MeOH 9:1 v/v, Rf: 0.54;
White solid;
Purification: recrystallization from MeOH;
Yield: 1.37 g, 78 %
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1H-NMR (DMSO-d6),  δ:  6.94 (d, J= 8.8 Hz, 2H, H-aromatic), 7.60 (d, J= 8.8 
Hz, 2H, H-aromatic), 10.05 (bs, NH).
13C-NMR (DMSO-d6),  δ:  115.52 (CH, C-aromatic), 126.09 (C, C-aromatic), 
126.31 (CH, C-aromatic), 158.40 (C, C-aromatic), 174.12 (C, C-1’).
Conclusions
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6.2.4 Benzylthio-1-aryl-1H-tetrazoles (20-25)
Ethyl 4-(5-(benzylthio)-4,5-dihydro-1H-tetrazol-1-yl)benzoate (20)
(C17H18N4O2S; M.W.= 340.42)
 12         17            20
General procedure 3;
Reagent: ethyl 4-(5-thioxo-4,5-dihydro-1H-tetrazol-1-yl)benzoate 12 (0.48 g, 
1.9 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.53;
Yellowish-brown oleum;
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 80:20 v/v);
Yield: 0.53 g, 83 %
1H-NMR (CDCl3),  δ:  1.43 (t, J= 7.1, 3H, H-3’), 4.44 (q, J= 7.1, 2H, H-2’), 4.66 
(s, 2H, H-5’), 7.29-7.35 (m, 3H, H-aromatic), 7.43-7.44 (m, 2H, H-aromatic), 
7.66 (d, J= 8.8 Hz, 2H, H-aromatic), 8.22 (d, J= 8.8 Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  14.28 (CH3, C-3’), 37.89 (CH2, C-2’), 61.61 (CH2, C-5’), 
114.53, 123.33, 128.33, 128.89 (CH, C-aromatic), 130.65 (C, C-aromatic), 
131.11 (CH, C-aromatic), 135.05, 135.54, 153.96 (C, C-aromatic), 165.07 (C, 
C-1’).
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5-(Benzylthio)-1-(4-nitrophenyl)-4,5-dihydro-1H-tetrazole (21)
(C14H13N5O2S; M.W.= 313.35)
  13  17                    21
General procedure 3;
Reagent: 1-(4-nitrophenyl)-1H-tetrazole-5(4H)-thione 13 (0.55 g, 2.46 
mmol);
T.L.C. System: n-hexane -EtOAc: 7:3 v/v, Rf: 0.94;
Yellow solid; 
Purification: recrystallization from MeOH;
Yield: 0.30 g, 38.9%;
Melting point: 69-72 oC; 
MS (ESI)+: 313.9 [M+H]+
1H-NMR (CDCl3), δ:  4.70 (s, 2H, H-2’), 7.31-7.39 (m, 3H, H-aromatic), 
7.44-7.46 (m, 2H, H-aromatic), 7.84 (d, J= 9.0 Hz, 2H, H-aromatic), 8.43 (d, 
J= 9.0 Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ: 38.14 (CH2, C-2’), 124.10, 125.29, 128.46, 128.97, 
129.27 (CH, C-aromatic), 134.77, 138.41, 148.00 (C, C-aromatic), 154.13 (C, 
C-1’).
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5-(Benzylthio)-1-(p-tolyl)-1H-tetrazole (22) 
(C15H14N4S; M.W.= 282.36)
      14   17    22
General procedure 3;
Reagent: 1-(p-tolyl)-1H-tetrazole-5(4H)-thione 14 (0.1 g, 0.52 mmol);
T.L.C. System: n-hexane -EtOAc: 8:2 v/v, Rf: 0.5;
White solid; 
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 90:10 v/v);
Yield: 0.08 g, 57 %; 
Melting point: 43-45 oC;
MS (ESI)+: 282.9 [M+H]+
1H-NMR (CDCl3),  δ:  2.43 (s, 3H, H-1’), 4.62 (s, 2H, H-3’), 7.35-7.27 (m, 3H, H-
aromatic), 7.41-7.36 (m, 2H, H-aromatic), 7.43-7.41 (m, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  21.26 (CH3, C-1’), 37.63 (CH2, C-3’), 128.16, 128.48, 
128.82, 129.56 (CH, C-aromatic), 130.30 (C, C-aromatic), 130.53 (CH, C-
aromatic), 135.37, 140.54 (C, C-aromatic), 153.91 (C, C-2’).
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5-(Benzylthio)-1-(4-methoxyphenyl)-1H-tetrazole (23) 
(C15H14N4OS; M.W.= 298.36)
 15   17          23
General procedure 3;
Reagents: 1-(4-methoxyphenyl)-1H-tetrazole-5(4H)-thione 15 (1.16 g, 5.57 
mmol);
T.L.C. System: n-hexane -EtOAc: 8:2 v/v, Rf: 0.3;
Red wax;
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 70:30 v/v);
Yield: 0.993 g, 59.6 %;
Melting point: 34-36 oC;
MS (ESI)+: 299.1 [M+H]+
1H-NMR (CDCl3),  δ:  3.87 (s, 3H, H-1’), 4.62 (s, 2H, H-3’), 7.02 (d, J= 6.9 Hz, 
2H, H-aromatic), 7.30-7.35 (m, 3H, H-aromatic), 7.37-7.44 (m, 4H, H-
aromatic).
13C-NMR (CDCl3),  δ:  37.57 (CH2, C-3’), 55.58 (CH3, C-1’), 125,55 (CH, C-
aromatic), 126.26 (C, C-aromatic), 127.59, 128.50, 128.84, 129.07 (CH, C-
aromatic), 135.35, 154.07, 160.76 (C, C-aromatic).
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Ethyl 4-(5-((4-methylbenzyl)thio)-1H-tetrazol-1-yl)benzoate (24) 
(C18H18N4O2S; M.W.= 354.43)
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 12        18                      24
General procedure 3;
Regent: 4-methylbenzyl bromide 17 (0.23 g, 1.2 mmol);
T.L.C. System: n-hexane -EtOAc: 8:2 v/v, Rf: 0.70;
White solid; 
Purification: recrystallization from MeOH;
Yield: 0.20 g, 47.6 %;
Melting point: 65-68 oC;
MS (ESI)+: 355.0 [M+H]+
1H-NMR (CDCl3),  δ:  1.43 (t, J= 7.0, 3H, H-3’), 4.43 (q, J= 7.0 Hz, 2H, H-2’), 
4.61 (s, 2H, H-5’), 7.13-7.24 (m, 2H, H-aromatic), 7.30-7.38 (m, 2H, H-
aromatic), 7.63-7.70 (m, 2H, H-aromatic), 8.19-8.25 (m, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  14.1 (CH3, C-3’), 21.3 (CH3, C-10’), 34.7 (CH2, C-5’), 60.9 
(CH2, C-2’), 122.5, 128.8, 129, 129.9 (CH, C-aromatic), 134.1 (C, C-aromatic), 
134.27 (CH, C-aromatic), 135.0, 136.8, 137.4, 155.1 (C, C-aromatic), 165.07 
(C, C-1’).
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Ethyl 4-(5-((4-chlorobenzyl)thio)-1H-tetrazol-1-yl)benzoate (25) 
(C17H15ClN4O2S; M.W.= 374.84)
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 12        19                    25
General procedure 3;
Reagent: 1-(bromomethyl)-4-chlorobenzene,19 (0.21 g, 1.03 mmol);
T.L.C. System: n-hexane -EtOAc: 8:2 v/v, Rf: 0.53;
White crystals;
Purification: recrystallization from MeOH;
Yield: 0.056 g, 15 %
Melting point: 160-163 oC
MS (ESI)+: 375.1 [M+H]+
1H-NMR (CDCl3),  δ:  1.44 (t, J= 7.1, 3H, H-3’), 4.44 (q, J= 7.1 Hz, 2H, H-2’), 
4.62 (s, 2H, H-5’), 7.31 (d, J= 8.4 Hz, 2H, H-aromatic), 7.40 (d, J= 8.4 Hz, 2H, 
H-aromatic), 7.66 (d, J= 8.6 Hz, 2H, H-aromatic), 8.23 (d, J= 8.6 Hz, 2H, H-
aromatic).
13C-NMR (CDCl3),  δ:  14.27 (CH3, C-3’), 37.01 (CH2, C-5’), 61.64 (CH2, C-2’), 
123.31, 129.05, 130.63, 131.16 (CH, C-aromatic), 131.87, 131.91, 133.76, 
134.27, 136.88 (C, C-aromatic), 165.07 (C, C-1’).
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4-(5-(Benzylthio)-1H-tetrazol-1-yl)phenol (26)
(C14H12N4OS; M.W.= 284.34) 
4-(5-((4-(benzyloxy)benzyl)thio)-1H-tetrazol-1-yl)phenol (27) (C21H18N4O2S; 
M.W.= 390.46)
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         16   17      26      27
Compound 26:
General procedure 3;
Reagent: 1-(4-hydroxyphenyl)-1H-tetrazole-5(4H)-thione 16 (1.37 g, 7.05 
mmol);
T.L.C. System: n-hexane -EtOAc: 7:3 v/v, Rf: 0.4;
White solid; 
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 85:15 v/v) and recrystallization from EtOAc/n-hexane;
Yield: 0.43 g, 21.5 %; 
Melting point: 85-88 oC;
MS (ESI)+: 284.9 [M+H]+
1H-NMR (CDCl3),  δ:  4.61 (s, 2H, H-2’), 6.91 (bs, OH), 7.06 (d, J= 6.4 Hz, 2H, 
H-aromatic), 7.27-7.46 (m, 7H, H-aromatic).
13C-NMR (CDCl3),  δ: 37.64 (CH2, C-2’), 116.63, 125.79 (CH, C-aromatic), 
125.86 (C, C-aromatic), 128.25, 128.87, 129.20 (CH, C-aromatic), 135.06, 
154.37, 157.88 (C, C-aromatic).
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Compound 27:
General procedure 3;
Reagent: 1-(4-hydroxyphenyl)-1H-tetrazole-5(4H)-thione 16 (1.37 g, 7.05 
mmol);
T.L.C. System: n-hexane -EtOAc, Rf: 0.75;
White solid; 
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 75:25 v/v);
Yield: 0.77 g, 28.5 %;
Melting point: 65-68 oC;
MS (ESI)+: 390.9 [M+H]+
1H-NMR (CDCl3),  δ: 4.63 (s, 2H, H-2’), 5.14 (s, 2H, H-7’), 7.10 (d, J= 7.4 Hz, 
2H, H-aromatic), 7.31-7.40 (m, 4H, H-aromatic), 7.41-7.47 (m, 8H, H-
aromatic).
13C-NMR (CDCl3),  δ:  37.62 (CH2, C-2’), 70.45 (CH2, C-7’), 115.76, 125.54 (CH, 
C-aromatic), 126.53 (C, C-aromatic), 127.48, 128.17, 128.33, 128.75, 128.84, 
129.23 (CH C-aromatic), 135.35, 136.07, 154.37, 159.92 (C, C-aromatic).
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6.2.5 (5-(Benzylthio)-1H-tetrazol-1-yl)benzoic acids (1, 28, 29)
4-(5-(Benzylthio)-1H-tetrazol-1-yl)benzoic acid (1)
(C15H12N4O2S; M.W.= 312.35)
   20    1
General procedure 4;
Reagent: ethyl 4-(5-(benzylthio)-1H-tetrazol-1-yl)benzoate 20 (0.32 g, 0.94 
mmol);
T.L.C. System: n-hexane-EtOAc: 9:1 v/v, Rf: 0.17;
White crystals;
Yield: 0.0942 g, 31.6 %;
Melting point: 149-152 oC;
MS (ESI)+: 312.9 M+H]+
1H-NMR (CDCl3),  δ:  4.69 (s, 2H, H-3’), 7.31-7.39 (m, 3H, H-aromatic), 7.74 (d, 
J= 8.8 Hz, 2H, H-aromatic), 7.45 (d, J= 5.4, 2H, H-aromatic), 8.29 (d, J= 8.8 
Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  37.97 (CH2, C-3’), 123.43, 128.35, 128.92, 129.26 (CH, 
C-aromatic), 130.30 (C, C-aromatic), 131.80 (CH, C-aromatic), 134.97, 
137.79, 153.99 (C, C-aromatic), 168.07 (C, C-1’).
N
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4-(5-((4-Methylbenzyl)thio)-1H-tetrazol-1-yl)benzoic acid (28)
(C16H14N4O2S; M.W.= 326.37)
  24     28
General procedure 4;
Reagent: ethyl 4-(5-((4-methylbenzyl)thio)-1H-tetrazol-1-yl)benzoate 24 (0.2 
g, 0.57 mmol);
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.14;
White solid; 
Yield: 0.064 g, 34 %;
Melting point: 163-165 oC;
MS (ESI)+: 327.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  2.27 (s, 3H, H-8’), 4.58 (s, 2H, H-3’), 7.12 (d, J= 2.0, 
2H, H-aromatic), 7.31 (d, J= 2.0, 2H, H-aromatic), 7.74 (d, J=1.9 Hz, 2H, H-
aromatic), 8.16 (d, J= 1.9 Hz, 2H, H-aromatic), 13.38 (bs, 1H, -COOH).
13C-NMR (DMSO-d6),  δ: 20.67 (CH3, C-8’), 36.68 (CH2, C-3’), 124.35, 129.02, 
129.10, 130.87 (CH, C-aromatic), 132.35, 132.84, 136.23, 137.16, 153.97 (C, 
C-aromatic), 166.11 (C, C-1’).
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4-(5-((4-Chlorobenzyl)thio)-1H-tetrazol-1-yl)benzoic acid (29)
(C15H11ClN4O2S; M.W.= 346.03)
   25    29
General procedure 4;
Reagent: ethyl 4-(5-((4-chlorobenzyl)thio)-1H-tetrazol-1-yl)benzoate 25 
(0.046 g, 0.11 mmol);
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.38;
White solid;
Yield: 0.013 g, 33 %;
Melting point: 102-104 oC;
MS (ESI)+: 347.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  4.62 (s, 2H, H-3’), 7.39 (d, J= 8.4, 2H, H-aromatic), 
7.48 (d, J= 8.4, 2H, H-aromatic), 7.76 (d, J= 8.7 Hz, 2H, H-aromatic), 8.16 (d, 
J= 8.7 Hz, 2H, H-aromatic), 13.45 (bs, 1H, -COOH).
13C-NMR (DMSO-d6),  δ:  35.90 (CH2, C-3’), 124.40, 128.48 (CH, C-aromatic), 
130.2 (C, C-aromatic), 130.89, 131.00 (CH, C-aromatic), 132.84, 135.39, 
137.16, 155.1 (C, C-aromatic), 166.11 (C, C-1’).
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6.2.6 Ethyl 4-(5-(benzylthio)-1H-tetrazol-1-yl)benzoates (30, 31)
Ethyl 4-(5-(benzylthio)-1H-tetrazol-1-yl)benzoate (30)
(C17H16N4O2S; M.W.= 340.40)
  1     30
General procedure 5;
Reagent: 4-(5-(benzylthio)-1H-tetrazol-1-yl)benzoic  acid 1 (0.08 g, 0.26 
mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.79;
Brown oleum;
Yield: 0.07 g, 87.5 %;
Melting point: 33-35 oC;
MS (ESI)+: 340.9 [M+H]+
1H-NMR (CDCl3),  δ:  1.44 (t, J= 7.1 Hz, 3H H-3’), 4.44 (q, J= 7.1 Hz, 2H, H-2’), 
4.67 (s, 2H, H-4’), 7.3-7.38 (m, 3H, H-aromatic), 7.45 (d, J= 6.9, 2H, H-
aromatic), 7.67 (d, J= 8.8 Hz, 2H, H-aromatic), 8.23 (d, J= 8.8 Hz, 2H, H-
aromatic).
13C-NMR (CDCl3),  δ:  14.27 (CH3, C-3’), 37.90 (CH2, C-2’), 61.62 (CH2, C-4’), 
123.32, 128.31, 128.90, 129.25, 131.11 (CH, C-aromatic), 131.88, 135.04, 
137.4, 155.4 (C, C-aromatic), 165.9 (C, C-1’).
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Ethyl 4-(5-((4-methylbenzyl)thio)-1H-tetrazol-1-yl)benzoate (31) 
(C18H18N4O2S; M.W.= 354.43)
  28     31
General procedure 5;
Reagent: 4-(5-((4-methylbenzyl)thio)-1H-tetrazol-1-yl)benzoic acid 29 (0.06 
g, 0.18 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.81;
White solid; 
Yield: 0.016 g, 25.8 %;
Melting point: 65-68 oC;
MS (ESI)+: 355.0 [M+H]+
1H-NMR (CDCl3),  δ:  1.44 (t, J= 7.2 Hz, 3H H-3’), 2.35 (s, 3H, H-9’), 4.44 (q, J= 
7.2 Hz, 2H, H-2’), 4.64 (s, 2H, H-4’), 7.16 (d, J= 7.9, 2H, H-aromatic), 7.33 (d, 
J= 7.9, 2H, H-aromatic), 7.67 (d, J= 9.0 Hz, 2H, H-aromatic), 8.22 (d, J= 9.0 
Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  14.30 (CH3, C-3’), 21.19 (CH3, C-9’), 37.70 (CH2, C-2’), 
61.64 (CH2, C-4’), (123.29, 129.19, 129.58, 131.11 (CH, C-aromatic), 131.80, 
131.91, 137.01, 138.24 , 155.1 (C, C-aromatic), 165.12 (C, C-1’).
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6.3 Synthesis of 2,5-bis-Aryl-1,3,4-oxadiazoles
6.3.1 General procedures 6-7
General procedure 6:  synthesis of aryl acetohydrazide  derivatives (38, 
39)
A mixture of arylacetic acid ester (1eq.) and hydrazine monohydrate (3 eq.) 
was refluxed in EtOH ( 2.9 mL/mmol eq.) for 24 hours. The mixture was 
cooled down and put in an ice-bath. The solid separated was filtered and 
used without further purification.
General procedure 7: 2,5-bis-aryl-1,3,4-oxadiazoles (32, 40)
H
N
O
NH2
R
 reflux, o.n.
R
N N
O
R
OH
O
R
+
POCl3
Aryl acetohydrazide (36,  37), (1 eq.) and arylacetic acid (38, 39) (1 eq.) were 
dissolved in phosphoryl chloride (8.3 mL/mmol eq.) and heated at reflux 
over night. The solvent was removed under reduced pressure and the 
residue was recrystallized to obtain the final product.
R
O
O
R
H
N
O
NH2NH2NH2 . H2O
EtOH, reflux, 24h
Conclusions
228
6.3.2 2-Phenylacetic acid (39)9
(C8H802; M.W.= 136.05)
   42    39
Ethyl 2-phenylacetate 39 (1.08 g, 6.6 mmol) in THF (50 mL) was  treated 
with LiOH monohydrate (2.01 g in 110 mL of water, 48 mmol). The mixture 
was stirred at room temperature for 24 h. Upon completion, the organic 
solvent was removed under reduced pressure. The residue was washed 
with EtOAc (2 x 30 mL). The aqueous layer, cooled in a ice  bath, was 
acidified with 3M  HCl to  pH 1-2 and stirred until the formation of a white 
precipitate that was filtrated and dried to afford the pure product.
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.55;
White solid;
Yield: 0.8 g, 88.8 %;
1H-NMR (CDCl3), δ:  3.68 (s, 2H, H-1’), 7.29-7.34 (m, 3H, H-aromatic), 
7.35-7.39 (m, 2H, H-aromatic), 11.1 (bs, 1H, -COOH).
13C-NMR (CDCl3),  δ:  41.04 (CH2, C-1’), 127.37, 128.66, 129.38 (CH, C-
aromatic), 133.27 (C, C-1), 177.75 (C, C-2’).
6.3.3 Ethyl 2-(4-nitrophenyl)acetate (41)10
(C10H11NO4; M.W.= 209.20)
  38      41
A solution of the 4-nitrophenylacetic acid 39 (0.5g, 2.7 mmol) in ethanol 
(41.5 mL) was treated with sulphuric acid (6.3 mL) at reflux for 24 h. The 
reaction was concentrated in vacuo. The residue was dissolved in ethyl 
O
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acetate (20 mL) and washed with saturated aqueous bicarbonate solution (3 
x 20 mL) and water (3 x 20 mL). The organic ayer was dried over MgSO4, 
filtered and concentrated in vacuo to give ethyl 2-(4-nitrophenyl)acetate 
without further purification.
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.54;
White solid;
Yield: 0.29 g, 51.4 %;
1H-NMR (CDCl3), δ:  1.28 (t, J= 7.1, 3H, H 4’), 3.78 (s, 2H, H-1’), 4.20 (q, J= 7.1 
Hz, 2H, H-3’), 7.48 (d, J= 8.6 Hz, 2H, H-aromatic), 8.21 (d, J= 8.6 Hz, 2H, H-
aromatic).
13C-NMR (CDCl3),  δ:  14.12 (CH3, C-4’), 41.08 (CH2, C-1’), 61.38 (CH2, C-3’), 
123.73, 130.27 (CH, C-aromatic), 141.45 (C, C-1), 147.22 (C, C-4), 170.16 (C, 
C-2’).
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6.3.4 Aryl acetohydrazides (36, 37)
2-(4-Nitrophenyl)acetohydrazide (36)11 
(C8H9N3O3; M.W.= 195.18)
  41      36
General procedure 6;
Reagent: Ethyl 2-(4-nitrophenyl)acetate 41 (0.3 g, 1.4 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 1;
White solid;
Yield: 0.16 g, 62 %;
1H-NMR (DMSO-d6),  δ:  3.53 (s, 2H, H-1’), 4.26 (bs, 2H, NH2), 7.54 (d, J= 8.8 
Hz, 2H, H-aromatic), 8.18 (d, 2H, J= 8.8 Hz, H-aromatic), 9.31 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  40.11 (CH2, C-1’), 123.28, 130.25 (CH, C-aromatic), 
144.31 (C, C-1), 147.22 (C, C-4), 168.34 (C, C-2’).
2-Phenylacetohydrazide (37)12 
(C8H10N2O; M.W.= 150.18)
                42        37
General procedure 6;
Reagent: Ethyl phenylacetate 42 (0.94 mL, 6.6 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 1;
White foam;
Yield: 0.251 g, 25.3 %;
1H-NMR (CDCl3),  δ:  3.58 (s, 2H, H-1’), 3.86 (bs, 2H, NH2), 6.75 (bs, 1H, NH), 
7.25-7.40 (m, 5H, H-aromatic).
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13C-NMR (CDCl3),  δ:  41.90 (CH2, C-1’), 127.49, 129.01, 129.36 (CH, C-
aromatic), 134.00 (C, C-1), 171.68 (C, C-2’).
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6.3.5 2,5-bis-Aryl-1,3,4-oxadiazoles (32, 40)
2,5-bis(4-Nitrobenzyl)-1,3,4-oxadiazole (32)
(C16H12N4O5; M.W.= 340.29)
H
N
O
NH2
O2N
 reflux, o.n.
OH
O
O2N
+
POCl3
N N
O1 1
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2'
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4'
5'
O2N
NO2
 36   38    32
General procedure 7;
Reagent: 4-nitro phenyl acetic acid 36 (0.160 g, 0.82 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.44;
Brownish solid;
Purification: recrystallization from EtOH;
Yield: 0.15 g, 53.2 %;
Melting point: 129-131 oC;
MS (ESI)+: 341.1 [M+H]+
1H-NMR (CDCl3),  δ: 4.30 (s, 4H, H-1’), 7.49 (d, 4H, J= 8.6 Hz, H-aromatic), 
8.22 (d, 4H, J= 8.6 Hz, H-aromatic).
13C-NMR (CDCl3),  δ:  31.53 (CH2, C-1’), 124.17, 129.84 (CH, C-aromatic), 
140.60 (C, C-2’), 147.60 (C, C-5’), 164.76 (C, C-1).
2,5-Dibenzyl-1,3,4-oxadiazole (41)13 
(C16H14N2O, M.W.=250.30)
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 37   39    40
General procedure 7;
Reagent: phenyl acetic acid 40 (0.66 g, 4.84 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.66;
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White solid;
Purification: recrystallization from EtOH/H20 ;
Yield: 0.65 g, 54 %;
Melting point: 92-94 oC; (lit. 97-99 oC)
MS (ESI)+: 251.1 [M+H]+
1H-NMR (CDCl3), δ:  4.16 (s, 4H, H-1’), 7.27-7.32 (m, 6H, H-aromatic), 
7.33-7.37 (m, 4H, H-aromatic).
13C-NMR (CDCl3),  δ:  31.79 (CH2, C-1’), 127.51, 128.57, 128.63, 128.69, 
128.80, 128.87, 129.19 (CH, C-aromatic), 133.85 (C, C-2’), 165.83 (C, C-1).
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6.4 1,3-bis-Aryl-1H-benzo[d]imidazol-2(3H)-ones (34, 46)
6.4 .1 General procedure 8 : synthesis of 1 ,3 -bis -aryl -1H -
benzo[d]imidazol-2(3H)-ones
N
H
H
N
O
R
Br
+
K2CO3, KIcat.
DMF, 85 oC, 2h, under N2 N
N
O
R
R
Aryl bromide (1.97 eq.), K2CO3 (5.5 eq.) and a catalytic amount of KI were 
added to a solution of benzoimidazol-2-one (1 eq.) in anhydrous  DMF (2.01 
mL/mmol eq.) under nitrogen atmosphere. The reaction mixture was 
heated at 85oC for 4h. After cooling, the mixture was  poured in a solution 
of water (39.8 mL) and 2N HCl in water (1.8 mL/mmol eq.). The resultant 
mixture was  extracted with ethyl acetate (2x 4.5 mL/mmol eq.) and the 
combined organic  phases were washed with brine and dried under MgSO4. 
The crude product was purified by recrystallization.
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6.4.2 1,3-1H-benzo[d]imidazol-2(3H)-one (43)14
       43
Carbonyldiimidazole (1.5 g, 9.24 mmol) was added portionwise over 10-15 
min to a stirred solution of o-phenylenediamine (1 g, 9.24 mmol) in DMF 
(13 mL). The reaction mixture was stirred at room temperature for 3h and 
successively diluted with water (15 mL). The solid was collected by 
filtration, washed with water and dried under MgSO4 to give the title 
product as dark brown solid.
T.L.C. System: n-hexane -EtOAc: 8:2 v/v, Rf: 0.32;
Yield: 0.74 g, 60 %
1H-NMR (DMSO-d6), δ: 6.90-6.92 (m, 4H, H-aromatic), 10.68 (bs, 2H, NH2).
13C-NMR (DMSO-d6),  δ:  108.43, 120.36 (CH, C-aromatic), 129.62 (C, C-2), 
155 (C, C-1).
NH2
NH2
N N
O
N
N
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H
N
O
1
2
2
3
3
4
4DMF, r.t., 2h
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6.4.3 1,3-bis-Aryl-1H-benzo[d]imidazol-2(3H)-ones (34, 46)
1,3-bis(4-Nitrobenzyl)-1H-benzo[d]imidazol-2(3H)-one (34)15
(C21H16N4O5; M.W.= 404.38)
  44    34
General procedure 6;
Reagent: 4-nitro benzyl bromide 45 (1.28 g, 5.96 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.56;
White solid;
Purification: recrystallization from MeOH/n-hexane; 
Yield: 0.2 g, 16 %;
Melting point: 162-165 oC; (lit. 168-170 oC)
MS (ESI)+: 405.1 [M+H]+
1H-NMR (CDCl3),  δ:  6.87-6.92 (m, 2H, H-1’), 7.05-7.11 (m, 2H, H-aromatic), 
7.52 (d, J= 8.8 Hz, 2H, H-aromatic), 8.23 (d, 2H, J= 8.8 Hz, H-aromatic).
13C-NMR (CDCl3),  δ:  44.46 (CH2, C-1’), 108.32, 122.24, 124.19, 128.20 (CH, 
C-aromatic), 128.85, 143.30 (C, C-aromatic), 147.67 (C, C-5’), 154.24 (C, C-1).
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1,3-Dibenzyl-1H-benzo[d]imidazol-2(3H)-one (46)16
(C21H18N2O; M.W.= 314.38)
  45    46
General procedure 6;
Reagent: benzyl bromide 45 (0.53 mL, 4.4 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.75;
White solid;
Purification: recrystallization from MeOH/H20; 
Yield: 0.075 g, 10.7 %;
Melting point: 93-96 oC; (lit. 106-108 oC)
MS (ESI)+: 315.1 [M+H]+
1H-NMR (CDCl3), δ:  5.17 (s, 4H, H-1’), 6.88-6.93 (m, 2H, H-aromatic), 
6.97-7.03 (m, 2H, H-aromatic), 7.26-7.32 (m, 2H, H-aromatic), 7.32-7.40 (m, 
8H, H-aromatic).
13C-NMR (CDCl3),  δ:  45.02 (CH2, C-1’), 108.35, 121.38, 127.50, 127.72, 
128.79 (CH, C-aromatic), 129.31, 136.34 (C, C-aromatic), 154.60 (C, C-1).
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6.5 Methyl-3,4-bis(phenylamino)-1H-pyrrole-2,5-dione (47) 
6.5.1 N-Methyl-3,4-dibromomaleimide (49)17
(C5H3Br2NO2; M.W.= 268.89)
  48             49
To a stirred solution of 3,4-dibromo-1H-pyrrole-2,5-dione 48 (1 g, 3.92 
mmol) in fresh-distilled acetone (15 mL), K2CO3 (0.6 g, 4.13 mmol) and 
dimethyl sulfate (0.4 mL, 4.21 mmol) were added. The mixture was stirred 
and heated at 56oC for 2 h. Upon completion, the solvent was  removed in 
vacuo and the residue was taken up with ethyl acetate (20 mL) and washed 
with water (2 x 20 mL). The organic phase was dried over MgSO4 and the 
solvent was removed in vacuo to afford the pure product.
T.L.C. System: n-hexane -EtOAc: 9:1 v/v, Rf: 0.28;
Yellowish solid; 
Yield: 0.18 g, 54.4 %; 
1H-NMR (CDCl3), δ: 3.15 (s, 3H, H-3).
13C-NMR (CDCl3), δ: 25.44 (CH3, C-3), 129.41 (C, C-2), 164.0 (C, C-1).
6.5.2 3-Bromo-1-methyl-4-(phenylamino)-1H-pyrrole-2,5-dione (50) 
(C11H9BrN2O2; M.W.= 281.11)
           49       50
NH
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Br
K2CO3, acetone, 56 oC, 2h
(CH3)2SO2
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To a mixture of N-methyl-3,4-dibromomaleimide 49 (0.15 g, 0.56 mmol) 
and Na2CO3 (0.15g, 1.4 mmol) in THF (8.4 mL), aniline was added (0.11 mL, 
1.2 mmol). The reaction mixture was stirred at room temperature for 30 
min and up to 2 h. The reaction was then warmed to 40 oC for 2 more h. 
The solvent was  evaporated under reduced pressure and the residue was 
taken with dichloromethane (2 x 20 mL), washed with water (2x 20 mL) and 
dried over MgSO4. The solvent was  removed in vacuo and the residue was 
purified by flash column chromatography to afford the title compound.
T.L.C. System: n-hexane -EtOAc: 7:3 v/v, Rf: 0.6;
Yellow solid;
Purification by flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 95:5 v/v);
Yield: 0.08 g, 53.3 %
1H-NMR (CDCl3),  δ:  3.12 (s, 3H, H-5), 7.12 (bs, 1H, NH), 7.20-7.24 (m, 2H, H-
aromatic), 7.29-7.31 (m, 1H, H-aromatic), 7.39-7.44 (m, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  24.66 (CH3, C-5), 97.9 (C, C-aromatic), 124.45, 126.40, 
128.78 (CH, C-aromatic), 142.2, 152.1, 164.0 (C, C-aromatic).
6.5.3 1-Methyl-3,4-bis(phenylamino)-1H-pyrrole-2,5-dione (47) 
(C17H15N3O2; M.W.= 293.32)
 50       47
Aniline (0.09 mL, 1.05 mmol) was added dropwise to a stirred solution of 
bromo-1-methyl-4-(phenylamino)-1H-pyrrole-2,5-dione 50 (0.08 g, 0.28 
mmol) in dimethylformamide (0.3 mL) followed by the addition of 
triethylamine (0.09 mL, 0.64 mmol). The mixture was stirred at room 
temperature for 72 h, then warmed to 100oC for 24 h. Upon completion, 
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dichloromethane (10 mL) was  added to the mixture and the residue was 
washed up with water (2 x 10 mL). The organic phase was dried with 
MgSO4, concentrated in vacuo and then purified by flash column 
chromatography (n-hexane:EtOAc: 100:0 v/v, increasing to 90:10 v/v) and 
recrystallization from EtOH to afford the title compound as a red solid.
T.L.C. System: n-hexane -EtOAc: 7:3 v/v, Rf: 0.5;
Yield: 0.005 g, 6 %;
Melting point: 102-105 oC
MS (ESI)+: 293.9 [M+H]+
1H-NMR (CDCl3),  δ:  3.11 (s, 3H, H-3), 6.33 (bs, 2H, NH), 6.67-6.78 (m, 6H, H-
aromatic), 6.97 7.05-(m, 4H, H-aromatic).
13C-NMR (CDCl3),  δ:  24.02 (CH3, C-3), 115.35 (C, C-aromatic), 117.68, 
121.64, 128.58 (CH, C-aromatic), 140.76 (C, C-aromatic), 169.79 (C, C-1).
Conclusions
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6.6 Synthesis of N1-phenylbenzene-1,2-diamine (52)18 
(C12H12N2; M.W.= 184.242)
To a flask charged with 1,2-diaminobenzene (0.43g, 4 mmol) in 6 mL of 
DMSO  was added CuI (0.15g, 0.8 mmol), L-proline (0.18 g, 1.6 mmol), 
iodobenzene (4g, 20 mmol) and K2CO3 (2.26 g, 16.4 mmol) and was stirred 
for 18 h at 80 oC. The reaction mixture was  cooled down and poured into 
20 mL of H2O and extracted with Et2O (2 x 20 mL). The organic  phase was 
dried with MgSO4, concentrated in vacuo and then purified by flash column 
chromatography (n-hexane:EtOAc: 100:0 v/v, increasing to  98:2 v/v) and to 
afford the title compound as a yellow solid.
             52
T.L.C. System: n-hexane -EtOAc: 9:1 v/v, Rf: 0.6;
Yield: 0.137 g, 18.7 %;
Melting point: 75-77 oC (lit. 77-79 oC)18
MS (ESI)+: 185.1 [M+H]+
1H-NMR (CDCl3),  δ:  3.79 (bs, 2H, NH2), 5.20 (bs, 1H, NH), 6.74-6.81 (m, 3H, 
H-aromatic), 6.81-6.88 (m, 2H, H-aromatic), 7.01-7.08 (m, 1H, H-aromatic), 
7.20-7.27 (m, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  115.24, 116.18, 119.17, 119.34, 124.92, 125.75 (CH, C-
aromatic), 128.57 (C, C-aromatic), 129.33 (CH, C-aromatic), 141.97, 145.38 
(C, C-aromatic).
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6.7 Synthesis of arylsulfonamides
6.7.1 General procedure 9: synthesis of bis-sulfonamido derivatives
To an ice-cold solution of o-phenylenediamine or 4-chloro-o-
phenylenediamine (0.5 g, 4.62 mmol) and pyridine (0.75 mL, 9.24 mmol) in 
12.5 mL of dichloromethane was added portionwise the sulfonyl chloride 
(9.24 mmol). The reaction mixture was warmed at r.t. and stirred until 
completion of reaction (TLC analysis). Water (10 mL) was introduced 
causing the product to precipitate. The solid formed was filtered, washed 
with H2O and dried to  give a residue which was purified by 
recrystallization.
N,N'-(1,2-Phenylene)dibenzenesulfonamide (61)19
(C18H16N2O4S2; M.W.= 388.06)
  55         61
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.53;
White solid;
Purification: recrystallization from EtOH;
Yield: 1.2 g, 67.5 %;
Melting point: 180-182 oC; (lit. 192-193 oC)
MS (ESI)+: 411.0 [M+Na]+
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H1 NMR (DMSO-d6),  δ:  6.96-7.02 (m, 2H, H-aromatic), 7.54-7.57 (m, 3H, H-
aromatic), 7.70-7.71 (m, 1H, H-aromatic), 7.71-7.72 (m, 1H, H-aromatic), 
9.33 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ: 123.40, 125.86, 126.80, 129.27 (CH, C-aromatic), 
129.69 (C, C-aromatic), 133.20 (CH, C-aromatic), 139.01 (C, C-1’).
N,N'-(1,2-Phenylene)bis(4-chlorobenzenesulfonamide) (62)20
(C18H14Cl2N2O4S2; M.W.= 455.98)
  56     62
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.48;
White fine powder;
Purification: recrystallization with EtOH;
Yield: 0.95 g, 45.2 %;
Melting point: 144-146 oC;
MS (ESI)+: 478.9 [M+Na]+
H1 NMR (CDCl3),  δ:  6.94 (bs, 1H, NH), 6.97-7.01 (m, 1H, H-aromatic), 
7.10-7.14, (m, 1H, H-aromatic), 7.44 (d, J= 8.7 Hz, 2H, H-aromatic), 7.65 (d, 
J= 8.7 Hz, 2H, H-aromatic).
13C NMR (CDCl3),  δ:  126.38, 127.89, 129.01, 129.36 (CH, C-aromatic), 
130.57 (C, C-1), 136.75 (C, C-4’), 140.00 (C, C-1’).
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N,N'-(1,2-Phenylene)bis(4-nitrobenzenesulfonamide) (63)19
(C18H14N4O8S2 ; M.W.= 478.03)
  57     63
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.3;
Off-White powder;
Purification: recrystallization from EtOH;
Yield: 1.13 g, 51.2 %;
Melting point: 240-242 oC; (lit. 255-256 oC)
MS (ESI)+: 501.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  6.94-6.98 (m, 1H, H-aromatic), 7.07-7.11 (m, 1H, H-
aromatic), 7.97 (d, J= 8.8 Hz, 2H, H-aromatic), 8.38 (d, J= 8.8 Hz, 2H, H-
aromatic), 9.68 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ: 124.60, 124.63, 126.80, 128.40 (CH, C-aromatic), 
129.98 (C, C-1), 144.87, 149.88 (C, C-aromatic).
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N,N'-(1,2-Phenylene)bis(4-cyanobenzenesulfonamide) (64)
(C20H14N4O4S2; M.W.= 438.05)
  58     64
General procedure 9;
T.L.C. System: n-hexane-EtOAc: 6:4 v/v, Rf: 0.74;
Pale orange powder;
Purification: recrystallization with EtOH;
Yield: 0.6 g, 30 %;
Melting point: 194-197 oC
MS (ESI)+: 461.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  6.92-6.96 (m, 1H, H-aromatic), 7.06-7.10 (m, 1H, H-
aromatic), 7.85 (d, J= 8.6 Hz, 2H, H-aromatic), 8.03 (d, J= 8.6 Hz, 2H, H-
aromatic), 9.62 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ:  115.53, 117.57 (C, C-aromatic), 124.46, 126.71, 
127.53 (CH, C-aromatic), 129.90 (C, C-aromatic), 133.47 (CH, C-aromatic), 
143.40 (C, C-1’).
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N,N'-(1,2-Phenylene)bis(4-methoxybenzenesulfonamide) (65)19
(C20H20N2O6S2; M.W.= 448.08)
  59     65
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.77;
White spongy powder;
Purification: recrystallization from EtOH;
Yield: 2.07 g, 73.4 %;
Melting point: 129-131 oC (lit. 130-132 oC)19
MS (ESI)+: 471.1 [M+Na]+
H1 NMR (CDCl3),  δ:  3,86 (s, 3H, H-5’), 6.90 (bs, 1H, NH), 6.90 (d, J= 9.0 Hz, 
2H, H-aromatic); 6.97-7.01 (m, 1H, H-aromatic), 7.04-7.08 (m, 1H, H-
aromatic), 7.64 (d, J= 9.0 Hz, 2H, H-aromatic).
13C NMR (CDCl3),  δ:  55.62, 114.15, 126.23, 127.33 (CH, C-aromatic), 129.73 
(C, C-aromatic), 129.96 (CH, C-aromatic), 130.98, 163.33 (C, C-aromatic).
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N,N'-(1,2-Phenylene)bis(4-(trifluoromethyl)benzenesulfonamide) (66)21
(C20H14F6N2O4S2; M.W.= 524.03)
  60     66
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.35;
White powder;
Purification: recrystallization with EtOH;
Yield: 0.5 g, 20.6 %;
Melting point: 135-138 oC;
MS (ESI)+: 547.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  6.96-6.99 (m, 1H, H-aromatic), 7.05-7.08 (m, 1H, H-
aromatic), 7.92-7.97 (m, 4H, H-aromatic), 9.61 (bs, 1H, NH).
13C NMR (DMSO-d6), δ:  122.26 (C, C-aromatic), 124.03 (CH, C-aromatic), 
124.43 (C, C-aromatic), 126.45, 126.53, 126.56, 127.78 (CH, C-aromatic), 
129.77 (C, C-aromatic), 132.34, 132.59, 132.85 (m, C, C-5’), 143.29 (C, C-
aromatic).
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N,N'-(4-Chloro-1,2-phenylene)dibenzenesulfonamide (67)22
(C18H15ClN2O4S2; M.W.= 422.02)
               55    67
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.68;
Off-White powder;
Purification: recrystallization from DCM/Hexane;
Yield: 0.4 g, 20.6 %;
Melting point: 139-142 oC; (lit. 154 oC)22
MS (ESI)+: 445.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  6.96-7.01 (m, 2H, H-aromatic), 7.06-7.10 (m, 1H, H-
aromatic), 7.53-7.62 (m, 4H, H-aromatic), 7.64-7.76 (m, 6H, H-aromatic), 
9.49 (bs, 1H, NH), 9.52 (bs, 1H, NH).
13C NMR (DMSO-d6), δ:  122.14, 125.11, 125.39, 126.80, 126.81 (CH, C-
aromatic), 128.13 (C, C-aromatic), 129.37, 129.45 (CH, C-aromatic), 129.62, 
131.30 (C, C-aromatic), 133.36, 133.50 (CH, C-aromatic), 138.71, 138.80 (C, 
C-1’, C-5’).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-chlorobenzenesulfonamide) (68)
(C18H13Cl3N2O4S2; M.W.= 489.94)
            56        68
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.9;
White powder;
Purification: recrystallization from EtOH;
Yield: 0.65 g, 28.7 %;
Melting point: 164-167 oC;
MS (ESI)+ 512.9 [M+Na]+
H1 NMR (DMSO-d6),  δ:  6.97 (d, J= 8.6 Hz, 1H, H-aromatic), 7.03 (d, J= 2.4 Hz, 
1H, H-aromatic), 7.14 (dd, J1= 8.8 Hz, J2= 2.4 Hz, 1H, H-aromatic) 7.65 (d, J= 
8.8 Hz, 2H, H-aromatic), 7.67 (d, J= 8.8 Hz, 2H, aromatic), 7.70 (d, J= 8.8 Hz, 
2H, aromatic), 7.74 (d, J= 8.8 Hz, 2H, H-aromatic), 9.58 (bs, 2H,- NH). 
13C NMR (DMSO-d6),  δ:  122.57, 125.69 (CH, C-aromatic), 128.17 (C, C-
aromatic), 128.73, 128.76, 129.52, 129.59 (CH, C-aromatic), 130.08, 137.74, 
138.25, 138.37 (C, C-1’, C-5’).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-nitrobenzenesulfonamide) (69)
C18H13ClN4O8S2; M.W.= 511.99)
          57     69
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.6;
White solid;
Purification: recrystallization from EtOH;
Yield: 1.08 g, 45.7 %;
Melting point: 217-219 oC;
MS (ESI)+: 535.0 [M+Na]+
H1 NMR (DMSO-d6),  δ: 6.92 (d, J= 8.7 Hz, 1H, H-2), 7.05 (d, J= 2.4 Hz, 1H, 
H-5), 7.14 (dd, J1= 8.7 Hz, J2= 2.4 Hz, 1H, H-3), 7.95 (d, J= 8.9 Hz, 2H, H-
aromatic), 8.01 (d, J= 8.9 Hz, 2H, H-aromatic), 8.37-8.41 (m, 4H, aromatic), 
9.87 (bs, 2H, NH).
13C NMR (DMSO-d6), δ:  123.04, 124.69, 124.73, 126.06, 126.35 (CH, C-
aromatic), 128.26 (C, C-aromatic), 128.38, 128.44 (CH, C-aromatic), 144.61, 
149.92, 149.98 (C, C-aromatic).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-cyanobenzenesulfonamide) (70)20
C20H13ClN4O4S2; M.W.= 472.01)
  58     70
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.74;
White solid;
Purification: recrystallization from MeOH;
Yield: 0.52 g, 24 %;
Melting point: 112-115 oC;
MS (ESI)+: 495.0 [M+Na]+
H1 NMR (DMSO-d6),  δ: 6.90 (d, J= 8.6 Hz, 1H, H-2), 7.00 (d, J= 2.3 Hz, 1H, 
H-5), 7.14 (dd, J1= 8.6 Hz, J2= 2.3 Hz, 1H, H-3), 7.86 (d, J= 8.7 Hz, 2H, H-
aromatic), 7.91 (d, J= 8.7 Hz, 2H, H-aromatic), 8.04-8.13 (m, 4H, H-
aromatic), 9.79, (bs, 2H, NH).
13C NMR (DMSO-d6),  δ:  115.63, 117.55 (C, C-aromatic), 123.05, 126.19, 
127.52, 127.56 (CH, C-aromatic), 128.32 (C, C-aromatic), 133.53, 133.58 
(CH, C-aromatic), 143.16 (C, C-aromatic).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-methoxybenzenesulfonamide) (71)
(C20H19ClN2O6S2; M.W.= 482.04)
  59        71
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.8;
Off-White powder;
Purification: recrystallization from MeOH;
Yield: 0.87 g, 39 %;
Melting point: 139-142 oC;
MS (ESI)+: 505.0 [M+Na]+
H1 NMR (DMSO),  δ:  3.83 (s, 6H, H-5’, H-10’), 6.99 (d, J= 8.6 Hz, 1H, H-2), 
7.04-7.11 (m, 6H, H-aromatic), 7.62 (d, J= 8.8 Hz, 2H, H-aromatic), 7.66 (d, 
J= 8.8 Hz, 2H, H-aromatic), 9.34 (bs, 2H, NH).
13C NMR (DMSO),  δ:  55.9 (CH, C-10’), 122.13, 125.09, 125.38, 126.79, 
126.81, 128.14, 129.37, 129.45 (CH, C-aromatic), 129.62, 130.2, 138.79, 
163.9 (C, C-aromatic).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-(trifluoromethyl)benzenesulfonamide) 
(72)20 (C20H13ClF6N2O4S2; M.W.= 557.99)
          60             72
General procedure 9;
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.72;
White, sponge solid;
Purification: recrystallization from DCM/Hexane;
Yield: 0.7 g, 28 %;
Melting point: 140-143 oC
MS (ESI)+: 581.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  6.97 (d, J= 8.7 Hz, 1H, H-aromatic), 7.01 (d, J= 2.0 Hz, 
1H, H-5), 7.14 (dd, J1= 8.6 Hz, J2= 2.0 Hz, 1H, H-aromatic), 7.94-7.96 (m, 3H, 
H-aromatic), 7.97-7.99 (m, 5H, H-aromatic), 9.80, (bs, 2H, NH).
13C NMR (DMSO-d6),  δ:  120.05, 122.20, 122.22 (C, C-aromatic), 122.90 (CH, 
C-aromatic), 124.37, 124.39 (C, C-aromatic), 125.74, 126.01, 126.57, 126.60, 
126.63, 126.66, 127.80 (CH, C-aromatic), 128.30, 130.21, 131.51 (C, C-
aromatic), 132.47, 132.59, 132.73, 132.85, 132.99, 133.11, 133.24, 133.36 
(C, C-5’, C-10’), 142.96, 143.05 (C, C-aromatic).
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6.8 Aryl amides
6.8.1 General procedure 10: synthesis of bis-amido derivatives
To an ice cold solution of o-phenylenediamine (4.62 mmol) and 
triethylamine (1.6 mL, 11.55 mmol) in dichloromethane (5 mL), a solution 
of the desired aryl chloride (9.24 mmol) in dichloromethane (5 mL) was 
added dropwise under cooling with ice and water. The reaction mixture 
was allowed to stir for 2h at room temperature. Water (20 mL) was 
introduced causing the product to precipitate. The solid was filtered and 
dried under vacuum. The residue collected was purified by 
recrystallization.
N,N'-(1,2-Phenylene)dibenzamide (79)  
(C20H16N2O2; M.W.= 316.12)
       73    79
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.4;
White powder;
Purification: recrystallization from EtOH;
Yield: 0.82 g, 58.6 %;
Melting point: charring >260 oC; (lit. 298-300 oC)
MS (ESI)+: 339.1 [M+Na]+
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H1 NMR (DMSO-d6),  δ:  7.28-7.33 (m, 1H, H-aromatic), 7.50-7.58 (m, 2H, H-
aromatic), 7.57-7.62 (m, 1H, H-aromatic), 7.65-7.69 (m, 1H, H-aromatic), 
7.92-7.98 (m, 2H, H-aromatic), 10.06 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ:  125.55, 125.83, 127.46, 128.26 (CH, C-aromatic), 
128.55 (C, C-aromatic), 131.29 (CH, C-aromatic), 131.83 (C, C-aromatic), 
165.44 (C, C-1’).
N,N'-(1,2Phenylene)bis(4-chlorobenzamide) (80)23
(C20H14Cl2N2O2; M.W.= 384.04)
	
 	
       74    80
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.3;
White powder;
Purification by recrystallization from MeOH;
Yield: 0.7 g, 41 %;
Melting point: charring >260 oC; (lit. 300 oC)23
MS (ESI)+: 407.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  7.27-7.34 (m, 1H, H-aromatic), 7.61 (d, J= 8.4 Hz, 2H, 
H-aromatic), 7.63-7.68 (m, 1H, H-aromatic), 7.97 (d, J= 8.4 Hz, 2H, H-
aromatic), 10.10 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ: 125.62, 126.00, 128.57, 129.49 (CH, C-aromatic), 
131.27, 133.07, 136.57 (C, C-aromatic), 164.46 (C, C-1’).
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N,N'-(1,2-Phenylene)bis(4-nitrobenzamide) (81)24
(C20H14N4O6 ; M.W.= 406.09)
        75    81
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.75;
Fine yellow powder;
Purification by recrystallization from MeOH;
Yield: 1.6 g, 83.7 %;
Melting point: charring >260 oC; (lit. 300 oC)24
MS (ESI)+: 407.1 [M+H]+
H1 NMR (DMSO-d6),  δ: 7.31-7.36, (m, 1H, H-aromatic), 7.66-7.72 (m, 1H, H-
aromatic), 8.18 (d, J= 8.8 Hz, 2H, H-aromatic), 8.37 (d, J= 8.8 Hz, 2H, H-
aromatic), 10.29 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ:  123.58, 125.88, 126.20, 129.17 (CH, C-aromatic), 
131.22, 140.21, 149.17 (C, C-aromatic), 163.99 (C, C-1’).
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N,N'-(1,2-Phenylene)bis(4-cyanobenzamide) (82) 
(C22H14N4O2; M.W.= 366.11)
  76     82
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.83;
White powder;
Purification by recrystallization from EtOH;
Yield: 1.1 g, 65.3 %;
Melting point: 264-266 oC;
MS (ESI)+: 367.1 [M+H]+
H1 NMR (DMSO-d6),  δ:  7.30-7.34 (m, 1H, H-aromatic), 7.64-7.69 (m, 1H, H-
aromatic), 8.01 (d, J= 8.4 Hz, 2H, H-aromatic), 8.09 (d, J= 8.4 Hz, 2H, H-
aromatic), 10.20 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ:  113.90, 118.23 (C, C-aromatic), 125.81, 126.15, 
128.47 (CH, C-aromatic), 140.21, 131.21, 132.48, 138.53 (C, C-aromatic), 
164.22 (C, C-1’).
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N,N'-(1,2-Phenylene)bis(4-methoxybenzamide) (83)25
(C22H20N2O4; M.W.= 376.14)
  77    83
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.65;
Fine, white powder;
Purification by recrystallization from MeOH;
Yield: 0.9 g, 53 %;
Melting point: 164-167 oC;
MS (ESI)+: 399.1 [M+Na]+
H1 NMR (DMSO-d6),  δ:  3.83 (s, 3H, H-6’), 7.06 (d, J= 8.8 Hz, 2H, H-aromatic), 
7.27-7.29 (m, 1H, H-aromatic), 7.63-7.66 (m, 1H, H-aromatic), 7.94 (d, J= 8.8 
Hz, 2H, H-aromatic), 9.96 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ: 55.44, 113.84, 125.33, 125.69 (CH, C-aromatic), 
126.14 (C, C-aromatic), 129.36 (CH, C-aromatic), 131.33, 162.11 (C, C-
aromatic), 164.85 (C, C-1’).
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N,N'-(1,2-Phenylene)bis(4-(trifluoromethyl)benzamide) (84)
(C22H14F6N2O2; M.W.= 452.10)
        78    84
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf:0.36;
White solid;
Purification: recrystallization from EtOH/H2O;
Yield: 0.7 g, 33.5 %;
Melting point: 175-177oC;
MS (ESI)+: 475.1 [M+Na]+
H1 NMR (CDCl3),  δ:  6.84-6.88 (m, 1H, H-aromatic), 7.34-7.39 (m, 1H, H-
aromatic), 7.83 (d, J= 8.1 Hz, 2H, H-aromatic), 8.15 (d, J= 8.1 Hz, 2H, H-
aromatic), 9.58 (bs, 1H, NH).
13C NMR (CDCl3),  δ:  125.85, 125.88, 126.63, 128.08 (CH, C-aromatic), 
130.39 (C, C-aromatic), 133.92 (C, C-6’), 134.18, 136.54 (C, C-aromatic), 
165.26 (C, C-1’).
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N,N'-(4-Chloro-1,2-phenylene)dibenzamide (85)26 
C20H15ClN2O2; M.W.= 350.08)
      73    85
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf:0.34;
White solid;
Purification: recrystallization from EtOH;
Yield: 0.43 g, 27 %;
Melting point: 220-223 oC; (lit. 227-228 oC)26
MS (ESI)+: 373.1 [M+Na]+
H1 NMR (DMSO-d6),  δ:  7.36 (dd, J1= 8.7 Hz, J2= 2.5 Hz, 1H, H-3), 7.50-7.56 
(m, 4H, H-aromatic), 7.57-7.63 (m, 2H, H-aromatic), 7.68 (d, J= 8.7 Hz, 1H, 
H-aromatic), 7.81 (d, J= 2.5 Hz, 1H, H-5), 7.92-7.99 (m, 4H, H-aromatic), 
10.08 (bs, 2H, NH).
13C NMR (DMSO-d6),  δ:  125.10, 125.16, 127.42, 127.55, 127.59, 128.52, 
128.55 (CH, C-aromatic), 129.14, 130.05 (C, C-aromatic), 131.91, 131.97 
(CH, C-aromatic), 132.74, 133.98, 134.01 (C, C-aromatic), 165.55, 165.65 (C, 
C-1’, C-6’).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-chlorobenzamide) (86)
(C20H13Cl3N2O2; M.W.= 418.00)
      74    86
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf:0.63;
White solid;
Purification: recrystallization from MeOH;
Yield: 1.5 g, 80 %;
Melting point: 224-227 oC;
MS (ESI)+: 441.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  7.36 (dd, J1= 8.9 Hz, J2= 2.5 Hz, 1H, H-3), 7.58-7.64 
(m, 4H, H-aromatic), 7.67 (d, J= 8.9 Hz, 1H, H-2), 7.79 (d, J= 2.5 Hz, 1H, H-5), 
7.93-8.01 (m, 4H, H-aromatic), 10.10 (bs, 2H, NH).
13C NMR (DMSO-d6),  δ:  125.25, 125.29, 127.57, 128.54, 128.57, 129.19, 
129.59 (CH, C-aromatic), 129.61, 130.01 (C, C-aromatic), 132.68 (CH, C-
aromatic), 132.89, 132.92, 136.64, 136.72 (C, C-aromatic), 164.60, 164.64 
(C, C-1’, C-6’).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-nitrobenzamide) (87)
(C20H13ClN4O6;M.W.= 440.05)
        75    87
General procedure 10;
T.L.C. System: n-hexane-EtOAc: 6:4 v/v, Rf:0.58;
Yellow powder;
Purification: recrystallization from EtOH;
Yield: 1.4 g, 71 %;
Melting point: 259-261 oC;
MS (ESI)+: 463.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  7.40 (dd, J1= 8.6 Hz, J2= 2.5 Hz, 1H, H-3), 7.71 (d, J= 
8.6 Hz, 1H, H-2), 7.82 (d, J= 2.5 Hz, 1H, H-5), 8.15-8.21 (m, 4H, H-aromatic), 
8.36-8.39 (m, 4H, H-aromatic), 10.35,(bs, 2H, NH).
13C NMR (DMSO-d6),  δ: 123.57, 123.58, 125.54, 127.76 (CH, C-aromatic), 
129.28 (C, C-aromatic), 129.42 (CH, C-aromatic), 129.97, 132.58, 139.99, 
149.25, 162.33 (C, C-aromatic).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-cyanobenzamide) (88)
(C22H13ClN4O2; M.W.= 400.07)
      76    88
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf:0.4;
Fine white powder;
Purification by recrystallization from MeOH;
Yield: 0.8 g, 48 %;
Melting point: 162-165 oC;
MS (ESI)+: 423.1 [M+Na]+
H1 NMR (DMSO-d6),  δ:  7.38 (dd, J1= 8.7 Hz, J2= 2.5 Hz, 1H, H-3), 7.69 (d, J= 
8.7 Hz, 1H, H-2), 7.80 (d, J= 2.5 Hz, 1H, H-5), 8.01-8.03 (m, 4H, H-aromatic), 
8.06-8.11 (m, 4H, H-aromatic), 10.25 (bs, 2H, NH).
13C NMR (DMSO-d6),  δ:  113.97, 114.02, 118.2 (C, C-aromatic), 125.46, 
127.70, 128.56 (CH, C-aromatic), 129.36, 129.95 (C, C-aromatic), 132.46, 
132.48 (CH, C-aromatic), 132.59, 138.33, 138.36, 164.41 (C, C-aromatic).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-methoxybenzamide) (89)
(C22H19ClN2O4; M.W.= 410.10)
  77    89
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf: 0.38
Fine white powder;
Purification by recrystallization from MeOH;
Yield: 1.3 g, 70 %;
Melting point: 148-150 oC;
MS (ESI)+: 433.1 [M+Na]+
H1 NMR (DMSO-d6),  δ:  3.83 (s, 6H, -H-6’, H-12’), 7.07 (d, J= 8.6 Hz, 4H, H-
aromatic), 7.33 (dd, J1= 8.6 Hz, J2= 2.3 Hz, 1H, H-3), 7.65 (d, J= 8.6 Hz, 1H, 
H-2), 7.79 (d, J= 2.3 Hz, 1H, H-aromatic), 7.93-7.95 (m, 4H, H-aromatic), 9.97 
(bs, 1H, NH), 9.99 (bs, 1H, NH).
13C NMR (DMSO-d6),  δ: 55.46, 113.82, 113.86, 124.93 (CH, C-aromatic), 
125.91, 125.95 (C, C-aromatic), 127.27 (CH, C-aromatic), 128.94 (C, C-
aromatic), 129.47, 129.52 (CH, C-aromatic), 130.06, 132.78, 162.19, 162.25 
(C, C-aromatic), 164.90, 165.07 (C, C-1’, C-7’).
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N,N'-(4-Chloro-1,2-phenylene)bis(4-(trifluoromethyl)benzamide) (90)
(C22H13ClF6N2O2; M.W.= 486.06)
  78    90
General procedure 10;
T.L.C. System: n-hexane -EtOAc: 6:4 v/v, Rf:0.8;
White solid;
Purification by recrystallization from MeOH;
Yield: 2.2 g, 30 %;
Melting point: 189.5 oC;
MS (ESI)+: 509.0 [M+Na]+
H1 NMR (DMSO-d6),  δ:  7.38 (dd, J1= 8.6 Hz, J2= 2.5 Hz, 1H, H-3), 7.71 (d, J= 
2.5 Hz, 1H, H-5), 7.83 (d, J= 8.6 Hz, 1H, H-2), 7.92 (d, J= 8.4 Hz, 4H, H-
aromatic), 8.11-8.16 (m, 4H, H-aromatic), 10.25 (bs, 2H, NH).
13C NMR (DMSO-d6), δ:  125.41, 125.44, 125.47, 127.67, 128.63 (CH, C-
aromatic), 129.32, 129.97, 132.62, 138.0, 138.11, 164.60 (C, C-aromatic).
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6.9 Synthesis of aryl coumarin structures
6.9.1 General procedures 11-13
General procedure 11: synthesis of aryl thio methyl-2H-chromen-2-one
To a solution of the desired arylthiol (4 mmol) in DMF (5 mL), cesium 
carbonate (1.56 g, 4.8 mmol) was added, followed by the addition of 7-
bromomethyl coumarin (1 g, 4.19 mmol). The solution was  stirred for 48 h 
at room temperature. The reaction mixture was poured into ethyl acetate 
(30 mL) and washed with water (3 x 30 mL) and brine (3 x 30 mL). The 
organic layer was dried over MgSO4, filtered, concentrated and purified by 
flash column chromatography and/or recrystallization to give the title 
compound.
General procedure  12: synthesis of aryl sulfinyl methyl-2H-chromen-2-
one
The appropriate aryl thio methyl-2H-chromen-2-one derivative (1eq.) was 
dissolved in dry DCM (4.13 mL/mmol eq.) and the solution was cooled to 
-20 oC. meta-Chloroperoxybenzoic  acid (1.3 eq.) was  added portionwise to 
this solution and the cooling bath was  maintained for 5-10’ (TLC check). 
The reaction mixture was poured into 15%  Na2CO3 (15 mL/mmol eq.), 
extracted with DCM (15 mL/ mmol eq.), washed with brine (15 mL/ mmol 
eq.) and dried over MgSO4. The crude product was  purified by flash column 
chromatography to afford the title compound.
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General procedure 13:  synthesis of aryl sulfonyl methyl-2H-chromen-2-
ones 
The aryl thio methyl-2H-chromen-2-one derivative (1eq.) was  dissolved in 
dry DCM (5.5 mL/mmol eq.) and the solution was cooled to -0 oC. 
meta-Chloroperoxybenzoic acid (3 eq.) was added portion wise to  this 
solution and the cooling bath was removed. The reaction mixture was 
stirred at room temperature, over night, then was poured into 15% Na2CO3 
(15 mL/mmol eq.), extracted with DCM (15 mL/mmol eq.), washed with 
brine and dried over MgSO4. The crude product was purified by flash 
column chromatography or recrystallization to afford the title compound.
6.9.2 Synthesis of 7-bromomethyl coumarin (102)27
(C10H7BrO2; M.W.= 239.07)
        101      102
To a stirred solution of 7-methylcoumarin (1 g, 6.24 mmol) in acetonitrile 
(20 mL) was added N-bromosuccinimide (1.3 g, 7.23 mmol), followed by a 
catalytic amount of benzoyl peroxide (0.07 g, 0.3 mmol). The mixture was 
heated at reflux for 3h. After that time, the resulting solution was  stirred 
over night at room temperature which allowed the product to  precipitate. A 
white solid was filtered off, washed with propan-2-ol (20 mL) and dried. 
The title compound was  obtained as a white solid and used without further 
purification. 
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.68;
Yield: 1.09 g, 66.6 %
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1H-NMR (CDCl3),  δ:  4.54 (s, 2H, H-1’), 6.45 (d, J= 9.5 Hz,1H, H-aromatic), 
7.33 (d, J= 7.9 Hz, 1H, H-aromatic), 7.34-7.35 (m, 1H, H-aromatic), 7.49 (d, 
J= 7.9 Hz, 1H, H-aromatic), 7.71 (d, J= 9.5 Hz, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  31.82 (CH2, C-1’), 117.15, 117.25 ( CH, C-aromatic), 
118.71 (C, C-aromatic), 125.20, 128.30 (CH, C-aromatic), 141.99 (C, C-
aromatic), 142.82 (CH, C-aromatic), 154.02 (C, C-aromatic), 160.41 (C, C-1). 
6.9.3 Synthesis of 6-amino coumarin(96)28
(C9H7NO2; M.W.= 161.16)
        95          96
6-Nitrocoumarin (0.3 g, 1.6 mmol) was dissolved in EtOH (14.5 mL) and a 
catalytic amount of palladium on carbon (0.6 g) was added. Hydrogen was 
refluxed until the starting material disappeared. The mixture was filtered 
off through celite to  remove the catalyst. The filtered solution was 
evaporated under pressure to afford the title compound as a brown solid 
that was used for the following step without further purification.
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.44;
Yield: 0.23 g, 92 %
1H-NMR (MeOD), δ:  3.75 (bs, 2H, NH2), 6.40 (d, J= 9.5 Hz, 1H, H-aromatic), 
6.74 (d, J= 2.7 Hz,1H, H-aromatic), 6.89 (dd, J1= 8.8 Hz, J2= 2.7 Hz, 1H, H-
aromatic), 7.17 (d, J= 8.8 Hz, 1H, H-aromatic), 7.59 (d, J= 9.5 Hz, 1H, H-
aromatic).
13C-NMR (MeOD), δ:  112.88, 116.87, 117.99 (CH, C-aromatic), 120.83 (C, C-
aromatic), 121.20, 145.84 (CH, C-aromatic), 146.39, 148.02 (C, C-aromatic), 
163.67 (C, C-1).
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6.9.4 Synthesis of 7-((1H-Benzo[d]imidazol-2-yl)methoxy)-2H-chromen-2-
one (91) (C17H12N2O3; M.W.= 292.29)
N
H
N
Cl
OHO O
1. NaH, DMF, 0 oC; rt, 1h
2. , over 10'; r.t., o.n.
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7-Hydroxycoumarin (0.5 g., 3 mmol) was charged in a flask and anhydrous 
DMF (7 mL) was added. Upon dissolution, the mixture was  cooled to 0 oC 
and allowed to  stir for 15 min. NaH (0.072 g, 3 mmol) was  then added and 
the mixture was stirred for 1h. 
A solution of 2-(chloromethyl)benzimidazole (0.6 g, 3.6 mmol) in 
anhydrous DMF (7 mL) was added dropwise over 10 min. The reaction was 
allowed to  warm to room temperature and was stirred overnight. After 
12h, the starting material was still present, therefore Et3N (0.4 mL, 3 mmol) 
was added and the reaction was stirred for additional 24 h. The reaction 
mixture was  quenched with water (20 mL) and extracted with EtOAc (2 x 20 
mL), dried over MgSO4 and concentrated in vacuo. The crude mixture was 
purified by flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 60:40 v/v) and recrystallized from EtOH to give the pure 
product as a white solid. 
T.L.C. System: EtOAc-Hexane: 9:1 v/v, Rf: 0.33;
Yield: 0.09 g, 10.2 %;
Melting point: 150-153 oC;
MS (ESI)+: 293.1[M+H]+
1H-NMR (DMSO-d6), δ: 5.45 (s, 2H, H-1’), 6.3 (d, 1H, J= 9.4 Hz, H-aromatic),
7.10 (d, 1H, J= 8.6 Hz), 7.15-7.27 (m, 3H, H-aromatic), 7.51 (d, 1H, J= 7.5 Hz, 
H-aromatic), 7.64 (d, 1H, J= 7.8 Hz, H-aromatic), 7.67 (d, 1H, J= 8.6 Hz, H-
aromatic), 8.00 (d, 1H, J= 9.4 Hz, H-aromatic), 12.7 (bs, 1H, NH). 
13C-NMR (DMSO-d6),  δ:  64.25 (CH2, C-1’), 101.71 ( CH, C-aromatic), 111.0 
(CH, C-aromatic), 112.5 (C, C-aromatic), 112.87, 112.91, 123.0, 129.57 (CH,
C-aromatic), 138.9, 144.21(C, C-aromatic), 149.22 (CH, C-aromatic), 155.18, 
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160.16 (C, C-aromatic), 160.91 (C, C-1).
6.9.5 Synthesis of N-(2-oxo-2H-chromen-7-yl)-1H-benzo[d]imidazole-2-
carboxamide (94) (C17H11N3O3; M.W.=305.29)
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  96  97     94
1H-Benzimidazole-2-carboxylic  acid (0.54 g 3.7 mmol) and TBTU (1.3 g, 4 
mmol) were suspended in anhydrous THF (20 mL) at room temperature. 
DIPEA (1.35 mL, 7.77 mmol) was added to the reaction mixture, followed by 
6-aminocoumarin (0.6 g, 3.36 mmol) and the stirring was  maintained for 
4h. From the solution, a precipitate was formed which was filtered and 
washed with THF. The crude product was recrystallized from EtOH to 
obtain the title compound as a white solid.
T.L.C. System: n-hexane -EtOAc: 5:5v/v, Rf: 0.4;
Yield: 0.2, 18 %;
Melting point: 269-271 oC;
MS (ESI)+: 306.0 [M+Na]+
1H-NMR (DMSO-d6),  δ:  6.52 (d, J= 9.5 Hz, 1H, H-aromatic), 7.34-7.40 (m, 2H), 
7.46 (d, J= 8.9 Hz 1H, H-aromatic), 7.60-7.63 (m, 1H, H-aromatic), 7.78-7.82 
(m, 1H, H-aromatic), 8.07 (d, J= 8.9 Hz 1H, H-aromatic), 8.12 (d, J= 9.5 Hz 
1H, H-aromatic), 8.36 (d, J= 2.4 Hz, 1H, H-aromatic), 11.19 (bs, 1H, -CONH), 
13.47 (bs, 1H, NH). 
13C-NMR (DMSO-d6),  δ:  112.70, 116.57, 116.63 (CH, C-aromatic), 118.56 (C, 
C-aromatic), 119.25, 120.03, 122.81, 124.53, 124.76 (CH, C-aromatic), 
134.66 (C, C7), 144.36 (CH, C-aromatic), 145.26, 149.93 (C, C-aromatic), 
157.46 (C, C-1’), 159.97 (C, C-1).
Conclusions
271
6.9.6 Aryl thio methyl 2H-chromen-2-ones (95, 96)
7-(((1H-Benzo[d]imidazol-2-yl)thio)methyl)-2H-chromen-2-one (99) 
(C17H12N2O2S; M.W.= 308.35)
       103       99
General procedure 11;
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.33;
Off white solid;
Purification: flash column chromatography (n-hexane:EtOAc: 100:0 v/v, 
increasing to 50:50 v/v) and recrystallization from EtOH;
Yield: 0.52 g, 42 %;
Melting point: 135-137 oC;
MS (ESI)+: 309.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  4.66 (s, 2H, H-1’), 6.45 (d, 1H, J= 9.5 Hz, H-aromatic), 
7.10-7.18 (m, 2H, H-aromatic), 7.34-7.40 (m, 1H, H-aromatic), 7.44 (dd, 1H, 
J1= 1.5 Hz, J2= 7.9 Hz, H-aromatic), 7.50 (s, 1H, H-aromatic), 7.53-7.59 (m, 
1H, H-aromatic), 7.65 (d, 1H, J= 8.0 Hz, H-aromatic), 8.01 (d, 1H, J= 9.5 Hz, 
H-aromatic), 12.62 (bs, 1H, NH). 
13C-NMR (DMSO-d6),  δ:  34.51 (CH2, C-1’), 110.39, 115.92 (CH, C-aromatic), 
116.35 (C, C-aromatic), 117.45, 117.80, 121.21, 121.76, 125.11, 128.45 (CH, 
C-aromatic), 142.81 (C, C-aromatic), 143.51 (CH, C-aromatic), 143.88 (C, C-
aromatic), 130.63 (CH, C-aromatic), 149.19, 153.34 (C, C-aromatic), 159.87 
(C, C-1).
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7-(((4,5-Diphenyl-1H-imidazol-2-yl)thio)methyl)-2H-chromen-2-one  (100) 
(C25H18N2O2S; M.W.= 410.49)
 104      100
General procedure 11;
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.75;
Off white solid;
Purification: flash column chromatography (n-hexane:EtOAc: 100:0 v/v, 
increasing to 50:50 v/v);
Yield: 0.140 g, 8.5%;
Melting point: 193-195 oC-
MS (ESI)+: 411.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  4.47 (s, 2H, H-1’), 6.46 (d, 1H, J= 9.4 Hz, H-aromatic), 
7.18-7.25 (m, 1H), 7.26-7.44 (m, 9H, H-aromatic), 7.47 (d, 2H, J= 7.5 Hz, H-
aromatic), 7.66 (d, 1H, J= 7.9 Hz, H-aromatic), 8.03 (d, 1H, J= 9.4 Hz, H-
aromatic), 12.60 (bs, 1H, NH). 
13C-NMR (DMSO-d6), δ: 36.51 (CH2, C-1’), 115.82, 116.45 (CH, C-aromatic), 
117.71 (C, C-aromatic), 125.22, 126.58, 126.90, 127.69, 127.80, 128.20, 
128.36, 128.66 (CH, C-aromatic), 128.74, 130.63, 134.78, 137.25, 138.60, 
143.12, 143.95, 153.34 (C, C-aromatic), 159.92 (C, C-1). 
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6.9.7 Aryl sulfinyl methyl-2H-chromen-2-ones (105, 106)
7-(((1H-Benzo[d]imidazol-2-yl)sulfinyl)methyl)-2H-chromen-2-one (105) 
(C17H12N2O3S; M.W. =324.35)
N
H
N S
O O
1
2
3
4
5
6
7
8
9
1'
2'
3'4'
5'
5' 4'
3'
O
N
H
N S
O O
  99      105
General procedure 12;
Reagent: 7-(((1H-benzo[d]imidazol-2-yl)thio)methyl)-2H-chromen-2-one 95 
(0.1 g, 0.32 mmol);
T.L.C. System: n-hexane -EtOAc: 2:8 v/v, Rf: 0.5;
White solid;
Purification: flash column chromatography (n-hexane:EtOAc: 100:0 v/v, 
increasing to 80:20 v/v);
Yield: 0.18 g, 59.2 %;
Melting point: 171-173 oC;
MS (ESI)+: 325.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  4.62 (d, 1H, J= 12.7 Hz, H-1’), 4.85 (d, 1H, J= 12.7 Hz, 
H-1’), 7.10-7.18 (m, 2H, H-aromatic), 6.48 (d, 1H, J= 9.5 Hz H-aromatic), 7.01 
(dd, 1H, J1= 7.8 Hz, J2= 1.3 Hz, H-aromatic), 7.23 (s, 1H, H-aromatic), 
7.28-7.31 (m, 2H, H-aromatic), 7.48-7.52 (m, 1H, H-aromatic), 7.56 (d, 1H, J= 
8.0 Hz, H-aromatic), 7.73-7.77 (m, 1H, H-aromatic)., 8.01 (d, 1H, J2= 9.6 Hz, 
H-aromatic), 13.35 (bs, 1H, NH). 
13C-NMR (DMSO-d6),  δ:  58.91 (CH2, C-1’), 116.36, 118.13 (CH, C-aromatic), 
118.44 (C, C-aromatic), 126.32, 128.20 (CH, C-aromatic), 134.04 (C, C-
aromatic), 143.85 (CH, C-aromatic), 153.00, 153.05 (C, C-aromatic), 159.71 
(C, C-1).
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7-(((4,5-Diphenyl-1H-imidazol-2-yl)sulfinyl)methyl)-2H-chromen-2-one 
(106) (C25H18N2O3S; M.W. =426.49)
  100     106
General procedure 12;
Reagent: 7-(((4,5-diphenyl-1H-imidazol-2-yl)thio)methyl)-2H-chromen-2-one 
96 (0.5 g, 1.2 mmol);
T.L.C. System: n-hexane -EtOAc: 3:7 v/v, Rf: 0.60;
White solid;
Purification: flash column chromatography (n-hexane:EtOAc: 100:0 v/v, 
increasing to 50:50 v/v);
Yield: 0.100 g, 19.6 %;
Melting point: 175-177 oC;
MS (ESI)+: 427.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  4.74 (d, J= 12.4 Hz, 1H, H-1’), 4.79 (d, J= 12.4 Hz, 1H, 
H1’), 6.49 (d, J= 9.5 Hz, 1H, H-aromatic), 7.22 (d, J= 7.8 Hz, 1H, H-aromatic), 
7.29 (s, 2H, H-aromatic), 7.32-7.53 (m, 9H, H-aromatic), 7.68 (d, J= 7.8 Hz 
1H, H-aromatic), 8.05 (d, J= 9.5 Hz, 1H), 13.58 (bs, 1H, NH). 
13C-NMR (DMSO-d6),  δ:  58.53 (CH2, C-1’), 116.32, 117.97 (CH, C-aromatic), 
118.39 (C, C-aromatic), 126.52, 127.15, 127.20, 128.34 (CH, C-aromatic), 
128.42 (C, C-aromatic), 128.70 (CH, C-aromatic), 129.79, 130.48, 134.78, 
137.86, 143.88, 153.20 (C, C-aromatic), 159.75 (C, C-1).
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6.9.8 Aryl sulfonyl methyl-2H-chromen-2-ones (107, 108)
7-(((1H-Benzo[d]imidazol-2-yl)sulfonyl)methyl)-2H-chromen-2-one (107) 
(C17H12N2O4S; M.W. = 340.35)
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  99      107
General procedure 13;
Reagent: 7-(((1H-benzo[d]imidazol-2-yl)thio)methyl)-2H-chromen-2-one 95 
(0.15g, 0.49 mmol);
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.4;
White solid;
Purification: flash column chromatography (n-hexane:EtOAc: 100:0 v/v, 
increasing to 50:50 v/v);
Yield: 0.020 g, 13%;
Melting point: 224-226 oC;
MS (ESI)+: 341.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  5.16 (s, 2H, H-1’), 6.51 (d, J= 9.6 Hz, 1H, H-aromatic), 
7.14 (d, J= 7.9 Hz, 1H, H-aromatic), 7.32 (s, 1H, H-aromatic), 7.35-7.45 (m, 
2H, H-aromatic), 7.62 (d, J= 7.9 Hz, 1H, H-aromatic), 7.69-7.72 (m, 2H, H-
aromatic), 8.02 d, J= 9.6 Hz, 1H, H-aromatic).
13C-NMR (DMSO-d6),  δ:  58.86 (CH2, C-1’), 116.80, 118.80 (CH, C-aromatic), 
118.87 (C, C-aromatic), 127.04, 128.33, 143.71 (CH, C-aromatic), 153.05 (C, 
C-aromatic), 159.60 (C, C-1).
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7-(((4,5-Diphenyl-1H-imidazol-2-yl)sulfonyl)methyl)-2H-chromen-2-one 
(108) (C25H18N2O4S; M.W.= 442.49)
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  100      100
General procedure 13;
Reagent: 7-(((4,5-diphenyl-1H-imidazol-2-yl)thio)methyl)-2H-chromen-2-one 
96 (0.12 g, 0.29 mmol);
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.42;
White solid;
Purification: recrystallization from DCM/n-hexane;
Yield: 0.05g, 39%;
Melting point:225-227 oC;
MS (ESI)+: 443.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  5.02 (s, 2H, H-1’), 6.52 (d, 1H, J= 9.5 Hz, H-aromatic), 
7.19 (d, 1H, J= 8.0 Hz, H-aromatic), 7.24 (s, 1H, H-aromatic), 7.27-7.55 (m, 
10H, H-aromatic), 7.71 (d, 1H, J= 7.9 Hz, H-aromatic), 8.07 (d, 1H, J= 9.5 Hz, 
H-aromatic), 13.86 (bs, 1H, NH). 
13C-NMR (DMSO-d6),  δ:  60.32 (CH2, C-1’), 116.68, 118.67 (CH, C-aromatic), 
118.78 (C, C-aromatic), 127.09, 128.28, 128.46 (CH, C-aromatic), 132.13 (C, 
C-aromatic), 143.79 (CH, C-aromatic), 143.95, 153.07 (C, C-aromatic), 
159.64 (C, C-1). 
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6.10 Synthesis of (2E)-N’-benzylidene aryl acrylohydrazides
6.10.1 General procedures 14-17
General procedure 14: synthesis of acrylic acids 
A mixture of malonic  acid (1.61g, 11.5 mmol), the desired aldehyde (5.7 
mmol) and a catalytic  amount of piperidine (0.1 mL) was heated in a 
solution of pyridine (5 mL) at reflux for 2 h. The resultant mixture was 
poured into ice and a solution of 2 M HCl aq. was added dropwise. The 
formed solid was collected by filtration, washed with water and purified by 
flash column chromatography (n-hexane:EtOAc 100:0 v/v, increasing to 
80:20 v/v) to give the title compound.
General procedure 15: synthesis of acryloyl chlorides 
To a stirred solution of acid (6 mmol), in DCM (50 mL) was  added oxalyl 
chloride (1 mL, 12 mmol), and the mixture was stirred at room temperature 
for 5 h. The resulting solution was concentrated under reduced pressure to 
give the desired product which was used without further purification.
O
O O
HO OH
+
cat. piperidine
Pyr, reflux,  2h
OH
O
R R
OH
O
Cl
O
Cl
O
Cl
O
DCM, r.t., 5h
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General procedure 16: synthesis of aryl hydrazones
A solution of the corresponding benzaldehyde (1 eq.) in ethanol (1.80 mL/
mmol eq.) was treated with hydrazine monohydrate (1.1 eq.). The mixture 
was heated under reflux for 3 h and the solvent was evaporated under 
reduced pressure. The solid residue was washed with hexane, collected by 
filtration and dried.
General procedure 17: synthesis of (2E)-N’-benzylidene aryl 
acrylohydrazides
Cl
O
+
N
NH2
THF, Et3N
oC; r.t., o.n., under N20
R3 R3
N
H
O
N
R2
R2
R1
R1
R
R
The desired acryloyl chloride (2.5 mmol) was  dissolved in dry THF (16 mL) 
and cooled to 0 oC. TEA (0.71 mL, 5 mmol) was then added. The hydrazide 
derivative (2.5 mmol), dissolved in dry THF (14 mL) was then added 
dropwise at 0 oC. The solution was  stirred for 24 h under nitrogen 
atmosphere. The reaction was stopped and water (30 mL) were added. The 
formed solid was filtered, dried and purified by flash column 
chromatography or recrystallization to afford the title compound.
N
NH2
O NH2NH2 . H2O
EtOH, reflux, 3hR1 R1
R
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6.10.2 Aryl acrylic acids (115-118)
(E)-3-(4-Isopropylphenyl)acrylic acid (115)29
(C12H14O2: M.W.= 190.24)
         111         115
General procedure 14;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.50;
White powder;
Yield: 0.098 g, 91 %
1H-NMR (CDCl3),  δ:  1.29 (d, J= 6.9 Hz, 6H, H-2’), 2.93-2.99 (m, 1H, H-1’), 
6.44 (d, J= 15.9 Hz, 1H, H-3’), 7.29 (d, J= 8.0 Hz, 2H, H-aromatic), 7.52 (d, 
J=8.0 Hz, 2H, H-aromatic), 7.81 (d, J= 15.9 Hz, 1H, H-4’), 11.75 (bs, 1H, -
COOH).
13C-NMR (CDCl3),  δ:  23.74 (CH3, C-2’), 34.13 (CH, C-1’), 116.18 (CH, C-3’), 
127.10, 128.51 (CH, C-aromatic), 131.74 (C, C-aromatic), 147.08 (CH, C-4’), 
152.16 (C, C-aromatic), 172.14 (C, C-5’).
(E)-3-(4-(Trifluoromethyl)phenyl)acrylic acid (116)40
(C10H7F3O2: M.W.=216.16)
  112    116
General procedure 14;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.32;
White powder;
Yield: 1.12 g, 91 %
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1H-NMR (DMSO-d6),  δ:  6.68 (d, J= 16.0 Hz, 1H, H-2’), 7.66 (d, J= 16.0 Hz, 1H, 
H-3’), 7.77 (d, J= 8.0 Hz, 2H, H-aromatic), 7.92 (d, J= 8.0 Hz, 2H, H-
aromatic), 12.59 (bs, 1H, -COOH).
13C-NMR (DMSO-d6),  δ:  122.16 (CH, C-2’), 125.09 (C, C-4), 125.64, 125.67, 
128.80 (CH, C-aromatic), 129.67 (C, C-1’), 138.27 (C, C-1), 142.03 (CH, C-3’), 
167.14 (C, C-5’).
(E)-3-(4-Methoxyphenyl)acrylic acid (117)40
(C10H10O3: M.W.= 178.18)
        113    117
General procedure 14;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.52;
White powder;
Yield: 0.81 g, 80 %
1H-NMR (CDCl3),  δ:  3.87 (s, 3H, H-1’), 6.35 (d, J= 15.8 Hz, 1H, H-2’), 6.95 (d, 
J= 8.8 Hz, 2H, H-aromatic), 7.53 (d, J= 8.8 Hz, 2H, H-aromatic), 7.77 (d, J= 
15.8 Hz, 1H, H-3’), 11.50 (bs, 1H, -COOH).
13C-NMR (CDCl3),  δ:  55.41 (CH3, C-1’), 114.42 (CH, C-aromatic), 114.58 (CH, 
C-2’), 126.85 (C, C-aromatic), 130.09 (CH, C-aromatic), 146.68 (CH, C-3’), 
161.77 (C, C-4’).
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(E)-3-(Biphenyl-4-yl)acrylic acid (118)40
(C15H12O2: M.W.= 224.25)
  114     118
General procedure 14;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.66;
White powder;
Yield: 1.17 g, 92 %
1H-NMR (DMSO-d6),  δ: 6.58 (d, J= 16.0 Hz, 1H, H-5’), 7.40-7.42 (m, 1H, H-
aromatic), 7.48-7.50 (m, 2H, H-aromatic), 7.64 (d, J= 16.0 Hz, 1H, H-6’), 
7.71-7.74 (m, 4H, H-aromatic), 7.79 (d, J= 8.4 Hz, 2H, H-aromatic), 12.40 (bs, 
1H, -COOH).
13C-NMR (DMSO-d6),  δ: 119.20 (CH, C-5’), 126.66, 127.04, 127.90, 128.82, 
128.99 (CH, C-aromatic), 133.36, 139.22, 141.68, 143.35 (CH, C-6’), 167.56 
(C, C-7’).
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6.10.3 Aryl acryloyl chlorides (119-122)
(E)-3-(4-Isopropylphenyl)acryloyl chloride (119)30
(C12H13ClO: M.W.= 190.14)
   115    119
General procedure 15;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.74;
Pale yellow oil;
Yield: 1.1 g, 100 %
1H-NMR (CDCl3),  δ: 1.29 (d, J= 6.9 Hz, 6H, H-2’), 2.93-3.02 (m, 1H, H-1’), 
6.63 (d, J= 15.4 Hz, 1H, H-3’), 7.32 (d, J= 8.0 Hz, 2H, H-aromatic), 7.53 (d, J= 
8.0 Hz, 2H, H-aromatic), 7.85 (d, J= 15.4 Hz, 1H, H-4’),
13C-NMR (CDCl3),  δ: 23.65 (CH3, C-2’), 34.25 (CH, C-1’), 121.29 (CH, C-3’), 
127.11, 129.31 (CH, C-aromatic), 130.75 (C, C-aromatic), 150.83 (CH, C-4’), 
153.76 (C, C-aromatic), 166.18 (C, C-5’).
(E)-3-(4-(Trifluoromethyl)phenyl)acryloyl chloride (120)31
(C10H6ClF3O: M.W.= 234.60)
   116    120
General procedure15;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.40;
Pale yellow powder;
Yield: 1.27 g, 91 %
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1H-NMR (DMSO-d6),  δ: 6.69 (d, J= 16.0 Hz, 1H, H-2’), 7.67 (d, J= 16.0 Hz, 1H, 
H-3’), 7.76 (d, J= 8.0 Hz, 2H, H-aromatic), 7.92 (d, J= 8.0 Hz, 2H, H-
aromatic).
13C-NMR (DMSO-d6),  δ: 122.16 (CH, C-2’), 125.09 (C, C-4), 125.64, 125.67, 
128.80 (CH, C-aromatic), 129.66, 129.92 (C, C-1’), 138.28 (C, C-1), 142.03 
(CH, C-3’), 167.13 (C, C-5’).
(E)-3-(4-Methoxyphenyl)acryloyl chloride (121)32
(C10H9ClO2: M.W.= 196.63)
        117     121
General procedure 15;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.56;
Yellow powder;
Yield: 1.10 g, 94 %
1H-NMR (CDCl3),  δ: 3.89 (s, 3H, H-1’), 6.54 (d, J= 15.4 Hz, 1H, H-2’), 6.97 (d, 
J= 8.7 Hz, 2H, H-aromatic), 7.56 (d, J= 8.7 Hz, 2H, H-aromatic), 7.82 (d, J= 
15.4 Hz, 1H, H-3’).
13C-NMR (CDCl3),  δ: 55.41 (CH3, C-1’), 114.43 (CH, C-aromatic), 114.58 (CH, 
C-2’), 126.85 (C, C-aromatic), 130.10 (CH, C-aromatic), 146.72 (CH, C-3’), 
161.78 (C, C-4’).
(E)-3-(Biphenyl-4-yl)acryloyl chloride (122)33
(C15H11ClO: M.W.= 242.70)
  118     122
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General procedure 15;
T.L.C. system: n-hexane-EtOAc 1:1 v/v, Rf: 0.56;
Pale yellow powder;
Yield: 1.42 g, 98 %
1H-NMR (DMSO-d6),  δ:  6.58 (d, J= 16.0 Hz, 1H, H-5’), 7.39-7.41 (m, 1H, H-
aromatic), 7.48-7.50 (m, 1H, H-aromatic), 7.64 (d, J= 16.0 Hz, 1H, H-6’), 
7.71-7.74 (m, 4H, H-aromatic), 7.78 (d, J= 8.4 Hz, 2H, H-aromatic).
13C-NMR (DMSO-d6),  δ:  119.16 (CH, C-5’), 126.66, 127.04, 127.89, 128.82, 
128.99 (CH, C-aromatic), 133.35, 139.21, 141.68 (C, C-aromatic), 143.37 
(CH, C-6’), 167.53 (C, C-7’).
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6.10.4 Aryl hydrazones (126-128) 
(4-Methylbenzylidene)hydrazine (126)34
(C8H10N2; M.W.= 134.178)
         123   126
General procedure 16;
Reagent: benzaldehyde () (1 g, 8.32 mmol);
T.L.C. system: n-hexane- EtOAc  1:1 v/v, Rf: 0.32
Pale yellow powder;
Yield: 0.851 g, 76 %
1H-NMR (DMSO-d6),  δ:  2.28 (s, 3H, H-1’), 6.62 (bs, 2H, NH2), 7.13 (d, J= 8.0 
Hz, 2H, H-aromatic), 7.36 (d, J= 8.0 Hz, 2H, H-aromatic), 7.67 (s, 1H, H-2’).
13C-NMR (DMSO-d6),  δ:  20.79 (CH3, C-1’), 125.11, 129.04 (CH, C-aromatic), 
133.64, 136.68 (C, C-aromatic).
(3,4-Diethoxybenzylidene)hydrazine (127) 
(C11H16N2O2; M.W.= 208.257)
          124          127
General procedure 16;
Reagent: 3,4-Diethoxybenzaldehyde () (1 g, 5.15 mmol);
T.L.C. system: n-hexane -EtOAc  1:1 v/v, Rf: 0.24 
Pale yellow powder;
Yield: 0.980 g, 91 %
1H-NMR (DMSO-d6),  δ:  1.30-1.34 (m, 6H, H-2’), 3.99-4.04 (m, 4H, H-1’), 6.49 
(bs, 2H, NH2), 6.90 (s, 2H, H-aromatic), 7.12 (s, 1H, H-aromatic), 7.62 (s,1H, 
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H-3’).
13C-NMR (DMSO-d6),  δ:  14.72 (CH3, C-2’), 63.55 (CH2, C-1’), 109.03, 113.14, 
118.74 (CH, C-aromatic), 129.38 (C, C-aromatic), 138.82 (CH, C-3’), 148.03, 
148.30 (C, C-aromatic).
(1-(4-Cyclohexylphenyl)ethylidene)hydrazine (120)
(C14H20N2; M.W.= 216.322)
  125     128
General procedure 16;
Reagent:4ʹ′-Cyclohexylacetophenone () (1 g, 4.94 mmol);
T.L.C. system: n-hexane- EtOAc  1:1 v/v, Rf: 0.61
Pale yellow powder;
Yield: 1.01 g, 94 %
1H-NMR (DMSO-d6),  δ:  1.19-1.27 (m, 1H, H-4’), 1.34-1.41 (m, 4H, CH2), 
1.69-1.71 (m, 1H, H-4’), 1.76-1.80 (m, 4H, CH2), 2.00 (s, 3H, H-6’), 2.46-2.49 
(m, 1H, H-1’), 6.24 (bs, 2H, NH2), 7.16 (d, J= 8.3 Hz, 2H, H-aromatic), 7.52 (d, 
J= 8.3 Hz, 2H, H-aromatic).
13C-NMR (DMSO-d6),  δ:  11.34 (CH3, C-6’), 25.58, 26.32, 33.88 (CH2), 43.39 
(CH, C-1’), 124.73, 126.29 (CH, C-aromatic), 137.51, 142.32, 146.34 (C, C-
aromatic).
4-(Hydrazonomethyl)phenol (168)32
(C7H8N2O; M.W.= 136.151)
          142           168
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General procedure 16;
Reagent: 4-hydroxybenzaldehyde (142) (1 g, 8.19 mmol);
T.L.C. system n-hexane- EtOAc  1:1 v/v, Rf: 0.15 
Pale yellow powder;
Yield: 1.16 g, 99 %
1H-NMR (DMSO-d6),  δ: 6.37 (bs, 2H, NH2), 6.72 (d, J= 8.5 Hz, 2H, H-
aromatic), 7.30 (d, J= 8.5 Hz, 2H, H-aromatic), 7.62 (s, 1H, H-1’), 9.36 (bs, 
1H, -OH).
13C-NMR (DMSO-d6),  δ:  115.30 (CH, C-aromatic), 126.60 (CH, C-aromatic), 
127.44 (C, C-aromatic), 139.34 (CH, C-1’), 157.16 (C, C-aromatic).
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6.10.5 N’-benzylideneacrylohydrazides (121-132)
3-(4-Isopropylphenyl)-N'-(4-methylbenzylidene)acrylohydrazide (129) 
(C20H22NO2; M.W.= 306.40)
Cl
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+
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NH2 N
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O
N
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 119  126     129a,b
General procedure 17;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.56;
White powder;
Purification: recrystallization from DCM/n-hexane;
Yield: 0.441 g, 58 %
Melting point: 157-161 oC
MS (ESI)+: 307.2 [M+H]+
Two species observed. Major/minor species ratio: 2:1
1H-NMR (DMSO-d6),  δ:  (major species, 129a) 1.21-1.24 (m, 6H, H-2’), 2.35 (s, 
3H, H-11’), 2.89-2.97 (m, 1H, H-1’), 6.66 (d, J= 15.6 Hz, 1H, H-3’), 7.27 (d, J= 
7.9 Hz, 2H, H-aromatic), 7.60-7.68 (m, 7H, H-aromatic, H-trans), 8.21 (s, 1H, 
H-6’), 11.57 (bs, s, 1H, H, NH).
1H-NMR (DMSO-d6),  δ:  (minor species, 129b) 1.21-1.24 (m, 6H, H-2’), 2.35 (s, 
3H, H-11’), 2.89-2.97 (m, 1H, H-1’), 7.27 (d, J= 7.9 Hz, 2H, H-aromatic), 
7.31-7.35 (m, 4H, H-aromatic, H-trans), 7.51-7.58 (m, 4H, H-aromatic, H-
trans), 8.03 (s, 1H, H-6’), 11.39 (bs, s, 1H, H, NH).
13C-NMR (DMSO-d6),  δ: 21.01 (CH3, C-11’), 23.62 (CH3, C-2’), 33.31 (CH, 
C-1’), 116.24, 119.29 (CH, C-3’), 126.83, 126.90, 126.94, 127.05, 127.80, 
128.25, 129.39 (CH, C-aromatic), 131.49, 131.60, 132.34, 132.53, 139.51, 
139.81 (C, C-aromatic), 140.37, 141.95 (CH, C-4’), 143.13, 146.57 (CH, C-6’), 
150.47, 150.62 (C, C-aromatic), 161.45, 166.02 (C, C-5’).
Conclusions
289
N'-(3,4-Diethoxybenzylidene)-3-(4-isopropylphenyl)acrylohydrazide (130) 
(C23H28N2O3; M.W.= 380.48)
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 119        127     130a,b
General procedure 17;
T.L.C. system: DCM-MeOH 95:5 v/v, Rf: 0.55;
Yellow powder;
Purification: flash column chromatography (DCM-MeOH 100:0 v/v, 
increasing to 98:2 v/v);
Yield: 0.120 g, 13 %
Melting point: 118-125 oC
MS (ESI)+: 403.2 [M+Na]+
Two major species observed. Major/minor species ratio: 5:3
1H-NMR (DMSO-d6), δ:  (major species, 130a) 1.27 (d, J= 1.24 Hz, 6H, H-2’), 
1.33-1.39 (m, 6H, H-14’), 2.89-2.97 (m, 1H, H-1’), 4.08 (q, J= 6.9 Hz, 3H, 
H-13’), 4.12-4.15 (m, 1H, H-13’), 6.65 (d, J= 15.7 Hz, 1H, H-3’), 7.01 (d, J= 8.3 
Hz, 1H, H-aromatic), 7.20 (d, J= 8.4 Hz, 1H, H-aromatic), 7.31-7.34 (m, 2H, 
H-aromatic, H-trans), 7.55 (d, J= 8.1 Hz, 3H, H-aromatic), 7.65 (d, J= 7.4 Hz, 
1H, H-aromatic), 8.15 (s, 1H, H-6’), 11.49 (bs, 1H, NH).
1H-NMR (DMSO-d6), δ:  (minor species, 130b) 1.27 (d, J= 1.24 Hz, 6H, H-2’), 
1.33-1.39 (m, 6H, H-14’), 2.89-2.97 (m, 1H, H-1’), 4.08 (q, J= 6.9 Hz, 3H, 
H-13’), 4.12-4.15 (m, 1H, H-13’), 7.01 (d, J= 8.3 Hz, 1H, H-aromatic), 7.24 (d, 
J= 8.4 Hz, 1H, H-aromatic), 7.31-7.34 (m, 4H, H-aromatic, H-trans), 7.58-7.60 
(m, 1H, H-aromatic), 7.61-7.63 (m, 1H, H-trans), 7.65 (d, J= 7.4 Hz, 1H, H-
aromatic), 7.97 (s, 1H, H-6’), 11.36 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  14.62, 14.91 (CH3, C-2’), 23.61 (CH3, C-14’), 33.30 (C, 
C-1’), 63.78, 63.85 (CH2, C-13’), 110.09, 110.77, 112.76, 112.98, 116.41, 
119.41, 120.70, 121.71, 126.92, 127.76, 128.17 (CH, C-aromatic), 132.37, 
132.57 (C, C-aromatic), 140.14 , 141.71, 143.10, 146.72 (CH, C-aromatic), 
148.36, 149.87, 150.14, 150.40, 150.58 (C, C-aromatic), 161.32, 165.91 (C, 
C-5’).
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N'-(1-(4-Cyclohexylphenyl)ethylidene)-3-(4-
isopropylphenyl)acrylohydrazide (131)
(C26H32N2O; M.W.= 388.55)
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General procedure 17;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.65;
White powder;
Purification: recrystallization from DCM/n-hexane;
Yield: 0.178 g, 18.3 %;
Melting point: 186-190 oC;
MS (ESI)+: 389.3 [M+H]+
Two species observed. Major/minor species ratio: 10:7
1H-NMR (DMSO-d6), δ:  (major species, 131a) 1.22 (d, J= 6.8 Hz, 6H, H-2’), 
1.27-1.30 (m, 1H, H-14’), 1.34-1.47 (m, 4H, CH2), 1.69-1.74 (m, 1H, CH2), 
1.78-1.82 (m, 4H, CH2), 2.31 (s, 3H, H-15’), 2.55-2.59 (m, 1H, H-11’), 
2.90-2.96 (m, 1H, H-1’), 7.00 (d, J= 15.9 Hz, 1H, H-3’), 7.27-7.30 (m, 2H, H-
aromatic), 7.33 (d, J= 8.1 Hz, 2H, H-aromatic), 7.54-7.60 (m, 2H, H-
aromatic), 7.61-7.69 (m, 1H, H-trans), 7.74 (d, J= 7.9 Hz, 2H, H-aromatic), 
10.49 (bs, 1H, NH).
1H-NMR (DMSO-d6), δ:  (minor species, 131b) 1.22 (d, J= 6.8 Hz, 6H, H-2’), 
1.27-1.30 (m, 1H, H-14’), 1.34-1.47 (m, 5H, CH2), 1.72 (d, J= 13.0 Hz, 1H, 
CH), 1.80 (d, J= 10.4 Hz, 4H, CH2), 2.28 (s, 3H, H-15’), 2.90-2.96 (m, 1H, CH), 
7.28 (d, J=7.3 Hz, 2H, H-aromatic), 7.33 (d, J= 8.1 Hz, 2H, H-aromatic), 
7.50-7.60 (m, 2H, H-aromatic, H-trans), 7.61-7.69 (m, 2H, H-aromatic, H-
trans), 7.74 (d, J= 7.9 Hz, 2H, H-aromatic), 10.57 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  12.68, 14.94 (CH3, C-15’), 23.81, 25.05 (CH3, C-2’), 
26.06, 26.13 (CH2, C-14’), 26.80, 26.84, 26.86 (CH2), 34.10 (CH, C-1’), 34.28, 
34.33 (CH2), 44.41, 44.46 (CH, C-14’), 115.76 (CH, C-4’), 126.20, 126.61, 
126.80, 126.88, 126.93, 127.01, 128.15, 128.42 (CH, C-aromatic), 132.93,
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135.67, 136.21 (C, C-aromatic), 143.44, 143.78 (CH, C-3’), 147.02, 149.66, 
149.76, 151.28, 157.62 (C, C-aromatic), 167.65 (C, C-5’).
N'-(4-Methylbenzylidene)-3-(4-(trifluoromethyl)phenyl)acrylohydrazide 
(132) (C18H15F3N2O; M.W.= 332.32)
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General procedure 17;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.37;
White powder;
Purification: recrystallization from EtOH/H2O
Yield: 0.05 g, 6 %
Melting point: 166-170 oC
MS (ESI)+: 355.1 [M+Na]+
Two species observed. Major/minor species ratio: 5:4
1H-NMR (DMSO-d6),  δ:  (major species, 132a) 2.36 (s, 3H, H-10’), 6.84 (d, J= 
16.0 Hz, 1H, H-2’), 7.26-7.29 (m, 2H, H-aromatic), 7.80 (d, J= 8.2 Hz, 4H, H-
aromatic, H-trans), 7.85 (d, J= 8.2 Hz, 2H, H-aromatic), 7.99 (d, J= 8.2 Hz, 
1H, H-aromatic), 8.23 (s, 1H, H-5’), 11.68 (bs, 1H, NH).
1H-NMR (DMSO-d6),  δ:  (minor species, 132b) 2.36 (s, 3H, H-10’), 7.26-7.29 
(m, 1H, H-aromatic, H-trans), 7.63-7.68 (m, 5H, H-aromatic), 7.71-7.74 (m, 
2H, H-aromatic, H-trans), 7.85 (d, J= 8.2 Hz, 1H, H-aromatic), 7.99 (d, J= 8.2 
Hz, 1H, H-aromatic), 8.05 (s, 1H, H-5’), 11.54 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  21.01, 21.59 (CH3, C-10’), 120.13, 123.20 (CH, C-2’), 
122.98, 125.14 (C, C-aromatic), 125.73, 125.82, 125.85, 126.94, 128.32, 
128.83, 129.39, 129.59 (CH, C-aromatic), 127.15, 131.36, 131.47 (C, C-
aromatic), 138.64, 140.17 (CH, C-3’), 138.73, 138.84, 139.66, 139.99 (C, C-
aromatic), 143.67, 147.19 (CH, C-5’), 160.84, 165.46 (C, C-4’).
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N'-(3,4-Diethoxybenzylidene)-3-(4-
(trifluoromethyl)phenyl)acrylohydrazide (133)
(C21H21F3N2O3; M.W.= 406.40)
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General procedure 17;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.62
Yellow powder;
Purification by flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 60:40 v/v);
Yield: 0.050 g, 5 %;
Melting point: 140-144 oC
MS (ESI)+: 429.1 [M+Na]+
Two major species observed. Major/minor species ratio: 10:6
1H-NMR (DMSO-d6), δ:  (major species, 133a) 1.36 (q, J= 6.7 Hz, 6H, H-13’), 
4.06-4.15 (m, 4H, H-12’), 6.84 (d, J= 15.9 Hz, 1H, H-2’), 7.02-7.04 (m, 1H, H-
aromatic), 7.22 (d, J= 8.2 Hz, 1H, H-aromatic), 7.34 (d, J= 7.6 Hz, 1H, H-
aromatic),7.68 (d, J= 15.9 Hz, 1H, H-3’), 7.73 (s, 1H, H-aromatic), 7.80 (d, J= 
8.5 Hz, 2H, H-aromatic), 7.85 (d, J= 8.2 Hz, 1H, H-aromatic), 7.96-7.99 (m, 
1H, H-aromatic), 8.17 (s, 1H, H-5’), 11.60 (bs, 1H NH).
1H-NMR (DMSO-d6), δ:  (minor species, 133b) 1.36 (q, J= 6.7 Hz, 6H, H-13’), 
4.06-4.15 (m, 4H, H-12’), 7.02-7.04 (m, 1H, H-trans), 7.26 (d, J= 8.2 Hz, 1H, 
H-aromatic), 7.34 (d, J= 7.6 Hz, 1H, H-aromatic), 7.80 (d, J= 8.5 Hz, 2H, H-
aromatic), 7.85 (d, J= 8.2 Hz, 2H, H-aromatic), 7.96-7.99 (m, 2H, H-aromatic, 
H-trans), 11.52 (bs, 1H- NH).
13C-NMR (DMSO-d6),  δ:  14.62, 14.70 (CH3, C-12’), 63.78, 63.87 (CH2, C-11’), 
110.14, 110.98, 112.75, 112.95, 120.34, 120.82, 121.85, 123.33, 125.81 (CH, 
C-aromatic), 126.81 (C, C-aromatic), 128.29, 128.74, 138.41 (CH, C-
aromatic), 138.87 (C, C-aromatic), 139.93, 143.65, 147.38 (CH, C-aromatic), 
147.85, 148.36, 150.26 (C, C-aromatic), 160.69 (C, C-4’).
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N'-(1-(4-Cyclohexylphenyl)ethylidene)-3-(4-(trifluoromethyl)phenyl) 
acrylohydrazide (134)
(C24H25F3N2O: M.W.= 414.46)
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General procedure 17;
T.L.C. system: n-hexane- EtOAc 1:1 v/v, Rf: 0.76;
White powder;
Purification by flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 75);
Yield: 0.120 g, 12 %;
Melting point: 200-206 oC
MS (ESI)+: 437.2 [M+Na]+
Two species observed. Major/minor species ratio: 2:1
1H-NMR (DMSO-d6), δ:  (major species, 134a) 1.21-1.31 (m, 1H, H-14’), 
1.34-1.47 (m, 5H, CH2), 1.71-1.73 (m, 1H, CH), 1.80-1.82 (m, 4H, CH2), 2.33 
(s, 3H, H-6’), 7.19 (d, J= 15.4 Hz, 1H, H-2’), 7.28 (d, J= 8.3 Hz, 2H, H-
aromatic), 7.68 (d, J= 15.4 Hz, 1H, H-3’), 7.75-7.78 (m, 3H, H-aromatic), 
7.79-7.87 (m, 2H, H-aromatic), 7.95 (d, J= 7.8 Hz, 1H, H-aromatic), 10.61 (bs, 
1H, NH).
1H-NMR (DMSO-d6), δ:  (minor species, 134b) 1.21-1.31 (m, 1H, H-14’), 
1.34-1.47 (m, 3H, CH2), 1.71-1.73 (m, 1H, CH), 1.80-1.82 (m, 4H, CH2), 2.31 
(s, 3H, H-6’), 2.53-2.57 (m, 2H, CH2), 7.28 (d, J= 8.3 Hz, 2H, H-aromatic), 
7.75-7.78 (m, 2H, H-aromatic, H-trans), 7.79-7.87 (m, 5H, H-aromatic, H-
trans), 7.95 (d, J= 7.8 Hz, 1H, H-aromatic), 10.72 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  13.71, 14.06 (CH3, C-6’), 25.54 (CH2, C-14’), 26.26, 
33.77 (CH2), 43.51 (CH, C-11’), 120.71 (CH, C-2’), 122.99 (C, C-aromatic), 
123.79 125.83, 126.17, 126.41, 126.58, 126.70, 128.23, 128.70 (CH, C-
aromatic), 137.75 (C, C-aromatic), 138.30, 140.03 (CH, C-3’), 138.97, 148.36, 
148.95, 152.26 (C, C-aromatic), 161.24 (C, C-4’).
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3-(4-Methoxyphenyl)-N'-(4-methylbenzylidene)acrylohydrazide (135)35
(C18H18N2O2; M.W.= 294.35)
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General procedure 17;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.40;
White powder;
Purification: recrystallization from EtOH/H2O;
Yield: 0.405 g, 55 %;
Melting point: 184-188 °C
MS (ESI)+: 295.1 [M+H]+
Two major species observed. Major/minor ratio: 7:5
1H-NMR (DMSO-d6), δ:  (major species, 135a) 2.35 (s, 3H, H-10’), 3.81 (s, 3H, 
H-1’), 6.56 (d, J= 15.8 Hz, 1H, H-2’), 7.01 (d, J= 7.5 Hz, 2H, H-aromatic), 7.27 
(d, J= 7.5 Hz, 2H, H-aromatic), 7.55-7.66 (m, 3H, H-aromatic, H-trans), 7.71 
(d, J= 8.20 Hz, 2H, H-aromatic), 8.20 (s, 1H, H-5’), 11.51 (bs, 1H, NH).
1H-NMR (DMSO-d6), δ:  2.35 (minor species, 135b) (s, 3H, H-10’), 3.82 (s, 3H, 
H-1’), 7.01 (d, J= 7.5 Hz, 2H, H-aromatic), 7.27 (d, J= 7.5 Hz, 2H, H-
aromatic), 7.45 (d, J= 15.8 Hz, 1H, H-2’), 7.55-7.66 (m, 5H, H-aromatic, H-
trans), 8.02 (s, 1H, H-5’), 11.34 (bs, 1H, NH),
13C-NMR (DMSO-d6),  δ:  21.00 (CH3, C-10’), 55.28 (CH3, C-1’), 114.39, 114.44, 
114.56 (CH, C-aromatic), 117.69 (CH, C-2’), 126.81, 127.02 (CH, C-aromatic), 
127.06, 127.46 (C, C-aromatic), 129.37, 129.87 (CH, C-aromatic), 131.54, 
131.66, 139.44, 139.74 (C, C-aromatic), 140.17 (CH, C-aromatic), 141.77 
(CH, C-aromatic), 142.93 (CH, C-aromatic), 146.33 (CH, C-5’), 160.62 (C, C-
aromatic), 161.64 (C, C-4’).
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N'-(3,4-Diethoxybenzylidene)-3-(4-methoxyphenyl)acrylohydrazide (136)
(C21H24N2O4; M.W.= 368.43)
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General procedure 17;
T.L.C. system: DCM-MeOH 95:5 v/v, Rf: 0.38;
Pale yellow powder;
Purification: flash column chromatography (DCM-MeOH 100:0 v/v, 
increasing to 99:1 v/v)
Yield: 0.32 g, 35%
Melting point: 140-146 oC
MS (ESI)+: 369.2 [M+H]+
Two species observed. Major/minor species: 10:7
1H-NMR (DMSO-d6), δ:  (major species, 136a) 1.33-1.38 (m, 6H, H-13’), 3.81 
(s, 3H, H-1’), 4.08 (q, J= 6.9 Hz, 4H, H-12’), 6.65 (d, J= 15.8 Hz, 1H, H-2’), 
7.01 (d, J= 8.5 Hz, 4H, H-aromatic), 7.19 (d, J= 8.2 Hz, 1H, H-aromatic), 
7.31-7.33 (m, 1H, H-aromatic), 7.62 (d, J= 15.8 Hz, 1H, H-3’), 7.58 (d, J= 8.2 
Hz, 1H, H-aromatic), 8.15 (s, 1H, H-5’), 11.44 (bs, 1H, NH).
1H-NMR (DMSO-d6), δ:  (minor species, 136b) 1.33-1.38 (m, 6H, H-13’), 3.82 
(s, 3H, H-1’), 4.08 (q, J= 6.9 Hz, 2H, H-12’), 4.11-4.15 (m, 2H, H-12’), 7.01 (d, 
J= 8.5 Hz, 1H, H-aromatic), 7.24 (d, J= 8.2 Hz, 1H, H-aromatic), 7.31-7.33 (m, 
1H, H-trans), 7.45 (d, J= 15.8 Hz, 1H, H-2’), 7.53-7.55 (m, 1H, H-trans), 7.58 
(d, J= 8.2 Hz, 2H, H-aromatic), 7.69 (d, J= 8.5 Hz, 2H, H-aromatic), 7.96 (s, 
1H, H-5’), 11.30 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  14.63, 14.71 (CH3, C-13’), 55.28 (CH3, C-1’), 63.78, 
63.85 (CH2, C-12’), 110.08, 110.85, 112.77, 113.00, 114.44, 114.75, 117.81,
120.64, 121.65 (CH, C-aromatic), 126.99, 127.29 (C, C-aromatic), 129.31, 
129.79, 139.94, 141.54, 142.92, 146.53, 148.36 (CH, C-aromatic), 148.36, 
150.20, 160.58 (C, C-aromatic), 161.50 (C, C-4’).
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N'-(1-(4-Cyclohexylphenyl)ethylidene)-3-(4-
methoxyphenyl)acrylohydrazide (137)
(C24H28N2O2; M.W.= 376.49)
O
Cl
O
+
N
NH2
N
H
O
N
1
3
24
2
3
2'
3'
4' 5'
6'
7'
8'
9'
10'
9'
8'
11' 12'
13'
14'
13'
12'
O
1'
 121  128     137
General procedure 17;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.48;
White powder;
Purification: recrystallization from DCM/n-hexane;
Yield: 0.085 g, 9 %
Melting point: 194-200 oC;
MS (ESI)+: 377.2 [M+H]+
1H-NMR (CDCl3), δ:  1.26-1.35 (m, 1H, CH2), 1.41-1.49 (m, 4H, CH2), 1.77-1.82 
(d, J= 12.6 Hz, 2H, CH), 1.86-1.94 (m, 4H, CH2), 2.27 (s, 3H, H-1’), 2.53-2.61 
(m, 1H, CH), 3.87 (s, 3H, H-6’), 6.95 (d, J= 8.6 Hz, 2H, H-aromatic), 7.30 (d, 
J= 8.0 Hz, 2H, H-aromatic), 7.51 (d, J= 15.9 Hz, 1H, H-2’), 7.61 (d, J= 8.4 Hz, 
2H, H-aromatic), 7.74 (d, J= 7.5 Hz, 2H, H-aromatic), 7.84 (d, J= 15.9 Hz, 1H, 
H-3’), 8.58 (bs, 1H, NH). 
13C-NMR (CDCl3),  δ:  12.64, 14.10 (CH3, C-6’), 26.06, 26.13, 26.80, 26.84, 
34.28, 34.33 (CH2), 44.41 (CH, C-11’), 55.37 (CH3, C-1’), 114.19, 114.22, 
114.27, 126.19, 126.61, 127.01, 128.14, 129.96 (CH, C-aromatic), 128.04, 
135.69 (C, C-aromatic), 143.11, 143.48 (CH, C-3’), 146.84 (C, C-5’), 149.64, 
161.12, 161.23 (C, C-aromatic), 167.70 (C, C-4’).
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3-(Biphenyl-4-yl)-N'-(4-methylbenzylidene)acrylohydrazide (138) 
(C23H20N2O; M.W.= 340.42)
Cl
O
+
N
NH2
N
H
O
N
1
3
24
2
3
1'
2'
3'
4'
3'
2'
5'
6'
7'
8'
9'
10'
11'
12'
10'
11' 13'
 122   126    138a,b
General procedure 17;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.39;
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 50:50 v/v);
White powder;
Yield: 0.095 g, 10.6 %;
Melting point: 194-197 oC;
MS (ESI)+: 363.1 [M+Na]+
Two species observed. Major/minor species ratio: 5:4
1H-NMR (DMSO-d6),  δ:  (major species, 138a) 2.36 (s, 3H, H-13’), 6.76 (d, J= 
15.7 Hz, 1H, H-5’), 7.28 (d, J= 7.8 Hz, 1H, H-aromatic), 7.39-7.43 (m, 1H, H-
aromatic), 7.48-7.53 (m, 1H, H-aromatic), 7.61-7.69 (m, 4H, H-aromatic), 
7.71-7.79 (m, 6H, H-aromatic, H-trans), 7.86, (d, J= 8.0 Hz, 1H, H-6’), 8.23 (s, 
1H, H-8’), 11.61 (bs, 1H, NH).
1H-NMR (DMSO-d6),  δ:  (minor species, 138b) 2.36 (s, 3H, H-13’), 7.28 (d, J= 
7.8 Hz, 2H, H-aromatic), 7.39-7.43 (m, 2H, H-aromatic, H-trans), 7.48-7.53 
(m, 3H, H-aromatic), 7.61-7.69 (m, 2H, H-aromatic), 7.71-7.79 (m, 5H, H-
aromatic, H-trans), 7.86, (d, J= 8.0 Hz, 1H, H-6’), 8.05 (s, 1H, H-8’), 11.45 (bs, 
1H, NH).
13C-NMR (DMSO-d6),  δ:  21.02 (CH3, C-13’), 117.13, 120.27, 126.61, 126.65, 
126.87, 127.08, 127.16, 127.85, 128.35, 128.83, 129.0, 129.39 (CH, H-
aromatic), 131.47, 131.59, 133.80, 133.97, 139.25 (C, C-aromatic), 139.90, 
141.48, 143.28, 146.72 (CH, C-aromatic), 161.33 (C, C-7’).
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3-(Biphenyl-4-yl)-N'-(3,4-diethoxybenzylidene)acrylohydrazide (139)
(C26H26N2O3; M.W.= 414.50)
Cl
O
+
O
N
NH2
N
H
O
N
O
1
3
24
2
3
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14' 15'
O
O 15'
16'
16'
 122       127     139a,b
General procedure 17;
T.L.C. system: DCM-MeOH 95:5 v/v, Rf: 0.38;
Pale yellow powder;
Purification: flash column chromatography (DCM-MeOH 100:0 v/v, 
increasing to 99:1 v/v) and recrystallization from MeOH;
Yield: 0.064 g, 6 %
Melting poiNt: 158-162 oC
MS (ESI)+: 415.2 [M+H]+
Two species observe. Major/minor species ratio: 10:7
1H-NMR (DMSO-d6), δ:  (major species, 139a) 1.34-1.39 (m, 6H, H-16’), 4.08 
(q, J= 6.7 Hz, 3H, H-15’), 4.14 (q, J= 6.7 Hz, 1H, H-15’), 6.75 (d, J= 15.7 Hz, 
1H, H-5’), 7.02 (d, J= 8.3 Hz, 1H, H-aromatic), 7.21 (d, J= 8.3 Hz, 1H, H-
aromatic), 7.34-7.36 (m, 1H, H-aromatic), 7.38-7.42 (m, 1H, H-aromatic), 
7.48-7.52 (m, 2H, H-aromatic), 7.62-7.67 (m, 1H, H-aromatic), 7.70-7.75 (m, 
1H, H-trans), 7.77 (d, J= 8.2 Hz, 4H, H-aromatic, H-6’), 7.84 (d, J= 8.2 Hz, 1H, 
H-aromatic), 8.18 (s, 1H, H-aromatic), 11.53 (bs, s, 1H, NH).
1H-NMR (DMSO-d6), δ:  (minor species, 139b) 1.34-1.39 (m, 6H, H-16’), 4.08 
(q, J= 6.7 Hz, 3H, H-15’), 4.14 (q, J= 6.7 Hz, 1H, H-15’), 7.02 (d, J= 8.3 Hz, 
1H, H-aromatic), 7.27 (d, J= 8.3 Hz, 1H, H-aromatic), 7.34-7.36 (m, 1H, H-
trans), 7.38-7.42 (m, 1H, H-aromatic), 7.48-7.52 (m, 2H, H-aromatic), 
7.62-7.67 (m, 1H, H-aromatic), 7.70-7.75 (m, 6H, H-trans), 7.84 (d, J= 8.2 Hz, 
1H, H-aromatic), 7.99 (s, 1H, H-aromatic), 11.41 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  14.63, 14.72 (CH3, C-16’), 63.79, 63.87 (CH2, C-17’), 
110.14, 112.78, 117.34, 120.40, 120.73, 121.76, 126.60 (CH, C-aromatic), 
126.92, 136.94, 139.27 (C, C-aromatic), 139.67, 143.25 (CH, C-aromatic), 
148.39, 150.21 (C, C-aromatic), 161.25 (C, C-7’).
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3-(Biphenyl-4-yl)-N'-(1-(4-cyclohexylphenyl)ethylidene)acrylohydrazide 
(140) (C29H30N2O; M.W.= 422.56)
Cl
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 122       128     140
General procedure 17;
T.L.C. system: DCM-MeOH 99:1 v/v, Rf: 0.43;
Pale yellow powder;
Purification: flash column chromatography (DCM-MeOH 100:0 v/v, 
increasing to 99:1 v/v) and recrystallization from EtOH;
Yield: 0.055 g, 5.3 %
Melting point: 212-220 oC
MS (ESI)+: 445.2 [M+Na]+
1H-NMR (CDCl3),  δ:  1.28-1.35 (m, 1H, H-17’), 1.39-1.53 (m, 4H, CH2), 
1.78-1.83 (m, 1H, H-17’), 1.87-1.95 (m, 4H, CH2), 2.29 (s, 3H, H-9’), 2.55-2.61 
(m, 1H, H-14’), 7.31 (d, J= 8.0 Hz, 2H, H-aromatic), 7.38-7.42 (m, 1H, H-
aromatic), 7.47-7.51 (m, 2H, H-aromatic, H-trans), 7.64-7.70 (m, 5H, H-
aromatic), 7.72-7.78 (m, 4H, H-aromatic), 7.93 (d, J= 15.9 Hz, 1H, H-6’), 8.68 
(bs, 1H, NH).
13C-NMR (CDCl3),  δ:  12.70 (CH3, C-9’), 26.13, 26.84, 34.33 (CH2), 44.42 (CH, 
C-14’), 116.57 (CH, C-5’), 126.23, 126.60, 127.06, 127.45, 127.49, 127.75, 
128.17, 128.82, 128.89 (CH, C-aromatic), 134.22, 135.62, 140.35, 142.79 (C, 
C-aromatic), 143.31 (CH, C-6’), 147.19, 149.75 (C, C-aromatic), 167.40 (C, 
C-7’).
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6.10.6 (E)-3-(4-isopropylphenyl)acrylohydrazide (143)
(C12H16N2O; M.W.= 204.27)
To a solution of (E)-3-(4-isopropylphenyl)acrylic acid 115 (1.68 g, 8.83 
mmol.) in Et2O  (30 mL) was added oxalyl chloride (0.75 mL, 8.83 mmol) at 
0°C  under nitrogen atmosphere. The cold bath was removed and the 
mixture was stirred at room temperature for 3 h. Hydrazine (0.86 mL, 
17.66 mmol) was added and the mixture was stirred for additional 2 h. The 
reaction mixture was diluted with EtOAc (30 mL) and the solid was filtered 
off by gravity filtration. The organic phase was  washed with NaHCO3 sat. 
solution (2 x 30 mL), Na2CO3 sat. solution (2 x 30 mL), brine, dried over 
MgSO4 and finally evaporated under reduced pressure to give the title 
compound as a pale yellow powder.
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.10;
Yield: 0.250 g, 15 %
1H-NMR (DMSO-d6,  δ:  1.19-1.23 (m, 6H, H-2’), 2.87-2.94 (m, 1H, H-1’), 4.60 
(bs, 2H, NH2), 6.51 (d, J= 15.7 Hz, 1H, H-3’), 7.28 (d, J= 8.2 Hz, 2H, H-
aromatic), 7.41 (d, J= 15.7 Hz, 1H, H-4’), 7.47 (d, J= 8.2 Hz, 1H, H-aromatic), 
7.53 (d, J= 8.2 Hz, 1H, H-aromatic), 9.30 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  23.63 (CH3, C-2’), 33.25 (CH, C-1’), 119.31 (CH, C-3’), 
126.89, 127.47 (CH, C-aromatic), 132.56, 139.95, 149.91 (C, C-aromatic), 
164.59 (C, C-5’).
OH
O
115
Cl
O
Cl
O
DCM, r.t., 5h
Cl
O
119
NH2NH2.H2O
Et2O, r.t., 2h, under N2
.
N
H
O
NH2
141, 15%
123
41'
2'
2'
3'
4'
5'
2
3
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6.10.7 N'-(4-Hydroxybenzylidene)-3-(4-isopropylphenyl)acrylohydrazide 
(143) (C19H20N2O2; M.W.= 308.37)
N
H
O
NH2
+
HO
O NH
O
N
OH
1
4
1'
2'
2'
3
3
2
2
3'
4'
5'
6'
7'
8'
9'
10'
9'
8'
EtOH
r.t., 72h
 141          142    143a,b
A mixture of (E)-3-(4-isopropylphenyl)acrylohydrazide 141 (0.250 g, 1.22 
mmol) and 4-hydroxybenzaldehyde 142 (0.180 g, 1.47 mmol) in ethanol (15 
mL) was stirred under reflux for 72 hours. The reaction mixture was dried 
under vacuum and the crude product was purified by flash column 
chromatography (n-hexane:EtOAc 100:0 v/v, increasing to 10:90 v/v) and 
then recrystallized from ethanol to  give the pure (2E,N'E)-N'-(4-
hydroxybenzylidene)-3-(4-isopropylphenyl)acrylohydrazide as a pale yellow 
powder.
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.55;
Yield: 0.026 g, 7 %
Melting point: 255-260 oC
MS (ESI)+: 309.2 [M+H]+
Two species observed. Major/minor species: 5:4
1H-NMR (DMSO-d6), δ:  (major species, 143a) 1.21-1.24 (m, 6H, H-2’), 
2.90-2.97 (m, 1H, H-1’), 6.64 (d, J= 15.9 Hz, 1H, H-3’), 6.84 (d, J= 7.8 Hz, 2H, 
H-aromatic), 7.30-7.34 (m, 3H, H-aromatic), 7.50-7.62 (m, 2H, H-aromatic, H-
trans), 7.65 (d, J= 8.0 Hz, 2H, H-aromatic), 8.14 (s, 1H, H-6’), 9.86 (bs, 1H, 
NH), 9.90 (bs, 1H, NH), 11.42 (bs, 1H, -OH).
1H-NMR (DMSO-d6), δ:  (minor species, 143b) 1.21-1.24 (m, 6H, H-2’), 
2.90-2.97 (m, 1H, H-1’), 6.84 (d, J= 7.8 Hz, 2H, H-aromatic), 7.30-7.34 (m, 
1H, H-trans), 7.50-7.62 (m, 7H, H-aromatic, H-trans), 7.96 (s, 1H, H-6’), 9.86 
(bs, 1H, NH), 11.26 (bs, 1H, -OH).
13C-NMR (DMSO-d6),  δ:  23.63 (CH3, C-2’), 33.30 (CH, C-1’), 115.65, 115.98, 
116.46, 118.43, 119.47 (CH, H-aromatic), 125.22, 125.29 (C, C-aromatic), 
126.88, 126.93, 127.74, 128.20, 128.55, 128.83 (CH, H-aromatic), 132.40, 
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132.60 (C, C-aromatic), 140.01, 141.63, 143.29, 146.83 (CH, C-aromatic), 
150.36, 150.53, 159.11, 159.36 (C, C-aromatic), 161.24, 165.81 (C, C-5’).
6.11 (E)-N-(1H-Benzo[d]imidazol-2-yl)-3-(4-tert-
butylphenyl)acrylamides
6.11.1 General procedures 18-19
General procedure 18: synthesis of 2-aminobenzimidazoles 
Aryl-1,2-diamine (4.62 mmol) was dissolved in a 1:1 mixture of methanol 
(40 mL) and water (40 mL). The reaction mixture was treated with BrCN 
(0.73 mL, 13.86 mmol) and heated at 50 oC for 1 h. After cooling to room 
temperature, methanol was removed under reduced pressure and the 
remaining reaction mixture was basified with 1M NaOH aq. to pH=8 and 
extracted with ethyl acetate (3x 30 mL). The combined organic fractions 
were washed with water (2x 50 mL), brine (2x 50 mL), dried over MgSO4 and 
the solvent was removed under reduced pressure to give pure 2-
aminobenzimidazole derivatives.
General procedure  19: synthesis of (E)-N-(1H-benzo[d]imidazol-2-yl)-3-(4-
tert-butylphenyl)acrylamides
N
N
H
NH2
N
H
O
N
HN
R
OH
O
+
TBTU
DIPEA, THF, r.t., 4h
R
(E)-3-(4-tert-Butylphenyl)acrylic acid (0.276 g, 1.35 mmol) and TBTU (0.433 
g, 1.35 mmol) were suspended in dry THF (7.3 mL) at room temperature. 
DIPEA (0.49 mL, 2.84 mmol) was then added to  the reaction mixture, 
followed by the desired 2-aminobenzbenzimidazoleimidazole  (1.35 mmol). 
The reaction was  stirred for 4 h. The organic solvent was  removed under 
vacuum and the residue was diluted with ethyl acetate (10 mL), then the 
H2O/MeOH (1:1) 
     50 oC, 1h
R NH2
NH2 N
H
N
NH2
R
BrCN
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organic layer was washed with NaHCO3 (2 x 10 mL) and brine. The crude 
mixture was purified by flash column chromatography (n-hexane:EtOAc 
100:0 v/v, increasing to 80:20 v/v) to give the desired compound.
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6.11.2 (E)-3-(4-tert-Butylphenyl)acrylic acid (153)36
(C13H16O2; M.W.= 204.260)
O
+ HOOC COOH
Pyr, reflux, 2h
OH
O
cat. piperidine 5'
4'
3'
123
4
3
21'
2'
2'
2'
 152             153
A mixture of malonic acid (12.32 mmol, 2 eq), aldehyde 152 (6.16 mmol) 
and catalytic  amount of piperidine (0.2 mL) was heated in a solution of 
pyridine (5 mL, 60 mmol) at reflux for 2 h. The resultant solution of 
pyridine was poured into  ice and a solution of 2 M HCl aq. was poured 
dropwise, which led the crude product to  precipitate. The solid was 
collected by filtration, washed with water and purified by flash column 
chromatography (n-hexane-EtOAc 100:0 v/v, increasing to  80:20 v/v) to 
give the pure (E)-3-(4-tert-butylphenyl)acrylic acid as a white solid.
T.L.C. system: n-hexane -EtOAc 6:4 v/v, Rf: 0.28
Yield: 1.060 g, 84 %
1H-NMR (CDCl3), δ:  1.36 (s, 9H, H-2’), 6.45 (d, J= 15.9 Hz, 1H, H-3’), 7.45 (d, 
J= 8.3 Hz, 2H, H-aromatic), 7.53 (d, J= 8.3 Hz, 2H, H-aromatic), 7.81 (d, J= 
15.9 Hz, 1H, H-4’), 11.57 (bs, 1H, COOH).
13C-NMR (DMSO),  δ:  25.89 (CH3, C-2’), 29.70 (C, C-1’), 111.05, 120.70 (CH, C-
aromatic), 122.99 (CH, C-3’), 126.09 (C, C-aromatic), 141.72 (CH, C-4’), 
149.16 (C, C-aromatic), 166.94 (C, C-5’).
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6.11.3 Substituted 2-aminobenzimidazoles (150, 151)
1H-Benzo[d]imidazol-2-amine (150)37
(C7H7N3: M.W.= 133.15)
          148   150
General procedure 18;
T.L.C. system: n-hexane -EtOAc 5:5 v/v, Rf: 0.1;
Light brown powder;
Yield: 0.530 g, 87 %
1H-NMR (DMSO-d6),  δ:  6.06 (bs, 2H, NH2), 6.83-6.85 (m, 2H, H-aromatic), 
7.08-7.10 (m, 2H, H-aromatic), 10.63 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  111.50, 118.90 (CH, C-aromatic), 115.21 (C, C-
aromatic).
5-Methyl-1H-benzo[d]imidazol-2-amine (143)38
(C8H9N3: M.W.= 147.18)
   149   151
General procedure 18;
T.L.C. system: n-hexane -EtOAc 5:5 v/v, Rf: 0.1;
Brown powder;
Yield: 0.59 g, 87 %
1H-NMR (CDCl3),  δ:  2.30 (s, 3H, H-1’), 6.01 (bs, s, 2H, NH2), 6.66 (d, J= 7.8 
Hz, 1H, H-aromatic), 6.91 (s, 1H, H-aromatic), 6.96 (d, J= 7.8 Hz, 1H, H-
aromatic), 10.54 (bs, s, 1H, NH).
NH2
NH2
N
N
H
NH2
2
3
4
4
3
2
1
NH2
NH2
N
N
H
NH2
2
6
5
4
3
2
1
1'
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13C-NMR (CDCl3),  δ:  21.20 (CH3, C-1’), 111.06, 111.89, 119.85 (CH, C-
aromatic), 127.57, 155.04 (C, C-aromatic).
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6.11.4 E)-N-(1H-Benzo[d]imidazol-2-yl)-3-(4-tert-butylphenyl)acrylamides 
(144, 145
(E)-N-(1H-Benzo[d]imidazol-2-yl)-3-(4-tert-butylphenyl)acrylamide (144)
(C20H21N3O: M.W.= 319.40)
OH
O
153
N
H
N
NH2 N
H
O
N
H
N1
2
3
4
3
2
5
2'
1'
1'
1'
3' 5'
4'
6'
6'
7'
7'
8'
8'
     150       144
General procedure 19;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.46;
Yield: 0.05 g, 11.6 %
Melting point: 260-261 oC;
MS (ESI)+: 320.2 [M+H]+
1H-NMR (DMSO-d6), δ:  1.31 (s, 9H, H-1’), 5.75 (s, 1H, H-aromatic), 6.93 (d, J= 
15.7 Hz, 1H, H-4’), 7.09-7.11 (m, 2H, H-aromatic), 7.46-7.48 (m, 2H, H-
aromatic), 7.50 (d, J= 8.3 Hz, 2H, H-aromatic), 7.59 (d, J= 8.3 Hz, 1H, H-
aromatic), 7.71 (d, J= 15.7 Hz, 1H, H-3’), 11.73 (bs, 1H, NH), 12.13 (bs, 1H, 
NH).
13C-NMR (DMSO-d6),  δ:  30.90 (CH3, C-1’), 34.61 (C, C-5), 119.67, 121.02, 
125.88, 127.82 (CH, C-aromatic), 131.63 (C, C-aromatic), 141.84 (CH, C-
aromatic), 143.75, 146.79, 153.18 (C, C-aromatic), 164.43 (C, C-4’).
3-(4-tert-Butylphenyl)-N-(5-methyl-1H-benzo[d]imidazol-2-yl)propanamide 
(145) (C21H25N3O; M.W.= 333.43)
OH
O
153
N
H
N
NH2 N
H
O
N
H
N1
2
3
4
3
2
5
2'
1'
1'
1'
3' 5'
4'
6'
11'
7'
10'
8'
9'
12'
      151              145
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General procedure 19;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.32’
Yield: 0.05 g, 10 %
Melting point: 202-207 oC;
MS (ESI)+: 334.2 [M+H]+
1H-NMR (DMSO-d6), δ:  1.31 (s, 9H, H-2’), 2.38 (s, 3H, H-12’), 6.92-6.97 (m, 
2H, H-aromatic, H-trans), 7.29 (s, 2H, H-aromatic), 7.34 (d, J= 7.3 Hz, 1H, 
H-2’), 7.49 (d, J= 7.5 Hz, 2H, H-aromatic), 7.58 (d, J= 7.5 Hz, 2H, H-
aromatic), 7.70 (d, J= 15.7 Hz, 1H, H-4’), 11.83 (bs, 1H, NH), 12.02 (bs, 1H, 
NH).
13C-NMR (DMSO-d6),  δ:  21.28 (CH3, C-11’), 30.89 (CH3, C-1’), 34.59 (C, C-1’), 
119.76 (CH, C-3’), 122.33, 125.88, 127.79 (CH, C-aromatic), 129.98, 131.64, 
139.53, 140.59 (C, C-aromatic), 141.72 (CH, C-4’), 153.15 (C, C-5’).
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6.12 Synthesis of N-(1H-benzo[d]imidazol-2-yl)-3-(4-tert-
butylphenyl)propanamides
6.12.1 General procedure 20: synthesis of N-(1H-benzo[d]imidazol-2-yl)-3-
(4-tert-butylphenyl)propanamides
Cl
O
+
N
N
H
NH2
DIPEA, THF
reflux, 2h N
H
O
N
HN
R
R
A solution of the desired aryl chloride (1 eq.) and DIPEA (3 eq.) in dry THF 
(0.5 mL/mmol eq.) was  added dropwise to 2-aminobenzimidazole (1 eq.). 
After stirring at reflux for 2 hours, the reaction mixture was diluted with 
DCM (5 mL/mmol eq.) and washed with water (5 mL/mmol eq.), NaHCO3 (5 
mL/mmol eq.) and brine. The organic  layer was  dried over MgSO4 and 
evaporated under reduced pressure. The resulting crude mixture was 
purified by flash column chromatography and/or recrystallization to give 
the desired compound.
6.12.2 3-(4-tert-Butylphenyl)propanoic acid (154)39
(C13H18O2; M.W.= 206.28)
  153     154
(E)-3-(4-tert-butylphenyl)acrylic acid (153) (0.5 g, 0.5 mmol) was dissolved 
in dry THF (9.5 mL) and a catalytic amount of 10%  Pd/C was added (0.122 
g) to carry out the hydrogenation. The reaction mixture was stirred for 5 
hours at room temperature under H2 atmosphere, after that time it was 
diluted with ethyl acetate (10 mL), filtered through celite and concentrated 
under reduced pressure to give 3-(4-tert-butylphenyl)propanoic acid as a 
white powder.
1
2
3
4
5
1'
2'
3'
4'OH
O
OH
O
H2, Pd/C
THF, r.t., 4h 2
31'
1'
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T.L.C. system: n-hexane -EtOAc 4:6 v/v, Rf: 0.76;
Yield: 0.5 g, 99 %
1H-NMR (CDCl3),  δ:  1.33 (s, 9H, H-1’), 2.71 (t, J= 7.8 Hz, 2H, H-2’), 2.96 (t, J= 
7.8 Hz, 2H, H-3’), 7.17 (d, J= 8.0 Hz, 2H, H-aromatic), 7.35 (d, J= 8.0 Hz, 2H, 
H-aromatic).
13C-NMR (CDCl3),  δ:  30.04 (CH2, C-2’), 31.37 (CH3, C-1’), 34.39 (C, C-5’), 
35.39 (CH2, C-3’), 125.45, 127.91 (CH, C-aromatic), 137.08, 149.23 (C, C-
aromatic), 178.25 (C, C-4’).
6.12.3 3-(4-tert-Butylphenyl)propanoyl chloride (155)40
(C13H17ClO: M.W.= 224.10)
  154      155
To a stirred solution of 3-(4-tert-butylphenyl)propanoic  acid 154 (2.94 
mmol), in DCM (15 mL) at room temperature was added oxalyl chloride (0.5 
mL, 5.88 mmol), and the mixture was stirred for 5 h. The resulting solution 
was concentrated under reduced pressure to give the desired product 
which was used without further purification.
T.L.C. system n-hexane -EtOAc 7:3 v/v, Rf: 0.76;
Pale yellow oil;
Yield: 0.540 g, 83 %
1H-NMR (CDCl3),  δ:  1.34 (s, 9H, H-1’), 3.01 (t, J= 7.5 Hz, 2H, H-2’), 3.22 (t, J= 
7.5 Hz, 2H, H-3’), 7.15 (d, J= 8.2 Hz, 2H, H-aromatic), 7.36 (d, J= 8.2 Hz, 2H, 
H-aromatic).
13C-NMR (CDCl3),  δ:  30.47 (CH2, C-2’), 31.34 (CH3, C-1’), 34.44 (C, C-
aromatic), 48.56 (CH2, C-3’), 125.65, 127.96 (CH, C-aromatic), 135.54, 
149.75 (C, C-aromatic), 173.14 (C, C-4’).
OH
O
Cl
O
1
2
3
4
5
1'
1'
1'
2
3
2'
3'
4'
DCM, r.t., 5h
Cl
O
O
Cl
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6.12.4 Benzoimidazol-4-tert-butylphenyl)propanamides (146, 147)
N-(1H-Benzo[d]imidazol-2-yl)-3-(4-tert-butylphenyl)propanamide (146)
(C20H23N3O; M.W.= 321.42)
Cl
O
N
N
H
NH2
1
2
3
451'
2'
3'
4'
5'
6'
7' 8'
N
H
O
N
HN
2
31'
1'
6'
7'
8'
155
 
    150        146
General procedure 20;
Reagent: 1H-benzo[d]imidazol-2-amine (150) (0.17g, 1.28 mmol);
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.42;
Yield: 0.02 g, 5 %
Melting point: 248-252 oC
MS (ESI)+: 322.2 [M+H]+
1H-NMR (DMSO-d6),  δ:  1.25 (s, 9H, H-1’), 2.76 (t, J= 7.4 Hz, 2H, H-2’), 2.92 (t, 
J= 7.4 Hz, 2H, H-3’), 7.07-7.09 (m, 2H, H-aromatic), 7.19 (d, J= 7.8 Hz, 2H, H-
aromatic), 7.31 (d, J= 7.8 Hz, 2H, H-aromatic), 7.43-7.48 (m, 2H, H-
aromatic), 11.50 (bs, 1H, NH), 12.02 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  29.84 (CH2, C-2’), 31.16 (CH3, C-1’), 34.04 (C, C-
aromatic), 36.96 (CH2, C-3’), 120.59, 121.14, 125.04, 127.89 (CH, C-
aromatic), 132.46, 137.69, 146.52, 148.27 (C, C-aromatic), 171.70 (C, C-4’).
3-(4-tert-Butylphenyl)-N-(5-methyl-1H-benzo[d]imidazol-2-yl)propanamide 
(147) (C21H25N3O: M.W.= 335.44)
N
H
O
N
H
N
4
3
2
1
2
3
5
1'
1'
1'
2'
3' 4' 5' 6' 7'
8'
9'
10'
11'
12'
N
N
H
NH2
Cl
O
147
      151        147
General procedure 20;
Reagent: 5-methyl-1H-benzo[d]imidazol-2-amine (151) (0.42 g, 2.85 mmol);
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T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.45;
White powder;
Yield: 0.05 g, 5.3 %;
Melting point: 206-211 oC
MS (ESI)+:336.2 [M+H]+
1H-NMR (DMSO-d6), δ:  1.25 (s, 9H, H-1’), 2.36 (s, 3H, H-11’), 2.72-2.77 (m, 
2H, H-2’), 2.89-2.94 (m, 2H, H-3’), 6.87-6.91 (m, 1H, H-aromatic), 7.16-7.24 
(m, 3H, H-aromatic), 7.28-7.32 (m, 3H, H-aromatic), 11.45 (bs, 1H, NH), 
11.89 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  21.25 (CH3, C-1’), 29.84 (CH2, C-2’), 31.15 (CH3, 
C-11’), 34.02 (C, C-aromatic), 36.94 (CH2, C-3’), 122.20, 125.03, 127.88 (CH, 
C-aromatic), 129.81, 137.69, 146.31, 148.27 (C, C-aromatic), 171.62 (C, 
C-4’).
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6.13 Synthesis of 1-Phenethyl-4-p-tolyl-1H-1,2,3-triazole
6.13.1 2-(Azidoethyl)benzene (151)41
(C8H9N3: M.W.= 147.18)
        158    159
A solution of (2-bromoethyl)benzene (158) (0.37 mL, 2.70 mmol) in DMF 
(10.8 mL) was treated with NaN3 (0.878 g, 13.5 mmol) under nitrogen 
atmosphere and the mixture was stirred at 80 oC for 24 h. The reaction 
mixture was cooled down to  room temperature and extracted with DCM (3 
x 20 mL). The combined organic layers were washed with water (3 x 20 mL) 
and brine, dried over MgSO4 and the solvent was removed under reduced 
pressure to give the pure (2-azidoethyl)benzene as a pale yellow oil.
T.L.C. system: n-hexane -EtOAc 9.8:0.2 v/v, Rf: 0.72
Yield: 0.290 g, 73 %
1H-NMR (CDCl3),  δ:  2.93 (t, J= 7.2 Hz, 2H, H-1’), 3.54 (t, J= 7.2 Hz, 2H, H-2’), 
7.25 (d, J= 7.0 Hz, 2H, H-aromatic), 7.29 (d, J= 7.0 Hz, 1H, H-aromatic), 
7.34-7.37 (m, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  35.37 (CH2, C-1’), 52.48 (CH2, C-2’), 126.79, 128.66, 
128.76 (CH, C-aromatic), 138.04 (C, C-1).
6.13.2 1-Phenethyl-4-p-tolyl-1H-1,2,3-triazole (157)42
(C17H17N3: M.W.= 263.34)
N3
+ Na ascorbate, CuSO4
24h, r.t.
N N
NDCM, H2O 1
2
3
4
3
2 1'
2'
3' 4'
5'
6'
7' 8'
7'
6'
9'
      159   160      157
Br
NaN3
    DMF, 80 oC, 24h
N3
1
2
3
4
3
2 1'
2'
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A solution of (2-azidoethyl)benzene (159) (0.290 g, 1.97 mmol) and 1-
ethynyl-4-methylbenzene (160) (0.322 mL, 2.54 mmol) in 4.8 mL of DCM 
was stirred at r.t. and 3.6 mL of water were added followed by 65 mg of 
CuSO4.5H2O. Sodium ascorbate (0.177 g, 0.89 mmol) was then added in 
small portions and the mixture was stirred at room temperature for 24 h. 
The DCM layer was  separated, dried over MgSO4 and removed under 
reduced pressure. The crude product was then recrystallized from DCM/n-
hexane to give the pure 1-phenethyl-4-p-tolyl-1H-1,2,3-triazole as  a off-
whiteoff-white powder.
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.74;
Yield: 0.128 g, 25 %;
Melting point: 96-100 oC
MS (ESI)+: 264.1 [M+H]+
1H-NMR (CDCl3),  δ:  2.39 (s, 3H, H-9’), 3.27 (t, J= 7.2 Hz, 2H, H-1’), 4.65 (t, J= 
7.2 Hz, 2H, H-2’), 7.16 (d, J= 6.6 Hz, 2H, H-aromatic), 7.24 (d, J= 7.5 Hz, 2H, 
H-aromatic), 7.32 (d, J= 7.5 Hz, 2H, H-aromatic), 7.34-7.38 (m, 1H, H-
aromatic), 7.45 (s, 1H, H-3’), 7.68 (d, J= 7.8 Hz, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  21.26 (CH3, C-9’), 36.82 (CH2, C-1’), 51.71 (CH2, C-2’), 
119.54, 125.62, 127.13 (CH, C-aromatic), 127.86 (C, C-aromatic), 128.74, 
128.85, 129.48 (CH, C-aromatic), 137.12, 137.92, 147.59 (C, C-aromatic).
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6.14 Synthesis of (E)-2-benzylidene-N-(4-tert-
butylstyryl)hydrazinecarboxamides
6.14.1 General procedure 21: synthesis of -2-benzylidene-N-(4-tert-
butylstyryl)hydrazinecarboxamides (154-157)
A solution of azide (1 eq.) in toluene (16 mL/mmol eq.) was  heated at 120 
oC for 4 h to give the isocyanate derivative that was  not isolated. After 
cooling the reaction to  r.t., the amine (1 eq.) was slowly added to the 
isocyanate solution. The reaction mixture was stirred at room temperature, 
overnight. The solid was filtered and washed with toluene (7 mL/mmol eq. 
The crude product was then recrystallized from ethanol to give the title 
compounds.
N3
O
N
C
O
H
N
H
N
O
N
R3
R2
N NH2
R3
R2
R1
Toluene
120 oC, 4h
r.t., o.n.
R1
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6.14.2 (E)-3-(4-tert-Butylphenyl)acryloyl azide (166)43
(C13H15N3O; M.W.= 229.278)
OH
O
I. Et3N, ClCOOEt, Acetone, 0o C, 1h
II. NaN3, H2O, 0oC, 7h
N3
O
1
3
24
2
3
1'
3'
4'
5'
2'
2'
2'
      153             166
A mixture of 3-(4-tert-butylphenyl)acrylic  acid (153) (0.750 g, 3.67 mmol), 
Et3N (0.56 mL, 4.03 mmol) and ethyl-chlorocarbonate (0.7 g, 3.67 mmol) in 
dry acetone (28.5 mL) was  stirred at 0 oC for 1 h under nitrogen 
atmosphere. Sodium azide (0.22 g, 3.67 mmol) dissolved in 6,4 mL of water 
was added and stirring was kept at 0 oC for 7 hours. The organic mixture 
was poured into  ice. The obtained precipitate was collected by filtration 
and washed with water to give the pure (E)-3-(4-tert-butylphenyl)acryloyl 
azide as a white powder.
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.37
Yield: 0.531 g, 63 %
1H-NMR (CDCl3),  δ:  1.35 (s, 9H, H-2’), 6.42 (d, J= 15.8 Hz, 1H, H-3’), 7.45 (d, 
J= 8.4 Hz, 2H, H-aromatic), 7.50 (d, J= 8.4 Hz, 2H, H-aromatic), 7.76 (d, J= 
15.8 Hz, 1H, H-4’).
13C-NMR (CDCl3),  δ:  31.11 (CH3, C-2’), 35.01 (C, C-1’), 118.18 (CH, C-3’), 
126.09, 128.48 (CH, C-aromatic), 131.11 (C, C-aromatic), 146.69 (CH, C-4’), 
154.93 (C, C-aromatic), 172.18 (C, C-5’).
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6.14.3 2-benzylidene-N-(4-tert-butylstyryl)hydrazinecarboxamides 
(162-165)
N-(4-tert-Butylstyryl)-2-(4-methylbenzylidene)hydrazinecarboxamide 
(162) (C21H25N3O; M.W.= 335.443)
General procedure 21;
T.L.C. system: n-hexane -EtOAc  1:1 v/v, Rf: 0.48
White powder;
Yield: 0.332 g, 42.9 %;
Melting point: 205-209 oC
MS (ESI)+: 336.2 [M+H]+
1H-NMR (DMSO-d6), δ:  1.27 (s, 9H, H-2’), 2.35 (s, 3H, H-13’), 6.39 (d, J= 14.5 
Hz, 1H, H-3’), 7.23-7.25 (m, 4H, H-aromatic), 7.31 (d, J= 8.2 Hz, 2H, H-
aromatic), 7.37 (dd, J1= 14.5 Hz J2= 10.4 Hz, 1H, H-4’), 7.74 (d, J= 8.2 Hz, 
2H, H-aromatic), 7.90 (s, 1H, H-6’), 9.17 (d, J= 10.4 Hz, 1H, NH), 10.76 (bs, 
1H, NH).
13C-NMR (DMSO-d6),  δ:  6.83 (C, C-1‘), 20.99 (CH3, C-13’) , 31.11 (CH3, C-2’), 
109.51 (CH, C-3’), 123.86 (CH, C-4’), 124.40, 125.38, 127.00, 129.15 (CH, C-
aromatic), 131.68, 134.43, 139.12, 147.90 (C, C-aromatic), 152.71 (C, C-5’).
N3
O
N
C
O
N
NH2
H
N
H
N
O
N
1
2
3
4
3
2
1'
2'
2'
2'
3'
4'
5'
6'
7'
8'
9'
10'
9'
8'
11'
118
166 167
162
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N-(4-tert-Butylstyryl)-2-(3,4-diethoxybenzylidene)hydrazinecarboxamide 
(163) (C24H31N3O3; M.W.= 409.521)
General procedure 21;
T.L.C. system: n-hexane -EtOAc  1:1 v/v, Rf: 0.47;
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 70:30 v/v) and recrystallization from ethanol; 
Yield: 0.055 g, 11 %;
Melting point: 145-158 oC
MS (ESI)+: 432.2 [M+Na]+
1H-NMR (DMSO-d6), δ:  1.27 (s, 9H, H-2’), 1.33-1.38 (m, 6H, H-14’), 4.07 (q, 
J1= 6.8 Hz, 2H, H-aromatic), 4.13 (q, J1= 6.8 Hz, 2H, H-aromatic), 6.36 (d, J= 
14.6 Hz, 1H, H-3’), 6.98 (d, J= 8.3 Hz, 1H, H-aromatic), 7.22-7.25 (m, 3H, H-
aromatic), 7.30 (d, J= 8.3 Hz, 2H, H-aromatic), 7.39 (dd, J1= 14.6 Hz, J2= 
10.3 Hz, 1H, H-4’), 7.50 (d, J= 1.7 Hz, 1H, H-aromatic), 7.85 (s, 1H, H-6’), 
9.18 (d, J= 10.3 Hz, 1H, NH), 10.69 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  14.66, 14.78 (CH3, C-14’), 31.11 (CH3, C-2’), 34.08 (C, 
C-1’), 63.76, 64.06 (CH2, C-13’), 109.38, 111.03 (CH, C-aromatic), 112.74 
(CH, C-3’), 121.35 (CH, C-4’), 123.92, 124.38, 125.37 (CH, C-aromatic),
127.11, 134.43 (C, C-aromatic), 141.58 (CH, C-6’), 147.87, 148.39, 149.77 (C, 
C-aromatic), 152.73 (C, C-10’).
N3
O
N
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O
H
N
H
N
O
N
O
1
2
3
4
3
2
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2'
2'
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3'
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7'
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11'
O
O
N
NH2
119
O 12'
12'
13'
13'
166 167
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N-(4-tert-Butylstyryl)-2-(1-(4-
cyclohexylphenyl)ethylidene)hydrazinecarboxamide (164)
(C27H35N3O; M.W.= 417.49)
      
General procedure 21;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.75
Pale yellow powder;
Purification: recrystallization with DCM;
Yield: 0.351 g, 29 %
Melting point: 158-165 oC
MS (ESI)+: 418.3 [M+H]+
1H-NMR (DMSO-d6),  δ:  1.25-1.30 (s, 10H, H-2’, H-14’), 1.37-1.45 (m, 4H, CH2), 
1.78-1.83 (m, 4H,CH2), 2.23 (s, 3H, H-7’), 2.53-2.57 (m, 1H, 14’), 6.39 (d, J= 
14.9 Hz, 1H, H-3’), 7.23-7.27 (m, 4H, H-aromatic), 7.30 (d, J= 8.0 Hz, 2H, H-
aromatic), 7.36-7.42 (m, 1H, H-4’), 7.83 (d, J=7.9 Hz, 2H, H-aromatic), 9.05 
(d, J= 10.5 Hz, 1H, NH), 9.84 (bs, 1H, NH).
13C-NMR (DMSO-D6),  δ: 13.75 (CH3, C-7’), 25.55 (CH2, C-17’), 26.28 (CH2, C-
aliphatic), 31.11 (CH3, C-2’), 34.09 (CH2, C-aliphatic), 34.09 (C, C-aromatic), 
43.48 (CH, C-14’), 109.62 (CH, C-3’), 123.78 (CH, C-4’), 124.42, 125.36, 
126.41, 126.43 (CH, C-aromatic), 134.42, 135.69, 146.60, 147.90 (C, C-
aromatic), 148.32 (C, C-5’).
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N-(4-tert-Butylstyryl)-2-(4-hydroxybenzylidene)hydrazinecarboxamide 
(165) (C20H23N3O2; M.W.= 337.416)
General procedure 21;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.49;
White powder;
Yield: 0.178 g, 40 %
Melting point: 156-160 oC
MS (ESI)+: 360.2 [M+Na]+
1H-NMR (DMSO-d6),  δ:  1.27 (s, 9H, H-2’), 6.37 (d, J= 14.6 Hz, 1H, H-3’), 6.81 
(d, J= 8.5 Hz, 2H, H-aromatic), 7.23 (d, J= 8.5 Hz, 2H, H-aromatic), 7.30 (d, 
J= 8.5 Hz, 2H, H-aromatic), 7.35-7.40 (m, 1H, H-4’), 7.67 (d, J= 8.5 Hz, 2H, H-
aromatic), 7.83 (s, 1H, H-6’), 9.10 (d, J= 10.4 Hz, 1H, NH), 9.79 (bs, 1H, NH), 
10.61 (bs, 1H, -OH).
13C-NMR (DMSO-d6), δ:  31.11 (CH3, C-2’), 109.26 (CH, C-3’), 115.40 (CH, C-
aromatic), 123.91 (CH, C-4’), 124.36, 125.37 (CH, C-aromatic), 125.45 (C, C-
aromatic), 128.69 (CH, C-aromatic), 134.48 (C, C-aromatic), 141.48 (CH, 
C-6’), 147.85, 152.75 (C, C-aromatic), 152.75 (C, C-5’), 158.84 (C, C-10’)
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6.15 Synthesis of 2-arylidene-N-
phenetylhydrazinecarbothioamides 
6.15.1 General procedure 22: synthesis of 2-aryl idene-N -
phenetylhydrazinecarbothioamides 
N
C
S
Toluene, r.t., o.n.
H
N
H
N
N
S
R1
R3
R2
R3
N
NH2
R1
R2
A solution of (2-isothiocyanatoethyl)benzene (0.4 g, 5.16 mmol) in toluene 
(30 mL) was stirred for few minutes to dissolve the isothiocyanate and then 
the aryl aldehyde azines  (5.16 mmol) was slowly added to the solution. The 
reaction mixture was stirred at room temperature overnight. The reaction 
was stopped, the solvent removed under reduced pressure and the 
obtained solid was collected by filtration and dried. The solid purified by 
flash column chromatography or recrystallization to give the title 
compounds.
6.15.2 (2-Isothiocyanatoethyl)benzene (176)44
(C9H9NS; M.W.= 149.213)
           175     176
Thiophosgene (0.32 mL, 4.13 mmol) was  added dropwise to a solution of 2-
phenylethanamine (175) (0.52 mL, 4.13 mmol) and TEA (1.72 mL, 12.37 
mmol) in THF (50 mL). The mixture was stirred for 30 min at 0 oC, then the 
cold bath was removed and the stirring was continued for another 30 min. 
The mixture was extracted with ethyl acetate (2 x 50 mL) and water (2 x 50 
mL). The organic layers were combined, washed with brine, dried over 
MgSO4 and the organic solvent was removed under reduced pressure to 
give the pure (2-isothiocyanatoethyl)benzene as a brown oil.
T.L.C. system: n-hexane -EtOAC 1:1 v/v, Rf: 0.92
Yield: 0.770 g, 100 %
NH2
THF, TEA
Cl Cl
S
0o C, 30'; r.t., 30'
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1H-NMR (CDCl3), δ:  3.02 (t, J= 6.9 Hz, 2H, H-1’), 3.75 (t, J2= 6.9 Hz, 2H, H-2’), 
7.24 (d, J= 6.8 Hz, 2H, H-aromatic), 7.30-7.32 (m, 1H, H-aromatic), 7.35-7.39 
(m, 2H, H-aromatic).
13C-NMR (CDCl3),  δ:  36.37 (CH2, C-1’), 45.84 (CH2, C-2’), 126.44, 127.21, 
128.78 (CH, C-aromatic), 137.00 (C, C-1).
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6.15.3 2-Arylidene-N-phenetylhydrazinecarbothioamides (171-174)
2-(4-Methylbenzylidene)-N-phenethylhydrazinecarbothioamide (171)
(C17H19N3S: M.W.= 297.42)
 118      171
General procedure 22;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.98;
Off-White powder;
Yield: 0.23 g, 15 %
Melting point: 121-130 oC
MS (ESI)+: 298.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  2.34 (s, 3H, H-9’), 2.91-2.95 (m, 2H, H-1’), 3.75-3.80 
(m, 2H, H-2’), 7.21-7.26 (m, 3H, H-aromatic), 7.27-7.30 (m, 2H, H-aromatic), 
7.31-7.35 (m, 2H, H-aromatic), 7.65 (d, J= 8.0 Hz, 2H, H-aromatic), 8.03 (s, 
1H, H-4’), 8.48 (t, J= 7.7 Hz, 1H, NH), 11.44 (bs, s, 1H, NH).
13C-NMR (DMSO-d6), δ:  21.01 (CH3, C-9’), 34.86 (CH2, C-1’), 44.95 (CH2, C-2’), 
126.16, 127.13, 128.43, 128.58, 129.25 (CH, C-aromatic), 131.44, 139.24, 
139.61 (C, C-aromatic), 142.01 (CH, C-4’), 176.86 (C, C-3’).
2-(3,4-Diethoxybenzylidene)-N-phenethylhydrazinecarbothioamide (172)
(C20H25N3O2S: M.W.= 371.50)
N
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     119           172
General procedure 22;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.75
Purification: flash column chromatography (n-hexane-EtOAc 100:0 v/v, 
increasing to 70:30 v/v);
White powder;
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Yield: 0.2 g, 10.5 %
Melting point: 88-91 oC
MS (ESI)+:  372.2 [M+H]+
1H-NMR (DMSO-d6),  δ:  1.35 (q, J= 7.0 Hz, 6H, H-12’), 2.93 (t, J= 7.6 Hz, 2H, 
H-1’), 3.76-3.81 (m, 2H, H-2’), 4.00-4.11 (m, 4H, H-11’), 6.98 (d, J= 8.4 Hz, 
1H, H-aromatic), 7.17-7.24 (m, 2H, H-aromatic), 7.28-7.34 (m, 4H, H-
aromatic), 7.37 (d, J= 1.6 Hz, 1H H-aromatic), 7.97 (s, 1H, H-4’), 8.40 (t, 1H, 
NH), 11.38 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  14.62 (CH3, C-12’), 34.70 (CH2, C-1’), 45.02 (CH2, 
C-2’), 63.78 (CH2, C-11’), 110.98, 112.77, 121.74, 126.43 (CH, C-aromatic), 
126.75 (C, C-aromatic), 128.39, 128.56 (CH, C-aromatic), 139.25, 140.37, 
142.38, 150.13 (C, C-aromatic), 176.69 (C, C-3’).
2-(1-(4-Cyclohexylphenyl)ethylidene)-N-
phenethylhydrazinecarbothioamide (173)
(C23H29N3S: M.W.= 379.56)
 120      173
General procedure 22;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.78;
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 70:30 v/v);
White powder;
Yield: 0.2 g, 10.2 %
Melting point: 87-92 oC
MS (ESI)+: 380.2 [M+H]+
1H-NMR (DMSO-d6),  δ:  1.24-1.31 (m, 1H, H-13’), 1.34-1.48 (m, 4H, CH2), 
1.70-1.74 (m, 1H, H-13’), 1.78-1.82 (m, 4H, CH2), 2.28 (s, 3H, H-5’), 2.54-2.57 
(m, 1H, H-10’), 2.91-2.94 (m 2H, H-1’), 3.80 (q, J= 8.1 Hz, 2H, H-2’), 7.24-7.26 
(m, 3H, H-aromatic), 7.28-7.30 (m, 2H, H-aromatic), 7.32-7.34 (m, 2H, H-
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aromatic), 7.74 (d, J= 8.4 Hz, 2H, H-aromatic), 8.39 (t, J= 5.7 Hz, 1H, NH), 
10.23 (bs, 1H, NH).
13C-NMR (DMSO-d6),  δ:  14.06 (CH3, C-5’), 25.52, 26.27, 33.75 (CH2, C-11’, 
12’, 13’), 34.70 (CH2, C-1’), 43.49 (CH, C-10’), 45.02 (CH2, C-2’), 126.18, 
126.51, 128.45, 128.59 (CH, C-aromatic), 135.35, 139.22, 147.93, 148.85 (C, 
C-aromatic), 177.81 (C, C-3’).
2-(4-Hydroxybenzylidene)-N-phenethylhydrazinecarbothioamide (174) 
(C16H17N3OS: M.W.= 299.39)
 168      174
General procedure 22;
T.L.C. system: n-hexane -EtOAc 1:1 v/v, Rf: 0.83
Pale yellow powder;
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 70:30 v/v);
Yield: 0.24 g, 16 %
Melting point: 121-128 oC
MS (ESI)+: 300.1 [M+H]+
1H-NMR (DMSO-d6),  δ:  2.90-2.94 (m, 2H, H-1’), 3.73-3.79 (m, 2H, H-2’), 6.8 
(d, J= 8.6 Hz, 2H, H-aromatic), 7.21-7.25 (m, 2H, H-aromatic), 7.27-7.29 (m, 
2H, H-aromatic), 7.31-7.35 (m, 2H, H-aromatic), 7.58 (d, J= 8.6 Hz, 2H, H-
aromatic), 7.96 (s, 1H, H-4’), 8.38 (t, J= 5.8 Hz, 1H, NH), 9.87 (bs, 1H, NH), 
11.31 (bs, 1H, -OH).
13C-NMR (DMSO-d6),  δ:  34.93 (CH2, C-1’), 44.89 (CH2, C-2’), 115.53 (CH, C-
aromatic), 125.12 (C, C-aromatic), 126.15, 128.43,), 128.57, 128.90 (CH, C-
aromatic), 139.27, 142.33, 159.23 (C, C-aromatic), 176.59 (C, C-3’).
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6.16 Synthesis of dithiocarbamate structures
6.16.1 General procedure 23-24
General procedure 23: synthesis of dithiocarbamates 
To a solution of amine (6 mmol) in DMF (4 mL) was  added dropwise carbon 
disulphide (0.46 g, 6 mmol) and anydrous sodium methoxide (0.1 g, 2 
mmol) at 0 oC. The resulting mixture was stirred at room temperature for 
30 min. The aryl methyl bromide/chloride (3 mmol) was added by one 
portion and the stirring was continued. After completion of the reaction 
(monitored by TLC) the mixture was diluted with ice-cold water (20 mL) 
and the precipitate was filtered. The collected solid was  purified by column 
chromatography and/or recrystallization to give the desired product.
General procedure 24: synthesis of dithiocarbamate methyl aryl acids 
The appropriate methyl ester derivative (1 eq.) was dissolved in THF (30.4 
mL/mmol eq.) and LiOH (7.3 eq.) in water (2.42 mL/mmol eq.). The mixture 
was stirred for 24 h, at room temperature. The organic layer was 
evaporated, then the residue was acidifed by the addition of a 2N HCl 
solution. The resulting precipitate was filtrated, washed with water and 
dried. The crude residue was purified by flash column chromatography 
and/or recrystallization to give the title compound.
Ar Y2.
1. CS2, NaOMe an., DMF, 0 oC; r.t, 30'NH
X
X = CH2, O, -NCH3, -NH, C6H5CH2
N
X
S
S
Ar
(Cl, Br)
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6.16.2 Benzyl piperazine (C11H16N2; M.W.= 176.26) (181)45
  180     181
Benzyl bromide (2 g, 11.7 mmol) was added dropwise at 0 oC to  a solution 
of piperazine (180) (5.03 g, 58 mmol) in dry DCM (25 mL). The reaction 
mixture was stirred at the same temperature for 1h, rinsed with NaHCO3 
(20 mL), dried over Na2SO4 and concentrated under vacuum. The crude 
product was used in the next step without further purification.
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.29;
Pale, yellow oil;
Yield: 1.85 g, 89.8%
1H-NMR (CDCl3),  δ:  2.29-2.36 (m, 4H, CH2), 2.81 (t, J= 4.8 Hz, 4H, 
piperidine), 3.42 (s, 2H, H-1’), 3.43 (bs, 1H, NH), 7.14-7.19 (m, 2H, H-
aromatic), 7.21-7.24 (m, 3H, H-aromatic).
13C-NMR (CDCl3),  δ:  46.12 (CH2, C-1’), 53.10, 53.15, 62.99, 63.08 (CH2, C-2’, 
C-3’), 126.97, 127.00, 128.17, 129.13, 129.22 (CH, C-aromatic), 138.11 (C-1).
6.16.3 2-(Bromomethyl)benzo[d]oxazole (193)46
(C8H6BrNO; M.W.= 212.04)
       191         192    193
To a mixture of 2-aminophenol (191) (0.5 g, 4.58 mmol) in polyphosphoric 
acid (4.6 g, 13.8 mmol), bromoacetic  acid (192) (0.95 g, 6.87 mmol) was 
added and stirred at 130 oC  for 48 h. The reaction mixture was diluted with 
water (25 mL) and extracted with DCM (2x 20 mL). The organic layer was 
separated, dried over Na2SO4 and evaporated under pressure. The crude 
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product was purified by flash column chromatography (n-hexane:EtOAc 
100:0 v/v, increasing to 90:10 v/v) to give a pale, yellow oil.
T.L.C. System: n-hexane -EtOAc: 8:2 v/v, Rf: 0.64;
Yield: 0.21g, 43.2%
1H-NMR (CDCl3), δ:  4.62 (s, 2H, H-1’), 7.37-7.44 (m, 2H, H-aromatic), 
7.56-7.58 (m, 1H, H-aromatic), 7.74-7.77 (m, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  20.60 (CH2, C-1’), 110.88, 120.53, 124.85, 126.00 (CH-
aromatic), 143.25, 151.18, 155.63 (C, C-aromatic).
6.16.4 2-(Chloromethyl)benzo[d]thiazole (200) (C8H6ClNS, M.W.=183.66)47
          198           199            200
To a solution of 2-aminothiophenol (198) (1.02 g, 10 mmol) in toluene (30 
mL), chloroacetic  acid (199) (0.88 mL, 11 mmol) was added dropwise with 
continuous stirring, over 15 min. The mixture was stirred for 24h at room 
temperature and then partitioned in H2O (20 mL) and EtOAc  (20 mL). The 
organic layer was  separated, washed with H2O, brine and dried over MgSO4. 
The crude mixture was purified by flash column chromatography (n-
hexane:EtOAc 100:0 v/v, increasing to 90:10 v/v) to give a colourless oil.
 
T.L.C. System: n-hexane -EtOAc: 2:8 v/v, Rf: 0.7;
Yield: 1.5g, 50 %
1H-NMR (CDCl3),  δ:  4.87 (s, 2H, H-1’), 7.35 (td, 1H, J1= 7.6 Hz, J2= 1.3 Hz, H-
aromatic), 7.43 (td, 1H, J1= 7.6 Hz, J2= 1.3 Hz, H-aromatic), 7.81-7.83 (m, 
1H, H-aromatic), 7.94-7.96 (m, 1H, H-aromatic).
13C-NMR (CDCl3),  δ: 42.06 (CH2, C-1’), 121.80, 123.47, 125.77, 126.49 (CH-
aromatic), 135.83, 152.81, 166.80 (C, C-aromatic).
SH
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6.16.5 Methyl 4-bromo-3-nitrobenzoate (202)48 
(C8H6BrNO4; M.W.= 274.07)
  201     202
A mixture of 4-(bromomethyl)-3-nitrobenzoic acid (201) (1 eq, 5.76 mmol) 
and thionyl chloride (2.1 eq., 12.4 mmol) in MeOH (9.6 mL) was refluxed 
overnight. The reaction mixture was then cooled to room temperature and 
dried under pressure. The remaining residue was  washed with cold MeOH 
and dried. 
T.L.C. System: n-hexane -EtOAc: 7:3 v/v, Rf: 0.47;
Orange oil;
Yield: 0.45 g, 82 %
1H-NMR (CDCl3),  δ:  4.01 (s, 3H, H-3’), 5.03 (s, 2H, H-1’), 7.85 (d, J= 8.1 Hz, 
1H, H-aromatic), 8.32 (d, J= 8.1 Hz, 1H, H-aromatic), 8.71 (s, 1H, H-2).
13C-NMR (CDCl3), δ: 42.35 (CH2, C-1’), 52.86 (CH3, C-3’), 126.28, 131.65 (CH,
C-aromatic), 131.77 (C, C-aromatic), 134.18 (CH, C-aromatic), 136.67, 158.9 
(C, C-aromatic), 165.9 (C, C-2’).
NO2
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6.16.6 2-Chloromethyl benzoimidazol carbodithioates (182-186)
(1H-Benzo[d]imidazol-2-yl)methyl piperidine-1-carbodithioate (182)49
C14H17N3S2; M.W.= 291.43)
    177         182
General procedure 23;
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.62;
Off-white solid;
Purification: recrystallization from EtOH/H2O;
Yield: 0.107 g, 12.3%;
Melting point: 170-173 oC; (lit. 184 oC)
MS (ESI)+: 292.1 [M+H]+
Microanalysis: Calculated for C14H17N3S2 (291.43); Theoretical: %C = 57.70, 
%H = 5.88, %N = 14.41; Found: %C = 57.47, %H = 5.93, %N = 14.42.
1H-NMR (CDCl3), δ:  1.69-1.79 (m, 6H, CH2), 3.88-3.94 (m, 2H, CH2), 4.33-4.42 
(m, 2H, CH2), 4.94 (s, 2H, H-2), 7.24-7.26 (m, 2H, H-aromatic), 7.41-7.44 (m,
1H, H-aromatic), 7.71-7.74 (m, 1H, H-aromatic), 10.49 (bs,  1H, NH).
13C-NMR (CDCl3),  δ:  24.06, 25.54, 26.02 (CH2), 33.80 (CH2, C-2), 52.01, 54.06 
(CH2-), 122.63 (CH-aromatic), 151.90 (C, C-aromatic), 195.08 (C, C-1).
(1H-Benzo[d]imidazol-2-yl)methyl morpholine-4-carbodithioate (183)50
(C13H15N3OS2; M.W.= 293.41)
     178        183
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General procedure 23;
T.L.C. System: DCM-MeOH 9:1;
Dark yellow solid;
Purification: flash column chromatography (DCM:MeOH: 100:0 v/v, 
increasing to 99:1 v/v) and recrystallization from DCM/n-hexane;
Yield: 0.09 g, 10.2 %;
Melting point: 165-168 oC; (lit. 178 oC)
MS (ESI)+: 294.1 [M+H]+
Microanalysis: Calculated for C13H15N3OS2 (293.41); Theoretical: %C = 53.22, 
%H = 5.15, %N = 14.32; Found: %C = 52.84, %H = 4.99, %N = 14.19.
1H-NMR (CDCl3), δ:  3.73-3.86 (m, 4H, CH2), 3.92-3.99 (m, 2H, CH2), 4.39-4.46 
(m, 2H, CH2), 4.96 (s, 2H, H-2), 7.25-7.27 (m, 2H, H-aromatic), 7.41-7.80 (m, 
2H, H-aromatic), 10.38 (bs,  1H, NH).
13C-NMR (CDCl3), δ:  33.63 , 50.91, 52.36, 65.87 (CH2), 66.45 (CH2, C-2) 
122.77 (CH-aromatic), 148.2, 151.33 (C, C-aromatic), 197.11 (C, C-1).
(1H-Benzo[d]imidazol-2-yl)methyl 4-methylpiperazine-1-carbodithioate 
(184) (C14H18N4S2; M.W.= 306.45)
          179      184
General procedure 23;
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.47;
Yellow solid;
Purification: flash column chromatography (DCM:MeOH: 100:0 v/v, 
increasing to 99:1 v/v) and recrystallization from DCM/n-hexane;
Yield: 0.1 g, 11 %;
Melting point: 154-156 oC;
MS (ESI)+: 307.1 [M+H]+
Microanalysis: Calculated for C14H18N4S2 (306.10); Theoretical: %C = 54.87, 
%H = 5.92, %N = 14.28; Found: %C = 54.50, %H = 5.52, %N = 17.87.
1H-NMR (CDCl3),  δ:  2.34 (s, 3H, H-3’), 2.47-2.59 (m, 4H, CH2), 3.92-3.98 (m, 
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2H, CH2), 4.41-4.72 (m, 2H, CH2), 4.94 (s, 2H, H-2), 7.27 (m, 2H, H-aromatic), 
7.47-7.75 (m, 2H, H-aromatic), 10.44 (bs,  1H, NH).
13C-NMR (CDCl3),  δ:  33.77 (CH2), 45.53 (CH3, C-3’), 50.38, 52.25 (CH2), 54.31 
(CH2, C-2), 122.65 (CH-aromatic), 151.58, 154.9 (C, C-aromatic), 196.50 (C, 
C-1).
(1H-Benzo[d]imidazol-2-yl)methyl piperazine-1-carbodithioate (185)50
(C13H16N4S2; M.W.= 292.42)
        180       185
General procedure 23;
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.5;
Whitish solid;
Purification: flash column chromatography (DCM:MeOH: 100:0 v/v, 
increasing to 99:1 v/v) and recrystallization from MeOH;
Yield: 0.09 g,10.3 %;
Melting point: 165-167 oC; (lit. 179 oC)
MS (ESI)+: 293.1 [M+H]+
Microanalysis: Calculated for C13H16N4S2 (292.42); Theoretical: %C = 53.40, 
%H = 5.51, %N = 19.16; Found: %C = 53.21, %H = 5.16, %N = 18.99.
1H-NMR (DMSO-d6), δ:  3.32-3.35 (m, 4H, CH2), 4.14-4.21 (m, 2H, CH2), 
4.35-4.40 (m, 2H, CH2), 4.80 (s, 2H, H-2), 7.13-7.18 (m, 2H, H-aromatic), 7.46 
(d, J=7.2 Hz, 1H, H-aromatic), 7.55 (d, J=7.2 Hz, 1H, H-aromatic), 12.38 (bs, 
1H, NH).
13C-NMR (DMSO-d6),  δ:  34.34, 47.59, 49.65, 54.87 (CH2), 58.02 (CH2, C-2), 
111.25, 118.39, 121.24, 122.12 (CH-aromatic), 143.15, 149.36 (C, C-
aromatic) 194.21 (C, C-1).
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(1H-Benzo[d]imidazol-2-yl)methyl 4-benzylpiperazine-1-carbodithioate 
(186) (C20H22N4S2; M.W.= 382.55)
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181       186
General procedure 23
T.L.C. System: n-hexane -EtOAc: 5:5 v/v, Rf: 0.5;
Brown solid;
Purification: recrystallization from EtOH;
Yield: 0.19 g, 17%;
Melting point: 104-106oC;
MS (ESI)+: 383.1 [M+H]+
Microanalysis: Calculated for C20H22N4S2 (382.55); Theoretical: %C = 62.79, 
%H = 5.80, %N = 14.65; Found: %C = 62.50, %H = 5.57, %N = 14.53.
1H-NMR (CDCl3),  δ:  2.51-2.55 (m, 2H, CH2), 2.60-2.63 (m, 2H, CH2), 3.56 (s, 
2H, CH2, H-3’), 3.92-3.95 (m, 2H, CH2), 4.41-4.45 (m, 2H, CH2), 4.94 (s, 2H, 
CH2, H-2), 7.23-7.27 (m, 2H, H-aromatic), 7.29-7.37 (m, 5H, H-aromatic), 
7.41-7.43 (m, 1H, H-aromatic), 7.71-7.74 (m, 1H, H-aromatic), 10.40 (bs, 1H, 
NH).
13C-NMR (CDCl3),  δ: 33.73 (CH2, C-3’), 50.56, 52.34 (CH2), 62.39 (CH2, C-2), 
127.50, 128.44, 129.09 (CH-aromatic), 137.17 (C, C-aromatic), 149.3, 151.63 
(C, C-aromatic), 196.29 (C, C-1).
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6.16.7 2-Chloromethyl benzo[d]oxazol carbodithioates (187-190)
Benzo[d]oxazol-2-yl-methyl piperidine-1-carbodithioate (187)
(C20H22N4S2; M.W.= 292.42)
         177      187
General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 8:2 v/v, Rf: 0.53;
Yellow wax;
Purification: flash column chromatography (n-hexane:EtOAc: 100:0 v/v, 
increasing to 80:20 v/v);
Yield: 0.81 g, 93.8 %;
Melting point: 53-55 oC;
MS (ESI)+: 293.1 [M+H]+
Microanalysis: Calculated for C14H16N2OS2 (292.42); Theoretical: %C = 57.50, 
%H = 5.52, %N = 9.58; Found: %C = 57.61, %H = 5.60, %N = 9.72.
1H-NMR (CDCl3), δ:  1.73-1.75 (m, 6H, CH2), 3.93-3.99 (m, 2H, CH2), 4.29-4.35 
(m, 2H, CH2), 4.96 (s, 2H, H-2), 7.32-7.35 (m, 2H, H-aromatic), 7.52-7.54 (m, 
1H, H-aromatic), 7.71-7.73 (m, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  24.21, 25.40, 26.11, 34.23, 51.57 (CH2), 53.71 (CH2, 
C-2), 110.64, 120.05, 124.38, 125.07 (CH-aromatic), 141.26, 141.23, 151.08, 
162.41 (C, C-aromatic), 192.84 (C, C-1). 
Benzo[d]oxazol-2-yl-methyl morpholine-4-carbodithioate (188)
(C13H14N2O2S2; M.W.= 294.39)
         178    188
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General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 5:5 v/v, Rf: 0.7;
White solid;
Purification: recrystallization from EtOH;
Yield: 0.12 g, 13.6 %;
Melting point: 61-64 oC;
MS (ESI)+: 295.1 [M+H]+
Microanalysis: Calculated for C13H14N2O2S2 (294.39); Theoretical: %C  = 
53.04, %H = 4.79, %N = 9.52; Found: %C = 52.92, %H = 4.60, %N = 9.29.
1H-NMR (CDCl3), δ:  3.79-3.82 (m, 4H, CH2), 3.98-4.08 (m, 2H, CH2), 4.31-4.41 
(m, 2H, CH2), 4.96 (s, 2H), 7.34-7.36 (m, 2H, H-aromatic), 7.53-7.55 (m, 1H, 
H-aromatic), 7.72-7.74 (m, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  33.92, 25.40 (CH2), 66.20 (CH2, C-2), 110.65, 120.10, 
124.47, 125.19 (CH-aromatic), 141.20, 141.23, 151.08, 162.02 (C, C-
aromatic), 194.73 (C, C-1).
Benzo[d]oxazol-2-yl-methyl 4-methylpiperazine-1-carbodithioate (189) 
(C14H17N3OS2; M.W.= 307.43)
             179         189
General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 5:5 v/v, Rf: 0.4;
Whitish sponge;
Purification: recrystallization from DCM;
Yield: 0.18 g, 19.5 %;
Melting point: 55-58 oC;
MS (ESI)+: 308.1 [M+H]+
Microanalysis: Calculated for C14H17N3OS2 (307.43); Theoretical: %C = 54.69, 
%H = 5.57, %N = 13.67; Found: %C = 54.51, %H = 5.20, %N = 13.42.
1H-NMR (CDCl3),  δ:  2.35 (s, CH3, H-3’), 2.52-2.55 (m, 4H, CH2), 3.97-4.06 (m, 
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2H, CH2), 4.35-4.43 (m, 2H, CH2), 4.96 (s, 2H, H-2), 7.33-7.36 (m, 2H, H-
aromatic), 7.52-7.55 (m, 1H, H-aromatic), 7.71-7.74 (m, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  34.13 (CH2), 45.52 (CH3, C-3’), 54.36 (CH2, C-2), 110.64, 
120.08, 124.42, 125.13 (CH-aromatic), 141.23, 141.07, 162.17 (C, C-
aromatic), 194.12 (C, C-1).
Benzo[d]oxazol-2-yl-methyl 4-benzylpiperazine-1-carbodithioate (190)
(C20H21N3OS2; M.W.= 383.53)
 181      180
General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 8:2 v/v, Rf: 0.53;
Fine, white powder;
Purification: flash column chromatography (n-hexane:EtOAc: 100:0 v/v, 
increasing to 70:30 v/v) and recrystallization from EtOH;
Yield: 0.33 g, 28.7 %;
Melting point: 86-88 oC;
MS (ESI)+: 384.1 [M+H]+
Microanalysis: Calculated for C20H21N3OS2 (383.11); Theoretical: %C = 62.63, 
%H = 5.52, %N = 10.96; Found: %C = 62.64, %H = 5.55, %N = 10.80.
1H-NMR (CDCl3),  δ:  2.56-2.59 (m, 4H, CH2), 3.57 (s, 2H, H-3’), 3.96-4.05 (m, 
2H,CH2), 4.32-4.42 (m, 2H, CH2), 4.96 (s, 2H, H-2), 7.29-7.33 (m, 1H, H-
aromatic), 7.32-7.36 (m, 6H, H-aromatic), 7.52-7.54 (m, 1H, H-aromatic), 
7.71-7.73 (m, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  34.11 (CH2, C-2), 52.35 (CH2), 62.47 (CH2, C-3’), 110.64, 
120.07, 124.42, 125.12, 127.46, 128.43, 129.11 (CH-aromatic), 139.65, 
141.23, 162.21 (C, C-aromatic), 193.93 (C, C-1).
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6.16.8 2-Chloromethyl benzo[d]thiazol carbodithioates (194-197)
Benzo[d]thiazol-2-yl-methyl piperidine-1-carbodithioates (194)
(C14H16N2S3; M.W.= 308.49)
        177    194
General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 5:5 v/v, Rf: 0.58;
Fine, white powder;
Purification: recrystallization from EtOH;
Yield: 0.61 g, 66 %;
Melting point: 81-84 oC;
MS (ESI)+: 309.1 [M+H]+
Microanalysis: Calculated for C14H16N2S3 (308.49); Theoretical: %C = 54.51, 
%H = 5.23, %N = 9.08; Found: %C = 54.58, %H = 5.49, %N = 8.77.
1H-NMR (CDCl3), δ:  1.72-1.76 (m, 6H, CH2), 3.90-3.95 (m, 2H, CH2), 4.32-4.36 
(m, 2H, CH2), 5.15 (s, 2H, H-2), 7.36-7.39 (m, 1H, H-aromatic), 7.45-7.47 (m, 
1H, H-aromatic), 7.83-7.85 (m, 1H, H-aromatic), 7.99-8.02 (m, 1H, H-
aromatic).
13C-NMR (CDCl3),  δ:  24.23, 25.48, 26.17 (CH2), 39.11 (CH2, C-2), 51.68, 53.84 
(CH2), 121.61, 122.86, 125.18, 126.02 (CH-aromatic), 135.75, 152.72, 168.19 
(C, C-aromatic), 193.15 (C, C-1).
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Benzo[d]thiazol-2-yl-methyl morpholine-4-carbodithioate (195)
(C13H14N2OS3; M.W.= 310.46)
         178    195
General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 5:5 v/v, Rf: 0.76;
Fine, white powder;
Purification: recrystallization from EtOH;
Yield: 0.65 g, 75 %;
Melting point: 80-82 oC;
MS (ESI)+: 311.1 [M+H]+
Microanalysis: Calculated for C13H14N2OS3 (310.03); Theoretical: %C = 50.30, 
%H = 4.55, %N = 9.02; Found: %C = 49.90, %H = 4.57, %N = 8.91.
1H-NMR (CDCl3), δ:  3.79-3.82 (m, 4H, CH2), 3.95-4.12 (m, 2H, CH2), 4.29-4.45 
(m, 2H, CH2), 5.15 (s, 2H, C-2), 7.36-7.39 (m, 1H, H-aromatic), 7.47-7.49 (m, 
1H, H-aromatic), 7.84-7.86 (m, 1H, H-aromatic), 8.00-8.02 (m, 1H, H-
aromatic).
13C-NMR (CDCl3),  δ:  38.79 (CH2), 66.41 (CH2, C-2), 121.63, 122.92, 125.32, 
126.14 (CH-aromatic), 135.68, 152.68, 167.46 (C, C-aromatic), 195.10 (C, 
C-1).
Benzo[d]thiazol-2-yl-methyl 4-methylpiperazine-1-carbodithioate (196)
(C14H17N3S3; M.W.= 323.50)
            179    196
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General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 2:8 v/v, Rf: 0.56;
Fine, whitish powder;
Purification: recrystallization from EtOH;
Yield: 0.26 g, 27 %;
Melting point: 61-64oC;
MS (ESI)+: 324.1 [M+H]+
Microanalysis: Calculated for C14H17N3S3 (323.50); Theoretical: %C = 51.98, 
%H = 5.30, %N = 12.99; Found: %C = 51.95, %H = 6.31, %N = 12.58.
1H-NMR (CDCl3),  δ:  2.35 (s, 3H, H-3’), 2.51-2.55 (m, 4H, CH2), 3.97-4.02 (m, 
2H, CH2), 4.39-4.44 (m, 2H, CH2), 5.14 (s, 2H, C-2), 7.37-7.39 (m, 1H, H-
aromatic), 7.47-7.49 (m, 1H, H-aromatic), 7.84-7.86 (m, 1H, H-aromatic), 
8.00-8.02 (m, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  39.04 (CH2), 45.57 (CH3, C-3’), 54.38 (CH2, C-2), 121.60, 
122.91, 125.23, 126.06 (CH-aromatic), 135.74, 152.74, 167.69 (C, C-
aromatic), 194.54 (C, 1).
Benzo[d]thiazol-2-yl-methyl 4-benzylpiperazine-1-carbodithioate (197)
(C20H21N3S; M.W.= 399.60)
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General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 5:5 v/v, Rf: 0.45;
White crystals;
Purification: flash column chromatography (n-hexane:EtOAc: 100:0 v/v, 
increasing to 70:30 v/v) and recrystallization from EtOH;
Yield: 0.5 g, 42 %;
Melting point: 59-61 oC;
MS (ESI)+: 400.1 [M+H]+
Microanalysis: Calculated for C20H21N3S3 (399.60); Theoretical: %C = 60.11, 
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%H = 5.30, %N = 10.52; Found: %C = 60.15, %H = 5.54, %N = 10.11.
1H-NMR (CDCl3),  δ:  2.54-2.60 (m, 4H, CH2), 3.57 (s, 2H, H-3’), 3.95-4.01 (m, 
2H, CH2), 4.36-4.43 (m, 2H, CH2), 5.14 (s, 2H, H-2), 7.29-7.35 (m, 4H, H-
aromatic), 7.36-7.40 (m, 2H, H-aromatic), 7.46-7.50 (m, 1H, H-aromatic), 
7.85 (d, J= 8.1 Hz, 1H, H-aromatic), 8.01 (d, J= 8.1 Hz, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  38.97 (CH2), 52.40 (CH2, C-2), 62.48 (CH2, C-3’), 121.62, 
122.89, 125.24, 126.07, 127.46, 128.44, 129.13 (CH-aromatic), 137.28, 
140.6, 152.8, 168.0 (C, C-aromatic), 196.8 (C, C-1).
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6.16.9 Aryl carbodithioates (206-220)
4-(Trifluoromethyl)benzyl piperidine-1-carbodithioate (206)51
(C14H16F3NS2; M.W.= 319.41)
  203         206
General procedure 23;
T.L.C. System: n-hexane -EtOAc: 9:1 v/v, Rf: 0.57;
Off-White solid;
Purification: recrystallization from MeOH;
Yield: 0.084 g, 88.5%;
Melting point: 49-51 oC;
MS (ESI)+: 320.1 [M+H]+
Microanalysis: Calculated for C14H16F3NS2 (319.41); Theoretical: %C = 52.64, 
%H = 5.05, %N = 4.39; Found: %C = 52.37, %H = 5.15, %N = 4.37.
1H-NMR (CDCl3), δ:  1.69-1.76 (m, 6H, CH2), 3.87-3.94 (m, 2H, CH2), 4.29-4.36 
(m, 2H, CH2), 4.69 (s, 2H, H-2), 7.53 (d, 2H, J= 8.2 Hz, H-aromatic), 7.58 (d, 
2H, J=8.2 Hz, H-aromatic).
13C-NMR (CDCl3),  δ:  24.26 (CH2, C-3’), 25.45, 26.08 (CH2), 41.15 (CH2, C-2), 
51.43, 53.28 (CH2), 124.18 (q, J= 270.2 Hz, C-7), 125.44 (q, J= 3.7 Hz, CH, 
C-5), 129.41 (C, C-6), 129.64 (CH, C-6), 140.94 (C, C-3), 194.36 (C, C-1).
4-(Trifluoromethyl)benzyl morpholine-4-carbodithioate (207)51
(C13H14F3NOS2; M.W.= 321.38)
  203     207
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General procedure 23;
T.L.C. System: n-hexane -EtOAc: 9:1 v/v, Rf: 0.56;
White sponge;
Purification: recrystallization from MeOH
Yield: 0.178 g, 18.5%;
Melting point: 57-59 oC;
MS (ESI)+: 322.1 [M+H]+
Microanalysis: Calculated for C13H14F3NOS2 (321.38); Theoretical: %C = 
48.58, %H = 4.39, %N = 4.36; Found: %C = 48.37, %H = 4.86, %N = 4.35.
1H-NMR (CDCl3), δ:  3.77-3.80 (m, 4H, CH2), 3.92-4.09 (m, 2H, CH2), 4.25-4.41 
(m, 2H, CH2), 4.68 (s, 2H, H-2), 7.53 (d, 2H, J=8.1 Hz, H-aromatic), 7.59 (d, 
2H, J=8.1 Hz, H-aromatic).
13C-NMR (CDCl3),  δ:  40.08 (CH2, C-2), 66.11 (CH2), 125.31 (q, J= 271.3, C-7), 
125.51 (q, J= 3.7 Hz, CH, C-5), 129.58 (CH, C-aromatic), 129.72 (q, J= 32.0 
Hz, C, C-6), 140.53 (C, C-3), 196.30 (C, C-1).
4-(Trifluoromethyl)benzyl 4-methylpiperazine-1-carbodithioate (208)50
(C14H17F3N2S2; M.W.= 334.42)
  203         208
General procedure 23;
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.34;
White solid;
Purification: recrystallization from EtOH/H2O;
Yield: 0.112 g,11.2%;
Melting point: 57-60 oC;
MS (ESI)+: 335.1 [M+H]+
Microanalysis: Calculated for C14H17F3N2S2 (334.42); Theoretical: %C = 50.28, 
%H = 5.12, %N = 8.38; Found: %C = 50.23, %H = 5.39, %N = 8.39. 
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1H-NMR (CDCl3),  δ:  2.35 (s, 3H, H-3’), 2.49-2.53 (m, 4H, CH2), 3.93-4.02 (m, 
2H, CH2), 4.32-4.43 (m, 2H, CH2), 4.66 (s, 2H, H-2), 7.53 (d, 2H, J=8.2 Hz, H-
aromatic), 7.58 (d, 2H, J=8.2 Hz, H-aromatic).
13C-NMR (CDCl3),  δ:  41.07 (CH2), 45.62 (CH3, C-3’), 54.39 (CH2, C-2), 124.14 
(q, J= 272.2, C-7), 125.42 (q, J= 3.7 Hz, CH, C-C-5), 129.70 (q, J= 32.0 Hz, C, 
C-6), 140.72 (C, C-3), 195.73 (C, C-1).
4-(Trifluoromethyl)benzyl piperazine-1-carbodithioate (209)
(C13H15F3N2S2; M.W.= 320.40)
       193          200
General procedure 23;
T.L.C. System: n-hexane -EtOAc: 3:7 v/v, Rf: 0.4;
Off-white, fine powder;
Purification by recrystallization from MeOH;
Yield: 0.308 g, 32%;
Melting point: 154-156o C;
MS (ESI)+: 321.1 [M+H]+
Microanalysis: Calculated for C13H15F3N2S2 (320.40); Theoretical: %C = 48.73, 
%H = 4.72, %N = 8.74; Found: %C = 39.31, %H = 5.28, %N = 8.91. 
1H-NMR (DMSO-d6),  δ:  2.91 (bs, 1H, NH), 3.02-3.04 (m, 2H, CH2), 4.10-4.13 
(m, 2H, CH2), 4.32-4.36 (m, 2H, CH2), 4.55-4.58 (m, 2H, CH2), 4.70 (s, 2H, 
H-2), 7.63 (d, J= 8.1 Hz, 2H, H-aromatic), 7.69 (d, J= 8.1 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6),  δ: 39.02, 43.03 CH2), 45.54 (CH2-H-2), 125.20, 125.23 
(CH, C-aromatic), 125.30 (C, C-7), 127.44 (C, C-6), 127.63 (C, C-aromatic), 
129.89 (CH, C-aromatic), 141.82 (C, C-aromatic), 194.5 (C, C-1).
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4-(Trifluoromethyl)benzyl 4-benzylpiperazine-1-carbodithioate (210)
(C20H21F3N2S; M.W.= 410.52)
 203      210
General procedure 24;
T.L.C. System: DCM-MeOH: 95:5 v/v, Rf: 0.82;
White solid;
Purification: recrystallization from EtOH/H2O;
Yield: 0.2 g, 16.2 %;
Melting point: 65-68 oC;
MS (ESI)+: 411.1 [M+H]+
Microanalysis: Calculated for C20H21F3N2S2 (410.52); Theoretical: %C = 58.51, 
%H = 5.16, %N = 6.82; Found: %C = 58.57, %H = 4.91, %N = 6.70.
1H-NMR (CDCl3),  δ:  2.52-2.59 (m, 4H, CH2), 3.57 (s, 2H, CH2, H-2), 3.89-3.99 
(m, 2H, CH2), 4.33-4.42 (m, 2H, CH2), 4.66 (s, 2H, CH2, H-3’), 7.31-7.38 (m, 
5H, H-aromatic), 7.52 (d, J= 8.0 Hz, 2H, H-aromatic), 7.58 (d, J= 8.0 Hz, 2H, 
H-aromatic).
13C-NMR (CDCl3),  δ:  41.05 (CH2), 52.37 (CH2, C-2), 62.49 (CH2, C-3’), 125.44, 
125.47, 127.45, 128.42, 129.11, 129.62 (CH-aromatic), 140.75, 157.2, 168.5, 
184.6 (C, C-aromatic), 195.54 (C, C-1).
3-Nitrobenzyl piperidine-1-carbodithioate (211)
(C13H16N2O2S2; M.W.= 296.41)
          204       211
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General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 8:2 v/v, Rf: 0.5;
Fine, white powder;
Purification: recrystallization from EtOH;
Yield: 0.17 g, 20 %;
Melting point: 78-81 oC
MS (ESI)+: 319.1 [M+Na]+
Microanalysis: Calculated for C13H16N2O2S2 (296.41); Theoretical: %C  = 
52.68, %H = 5.44, %N = 9.45; Found: %C = 52.78, %H = 5.36, %N = 9.26.
1H-NMR (CDCl3), δ:  1.70-1.75 (m, 6H, CH2), 3.88-3.95 (m, 2H, CH2), 4.27-4.35 
(m, 2H, CH2), 4.72 (s, 2H, H-2), 7.47-7.49 (m, 1H, H-aromatic), 7.78 (d, 1H, J= 
8.3 Hz, H-aromatic), 8.12 (d, 1H, J= 8.3 Hz, H-aromatic), 8.27 (s, 1H, H-
aromatic).
13C-NMR (CDCl3),  δ:  24.23, 25.38, 26.07 (CH2), 40.55 (CH2, C-2), 51.49, 53.40 
(CH2), 122.32, 124.15, 129.29, 135.48 (CH, C-aromatic), 139.38 (C, C-3), 
148.32 (C, C-5), 193.85 (C, C-1).
3-Nitrobenzyl morpholine-4-carbodithioate (212)51
(C12H14N2O3S2; M.W.= 298.38)
         204      212
General procedure 23;
T.L.C. System: n-hexane -EtOAc-: 8:2 v/v, Rf: 0.26;
Fine, white powder;
Purification: recrystallization from EtOH;
Yield: 0.26 g, 29.2 %;
Melting point: 83-85 oC;
MS (ESI)+: 321.1 [M+Na]+
Microanalysis: Calculated for C12H14N2O3S2 (298.38); Theoretical: %C  = 
48.30, %H = 4.73, %N = 9.38; Found: %C = 48.43, %H = 4.63, %N = 9.17.
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1H-NMR (CDCl3), δ:  3.78-3.81 (m, 4H, CH2), 3.93-4.06 (m, 2H, CH2), 4.28-4.40 
(m, 2H, CH2), 4.73 (s, 2H, H-2), 7.48-7.50 (m, 1H, H-aromatic), 7.77 (d, 1H, J= 
7.6 Hz, H-aromatic), 8.14 (d, 1H, J= 8.2 Hz, H-aromatic), 8.27 (s, 1H, H-
aromatic).
13C-NMR (CDCl3),  δ:  40.28 (CH2), 66.23 (CH2, C-2), 122.48, 124.17, 129.36, 
135.46 (CH, C-aromatic), 138.96 (C, C-3), 148.34 (C, C-5), 195.76 (C, C-1).
3-Nitrobenzyl 4-methylpiperazine-1-carbodithioate (213)
(C13H17N3O2S2; M.W.= 311.42)
          204     213
General procedure 23;
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.2;
Fine, pale yellow powder;
Purification: recrystallization from EtOH;
Yield: 0.13 g, 14 %;
Melting point 78-81 oC;
MS (ESI)+: 312.1 [M+H]+
Microanalysis: Calculated for C13H17N3O2S2 (311.42); Theoretical: %C  = 
50.14, %H = 5.50, %N = 13.49; Found: %C = 50.24, %H = 5.44, %N = 13.64.
1H-NMR (CDCl3),  δ:  2.25 (s, 3H, H-3’), 2.41-2.44 (m, 4H, CH2), 3.84-3.92 (m, 
2H, CH2), 4.24-4.33 (m, 2H, CH2), 4.62 (s, 2H, H-2), 7.38-7.40 (m, 1H, H-
aromatic), 7.67 (d, 1H, J= 7.8 Hz, H-aromatic), 8.02-8.04 (m, 1H, H-
aromatic), 8.17 (s, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  40.45, 45.65 (CH, C-3’), 49.90, 51.57 (CH2), 54.38 (CH2, 
C-2), 122.45, 124.18, 129.36, 135.54 (CH, C-aromatic), 139.09 (C, C-3), 
148.27 (C, C-5), 195.11 (C, C-1).
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3-Nitrobenzyl piperazine-1-carbodithioate (214)
(C12H15N3O2S2; M.W.= 297.40)
          204        215
General procedure 23;
T.L.C. System: n-hexane -EtOAc: 7:3 v/v, Rf: 0.54;
Fine, grey yellow powder;
Purification: flash column chromatography (DCM-MeOH: 100:0 v/v, 
increasing to 90:10 v/v) and recrystallization from EtOAc/n-hexane;
Yield: 0.14 g, 15.7 %;
Melting point: 139-141 oC;
MS (ESI)+: 298.1 [M+H]+
Microanalysis: Calculated for C12H15N3O2S2 (297.06); Theoretical: %C  = 
48.46, %H = 5.08, %N = 14.13; Found: %C = 48.24, %H = 5.22, %N = 14.02.
1H-NMR (DMSO-d6), δ:  2.54-2.58 (m, 4H, CH2), 4.10-4.11 (m, 2H, CH2), 
4.33-4.37 (m, 2H, CH2), 4.77 (s, 2H, H-2), 7.62-7.64 (m, 1H, H-aromatic), 7.88 
(d, J= 7.5 Hz, 1H, H-aromatic), 8.11-8.14 (m, 1H, H-aromatic), 8.29-8.30 (m, 
1H, H-4).
13C-NMR (DMSO-d6),  δ:  38.98, 39.96, 40.03, 47.57 (CH2), 47.89 (CH2, C-2), 
122.20, 123.66, 129.84, 135.89 (CH, C-aromatic), 139.56 (C, C-3), 147.64 (C, 
C-5), 194.35 (C, C-1).
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3-Nitrobenzyl 4-benzylpiperazine-1-carbodithioate (215)
(C19H21N3O2S2; M.W.= 387.52)
    204       214
General procedure 23;
T.L.C. System: DCM-MeOH: 95:5 v/v, Rf: 0.62;
Whitish solid;Yield: 0.18 g, 16.2 %;
Purification: flash column chromatography (DCM-MeOH: 100:0 v/v, 
increasing to 99:1 v/v) and recrystallization from EtOH;
Melting point: 63-65oC;
MS (ESI)+: 388.1 [M+H]+
Microanalysis: Calculated for C19H21N3O2S2 (387.52); Theoretical: %C  = 
58.89, %H = 5.46, %N = 10.84; Found: %C = 58.62, %H = 5.31, %N = 10.57.
1H-NMR (CDCl3),  δ:  2.46-2.62 (m, 4H, CH2), 3.54 (s, 2H, CH2, H-3’), 3.83-4.02 
(m, 2H, CH2), 4.22-4.38 (m, 2H, CH2), 4.61 (s, 2H, CH2, H-2), 7.20-7.29 (m, 
5H, H-aromatic), 7.38-7.40 (m, 1H, H-aromatic), 7.66 (d, J= 7.6 Hz, 1H, H-
aromatic), 8.04 (d, J= 8.3 Hz, 1H, H-aromatic), 8.17 (s, 1H, H-4).
13C-NMR (CDCl3),  δ:  40.50 (CH2), 52.17 (CH2, C-2), 62.32 (CH2, C-3’), 122.14, 
124.14, 128.58, 129.35, 135.47 (CH-aromatic), 139.03, 146.6 (C, C-
aromatic), 148.33 (C, C-5), 195.3 (C, C-1).
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Methyl 3-nitro-4-(((piperidine-1-carbonothioyl)thio)methyl)benzoate (216)
(C15H18N2O4S2; M.W.= 354.44)
        205       216
General procedure 23;
T.L.C. System: n-hexane -EtOAc: 8:2 v/v, Rf: 0.56;
Yellow wax;
Purification: flash column chromatography (n-hexane:EtOAc 100:0 v/v, 
increasing to 85:15 v/v)
Yield: 0.87 g, 83%;
Melting point: 50-52 oC;
MS (ESI)+: 356.1 [M+2H+]
Microanalysis: Calculated for C15H18N2O4S2 (354.44); Theoretical: %C  = 
50.83, %H = 5.12, %N = 7.90; Found: %C = 50.70, %H = 4.88, %N = 7.77.
1H-NMR (CDCl3),  δ:  1.66-1.72 (m, 6H, CH2), 3.85-3.91 (m, 2H, CH2), 3.98 (s, 
3H, H-10), 4.23-4.31 (m, 2H, CH2), 5.07 (s, 2H, H-2), 7.98 (d, J= 8.0 Hz, 2H, 
H-aromatic), 8.20 (dd, J1= 8.0 Hz, J2= 1.7 Hz, 1H, H-aromatic), 8.64 (d, J= 1.7 
Hz, 1H, H-aromatic).
13C-NMR (CDCl3), δ: 24.19 (CH2), 38.01 (CH2, C-2), 52.69 (CH3, C-10), 126.03
(CH-aromatic), 127.94, 130.58 (C, C-aromatic), 133.17, 133.64 (CH, C-
aromatic), 138.23 (C, C-aromatic), 164.83 (C, C-9), 193.82 (C, C-1).
Methyl 4-(((morpholine-4-carbonothioyl)thio)methyl)-3-nitrobenzoate 
(217) (C14H16N2O5S; M.W.= 356.42)
    205         217
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General procedure 23;
T.L.C. System: n-hexane -EtOAc: 8:2 v/v, Rf: 0.65;
Fine, off-white powder;
Purification: flash column chromatography (n-hexane:EtOAx: 100:0 v/v, 
increasing to 80:20 v/v) and recrystallization from EtOH;
Yield: 0.27 g, 26 %;
Melting point: 67-70 oC;
MS (ESI)+: 379.1 [M+Na]+
Microanalysis: Calculated for C14H16N2O5S2 (356.42); Theoretical: %C  = 
47.18, %H = 4.52, %N = 7.86; Found: %C = 47.32, %H = 4.55, %N = 7.55.
1H-NMR (CDCl3),  δ:  3.74-3.79 (m, 6H, CH2), 3.98 (s, 3H, H-10), 4.21-4.38 (m, 
2H, CH2), 5.08 (s, 2H, H-2), 7.96 (d, J= 8.0 Hz, 1H, H-aromatic), 8.21 (dd, J1= 
8.0 Hz, J2= 1.9 Hz, 1H, H-aromatic), 8.66 (d, J= 1.9 Hz, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  37.86 (CH2), 52.73 (CH3, C-10), 59.35 (CH2, C-2), 126.13 
(CH-aromatic), 130.81 (C, C-aromatic), 133.20, 133.71 (CH, C-aromatic), 
137.73, 148.7 (C, C-aromatic), 164.75 (C, C-9), 195.79 (C, C-1).
Methyl 4-(((4-methylpiperazine-1-carbonothioyl)thio)methyl)-3-
nitrobenzoate (218) (C15H19N3O4S2; M.W.= 369.46)
 205      218
General procedure 23;
T.L.C. System: DCM-MeOH: 9:1 v/v, Rf: 0.32;
White solid;
Yield: 0.36 g, 32.7 %;
Purification: recrystallization from EtOH;
Melting point: 70-72 oC;
MS (ESI)+: 370.1 [M+H]+
Microanalysis: Calculated for C15H19N3O4S2 (369.08); Theoretical: %C  = 
48.76, %H = 5.18, %N = 11.37; Found: %C = 48.65, %H = 4.87, %N = 11.31.
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1H-NMR (CDCl3), δ:  2.33 (s, 3H, H-3), 2.48-2.51 (m, 4H, CH2), 3.88-3.95 (m, 
1H, CH2), 3.96-4.00 (m, 4H, H-10, CH2), 4.28-4.48 (m, 2H, CH2), 5.07 (s, 2H, 
H-2), 7.97 (d, J= 8.0 Hz, 1H, H-aromatic), 8.20 (d, J= 8.0 Hz, 1H, H-aromatic), 
8.65 (s, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  37.99 (CH2), 45.57 (CH3, C-3’), 52.71 (CH3, C-10), 54.35 
(CH2, C-2), 126.08 (CH-aromatic), 130.70 (C, C-aromatic), 133.18, 133.68 
(CH, C-aromatic), 137.94, 148.7 (C, C-aromatic), 164.78 (C, C-9), 195.15 (C, 
C-1).
Methyl 3-nitro-4-(((piperazine-1-carbonothioyl)thio)methyl)benzoate 
(219) (C14H17N3O4S2; M.W.= 355.43)
 205       219
General procedure 23;
T.L.C. System: n-hexane -EtOAc: 7:3 v/v, Rf: 0.45;
White solid;
Yield: 0.83 g, 75.4 %;
Purification: recrystallization from MeOH;
Melting point: 145-148 oC;
MS (ESI)+: 357.1 [M+2H]+
Microanalysis: Calculated for C14H17N3O4S2 (355.07); Theoretical: %C  = 
47.31, %H = 4.82, %N = 11.82; Found: %C = 47.15, %H = 4.58, %N = 11.79.
1H-NMR (DMSO-d6),  δ:  3.30-3.31 (m, 4H, CH2), 3.91 (s, 3H, H-10), 4.07-4.11 
(m, 2H, CH2), 4.28-4.32 (m, 2H, CH2), 4.97 (s, 2H, H-2), 7.93 (d, J= 8.2 Hz, 
1H, H-8), 8.22 (dd, J1= 8.2 Hz, J2= 1.7 Hz, 1H, H-7), 8.45 (d, J= 1.7 Hz, 1H, 
H-5).
13C-NMR (DMSO-d6),  δ:  36.87 (CH2), 47.98, 49.74 (CH2, C-2), 52.77 (CH3, 
C-10), 125.16 (CH-aromatic), 129.96 (C, C-aromatic), 133.04, 133.48 (CH, C-
aromatic), 137.22, 148.63 (C, C-4), 164.25 (C, C-9), 193.82 (C, C-1).
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Methyl 4-(((4-benzylpiperazine-1-carbonothioyl)thio)methyl)-3-
nitrobenzoate (220) (C21H23N3O4S2; M.W.= 445.56)
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General procedure 23;
T.L.C. System: n-hexane-EtOAc: 8:2 v/v, Rf: 0.26;
Yellow oil;
Yield: 1.1 g, 82.7 %;
Purification: flash column chromatography (n-hexane:EtOAx: 100:0 v/v, 
increasing to 60:40 v/v);
MS-(ESI)+: 446.1 (M+H);
1H-NMR (CDCl3),  δ:  2.51-2.57 (m, 4H, CH2), 3.55 (s, CH2, C-3’), 3.86-3.95 (m, 
1H, CH2), 3.98 (s, 3H, H-10), 4.01-4.16 (m, 1H, CH2), 5.07 (s, 2H, H-2), 
7.30-7.37 (m, 5H, H-aromatic), 7.96 (d, J= 8.0 Hz, 1H, H-aromatic), 8.20 (d, 
J= 8.0 Hz, 1H, H-aromatic), 8.65 (s, 1H, H-aromatic).
13C-NMR (CDCl3),  δ:  37.97 (CH2, C-3’), 51.96, 52.33, 52.71 (CH2), 53.42 (CH3, 
C-10), 62.44 (CH2, C-2), 126.07, 127.44, 128.41, 129.10 (CH-aromatic), 
130.68 (C, C-aromatic), 133.18, 133.68 (CH, C-aromatic), 137.25, 137.97 (C, 
C-aromatic), 148.57 (C, C-4), 164.79 (C, C-9), 194.95 (C, C-1). 
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6.16.10 Dithiocarbamate methyl aryl acids (221-224)
3-Nitro-4-(((piperidine-1-carbonothioyl)thio)methyl)benzoic acid (221)
(C14H16N2O4S2; M.W.= 340.42)
  216     221
General procedure 24;
Reagent: Methyl 3-nitro-4-(((piperidine-1-
carbonothioyl)thio)methyl)benzoate 216 (0.28 g, 0.79 mmol);
Pale, yellow powder;
Purification: recrystallization from EtOH/H2O;
Yield: 0.135 g, 50.3 %;
Melting point: 162-164 oC;
MS (ESI)+: 341.1 [M+H]+
Microanalysis: Calculated for C14H16N2O4S2 (340.42); Theoretical: %C  = 
49.40, %H = 4.74, %N = 8.23; Found: %C = 49.01, %H = 4.66, %N = 8.37.
1H-NMR (CDCl3), δ:  1.67-1.76 (m, 6H, CH2), 3.85-3.94 (m, 2H, CH2), 4.25-4.33 
(m, 2H, CH2), 5.10 (s, 2H, H-2), 8.04 (d, J= 7.1 Hz 1H, H-aromatic), 8.26 (d, J= 
7.1 Hz, 1H, H-aromatic), 8.71 (s, 1H, H-5), 10.84 (bs, 1H, -COOH).
13C-NMR (CDCl3),  δ: 24.18 (CH2), 37.18 (CH2, C-2), 126.63 (CH-aromatic), 
129.54 (C, C-aromatic) 133.37, 134.10 (CH-aromatic), 139.29, 148.7 (C, C-
aromatic), 168.91 (C, C-9), 193.70 (C, C-1’).
4-(((Morpholine-4-carbonothioyl)thio)methyl)-3-nitrobenzoic acid (222)
(C13H14N2O5S2; M.W.= 342.39)
  217     222
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General procedure 24;
Reagent: Methyl 4-(((morpholine-4-carbonothioyl)thio)methyl)-3-
nitrobenzoate 217 (0.18 g, 0.5 mmol);
Off-White solid;
Purification: recrystallization from EtOH/H2O;
Yield: 0.05 g, 29.4 %;
Melting point: 166-168 oC;
MS (ESI)+: 365.1 [M+Na]+
Microanalysis: Calculated for C13H14N2O5S2 (342.39); Theoretical: %C  = 
45.60, %H = 4.12, %N = 8.18; Found: %C = 45.65, %H = 4.22, %N = 7.90.
1H-NMR (DMSO-d6), δ:  3.64-3.68 (m, 4H, CH2), 3.88-3.97 (m, 2H, CH2), 
4.15-4.24 (m, 2H, CH2), 4.97 (s, 2H, H-2), 7.90 (d, J= 7.9 Hz, 1H, H-aromatic), 
8.20 (dd, J1= 7.9 Hz, J2= 1.5 Hz, 1H, H-aromatic), 8.43 (d, J= 1.5 Hz, 1H, H-
aromatic), 13.61 (bs, 1H, -COOH).
13C-NMR (DMSO-d6),  δ:  36.86 (CH2), 65.48 (CH2, C-2), 125.21 (CH-aromatic), 
131.33 (C, C-aromatic) 132.87, 133.62 (CH-aromatic), 136.73, 148.7 (C, C-
aromatic), 165.23 (C, C-9), 194.05 (C, C-1).
4-(((4-Methylpiperazine-1-carbonothioyl)thio)methyl)-3-nitrobenzoic acid 
(223) (C14H17N3O4S2; M.W.= 355.43)
  218     223
General procedure 24;
Reagent: methyl 4-(((4-methylpiperazine-1-carbonothioyl)thio)methyl)-3-
nitrobenzoate 218 (0.12 g, 0.32 mmol);
White solid;
Purification: recrystallization from DCM;
Yield: 0.035 g, 30.9 %;
Melting point: 206-209 oC;
MS (ESI)+: 356.1 [M+H]+
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Microanalysis: Calculated for C14H17N3O4S2 (355.43); Theoretical: %C  = 
47.31, %H = 4.82, %N = 11.82; Found: %C = 46.93, %H = 5.20, %N = 11.57.
1H-NMR (DMSO-d6),  δ:  2.22 (s, 3H, H-3’), 2.40-2.43 (m, 4H, CH2), 3.86-3.93 
(m, 2H, CH2), 4.17-4.23 (m, 2H, CH2), 4.94 (s, 2H, H-2), 7.88 (d, J= 8.0 Hz, 
1H, H-aromatic), 8.19 (dd, J1= 8.0 Hz, J2= 1.7 Hz,1H, H-aromatic), 8.42 (d, J= 
1.7 Hz, 1H, H-aromatic).
13C-NMR (DMSO-d6),  δ:  37.02 (CH2), 44.86 (CH3, H-3’), 49.51, 51.16 (CH2), 
53.81 (CH2, C-2), 125.20 (CH-aromatic), 131.76 (C, C-aromatic) 132.79, 
133.63 (CH-aromatic), 136.58, 148.59 (C, C-aromatic), 165.33 (C, C-9), 
194.57 (C, C-1).
4-(((4-Benzylpiperazine-1-carbonothioyl)thio)methyl)-3-nitrobenzoic acid 
(224) (C20H21N3O4S2; M.W. = 431.53)
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General procedure 24;
Reagent: methyl 4-(((4-benzylpiperazine-1-carbonothioyl)thio)methyl)-3-
nitrobenzoate 220 (0.3 g, 0.67 mmol);
Yellow, fine powder;
Yield: 29.5 g, 10.4 %;
Purification: recrystallization from EtOH/H2O;
MS (ESI)+: 432.1 [M+H]+
Microanalysis: Calculated for C20H21N3O4S2 (431.10); Theoretical: %C  = 
55.67, %H = 4.91, %N = 9.74; Found: %C = 55.70, %H = 4.73, %N = 9.41.
1H-NMR (CDCl3),  δ:  3.38-3.44 (m, 4H, CH2), 3.58 (s, CH2, C-10’), 3.89-3.96 
(m, 2H, CH2), 4.18-4.29 (m, 2H, CH2), 4.94 (s, 2H, H-2), 7.32-7.36 (m, 5H, H-
aromatic), 7.87-7.91 (m, 1H, H-aromatic), 8.18-8.21 (m, 1H, H-aromatic), 
8.42-8.43 (s, 1H, H-aromatic).
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13C-NMR (CDCl3),  δ:  37.09 (CH2, C-10’), 40.03 (CH2), 49.51, 51.16 (CH2), 
61.02 (CH2, C-2), 125.20, 127.28, 128.26, 129.07 (CH-aromatic), 131.30 (C, 
C-aromatic) 132.85, 133.61 (CH-aromatic), 136.75 (C, C-aromatic), 148.64 
(C, C-4’), 165.24 (C, C-9’), 193.51 (C, C-1).
Conclusions
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Appendix
Structure and biological evaluation for purchased compounds
The tables below contain all the compounds selected by virtual screening 
studies from Specs database that were tested for their antiviral activity in 
cytostatic assays at Rega Institute in Leuven, Belgium.
Virtual screening on 3A protein
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number Chemical structure EC50 (µM) EC90 (µM) CC50 (µM)
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Purchased analogues of hit compound 1
Compound 
number
Chemical structure EC50 (µM) EC90 (µM) CC50 (µM)
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Structure-Based Virtual Screening on the CVB3 3D polymerase
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number
Chemical structure EC50 (µM)
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(µM)
CC50 (µM)
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Ligand-Based Virtual Screening on GPC-N114
Compound 
number
Chemical structure EC50 (µM) EC90 (µM) CC50 (µM)
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Structure-based virtual screening on the FMDV 3D polymerase
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number
Chemical structure EC50 (µM) EC90 (µM) CC50 (µM)
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Structure-based virtual screening on the M2-1 protein
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number
Chemical structure IC50 (µM) CC50 (µM)
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Ligand-based virtual screening on the TMC-353121
Compound 
number
Chemical structure EC50 (µM) CC50 (µM)
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